<SEC-DOCUMENT>0001144204-12-040031.txt : 20120718
<SEC-HEADER>0001144204-12-040031.hdr.sgml : 20120718
<ACCEPTANCE-DATETIME>20120718171600
ACCESSION NUMBER:		0001144204-12-040031
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20120430
FILED AS OF DATE:		20120718
DATE AS OF CHANGE:		20120718

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CHAMPIONS ONCOLOGY, INC.
		CENTRAL INDEX KEY:			0000771856
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				521401755
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-17263
		FILM NUMBER:		12968533

	BUSINESS ADDRESS:	
		STREET 1:		855 N. WOLFE STREET
		STREET 2:		SUITE 619
		CITY:			BALTIMORE
		STATE:			MD
		ZIP:			21205
		BUSINESS PHONE:		410-369-0365

	MAIL ADDRESS:	
		STREET 1:		855 N. WOLFE STREET
		STREET 2:		SUITE 619
		CITY:			BALTIMORE
		STATE:			MD
		ZIP:			21205

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHAMPIONS BIOTECHNOLOGY, INC.
		DATE OF NAME CHANGE:	20070220

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHAMPIONS SPORTS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERNATIONAL GROUP INC
		DATE OF NAME CHANGE:	19860319
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>v316311_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 3.5pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>Form 10-K</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left">(Mark One)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; text-align: center; font-family: Wingdings; font-weight: bold">&thorn;</TD>
    <TD STYLE="width: 93%; text-align: left; font-weight: bold">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left; font-weight: bold">For the fiscal year ended April 30, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold">or</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-family: Wingdings; font-weight: bold">&uml;</TD>
    <TD STYLE="text-align: left; font-weight: bold">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><B>For the transition period from</B> &#9;<B>to</B> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission file number 0-17263</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CHAMPIONS ONCOLOGY, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><I>(Exact name of registrant
as defined in its charter)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: center; font-weight: bold">Delaware</TD>
    <TD STYLE="width: 50%; text-align: center; font-weight: bold">52-1401755</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(State or other jurisdiction of</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>incorporation or organization)</I></P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(I.R.S. Employer</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Identification No.)</I></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-style: italic">&nbsp;</TD>
    <TD STYLE="text-align: center; font-style: italic">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-weight: bold">One University Plaza, Suite 307</TD>
    <TD STYLE="text-align: center; font-weight: bold">07601</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-weight: bold">Hackensack, New Jersey</TD>
    <TD STYLE="text-align: center; font-style: italic">(Zip Code)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-style: italic">(Address of principal executive offices)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registrant&rsquo;s telephone number,
including area code:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(201) 808-8400</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities registered pursuant to Section
12(g) of the Act:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: center; font-weight: bold; text-decoration: underline">Title of Each Class</TD>
    <TD STYLE="width: 50%; text-align: center; font-weight: bold; text-decoration: underline">Name of Each Exchange on Which Registered</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">Common Stock, par value $0.001 per share</TD>
    <TD STYLE="text-align: center">Over-the-Counter Bulletin Board (OTCBB)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt"><FONT STYLE="font-size: 10pt">Indicate
by check mark whether the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-size: 10pt">
&nbsp;&nbsp;&nbsp;No <FONT STYLE="font-family: Wingdings">&thorn;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt"><FONT STYLE="font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-size: 10pt">
&nbsp;&nbsp;&nbsp;No <FONT STYLE="font-family: Wingdings">&thorn;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt"><FONT STYLE="font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. Yes <FONT STYLE="font-family: Wingdings">&thorn;</FONT>
&nbsp;&nbsp;&nbsp;No </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt"><FONT STYLE="font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&sect;232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes <FONT STYLE="font-family: Wingdings">&thorn;</FONT>
&nbsp;&nbsp;&nbsp;No </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt"><FONT STYLE="font-size: 10pt">Indicate
by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (&sect;229.405 of this chapter) is not
contained herein, and will not be contained, to the best of registrant&rsquo;s knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt">Indicate by check mark
whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.
See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo;
in Rule 12b-2 of the Exchange Act. (Check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 21%; text-align: left"><FONT STYLE="font-size: 10pt">Large accelerated filer </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 17%; text-align: center"><FONT STYLE="font-size: 10pt">Accelerated filer </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 38%; text-align: center"><FONT STYLE="font-size: 10pt">Non-accelerated filer </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 24%; text-align: right">Smaller reporting company <FONT STYLE="font-family: Wingdings">&thorn;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">(Do not check if a smaller reporting company)</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt"><FONT STYLE="font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-size: 10pt">
&nbsp;&nbsp;&nbsp;No <FONT STYLE="font-family: Wingdings">&thorn;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt">The approximate aggregate
market value of the voting stock held by non-affiliates of the Registrant as of October 31, 2011 was $18.7 million based on the
closing price of the Registrant&rsquo;s Common Shares as quoted on the OTCBB as of that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt">The number of Common
Shares of the Registrant outstanding as of July 6, 2012 was 47,074,942.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DOCUMENTS INCORPORATED BY REFERENCE -
None</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 3.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEX TO FORM 10-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE YEAR ENDED APRIL 30, 2012</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="width: 10%; text-align: left; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 80%; text-align: center; font-weight: bold">PART I</TD>
    <TD STYLE="width: 10%; text-align: right; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left">Item 1.</TD>
    <TD STYLE="padding-left: 0.1in; text-align: left; text-indent: -0.1in">Business</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">2</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Item 1A.</TD>
    <TD STYLE="padding-left: 0.1in; text-align: left; text-indent: -0.1in">Risk Factors</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">6</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left">Item 1B.</TD>
    <TD STYLE="padding-left: 0.1in; text-align: left; text-indent: -0.1in">Unresolved Staff Comments</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">10</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Item 2.</TD>
    <TD STYLE="padding-left: 0.1in; text-align: left; text-indent: -0.1in">Properties</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">10</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left">Item 3.</TD>
    <TD STYLE="padding-left: 0.1in; text-align: left; text-indent: -0.1in">Legal Proceedings</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">11</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Item 4.</TD>
    <TD STYLE="padding-left: 0.1in; text-align: left; text-indent: -0.1in">Mine Safety Disclosures</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">11</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="padding-left: 0.1in; text-align: left; text-indent: -0.1in">&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold">PART II</TD>
    <TD STYLE="text-align: right; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left">Item 5.</TD>
    <TD STYLE="padding-left: 0.1in; text-align: left; text-indent: -0.1in">Market for Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">11</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Item 6.</TD>
    <TD STYLE="padding-left: 0.1in; text-align: left; text-indent: -0.1in">Selected Financial Data</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">12</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left">Item 7.</TD>
    <TD STYLE="padding-left: 0.1in; text-align: left; text-indent: -0.1in">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">12</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Item 7A.</TD>
    <TD STYLE="padding-left: 0.1in; text-align: left; text-indent: -0.1in">Quantitative and Qualitative Disclosures About Market Risk</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">18</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left">Item 8.</TD>
    <TD STYLE="padding-left: 0.1in; text-align: left; text-indent: -0.1in">Financial Statements and Supplementary Data</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">18</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Item 9.</TD>
    <TD STYLE="padding-left: 0.1in; text-align: left; text-indent: -0.1in">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">18</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left">Item 9A.</TD>
    <TD STYLE="padding-left: 0.1in; text-align: left; text-indent: -0.1in">Controls and Procedures</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">18</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Item 9B.</TD>
    <TD STYLE="padding-left: 0.1in; text-align: left; text-indent: -0.1in">Other Information</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">19</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="padding-left: 0.1in; text-align: left; text-indent: -0.1in">&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold">PART III</TD>
    <TD STYLE="text-align: right; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left">Item 10.</TD>
    <TD STYLE="padding-left: 0.1in; text-align: left; text-indent: -0.1in">Directors, Executive Officers and Corporate Governance</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">19</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Item 11.</TD>
    <TD STYLE="padding-left: 0.1in; text-align: left; text-indent: -0.1in">Executive Compensation</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">22</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left">Item 12.</TD>
    <TD STYLE="padding-left: 0.1in; text-align: left; text-indent: -0.1in">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">25</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Item 13.</TD>
    <TD STYLE="padding-left: 0.1in; text-align: left; text-indent: -0.1in">Certain Relationships and Related Transactions, and Director Independence</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">27</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left">Item 14.</TD>
    <TD STYLE="padding-left: 0.1in; text-align: left; text-indent: -0.1in">Principal Accounting Fees and Services</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">27</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="padding-left: 0.1in; text-align: left; text-indent: -0.1in">&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold">PART IV</TD>
    <TD STYLE="text-align: right; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Item 15.</TD>
    <TD STYLE="padding-left: 0.1in; text-align: left; text-indent: -0.1in">Exhibits, Financial Statement Schedules</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">28</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">As used in this Annual
Report on Form 10-K, &ldquo;Champions Oncology, Inc.,&rdquo; &ldquo;Champions,&rdquo; the &ldquo;Company,&rdquo;, &ldquo;we,&rdquo;
&ldquo;ours,&rdquo; and &ldquo;us&rdquo; refer to Champions Oncology, Inc. and its subsidiaries, except where the context otherwise
requires or as otherwise indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">DISCLOSURE REGARDING
FORWARD-LOOKING STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">This document contains
&ldquo;forward-looking statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933 (&ldquo;Securities Act&rdquo;)
and Section 21E of the Securities Exchange Act of 1934 (&ldquo;Exchanges Act&rdquo;) that inherently involve risk and uncertainties.&nbsp;&nbsp;Forward-looking
statements may be identified by the words &ldquo;project,&rdquo; &ldquo;believe,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;plan,&rdquo;
&ldquo;expect,&rdquo; &ldquo;estimate,&rdquo; &ldquo;intend,&rdquo; &ldquo;should,&rdquo; &ldquo;would,&rdquo; &ldquo;could,&rdquo;
&ldquo;will,&rdquo; &ldquo;may,&rdquo;,&rdquo; &ldquo;likely&rdquo; or similar expressions. Forward-looking statements in this
Annual Report include statements about our business strategies and product and services development activities, including the anticipated
benefits and risks associated with those strategies as well as statements about the sufficiency of our capital resources.&nbsp;&nbsp;One
should not place undue reliance on these forward-looking statements.&nbsp;&nbsp;We cannot guarantee that we will achieve the plans,
intentions or expectations expressed or implied in our forward-looking statement.&nbsp;&nbsp;There are a number of important factors
that could cause actual results, levels of activity, performance or events to differ materially from those expressed or implied
in the forward-looking statements we make.&nbsp;&nbsp;These important factors are described under &ldquo;Risk Factors&rdquo; set
forth below.&nbsp;&nbsp;In addition, any forward-looking statements we make in this document speak only as of the date of this
document, and we do not intend to update any such forward-looking statements to reflect events or circumstances that occur after
that date, except as required by law.&nbsp;&nbsp;As a result of these and other factors, our stock price may fluctuate dramatically.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART I</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 1.<I> Business</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Champions Oncology, Inc.
is engaged in the development of advanced technology solutions to personalize the development and use of oncology drugs.&nbsp;&nbsp;The
Company&rsquo;s TumorGraft Technology Platform is a novel approach to personalizing cancer care, based upon the implantation of
human tumors in immune-deficient mice.&nbsp;&nbsp;The Company uses this technology, in conjunction with related services, to offer
solutions for two customer groups:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Our Personalized Oncology Solutions (&ldquo;POS&rdquo;) business, which provides services to physicians
and patients looking for information to help guide the development of personalized treatment plans.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Our Translational Oncology Solutions (&ldquo;TOS&rdquo;) business, which provides services to pharmaceutical
and biotechnology companies seeking personalized approaches to drug development that will lower costs and increase the speed of
developing new drugs, as well as increase the adoption of existing drugs.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>TumorGraft Technology Platform</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Our technology platform
consists of processes, physical tumors, and information that we use to personalize the development and use of oncology drugs.&nbsp;&nbsp;Our
process technology involves the:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">implantation of human tumor fragments in immune-deficient mice;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">expansion of the original human tumor into a larger colony of mice through the passage of the tumor to
a limited number of generations of mice;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">treatment of the implanted mice with oncology drugs; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">measurement of tumor growth inhibition in treated mice relative to a control group of mice to determine
the response of the tumor to the drug.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Our process is used for
our POS business to test numerous drugs or drug combinations against a single patient&rsquo;s tumor to determine which therapy
results in the most efficacious response from the tumor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Our platform also includes
a bank of&nbsp;&nbsp;tumors that we have acquired, collected, processed, validated, and stored for use in our TOS business.&nbsp;&nbsp;We
implant these tumors in mice to provide pharmaceutical and biotechnology companies the opportunity to test oncology compounds on
multiple tumors to test efficacy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">We are also developing an extensive database
of information about the tumors in our Tumorbank.&nbsp;&nbsp;This will include information about the patient (e.g. age, gender),
the response of the tumor to different oncology drugs or drug combinations, mutational status of key oncogenes, and other genetic
and epigenetic data about each tumor.&nbsp;&nbsp;Our intention is to use this database to provide our pharmaceutical and biotechnology
customers with information that may assist them with the drug development process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Our strategy is to use
TumorGrafting as a platform technology to drive multiple synergistic revenue streams. We continue to build this platform with investments
in research and development, as well as contributions from both the POS and TOS businesses. The platform is then used to deliver
products that serve both the POS and TOS customers in mutually complementary ways. The result is well-differentiated products for
patients, physicians, and drug development companies. In addition, we are looking for additional opportunities to utilize the data
we are gathering to develop proprietary biomarkers and signatures of response that can predict the resistance or sensitivity of
individual tumors to oncology drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Personalized Oncology Solutions (&ldquo;POS&rdquo;)
Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Our POS
business offers physicians and patients information to help guide the development of personalized treatment
plans.&nbsp;&nbsp;Our core offering utilizes our technology platform to empirically test the response of a patient&rsquo;s
tumor to multiple oncology drugs or drug combinations.&nbsp;&nbsp;The process begins by implanting a fresh fragment of the
patient&rsquo;s tumor, typically received within 24 hours of surgery or biopsy, in a small colony of immune-deficient mice to
grow the tumor tissue.&nbsp;&nbsp;This colony is then expanded by implanting the grown tumor tissue into a limited number
of generations of mice until a sufficient number of mice are available for testing.&nbsp;&nbsp;At that point, the colony is
allocated to different groups, and each mouse in a group is dosed with a different drug or drug combination.&nbsp;&nbsp;The
response of the tumor in each mouse is tracked over time and analyzed to determine which drug or drug combination is
providing the highest level of tumor growth inhibition.&nbsp;&nbsp;Our data demonstrates that there is a high correlation
between the response to drugs of the tumor in mice with the response of the tumor in the patient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">In addition to our
core product, we also offer related personalized oncology services to our customers, including personalized tumor
panels.&nbsp;&nbsp;Personalized tumor panels are designed to provide access to world-renowned oncologists with expertise in
particular tumor types.&nbsp;&nbsp;These panels can be done in person or by teleconference and can include from 3 to more
than 15 physicians. The physicians on the panel receive an overview of the patient&rsquo;s history of treatment and current
status, typically from the treating physician, and may include advanced molecular and sensitivity testing, which may include
information based on our TumorGraft testing. Based on their expertise and the cutting edge information available to them from
their academic institutions and colleagues, these physicians can offer useful insight into possible treatments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">We rely on the internet,
word of mouth, and a small sales force to market these products to patients and physicians.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">For the year ended April 30, 2012, our
revenues from POS totaled $2,332,000, a 31% decrease from the previous year. The decrease was due to the strategic decision to
make the core products affordable to a broader patient base, lower prices in an effort to maximize synergies between our POS and
TOS business, increase our tumor model offerings to our TOS sponsors, and increase the number of models in our Tumorbank.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Translational Oncology Solutions (&ldquo;TOS&rdquo;)
Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Our TOS business utilizes
our technology platform to assist pharmaceutical and biotechnology companies with the drug development process.&nbsp;&nbsp;We provide
studies that predict the efficacy of experimental oncology drugs or approved drugs as stand-alone therapies or in combination with
other drugs.&nbsp;&nbsp;These studies include in vivo studies that rely on implanting multiple tumors from our Tumorbank in mice
and testing the therapy of interest on these tumors.&nbsp;&nbsp;Studies may also include bioinformatics analyses that reveal the
differences in the genetic signatures of the tumors that responded to a therapy as compared to the tumors that did not respond.&nbsp;&nbsp;Our
studies can be used to determine which types of cancer, if any, are inhibited by a drug.&nbsp;&nbsp;The studies can also be used
to identify specific sub-populations, often characterized by particular genetic mutations that are differentially sensitive or
resistant to a drug or drug combination.&nbsp;&nbsp;These studies, used in pre-clinical testing or during phase I or II of a clinical
trial, can help guide the clinical development path of new compounds and find new indications or combinations for compounds that
are already approved by the United States Food and Drug Administration (&ldquo;FDA&rdquo;).&nbsp;&nbsp;The results can lead to
lower costs and shorter timeframes for drug development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Our sales and marketing
efforts are dependent on a dedicated sales force that sells directly to pharmaceutical and biotechnology companies. Currently,
we have contracts with 32 different biotechnology and pharmaceutical companies, of which 13 were repeat customers in fiscal 2012,
having entered into more than one contracted study with us.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">For the year ended April
30, 2012, our revenues from TOS services totaled $4,817,000, an increase of 38% from the previous year</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operations and Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Until fiscal 2011, we relied solely on
a single contract research organization (&ldquo;CRO&rdquo;) for substantially all of our in vivo studies and Tumorbank development.&nbsp;&nbsp;During
the fourth quarter of 2011, we started the process of developing in-house capabilities to supplement the activities of the CRO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">During fiscal 2012, we
modified our POS business strategy to focus on growing our core technology products, which includes TumorGraft implants and drug
studies. As part of this strategy, we significantly reduced the price of our core technology products to make the products affordable
to a broader patient base, to increase the number of models available in our Tumorbank, and to increase offerings to our TOS sponsors.
In addition, we have increased spending on sales and marketing efforts to support this strategy. We will continue to offer related
personalized oncology services to our customers; however, we expect future
POS revenues to be driven by our core products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">During the second half of
fiscal 2012, we transitioned the laboratory activities that support the POS and TOS businesses from the third-party CRO to
our facility in Baltimore, Maryland. We believe that bringing these activities in-house will significantly reduce the future
cost of providing our services and allow us to implement and maintain a more competitive pricing strategy. To facilitate this
strategy and support the increase in current and expected volume, we have invested in the infrastructure and increased our
laboratory staff.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Currently, all POS, TOS,
and Tumorbank models are being expanded in-house. Additionally, all POS and new TOS drug studies are now solely performed in our
laboratory. We are evaluating options to increase our lab capacity to meet expected future demand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>In-licensed Compounds</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Historically, our strategy
was to use our technology platform to identify promising compounds that could be in-licensed during the preclinical phase.&nbsp;&nbsp;The
strategy was to invest in the clinical development of these compounds and then seek a partner that would bring them to market in
exchange for some combination of upfront payments, milestone payments and royalties on future sales.&nbsp;&nbsp;Since 2007, we
pursued this strategy with four compounds.&nbsp;&nbsp;All four of these compounds were subjected to TumorGraft testing, and the
results of one of the compounds, Irinophore C, were positive and merited further investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">In February 2010, we
entered into an exclusive option agreement to review Irinophore C, a nanoparticle drug compound, for the treatment of various forms
of cancer, including melanoma, prostate, breast and lung cancer through April 2011, and we exercised our option to license Irinophore
C in March 2011. During the end of fiscal 2011, we modified our strategy and no longer plan to in-license additional compounds
and will instead focus on developing advanced technologies to personalize the development and use of oncology drugs. As such, we
terminated the license agreements for all compounds, with the exception of Irinophore C. We are currently evaluating strategic
options, including finding a partner, to finance the future development of Irinophore C.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Competition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Our TumorGraft Technology
Platform is proprietary and requires significant know-how to both initiate and operate, but is not patented.&nbsp;&nbsp;It is,
therefore, possible for competitors to develop other implantation procedures or to discover the same procedures utilized by the
Company that could compete with the Company in its market.&nbsp;&nbsp;Competition in our industry is intense and based significantly
on scientific, technological, and market forces, which include the availability of patent and other protection for technology and
products, the ability to commercialize technological developments and the ability to obtain government approval for testing, manufacturing,
and marketing.&nbsp;&nbsp;The Company faces significant competition from other healthcare companies in the United States and abroad.&nbsp;&nbsp;The
majority of these competitors are, and will be, substantially larger than the Company, and have substantially greater resources
and operating histories.&nbsp;&nbsp;There can be no assurance that developments by other companies will not render our products
or technologies obsolete or non-competitive or that we will be able to keep pace with the technological or product developments
of our competitors.&nbsp;&nbsp;These companies, as well as academic institutions, governmental agencies, and private research organizations
also compete with us in recruiting and retaining highly qualified scientific, technical and professional personnel and consultants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Patent Applications</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">It is our intention to
protect our proprietary property through the filing of United States and international patent applications, where necessary and
reasonable. In February 2007, we acquired rights to a U.S. and international patent application family filed October 6, 2005 entitled
&ldquo;LIPOSOMES WITH IMPROVED DRUG RETENTION FOR TREATMENT OF CANCER&rdquo;. The Japanese and Australian patents in this group
have issued, and the remaining patent applications are still being pursued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">In certain instances
where we have previously filed (or acquired) U.S. and/or international patent applications and subsequently decided to no longer
pursue the development of the compounds which are the subject of the applications, we have opted to no longer pursue the patent
applications.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><B>Research and Development</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">For the years ended April 30, 2012 and
2011, we spent approximately $2,937,000 and $2,910,000, respectively, to develop our TumorGraft Technology Platform. Champions
continues to expand its TumorGraft bank through the acquisition of tumor tissue and implanted models from procurement sites, as
well as through the POS business. The increase from 2012 to 2011 is primarily related to increased spending on our technology platform,
offset by decreased spending on evaluating in-licensed compounds. Our research and development efforts were focused on increasing
our understanding of our TumorGraft models, their clinical predictability, improving growth and tumor take rates, and other biological
and molecular characteristics of the models.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Government Regulation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The research, development, and marketing
of&nbsp;&nbsp;our products are generally subject to federal, state, local, or foreign legislation or regulation, including the
interpretation of and compliance with existing, proposed, and future regulatory requirements imposed by the FDA and by comparable
authorities in other countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Employees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">As of April 30, 2012,
we had 36 full-time equivalent employees (FTEs), including 12 with doctoral or other advanced degrees.&nbsp;&nbsp;Of our workforce,
18 FTEs are engaged in research and development and laboratory operations, 11 FTEs are engaged in sales and marketing, and 7 FTEs
are engaged in finance and administration.&nbsp;&nbsp;None of our employees are represented by a labor union or covered by collective
bargaining agreements.&nbsp;&nbsp;We have never experienced a work stoppage and believe our relationship with our employees is
good.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Company History</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Our predecessor was incorporated
under the laws of the State of Delaware on June 4, 1985, as &ldquo;International Group, Inc.&rdquo;&nbsp;&nbsp;In September 1985,
we completed a public offering and shortly thereafter, acquired the world-wide rights to the Champions sports-theme restaurant
concept and changed our name to &ldquo;Champions Sports, Inc.&rdquo;&nbsp;&nbsp;In November 1997, we sold our Champions service
mark and concept to Marriott International, Inc. and until 2005, were a consultant to Marriott International, Inc. and operated
one Champions sports bar restaurant.&nbsp;&nbsp;In January 2007, we changed our business direction to focus on biotechnology and
subsequently changed our name to Champions Biotechnology, Inc.&nbsp;&nbsp;In April 2011, we changed our name to Champions Oncology,
Inc. to reflect the Company's new strategic focus on developing advanced technologies to personalize the development and use of
oncology drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Available Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Our internet website address is www.championsoncology.com.&nbsp;&nbsp;Through
our website, we make available, free of charge, access to all reports filed with the United States Securities and Exchange Commission
(&ldquo;SEC&rdquo;), including our Annual Reports on Form 10-K, our Quarterly Reports on Form 10-Q, our Current Reports on Form
8-K, and amendments to those reports, as filed with or furnished to the SEC pursuant to Section 13(a) or 15(d) of the Exchange
Act of 1934, as amended, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the
SEC.&nbsp;&nbsp;Copies of any materials we file with, or furnish to, the SEC can also be obtained free of charge through the SEC&rsquo;s
website at http://www.sec.gov or at the SEC&rsquo;s Public Reference Room at 100 F Street, N.E., Room 1580, Washington, DC 20549.&nbsp;&nbsp;You
may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;<B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 1A. <I>Risk Factors</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">You should carefully
consider the risks described below together with all of the other information included in this report.&nbsp;&nbsp;The risks and
uncertainties described below are not the only ones we face.&nbsp;&nbsp;Additional risks not presently known, or those we currently
consider insignificant, may also impair our business operations in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"><B>We historically incurred
losses from operating activities, expect losses for the foreseeable future, require significant capital and may never achieve profitability.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">For the years ended April
30, 2012 and 2011, the Company had a net loss of $8,661,000 and $3,802,000, respectively.&nbsp;&nbsp;As of April 30, 2012, the
Company has an accumulated deficit of $25,143,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The amount of these losses
may vary significantly from year-to-year and quarter-to-quarter and will depend on, among other factors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the timing and cost of development for our TOS platform, products and technology;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the cost of building out our TumorGraft Technology Platform;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the cost and rate of progress toward growing our POS business;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the cost and rate of progress toward building our sales forces;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the cost of acquiring and operating our own laboratory and animal testing facilities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the cost of securing and defending our intellectual property;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the timing and cost of obtaining necessary regulatory approvals;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the cost of expanding and building out the infrastructure; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the cost incurred in hiring and maintaining qualified personnel.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Currently, the Company
derives revenue from two sources: POS and TOS services, while pursuing development efforts to develop its bioinformatics and TumorGraft
Technology Platform.&nbsp;&nbsp;In addition, we are building our sales and marketing operations to grow our TOS and POS services.&nbsp;&nbsp;Accordingly,
we expect to generate operating losses in the future until such time as we are able to generate more significant revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">To become profitable,
we will need to generate revenues to offset our operating costs, including our research and development and general and administrative
expenses. We may not achieve or, if achieved, sustain our revenue or profit objectives. Our losses may increase in the future,
and, ultimately, we may have to cease operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">In order to grow revenues,
we must invest capital to implement our sales and marketing efforts and to successfully develop our bioinformatics and TumorGraft
Technology Platform. Because we do not have a history of commercial efforts, our sales and marketing efforts&nbsp;may never generate
significant revenues or achieve profitability and it is likely that we will be required to raise additional capital to continue
our operations as currently contemplated. If we must devote a substantial amount of time to raising capital, it will delay our
ability to achieve our business goals within the time frames that we now expect, which could increase the amount of capital we
need. In addition, the amount of time expended by our management on fundraising distracts them from concentrating on our business
affairs. If we require additional capital and are not successful in raising the needed capital, we may have to cease operations.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"><B>We have limited experience
marketing and selling our services&nbsp;&nbsp;and may need to rely on third parties to successfully market and sell our products
and generate revenues.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">We need to continue building
a marketing and sales function or enter into agreements with consultants to market our products. Our ability to gain market acceptance
and generate revenues will be substantially dependent upon our ability to successfully market our services and/or enter into such
agreements on favorable terms and to manage the efforts of those employees or service providers, as the case may be.&nbsp;&nbsp;If
we are not successful in building market share, profitability, and our future prospects will not be realized</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"><B>We have very limited
staffing and will continue to be dependent upon key employees.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Our success, currently, is dependent upon
the efforts of several full-time scientific managers, the loss of the services of one or more of which would have a material adverse
effect on our business and financial condition. We intend to continue to develop our management team and attract and retain qualified
personnel in all functional areas to expand and grow our business. This may be difficult in the healthcare industry where competition
for skilled personnel is intense, even as the United States has seen an overall downturn in its economy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"><B>Because our industry
is very competitive and many of our competitors have substantially greater capital resources and more experience in research and
development, we may not succeed in developing our products and technologies and having them brought to market.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">We are engaged in a rapidly
changing and highly competitive field. Potential competitors in the United States and abroad are numerous and include pharmaceutical
and biotechnology companies, most of which have substantially greater capital resources and more experience in research and development
capabilities. Furthermore, new companies will likely enter our market from the United States and abroad, as scientific developments
surrounding other cancer therapies continue to accelerate in the multibillion dollar oncology marketplace.&nbsp;&nbsp;Our competitors
may succeed in obtaining patent protection, receiving FDA approval, or commercializing similar competing drug compounds before
we do.&nbsp;&nbsp;In addition, academic institutions, hospitals, governmental agencies, and other public and private research organizations
also may conduct similar research, seek patent protection, and may develop and commercially introduce competing products or technologies
on their own or through joint ventures. If one or more of our competitors succeeds in developing similar technologies and products
more rapidly than we do, and commercially introduce such technologies and products to the marketplace, prior to introduction of
our products, or if these competing technologies and products are more effective or successful than any of those that we currently
are developing or will develop, our results of operations will be significantly adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"><B>If we are unable to
protect our intellectual property, we may not be able to compete as effectively.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">It is important in the
healthcare industry to obtain patent and trade secret protection for new technologies, products, and processes. Our success will
depend, in part, upon our ability to obtain, enjoy, and enforce protection for any products we develop or acquire under United
States and foreign patent laws and other intellectual property laws, preserve the confidentiality of our trade secrets, and operate
without infringing the proprietary rights of third parties. Where appropriate, we will seek patent protection for certain aspects
of our technology. However, our owned and licensed patents and patent applications may not ensure the protection of our intellectual
property for a number of reasons, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Our TumorGraft Technology Platform is proprietary and requires significant know-how to both initiate
and operate, but is not patented. It is, therefore, possible for competitors to develop other implantation procedures, or to discover
the same procedures utilized by us, that could compete with us in our market.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">If we are successful in obtaining our patents, competitors may interfere with our patents and patent
process in a variety of ways. Competitors may claim that they invented the claimed invention before us or may claim that we are
infringing on their patents and, therefore, we cannot use our technology as claimed under our patent. Competitors may also have
our patents reexamined by showing the patent examiner that the invention was not original or novel or was obvious.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">We are in the process of developing our proposed products and technologies. The mere receipt of
a patent does not necessarily provide practical protection. If we receive a patent with a narrow scope, then it will be easier
for competitors to design products that do not infringe on our patent. Even if the development of our proposed products is successful
and approval for sale is obtained, there can be no assurance that applicable patent coverage, if any, will not have expired or
will not expire shortly after this approval. Any expiration of the applicable patent could have a material adverse effect on the
sales and profitability of our proposed product.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Obtaining and enforcing patents is expensive and may require significant time by our management.
In litigation, a competitor could claim that our issued patents are not valid for a number of reasons. If the court agrees, we
would lose protection on products covered by those patents.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">We also may support and collaborate in research conducted by government organizations or universities.
We cannot guarantee that we will be able to acquire any exclusive rights to technology or products derived from these collaborations.
Obtaining the required or necessary licenses or rights from such collaborative research can be time consuming and expensive. If
we do not obtain required licenses or rights, we could encounter delays in product development while we attempt to design around
other patents or we may be prohibited from developing, manufacturing or selling products requiring these licenses. There is also
a risk that disputes may arise as to the rights to technology or products developed in collaboration with other parties.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">It also is unclear whether efforts to secure our trade secrets will provide useful protection.
While we will use reasonable efforts to protect our trade secrets, our employees or consultants may unintentionally or willfully
disclose our proprietary information to competitors resulting in a loss of protection. Enforcing a claim that someone else illegally
obtained and is using our trade secrets, like patent litigation, is expensive and time consuming, and the outcome is unpredictable.
In addition, courts outside the United States are sometimes less willing to protect trade secrets. Finally, our competitors may
independently develop equivalent knowledge, methods and know-how.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"><B>Claims by others that
our products infringe their patents or other intellectual property rights could adversely affect our financial condition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The healthcare industry
has been characterized by frequent litigation regarding patent and other intellectual property rights. Patent applications are
maintained in secrecy in the United States and also are maintained in secrecy outside the United States until the application is
published. Accordingly, we can conduct only limited searches to determine whether our technology infringes the patents or patent
applications of others. Any claims of patent infringement asserted by third parties would be time-consuming and could likely:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">result in costly litigation;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">divert the time and attention of our technical personnel and management;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">cause product development delays;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">require us to develop non-infringing technology; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">require us to enter into royalty or licensing agreements.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Although patent and intellectual
property disputes in the biotechnology industry have often been settled through licensing or similar arrangements, costs associated
with these arrangements may be substantial and often require the payment of ongoing royalties, which could hurt our gross margins.
In addition, we cannot be sure that the necessary licenses would be available to us on satisfactory terms, or that we could redesign
our products or processes to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative
proceeding, or the failure to obtain necessary licenses, could prevent us from developing, manufacturing and selling some of our
products, which could harm our business, financial condition and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"><B>If any of our products
that we license or partner with pharmaceutical and/or biotechnology companies fail to obtain regulatory approval or if approval
is delayed or withdrawn, we may be unable to generate revenue from the sale or license of our products.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Our products are subject
to federal, state, local, or foreign legislation or regulation, including the interpretation of and compliance with existing, proposed,
and future regulatory requirements imposed by the FDA in the United States and by comparable authorities in other countries. In
the United States, approval from the FDA has to be obtained for each drug to be commercialized. The FDA approval process is typically
lengthy and expensive, and approval is never certain. Products to be commercialized abroad are subject to similar foreign government
regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Generally, only a very
small percentage of newly discovered pharmaceutical products that enter preclinical development are approved for sale. Because
of the risks and uncertainties in biopharmaceutical development, our proposed drug products could take a significantly longer time
to gain regulatory approval than we expect or may never gain approval. If regulatory approval is delayed or never obtained, our
management&rsquo;s credibility, the value of our Company, our operating results and liquidity might be adversely affected. Furthermore,
even if a product gains regulatory approval, the product and the manufacturer of the product may be subject to continuing regulatory
review. Even after obtaining regulatory approval, such approval may entail limitations on the indicated uses for which the product
may be marketed. Moreover, a marketed product, its manufacturer, its manufacturing facilities, and its suppliers are subject to
continual review and periodic inspections. Discovery of previously unknown problems, or the exacerbation of problems previously
deemed acceptable, with the product, manufacturer, or facility may result in restrictions on such product or manufacturer, potentially
including withdrawal of the product from the market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"><B>Because the healthcare
industry is heavily regulated, we face significant costs and uncertainties associated with our efforts to comply with applicable
regulations. Should we fail to comply, we could experience material adverse effects on our business, financial position and results
of operations, and the market value of our common stock could decline.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The biotechnology industry
is subject to regulation by various federal and state governmental authorities. For example, we must comply with FDA requirements
with respect to the development of our proposed products and our early clinical trials, and if any of our proposed products are
approved, the manufacture, labeling, sale, distribution, marketing, advertising and promotion of our products. Failure to comply
with FDA and other governmental regulations can result in fines, disgorgement, unanticipated compliance expenditures, recall or
seizure of products, total or partial suspension of production and/or distribution, suspension of the FDA&rsquo;s review of New
Drug Applications (&ldquo;NDAs&rdquo;), enforcement actions, injunctions and criminal prosecution. Under certain circumstances,
the FDA also has the authority to revoke previously granted drug approvals. Despite our efforts at compliance, there is no guarantee
that we may not be deemed to be deficient in some manner in the future. If we were deemed to be deficient in any significant way,
our business, financial position and results of operations could be materially affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"><B>If our laboratory
facility is damaged or destroyed, our business would be negatively affected.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">We currently utilize
a single laboratory in Baltimore, Maryland to perform the majority of our tumor studies and develop and bank our TumorGraft&nbsp;&nbsp;Technology
Platform models. If this facility were to be significantly damaged or destroyed, we could suffer a loss of some of our ongoing
and future drug studies, as well as our TumorGraft bank. Plans to house our TumorGraft bank in different locations to avoid a catastrophic
event damaging this asset are being developed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"><B>Investment in our
common stock may be diluted if we issue additional shares in the future.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">We may issue additional shares of common
stock, which will reduce shareholders&rsquo; percentage ownership and may dilute per share value. Our Certificate of Incorporation
authorizes the issuance of 125,000,000 shares of common stock. As of July 6, 2012, we had 50,273,678 shares of common stock issued
and 47,074,942 shares outstanding. Of the outstanding shares of common stock,&nbsp;12,333,000 shares&nbsp;are accounted for as
mezzanine financing, a classification outside of permanent equity, due to certain contingent &ldquo;put&rdquo; features associated
with such shares. The future issuance of all or part of the remaining authorized common stock would result in substantial dilution
in the percentage of the common stock held by existing shareholders. The issuance of common stock for future services, acquisitions,
or other corporate actions may have the effect of diluting the value of the shares held by existing shareholders, and might have
an adverse effect on any market for our common stock.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"><B>There is a limited
trading market for our common stock, which may make it difficult for you to sell your shares.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Our common stock is quoted
on the over-the-counter (&ldquo;OTC&rdquo;) Bulletin Board. Like many stocks quoted on the OTC Bulletin Board, trading in our common
stock is thin and characterized by wide fluctuations in trading prices, due to many factors that may have little to do with our
operations or business prospects. This volatility could depress the market price of our common stock for reasons unrelated to operating
performance. Moreover, trading on the OTC Bulletin Board is often more sporadic and volatile than the trading on security exchanges
like NASDAQ, American Stock Exchange or New York Stock Exchange. Accordingly, you may have difficulty reselling your shares of
our common stock in short time periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"><B>The exercise of outstanding
options and warrants may dilute current shareholders.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">As of July 6, 2012, there
were outstanding warrants and options to purchase 16,342,705 shares of our common stock. The exercise of a substantial number of
these outstanding warrants and options could adversely affect our share price and dilute current shareholders.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"><B>Our stock price is
volatile.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The stock market in general
and the market for biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the
operating performance of particular companies. As a result of this volatility, investors may not be able to sell their common stock
at or above the price they paid for it. The market price for our common stock may be influenced by many factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">results of clinical trials of our drug compound or of those of our competitors;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">regulatory developments in the United States and foreign countries;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">variations in our financial results or those of companies that are perceived to be similar to us;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">changes in the healthcare payment system;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">announcements by us of significant acquisition, strategic partnerships, joint ventures or capital
commitments;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">sales of significant shares of stock by large investors;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">intellectual property, product liability, or other litigation against us;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the loss of a key development partner; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the other key facts described in this &ldquo;Risk Factors&rdquo; section.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"><B>Our common stock may
be deemed a &ldquo;penny stock,&rdquo; which would make it more difficult for you to sell your shares.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Our common stock is subject
to the &ldquo;penny stock&rdquo; rules adopted under Section 15(g) of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange
Act&rdquo;). These rules require, among other things, that brokers who trade penny stocks complete certain documentation, make
suitability inquiries of investors and provide investors with certain information concerning trading in the security, including
a risk disclosure document and quote information under certain circumstances. Many brokers have decided not to trade penny stocks
because of the requirements of the penny stock rules and, as a result, the number of broker-dealers willing to act as market makers
in such securities is limited. If we remain subject to the penny stock rules for any significant period, it could have an adverse
effect on the market, if any, for our common stock. Because our common stock is subject to the penny stock rules, you may find
it more difficult to dispose of the shares of our common stock that you have purchased.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"><B>Certain provisions
of Delaware law and of our charter and bylaws contain provisions that could delay and discourage takeover attempts and any attempts
to replace our current management by shareholders.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Certain provisions of
our certificate of incorporation and bylaws, and applicable provisions of Delaware corporate law, could make it difficult for or
prevent a third party from acquiring control of us or changing our Board of Directors and management. These provisions include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the ability of our Board of Directors to issue preferred stock with voting or other rights or preferences;
and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">requirements that our stockholders comply with advance notice procedures in order to nominate compounds
for election to our Board of Directors or to place stockholders&rsquo; proposals on the agenda for consideration at meetings of
stockholders.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"><B>Insiders own a significant
amount of the outstanding common stock.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Insiders own a significant
amount of our outstanding common stock which could discourage takeover attempts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 1B. <I>Unresolved Staff Comments</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 2.<I> Properties</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">We lease the following
facilities under operating lease agreements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">One University Plaza, Suite 307, Hackensack, New Jersey 07601, which serves as our corporate headquarters
and consists of approximately 3,800 square feet of office space. The lease expires in April 2014. We incurred $71,000 of rental
costs in fiscal 2012 relative to this lease.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">855 North Wolfe Street, Suite 619, Baltimore, Maryland 21205, which consists of approximately 1,650
square feet of laboratories and office space where we conduct operations related to our primary service offerings.&nbsp; The lease
expires in June 2014.&nbsp;We incurred $65,000 of rental costs in fiscal 2012 relative to this lease.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">17 Hatidhar Street<FONT STYLE="font: 10pt Times New Roman, Times, Serif">, Ra&rsquo;anana, Israel, which
consists of approximately 1,500 square feet and serves as office headquarters for Champions Oncology, Israel. The lease expires
in July 2012. We incurred $29,000 of rental costs in fiscal 2012 relative to this lease. The Company plans to extend this lease.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 3.<I> Legal Proceedings</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 4.<I> Mine Safety Disclosures</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 9pt">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 5. <I>Market for Registrant&rsquo;s
Common Equity, Related Stockholder</I></B> <B><I>Matters and Issuer Purchases of Equity Securities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Principal Market or Markets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The following information
sets forth the high and low quotation price for our common stock for each quarter within the last two fiscal years.&nbsp;&nbsp;Our
common stock (symbol CSBR) is traded over-the-counter and quoted on the electronic Bulletin Board maintained by the National Association
of Securities Dealers.&nbsp;&nbsp;The quotations represent prices between dealers and do not reflect the retailer markups, markdowns
or commissions, and may not represent actual transactions.&nbsp;&nbsp;Our securities are presently classified as &ldquo;penny stocks&rdquo;
as defined by existing securities laws.&nbsp;&nbsp;This classification places significant restrictions upon broker-dealers desiring
to make a market in such securities.&nbsp;&nbsp;High and low closing prices for our common stock for the last two fiscal years
were:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">High</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Low</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0">Fiscal Year Ended April 30, 2012:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 54%; text-align: left; text-indent: 0; padding-left: 0.12in">First quarter</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 20%; text-align: right">1.20</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 20%; text-align: right">0.76</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: 0; padding-left: 0.12in">Second quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.05</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.65</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding-left: 0.12in">Third quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.95</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.62</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: 0; padding-left: 0.12in">Fourth quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.62</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">High</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Low</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0">Fiscal Year Ended April 30, 2011:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 54%; text-align: left; text-indent: 0; padding-left: 0.12in">First quarter</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 20%; text-align: right">0.99</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 20%; text-align: right">0.60</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: 0; padding-left: 0.12in">Second quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.95</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.60</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding-left: 0.12in">Third quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.99</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.70</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: 0; padding-left: 0.12in">Fourth quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.25</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.40</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Approximate Number of Holders of Common
Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">As of July 6, 2012,
there were approximately 2,147 record holders of the Company&rsquo;s common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dividends</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Holders of our common
stock and redeemable common stock are entitled to receive such dividends as may be declared by our Board of Directors.&nbsp;&nbsp;No
dividends have been paid with respect to our common stock and redeemable common stock and no dividends are anticipated to be paid
in the foreseeable future.&nbsp;&nbsp;Any future decisions as to the payment of dividends will be at the discretion of our Board
of Directors, subject to applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Securities Authorized for Issuance Under
Equity Compensation Plans</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 9pt">The information regarding
securities authorized for issuance under our equity compensation plans is disclosed in Item 12 &ldquo;Security Ownership of Certain
Beneficial Owners and Management and Related Stockholder Matters.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Recent Sales by the Company of Unregistered
Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Repurchases of Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 6.<I> Selected Financial Data</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 7.<I> Management&rsquo;s Discussion
and Analysis of Financial Condition and</I></B> <B><I>Results of Operations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"><I>You should read the
following discussion and analysis together with our consolidated financial statements and the related notes included elsewhere
in this Annual Report on Form 10-K.&nbsp;&nbsp;This discussion contains forward-looking statements that are based on our current
expectations, estimates, and projections about our business and operations.&nbsp;&nbsp;Our actual results may differ materially
from those currently anticipated and expressed in such forward-looking statements as a result of a number of factors, including
those we discuss under Item 1A &ndash; &ldquo;Risk Factors&rdquo; and elsewhere in this Annual Report.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview and Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Champions Oncology, Inc.
is engaged in the development of advanced technology solutions to personalize the development and use of oncology drugs.&nbsp;&nbsp;The
Company&rsquo;s TumorGraft Technology Platform is a novel approach to personalizing cancer care, based upon the implantation of
human tumors in immune-deficient mice.&nbsp;&nbsp;The Company uses this technology, in conjunction with related services, to offer
solutions for two customer groups:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Our Personalized Oncology Solutions (&ldquo;POS&rdquo;) business, which provides services to physicians
and patients looking for information to help guide the development of personalized treatment plans.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Our Translational Oncology Solutions (&ldquo;TOS&rdquo;) business, which provides services to pharmaceutical
and biotechnology companies seeking personalized approaches to drug development that will lower costs and increase the speed of
developing new drugs, as well as increase the adoption of existing drugs.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">We plan to
continue our efforts to expand our TumorGraft Technology Platform in order to expand our TOS program. In fiscal 2012, we
modified our POS business strategy to focus on growing our core technology products, which includes TumorGraft implants and
drug studies. As part of this strategy, we significantly reduced the price of our core technology products to make the
products affordable to a broader patient base, maximize synergies between our POS and TOS businesses, increase our tumor
model offerings to our TOS sponsors, and increase the number of models in our Tumorbank. We have increased spending on sales
and marketing efforts to support this strategy. We will continue to offer related personalized oncology services to our
customers; however, we expect future POS revenue to be driven by our core products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">During the second half
of fiscal 2012, we transitioned the laboratory activities that support the POS and TOS services from a third-party contract research
organization (&ldquo;CRO&rdquo;) to our facility in Baltimore, Maryland. To facilitate this strategy and support the increase in
current and expected volume, we have invested in the infrastructure and increased our laboratory staff and are evaluating options
to increase our lab capacity to meet the future demand. We believe that bringing these activities in house will significantly reduce
the future cost of providing our services and allow us to maintain a more competitive pricing strategy.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The following table summarizes
our operating results for the periods presented below (dollars in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="18" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the Years Ended April 30,</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">% of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">% of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">%</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Revenue</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Revenue</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Change</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">Operating revenue:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 43%; text-align: left; padding-left: 0.12in">Personalized oncology solutions</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">2,332</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">32.6</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">3,382</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">49.1</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">(31.0</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.12in; padding-bottom: 1pt">Translational oncology solutions</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">4,817</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">67.4</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">3,500</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">50.9</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: right; padding-bottom: 1pt">37.6</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total operating revenue</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">7,149</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">100.0</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">6,882</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">100.0</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: right; padding-bottom: 1pt">3.9</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">Costs and operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.12in">Cost of personalized oncology solutions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,356</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33.0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,665</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24.2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">41.5</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.12in">Cost of translational oncology solutions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,543</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35.6</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,846</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26.8</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37.8</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.12in">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,937</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">41.1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,910</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">42.3</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.9</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.12in">Sales and marketing</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,928</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">41.0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,085</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15.8</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">169.9</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.12in">General and administrative</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">5,450</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">76.2</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">4,611</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">67.0</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: right; padding-bottom: 1pt">18.2</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total costs and operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">16,214</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">226.9</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">12,117</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">176.1</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: right; padding-bottom: 1pt">33.8</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Loss from operations</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(9,065</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(126.9</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)%</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(5,235</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(76.1</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)%</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">73.2</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B><I>Operating Revenues</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Operating revenues for
the years ended April 30, 2012 and 2011 were $7.1 and $6.9 million, respectively, an increase of $0.2 million, or 3%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">POS revenues were $2.3
million and $3.4 million for the years ended April 30, 2012 and 2011, respectively, a decrease of $1.1 million, or 31%. Panel revenue,
a component of POS revenue, decreased $1.2 million from the prior year, which is primarily attributable to a decrease in pricing
per panel. Excluding panel revenue, POS revenue was $1.8 million and $1.7 million for the years ended April 30, 2012 and 2011,
respectively, an increase of $0.1 million. During fiscal 2012, the Company experienced significantly higher volumes of implants
and drug studies compared to fiscal 2011. For the year ended April 30, 2012, the Company performed 97 TumorGraft implants, compared
to 12 in the prior year. For the year ended April 30, 2012, the Company completed 19 drug studies, compared to 5 in the prior year.
The increase in volume was offset by decreased pricing for both the TumorGraft implants and drug studies, as part of our strategic
decision to obtain more tumors to increase our tumor model offerings to our TOS sponsors and increase the number of models in our
Tumorbank.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">TOS revenues were $4.8
million and $3.5 million for the years ended April 30, 2012 and 2011, respectively, an increase of $1.3 million or 38%. The increases
in TOS revenues were due primarily to increased sales efforts and investments in growing our Tumorbank.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Cost of Personalized Oncology Solutions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Cost of POS was $2.4
million and $1.7 million for the years ended April 30, 2012 and 2011, respectively, an increase of $0.7 million, or 42%. Gross
margin for POS was -1% and 51% for the years ended April 30, 2012 and 2011, respectively. Gross margins declined due to the strategic
decision to decrease prices to drive increased volumes. Additionally, during the second half of fiscal 2012, the Company transitioned
its laboratory work in-house from a third-party CRO. While this has resulted in increased costs during the transition, it is expected
to yield future savings. Finally, costs related to POS studies are expensed as incurred, so expenses include ongoing costs related
to 11 POS drug studies in progress at April 30, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Cost of Translational Oncology Solutions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Cost of TOS was $2.5
million and $1.8 million for the years ended April 30, 2012 and 2011, respectively, an increase of $0.7 million, or 38%. The increase
in costs was due to the increased volume of the TOS business. Gross margin for TOS was 47% for the years ended April 30, 2012 and
2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Research and Development</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Research and development
expense was $2.9 million for the years ended April 30, 2012 and 2011. Our research and development efforts are focused on increasing
our understanding of our TumorGraft models, their clinical predictability, improving growth and tumor take rates, and other biological
and molecular characteristics of the models. In fiscal 2012, we increased these efforts, but this was offset by decreased expenses
incurred on testing in-licensed compounds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Sales and Marketing</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Sales and marketing expense
was $2.9 million and $1.1 million for the years ended April 30, 2012 and 2011, respectively, an increase of $1.8 million, or 170%.
The increase for fiscal 2012 is primarily related to employee costs associated with increases in our sales force and marketing
expenses incurred in connection with growing our POS and TOS businesses in the United States and in our overseas operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>General and Administrative</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">General and administrative
expense was $5.5 million and $4.6 million for the years ended April 30, 2012 and 2011, respectively, an increase of $0.9 million,
or 18%. Stock-based compensation expense was $3.0 million and $2.9 million for the years ended April 30, 2012 and 2011, respectively.
Excluding stock-based compensation, general and administrative expense increased $0.8 million, which primarily relates to the expansion
of our infrastructure, the addition of our corporate offices in New Jersey, and other costs associated with the Company&rsquo;s
growth strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Other Income </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Other income was $0.4
million and $1.4 million for the years ended April 30, 2012 and 2011, respectively, a decrease of $1.0 million. In fiscal 2011,
other income primarily consisted of $1.5 million of cash grants awarded to the Company under the Qualifying Therapeutic Discovery
Project program administered under section 48D of the Internal Revenue Code, offset by a charge of less than $0.1 million for the
change in the fair value of warrants. In fiscal 2012, the Company recognized income of $0.4 million related to the change in the
fair value of warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Our liquidity needs have
typically arisen from the funding of our research and development programs and the launch of new products, working capital requirements,
and other strategic initiatives. In the past, we have met these cash requirements through our cash and cash equivalents, working
capital management, and proceeds from certain private placements of our securities. As of April 30, 2012, we had working capital
of $2.1 million and cash and cash equivalents of $4.8 million. We believe that our cash and cash equivalents on hand at April 30,
2012 are adequate to fund operations for at least the next twelve months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">On March 24, 2011, the
Company entered into a Securities Purchase Agreement with several accredited investors for the sale to the investors of an aggregate
12,533,333 shares of the Company&rsquo;s common stock at a purchase price of $0.75 per share, or an aggregate of $9.4 million,
of which, $0.5 million was sold to officers and directors of the Company. As part of this transaction, we issued warrants to purchase
an aggregate 1,266,667 shares of common stock at an exercise price of $0.90 per share. These warrants expire five years after the
closing date, which occurred on April 4, 2011. The Securities Purchase Agreement contains certain anti-dilution protections for
the investors and certain registration rights with respect to the shares of common stock issued to the investors. Furthermore,
investors have the right to require the Company to repurchase the purchased common shares held (the &ldquo;Put Option&rdquo;) for
cash for $0.75 per share upon a change of control or sale of substantially all of the company&rsquo;s assets. The Put Option will
terminate upon the achievement of certain financial milestones by the Company, the sale of 25% of the common shares purchased by
an investor, with respect only to the shares owned by such investor, or in certain other circumstances as outlined in the Securities
Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The warrants issued in
connection with the Securities Purchase Agreement contain certain exercise price reset provisions. Under these provisions, the
exercise price of the warrants may be adjusted downward should the Company have future sales of its common stock for no consideration
or for a consideration per share less than the Per Share Price (as such term is defined in the Securities Purchase Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">If we require additional
cash, there can be no assurance that management will be successful in raising additional capital on terms acceptable to us, if
at all. Our ability to successfully complete a raise of capital will depend on the conditions of the capital markets and our financial
condition and prospects. Even if we are able to successfully raise additional capital, such capital could be in the form of debt
and could be at high interest rates and/or require us to comply with restrictive covenants that limit financial and business activities.
In addition, even if we are able to successfully raise equity capital, this could dilute the interest of existing shareholders
and/or be issued with preferential liquidation, dividend or voting rights to those currently held by our common stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Cash Flows</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The following discussion
relates to the major components of our cash flows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>Cash Flows from Operating Activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Net cash used in operating
activities was $5.2 million and $0.1 million for the years ended April 30, 2012 and 2011, respectively. The increase of cash used
in operating activities was primarily due to net losses incurred and higher working capital requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>Cash Flows from Investing Activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Net cash used in investing
activities was $0.5 million and $0.1 million for the years ended April 30, 2012 and 2011, respectively. Cash used for both fiscal
2012 and 2011 primarily relates to the purchase of property and equipment for both the operations of the Company and the establishment
of our new corporate headquarters in Hackensack, New Jersey.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>Cash Flows from Financing Activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Net cash provided by
financing activities was $0.1 million and $8.1 million for the years ended April 30, 2012 and 2011, respectively. Cash provided
from financing activities for fiscal 2012 primarily relates to the exercise of warrants. During fiscal 2011, we raised $9.4 million
from the sale of redeemable common shares and warrants in a private placement transaction.&nbsp;&nbsp;In conjunction with this
offering, we&nbsp;incurred fees of approximately $0.3 million and we used $1.0 million for the purchase of treasury stock.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Critical Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">We believe that of our
significant accounting policies (refer to the Notes to Consolidated Financial Statements contained&nbsp;in Item 15 of this Annual
Report), the following may involve a higher degree of judgment and complexity:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>General</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Our discussion and analysis
of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared
in accordance with accounting principles generally accepted in the United States (&ldquo;GAAP&rdquo;).&nbsp;&nbsp;The preparation
of the consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets,
liabilities, revenue, expenses, and related disclosure of contingent assets and liabilities.&nbsp;&nbsp;On an ongoing basis, we
evaluate our estimates, including those related to areas that require a significant level of judgment or are otherwise subject
to an inherent degree of uncertainty.&nbsp;&nbsp;These areas include the carrying amounts of long-lived assets and deferred taxes.&nbsp;&nbsp;We
base our estimates on historical experience, our observance of trends in particular areas and information or valuations and various
other assumptions that we believe to be reasonable under the circumstances and which form the basis for making judgments about
the carrying value of assets and liabilities that may not be readily apparent from other sources.&nbsp;&nbsp;Actual amounts could
differ significantly from amounts previously estimated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Revenue Recognition</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">We derive revenue from
our POS and TOS businesses.&nbsp;&nbsp;Personalized oncology solutions (&ldquo;POS&rdquo;) assist physicians by providing information
to help guide the development of personalized treatment plans for their patients using our core offerings, including testing oncology
drugs and drug combinations on personalized TumorGrafts, and through other services.&nbsp;&nbsp;Translational oncology solutions
(&ldquo;TOS&rdquo;) offer a preclinical TumorGraft platform to pharmaceutical and biotechnology companies using proprietary TumorGraft
studies, which have been shown to be predictive of how drugs may perform in clinical settings.&nbsp;&nbsp;We recognize revenue
when the following four basic criteria are met: (i) a contract has been entered into with our customers; (ii) delivery has occurred
or services have been rendered to our customers; (iii) the fee charged is fixed and determinable as noted in the contract; and
(iv) collectability is reasonably assured.&nbsp;&nbsp;For TOS, we utilize a proportional performance revenue recognition model,
under which we recognize revenue as performance occurs, based on the relative outputs of the performance that have occurred up
to that point in time under the respective agreement, typically the delivery of reports to our customers documenting the results
of our testing protocols.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">When a POS or TOS arrangement
involves multiple elements, the items included in the arrangement (deliverables) are evaluated to determine whether they represent
separate units of accounting.&nbsp;&nbsp;We perform this evaluation at the inception of an arrangement and as each item in the
arrangement is delivered.&nbsp;&nbsp;Generally, we account for a deliverable (or a group of deliverables) separately if: (i) the
delivered item(s) has standalone value to the customer, and (ii) we have given the customer a general right of return relative
to the delivered item(s) and the delivery or performance of the undelivered item(s) or service(s) is probable and substantially
in our control. Revenue on multiple element arrangements is recognized using a proportional method for each separately identified
element.&nbsp;&nbsp;All revenue from contracts determined not to have separate units of accounting is recognized based on consideration
of the most substantive delivery factor of all the elements in the contract or if there is no predominant deliverable upon delivery
of the final element of the arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Share-Based Payments</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">We typically recognize
expense for share-based payments based on the fair value of awards on the date of grant.&nbsp;&nbsp;We use the Black-Scholes option
pricing model to estimate fair value.&nbsp;&nbsp;The option pricing model requires us to estimate certain key assumptions such
as expected life, volatility, risk free interest rates, and dividend yield to determine the fair value of share-based awards.&nbsp;&nbsp;These
assumptions are based on historical information and management judgment.&nbsp;&nbsp;We expense share-based payments over the period
that the awards are expected to vest, net of estimated forfeitures.&nbsp;&nbsp;If actual forfeitures differ from management&rsquo;s
estimates, compensation expense is adjusted.&nbsp;&nbsp;We report cash flows resulting from tax deductions in excess of the compensation
cost recognized from those options (excess tax benefits) as financing cash flows when the cash tax benefit is received.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Goodwill</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Goodwill represents the
excess of the cost over the fair market value of the net assets acquired including identifiable assets.&nbsp;&nbsp;Goodwill is
tested annually, or more frequently, if circumstances indicate potential impairment, by comparing its fair value to its carrying
amount.&nbsp;&nbsp;The determination of whether or not goodwill is impaired involves significant judgment.&nbsp;&nbsp;Although
we believe our goodwill is not impaired, changes in strategy or market conditions could significantly impact the judgments and
may require future adjustments to the carrying value of goodwill.&nbsp;&nbsp;We use a two-step process to test for goodwill impairment.&nbsp;&nbsp;The
first step is to screen for potential impairment, while the second step measures the amount of the impairment, if any.&nbsp;&nbsp;The
first step of the goodwill impairment test compares the fair value of each reporting unit with its carrying amount, including goodwill.&nbsp;&nbsp;If
the fair value of the reporting unit exceeds its carrying value, goodwill is not impaired.&nbsp;&nbsp;If the carrying value of
the reporting unit&rsquo;s net assets, including goodwill, exceeds the fair value of the reporting unit, then we determine the
implied fair value of goodwill.&nbsp;&nbsp;If the carrying value of goodwill exceeds its implied fair value, then an impairment
of goodwill has occurred and an impairment loss would be recognized for the difference between the carrying amount and the implied
fair value of goodwill as a component of operating income.&nbsp;&nbsp;The implied fair value of goodwill is calculated by subtracting
the fair value of tangible and intangible assets associated with the reporting unit from the fair value of the unit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">We have two reporting
units and two operating segments.&nbsp;&nbsp;In determining fair value, we primarily utilize our market capitalization, which is
determined based on the fair value of our common stock.&nbsp;&nbsp;However, we may test the results of fair value under this method
using (i) discounted cash flows; (ii) operating results based on a comparative multiple of earnings or revenues; (iii) offers from
interested investors, if any; or (iv) appraisals.&nbsp;&nbsp;Additionally, there may be instances where these alternative methods
provide a more accurate measure or indication of fair value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">In addition, we evaluate
impairment if events or circumstances change between the annual assessments, indicating a possible impairment.&nbsp;&nbsp;Examples
of such events or circumstances include: (i) a significant adverse change in legal factors or in the business climate; (ii) an
adverse action or assessment by a regulator; or (iii) a significant decline in market capitalization as compared to book value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The estimated fair value
of each reporting unit, as calculated for the April 30, 2012 impairment test, exceeded the carrying value of the reporting unit.&nbsp;&nbsp;Judgments
regarding the existence of impairment indicators are based on legal factors, market conditions and operational performance of the
acquired businesses.&nbsp;&nbsp;Future events, including but not limited to continued declines in economic activity, loss of contracts
or a significant number of customers or a rapid increase in costs or capital expenditures, could cause us to conclude that impairment
indicators exist and that goodwill is impaired.&nbsp;&nbsp;Any resulting goodwill impairment could have a material adverse impact
on our financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Accounting for Income Taxes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">We use the asset and
liability method to account for income taxes.&nbsp;&nbsp;Significant management judgment is required in determining the provision
for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against net deferred tax assets.&nbsp;&nbsp;In
preparing the consolidated financial statements, we are required to estimate income taxes in each of the jurisdictions in which
we operate.&nbsp;&nbsp;This process involves estimating the actual current tax liability together with assessing temporary differences
resulting from differing treatment of items, such as deferred revenue, depreciation on property, plant and equipment, goodwill
and losses for tax and accounting purposes.&nbsp;&nbsp;These differences result in deferred tax assets, which include tax loss
carry-forwards, and liabilities, which are included within the consolidated balance sheet.&nbsp;&nbsp;We then assess the likelihood
that deferred tax assets will be recovered from future taxable income, and to the extent that recovery is not likely or there is
insufficient operating history, a valuation allowance is established.&nbsp;&nbsp;To the extent a valuation allowance is established
or increased in a period, we include an expense within the tax provision of the consolidated statements of operations.&nbsp;&nbsp;As
of April 30, 2012 and 2011, we have established a full valuation allowance for all deferred tax assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">As of April 30, 2012
and 2011, we did not recognize any assets or liabilities relative to uncertain tax positions, nor do we anticipate any significant
unrecognized tax benefits will be recorded during the next 12 months.&nbsp;&nbsp;Any interest or penalties related to unrecognized
tax benefits is recognized in income tax expense. Since there are no unrecognized tax benefits as a result of tax positions taken,
there are no accrued penalties or interest. In fiscal 2012, the Company has accounted for a disallowance to the net operating loss
carryforwards of $607,000, offset by a corresponding increase to amortizable intangible assets related to capitalized research
and development expenditures of $542,000, in connection with a tax examination by the Internal Revenue Service of the Company&rsquo;s
2009 and 2010 tax years. For further discussion on this examination, see Note 13 to the Company&rsquo;s audited financial statements
included with this report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 9pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Recent Accounting Pronouncements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During September 2011,
the Financial Accounting Standards Board (&ldquo;FASB&rdquo;) issued Accounting Standards Update (&ldquo;ASU&rdquo;) No. 2011-08,
&ldquo;Testing Goodwill for Impairment&rdquo; (&ldquo;ASU 2011-08&rdquo;). ASU 2011-08 is intended to simplify the testing of goodwill
for impairment by permitting an entity to first assess qualitative factors to determine whether it is more likely than not that
the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform
the two-step goodwill impairment test, which is currently required for all companies that report goodwill. The amendments are effective
for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011, although early adoption
is permitted. The Company does not anticipate that the adoption of this guidance will have a material impact on its financial position
and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During June 2011, the
FASB issued ASU No. 2011-05, &ldquo;Presentation of Comprehensive Income&rdquo; (&ldquo;ASU 2011-05&rdquo;). ASU 2011-05 provides
for the option to present the total of comprehensive income, the components of net income and the components of other comprehensive
income (&ldquo;OCI&rdquo;) either in a single continuous statement of comprehensive income or in two separate but consecutive statements.
Regardless of which format is chosen, the amendments establish a requirement for entities to present on the face of the financial
statements reclassification adjustments for items that are reclassified from OCI to net income in the statement(s) where the components
of net income and the components of OCI are presented. The amendments in ASU 2011-05 are effective, on a retrospective basis, for
public entities for interim and annual periods beginning after December 15, 2011; however, during December 2011 the FASB issued
ASU No. 2011-12, which defers those changes in ASU 2011-05 that relate to the presentation of reclassification adjustments. The
Company has adopted this standard, which only impacts the disclosures required, but has no impact on the financial position or
results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During May 2011, the
FASB issued ASU No. 2011-04, &ldquo;Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP
and IFRS&rdquo; (&ldquo;ASC 2011-04&rdquo;). The amendments in ASC 2011-04 were issued in order to align the fair value measurement
and disclosure requirements in GAAP and International Financial Reporting Standards. Consequently, the amendments change the wording
used to describe many of the requirements in GAAP for measuring fair value and for disclosing information about fair value measurements.
However, many of the amendments in ASC 2011-04 will not result in a change in the application of the requirements in ASC 820, Fair
Value Measurement. The amendments in ASU 2011-04 are effective, on a prospective basis, for public entities for interim and annual
periods beginning after December 15, 2011. The Company has adopted this standard, which had no impact on its financial position
or results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Off-Balance Sheet Financing</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">We have no off-balance
sheet debt or similar obligations.&nbsp;&nbsp;We have no transactions or obligations with related parties that are not disclosed,
consolidated into or reflected in our reported results of operations or financial position.&nbsp;&nbsp;We do not guarantee any
third-party debt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 7A.<I> Quantitative and Qualitative
Disclosures About Market Risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 8.<I> Financial Statements and Supplementary
Data</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt">Consolidated balance
sheets as of April 30, 2012 and 2011, consolidated statements of operations, comprehensive loss, stockholders&rsquo; equity (deficit),
and cash flows for each of the years in the two-year period then ended April 30, 2012 together with the report of our independent
registered public accounting firm, are set forth in the &ldquo;F&rdquo; pages of this Annual Report on Form 10-K in Item 15.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 9.<I> Changes in and Disagreements
With Accountants on Accounting and</I></B> <B><I>Financial Disclosure</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 9A.<I> Controls and Procedures</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Conclusion Regarding the Effectiveness
of Disclosure Controls and Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Our management, with
the participation of our Chief Executive Officer and Chief Financial Officer, have reviewed and evaluated our disclosure controls
and procedures (as defined in the Securities Exchange Act Rule 13a-15(e)) as of the end of the period covered by this Form 10-K.&nbsp;&nbsp;Based
on that evaluation, our management, including our Chief Executive Officer and Chief Financial Officer, has concluded that our disclosure
controls and procedures were effective at the reasonable assurance level as of the end of the period covered by this Form 10-K
in ensuring that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of
1934 is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&rsquo;s
rules and forms and is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer,
as appropriate, to allow timely decisions regarding required disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Management&rsquo;s Annual Report on
Internal Control Over Financial Reporting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The management of Champions
Oncology, Inc. is responsible for establishing and maintaining adequate internal control over financial reporting, as such term
is defined in Exchange Act Rule 13a&ndash;15(f). Under the supervision and with the participation of our management, including
our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control
over financial reporting based on the framework in Internal Control&ndash;Integrated Framework issued by the Committee of Sponsoring
Organizations of the Treadway Commission.&nbsp;&nbsp;Based on our evaluation under the framework in Internal Control&ndash;Integrated
Framework, our management concluded that our internal control over financial reporting was effective as of April 30, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Management&rsquo;s Annual Report on
Changes in Internal Controls</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">There were no changes
in our internal controls over financial reporting during the year ended April 30, 2012, that have materially affected, or are reasonably
likely to materially affect, our internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 9B.<I> Other Information</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART III</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 10.<I> Directors, Executive Officers
and Corporate Governance</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Directors and Executive Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The directors and executive
officers of the Company as of April 30, 2012 are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; margin-left: 9pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 43%; border-bottom: windowtext 1pt solid; text-align: justify; font-style: italic; font-weight: bold; text-indent: 9pt">Name</TD>
    <TD STYLE="width: 1%; text-align: justify; text-indent: 9pt">&nbsp;</TD>
    <TD STYLE="width: 56%; border-bottom: windowtext 1pt solid; text-align: center; font-style: italic; font-weight: bold; text-indent: 9pt">Position(s) Presently Held</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">David Sidransky, M.D.</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Director, Chairman of the Board</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Joel Ackerman</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Chief Executive Officer, Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Ronnie Morris, M.D.</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">President and Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Gary G. Gemignani</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Executive Vice President and Chief Financial Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">James M. Martell</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Abba David Poliakoff</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Ana I. Stancic</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Scott R. Tobin</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Director</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"><B>David Sidransky, M.D</B>.,
age 52, has served as Chairman of the Company since October 2007 and a director of the Company since August 2007.&nbsp;&nbsp;Dr.
Sidransky is the Director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine and is a
Professor of Oncology, Otolaryngology-Head and Neck Surgery, Cellular &amp; Molecular Medicine, Urology, Genetics, and Pathology
at Johns Hopkins University and Hospital.&nbsp;&nbsp;In the field of oncology, Dr. Sidransky is one of the most highly-cited researchers
in clinical and medical journals in the world, with over 400 peer-reviewed publications in the past decade.&nbsp;&nbsp;He has also
contributed to more than 60 cancer reviews and chapters.&nbsp;&nbsp;Dr. Sidransky is a founder of a number of biotechnology companies
and holds numerous biotechnology patents.&nbsp;&nbsp;He has served as Vice Chairman of the Board of Directors of ImClone Systems,
Inc., a global biopharmaceutical company committed to advancing oncology care, and was a director, until its merger with Eli Lilly.
Dr. Sidransky remains Chairman of Tamir Biotechnology and serves on the Boards of Directors of KV Pharmaceutical Company and Rosetta
Genomics.&nbsp;&nbsp;Dr. Sidransky is serving and has served on scientific advisory boards of MedImmune, Roche, Amgen and Veridex,
LLC (a Johnson &amp; Johnson diagnostic company), among others. From 2005 to 2008, Dr. Sidransky served as Director of the American
Association for Cancer Research (AACR) and was the Chairperson of the first and second (September 2006 and 2007) AACR International
Conferences on Molecular Diagnostics in Cancer Therapeutic Development:&nbsp;&nbsp;Maximizing Opportunities for Individualized
Treatment.&nbsp;&nbsp;Dr. Sidransky is the recipient of many awards and honors, including the 1997 Sarstedt International Prize
from the German Society of Clinical Chemistry, the 1998 Alton Ochsner Award Relating Smoking and Health by the American College
of Chest Physicians, and the 2004 Hinda and Richard Rosenthal Award from the AACR.&nbsp;&nbsp;Dr. Sidransky is certified in Internal
Medicine and Medical Oncology by the American Board of Medicine.&nbsp;&nbsp;Dr. Sidransky received his bachelor&rsquo;s degree
from Brandeis University and his medical degree from the Baylor College of Medicine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Dr. Sidransky is well-qualified
to serve as the non-executive Chairman of the Company and a member of the Company&rsquo;s Board of Directors, based on his extensive
experience in clinical and medical oncology, his stature as a leading researcher in the field, and his experience with biotechnology
companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"><B>Joel Ackerman</B>,
age 46, has served as Chief Executive Officer and a director of the Company since October 2010.&nbsp;&nbsp;Mr. Ackerman received
a bachelor&rsquo;s degree from Columbia University, where he graduated summa cum laude in 1988, and a master&rsquo;s degree in
Physics from Harvard University in 1990.&nbsp;&nbsp;From 1990 to 1993, Mr. Ackerman was an associate with Mercer Management Consulting,
a global strategy consulting firm offering in-depth advice to Fortune 1000 companies in a broad range of industries.&nbsp;&nbsp;From
1993 to 2008, Mr. Ackerman was employed by Warburg Pincus, LLC, a global private equity investment firm.&nbsp;&nbsp;There, Mr.
Ackerman served in various capacities including Managing Director, Head of Healthcare Services, and as a member of the firm&rsquo;s
executive management team. During 2010, Mr. Ackerman served as a senior portfolio fellow with Acumen Fund, a non-profit global
venture fund that uses entrepreneurial approaches to address global poverty.&nbsp;&nbsp;Mr. Ackerman is currently a member of the
board of directors of Coventry Health Care, Inc., a publicly traded managed care company, and of Kindred Healthcare, Inc., a publicly
traded company that operates hospitals and nursing homes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Mr. Ackerman is well-qualified
to serve as a member of the Company&rsquo;s Board of Directors, due to his broad and extensive operational and financial experience
in the healthcare and biomedical industries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"><B>Ronnie Morris, M.D.</B>,
age 45, has served as President and a director of the Company since October 2010. Dr. Morris received his medical degree from the
University of Medicine and Dentistry of New Jersey in 1993, completed his residency at the Long Island Jewish Medical Center in
1996, and obtained his certification from the American Board of Internal Medicine in 1996. From 1996 to 2004, Dr. Morris practiced
internal medicine and was a managing partner of Prohealth Medical Group in Boca Raton, Florida where, in addition to his personal
medical practice of more than 2,500 patients, he managed over 30 physicians in a multi-specialty practice, was responsible for
the practice&rsquo;s financial operations, and coordinated and created ancillary revenue services for the practice. From 2004 to
2006, Dr. Morris was Vice President and Medical Director of AllianceCare Inc. in Boynton Beach, Florida, a company that provides
home health care, physical therapy, and doctor &ldquo;house calls&rdquo;. In that capacity, Dr. Morris was responsible for the
physician house call business, developed new markets, managed and directed 150 employees, tripled revenue and brought his division
to profitability. In 2001, in Boca Raton, Florida, Dr. Morris co-founded MDVIP, Inc., a personalized healthcare services company.
Until 2009, when MDVIP was acquired by Procter and Gamble Co., Dr. Morris served on MDVIP&rsquo;s Board of Directors, as Medical
Director, and as a member of its executive management team. In those capacities, Dr. Morris conceptualized, developed and helped
build MDVIP from a start-up company into a national leader in personalized healthcare services, with a network of 400 doctors in
29 states and 125,000 consumers/patients. Since 2009, Dr. Morris has been a private investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Dr. Morris is well-qualified
to serve as a member of the Company&rsquo;s Board of Directors, due to his extensive operational and managerial experience in the
healthcare industry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"><B>Gary G. Gemignani,
</B>age 47, has served as Executive Vice President and Chief Financial Officer of the Company since November 2011. From May 2010
until May 2011, Mr. Gemignani served as Executive Vice President, Chief Operating Officer and Chief Financial Officer of Coronado
Biosciences, a company focused on novel immunotherapy agents for cancer and inflammatory diseases. From June 2005 through March
2010, Mr. Gemignani served as Executive Vice President, Chief Operating Officer and Chief Financial Officer for Gentium S.p.A.,
a biotechnology company focused on developing products to address complications of cancer therapy. Prior to that, Mr. Gemignani
held management positions of increasing responsibility at Wyeth, Novartis and Prudential Financial. Mr. Gemignani received his
bachelor&rsquo;s degree in accounting from St. Peter&rsquo;s College in 1987.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"><B>James M. Martell,</B>
age 65, Director, founded the Company in 1985 and since then, has served in various capacities. He served as the Company&rsquo;s
Chairman, President and CEO until 2007, when the Company changed its business direction to focus on biotechnology. Until March
2008, Mr. Martell served as its President and CEO; and from March 2008 until May 2009, as its Chief Administrative Officer. Mr.
Martell continues to be a consultant to the Company. From 1983 to 1987, Mr. Martell was a partner of Tomar Associates, a consulting
company specializing in European-American joint ventures, venture capital financing, technology transfer, and corporate finance.
From 1981 to 1983, Mr. Martell was a partner of International Group, a company involved in promoting national and international
business development. He held various administrative positions from 1973 to 1981 with the United States Department of Energy. Mr.
Martell received a bachelor&rsquo;s degree in Chemistry in 1968, and a master&rsquo;s degree in Geochemistry in 1973, from George
Washington University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Mr. Martell is well-qualified
to serve as a member of the Company&rsquo;s Board due to his prior extensive business experience and experience as a public company
Chairman, President and Chief Executive Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"><B>Abba David Poliakoff</B>,
age 60, has served as a director of the Company since March 2008. Mr. Poliakoff is a member of the law firm of Gordon Feinblatt&nbsp;LLC
in Baltimore, Maryland, and chair of its Securities Law Group. He is a member of the Maryland State Bar Association&rsquo;s Business
Law Section, former Chair of its Committee on Securities, and a former member of the Business Regulations Article Review Committee
of the Committee to Revise the Maryland Annotated Code.&nbsp; Mr. Poliakoff is the Chairman of the Maryland Israel Development
Center, a joint venture between the State of Maryland Department of Business&nbsp;and Economic Development and the State of Israel
Ministry of Industry and Trade. He is also a co-founder and on the Board of Directors of the Maryland Middle Eastern Chamber of
Commerce. Governor Martin J. O&rsquo;Malley of Maryland&nbsp;has appointed Mr. Poliakoff to the Governor&rsquo;s International
Advisory Council on International Commerce and Trade. He was previously appointed by Maryland Governor Robert C. Ehrlich, Jr. to
the Governor&rsquo;s Transition Committee. &nbsp;In his community work, he is on the Board of Directors of the Baltimore Jewish
Council, and on the Board of Directors of The Associated Jewish Community Federation of Baltimore, and a founder and past president
of the Jewish Arbitration and Mediation Board of Baltimore<I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"><I>&nbsp;</I></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Mr. Poliakoff is well-qualified
to serve as a member of the Company&rsquo;s Board due to his extensive experience with biotechnology, start-up companies, and venture
capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"><B>Ana I. Stancic</B>,
age 54, has served as a Director of the Company since March 2008. Since her promotion in October 2011, until her departure in May
2012, Ms. Stancic served as Chief Executive Officer, Chief Operating Officer and Executive Vice President of Enzon Pharmaceuticals,
Inc. Ms. Stancic joined Enzon in June 2011 as Senior Vice President of Finance and Chief Financial Officer. From 2010 to 2011,
Ms. Stancic served as Senior Vice President and Chief Financial Officer of M2Gen, a wholly-owned, for-profit subsidiary of Moffitt
Cancer Center. Prior to M2Gen, from 2008 to 2009, she served as Chief Financial Officer at Aureon Biosciences, Inc. From 2007 to
2008, she was Executive Vice President and Chief Financial Officer at Omrix Biopharmaceuticals, Inc., which was acquired by Johnson
&amp; Johnson. From 2004 to 2007, Ms. Stancic worked at ImClone Systems, Inc., which was acquired by Eli Lilly, Inc. At ImClone,
she served in various leadership roles, including Senior Vice President of Finance. Prior to joining ImClone, she served as Vice
President and Controller at Savient Pharmaceuticals, Inc. Ms. Stancic began her career at PricewaterhouseCoopers in the Assurance
practice, where she had responsibility for international and national companies in the pharmaceutical and services industries.
Ms. Stancic is a certified public accountant and holds a master&rsquo;s degree in Business Administration from Columbia University
Graduate School of Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Ms. Stancic is well-qualified
to serve as a member of the Company&rsquo;s Board of Directors, and Chair and financial expert of its Audit Committee, due to her
extensive finance, accounting and operational experience in the healthcare industry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Scott R. Tobin,</B> age 41, has served
as a director of the Company since June 2011, pursuant to the terms of the Securities Purchase Agreement dated on March 24, 2011,
between the Company, Battery Partners IX, LLC and Battery Ventures IX, L.P., a venture capital firm, in which the Company agreed
to appoint one nominee nominated by Battery to become a member of the Company&rsquo;s Board of Directors. In 1997, Mr.&nbsp;Tobin
joined Battery Ventures, where he has been a managing member of various funds affiliated with Battery Ventures, since May 2000.
Prior to joining Battery, Mr. Tobin held positions at First Albany Corp. and at Future Vision, a venture-backed software company
that was sold to Softkey International.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Mr. Tobin is well-qualified
to serve on the Company&rsquo;s Board of Directors due to his extensive corporate finance and multi-national operational experience.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The term of office of
each director is until the next annual election of Directors and until a successor is elected and qualified or until the Director&rsquo;s
earlier death, resignation or removal. Officers are appointed by the Board of Directors and serve at the discretion of the Board.
There is no family relationship between or among any of the Company&rsquo;s directors or officers. The Board of Directors met five
times during the year ended April 30, 2012. No incumbent director attended fewer than 80% of the total number of meetings of the
Board of Directors held during the 2012 fiscal year and the total number of meetings held by all committees on which the director
served during such year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Leadership Structure and Risk Oversight</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">While the Board believes
that there are various structures which can provide successful leadership to the Company, we currently have separate individuals
serving in the roles of Chairman of the Board and Chief Executive Officer in recognition of the differences between the two roles.
The Chief Executive Officer is responsible for setting the strategic direction for the Company and the day-to-day leadership of
the Company, while the Chairman of the Board provides guidance to the Chief Executive Officer and presides over meetings of the
full Board. This structure is appropriate at this time to the Company&rsquo;s business because it reflects the industry experience,
vision and energy brought to the Board of Directors by the Chairman, Dr. Sidransky, and the Chief Executive Officer, Mr. Ackerman.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Management is responsible
for the day-to-day management of risks the Company faces, while the Board, as a whole and through its committees, has responsibility
for the oversight of risk management. In its risk oversight role, the Board of Directors has the responsibility to satisfy itself
that the risk management process designed and implemented by management are adequate and functioning as designed. To do this, the
Chairman of the Board meets regularly with management to discuss strategy and the risks facing the Company. Senior management attends
the Board meetings and is available to address any questions or concerns raised by the Board on risk management and any other matters.
The Chairman of the Board and independent members of the Board work together to provide strong, independent oversight of the Company&rsquo;s
management and affairs through its standing committees and, when necessary, special meetings of independent directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Board Committees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The Board of Directors
has appointed an Audit Committee, a Compensation Committee, and a Nominating and Corporate Governance Committee and has adopted
charters for each of these committees. The members of the committees are as follows (an asterisk (*) denotes that the individual
chairs the relevant committee):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 49%; border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Director</TD>
    <TD STYLE="width: 2%; text-align: justify; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; font-weight: bold; width: 15%">Audit&nbsp;Committee</TD>
    <TD STYLE="width: 2%; text-align: justify; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 15%; border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Compensation<BR> Committee</TD>
    <TD STYLE="width: 2%; text-align: justify; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 15%; border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Nominating&nbsp;and<BR> Governance<BR> Committee</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">David Sidransky, M.D.</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp; X*</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Abba David Poliakoff</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp; X*</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Ana Stancic</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp; X*</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The Board of Directors
has determined that Ana Stancic qualifies as the &ldquo;audit committee financial expert&rdquo;, as such term is defined in the
rules promulgated by the SEC, and that she is &ldquo;independent&rdquo; within the meaning of the independence standards applicable
to the Audit Committee. Ms. Stancic&rsquo;s biographical information is set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Code of Ethics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The Company has a Code
of Ethics that applies to all Company employees, including the Chief Financial Officer, as well as members of the Board of Directors.
The Company&rsquo;s Code of Ethics has been filed as Exhibit 14 to the Company&rsquo;s Annual Report on Form 10-KSB for the year
ended April 30, 2008.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Compliance with Section 16(a) Beneficial
Ownership Reporting Compliance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Section 16(a) of the
Exchange Act requires that the Company&rsquo;s directors and executive officers and each person who owns more than 10% of the Company&rsquo;s
Shares, file with the SEC an initial report of beneficial ownership and subsequent reports of changes in beneficial ownership of
the Shares. To the Company&rsquo;s knowledge, based solely upon the review of the copies of such reports furnished to us, all of
these reporting persons complied with the Section 16(a) filing requirements applicable to them with respect to transactions during
the fiscal year ended April 30, 2012, except for one report, filed by a director, Abba David Poliakoff, with respect to three transactions,
which was filed after the deadline, due to clerical error.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 9pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 11.<I> Executive Compensation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Introduction</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">In this section, information
is discussed with respect to &ldquo;named executive officers&rdquo;. As defined by the SEC regulations applicable to the Company,
&ldquo;named executive officers&rdquo; include the following: all individuals who served as the Company&rsquo;s principal executive
officer, or acting in a similar capacity, during the fiscal year ended April 30, 2012; the Company&rsquo;s two most highly compensated
executive officers whose total compensation for the fiscal year ended April 30, 2012 exceeded $100,000 (other than principal executive
officer) and who were serving in such capacities on April 30, 2012; and up to two of the Company&rsquo;s most highly compensated
non-executive officer employees whose total compensation during the fiscal year exceeded $100,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Summary Compensation Table</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The following table sets
forth information regarding the total compensation paid or earned by the named executive officers as compensation for their services
in all capacities during the fiscal years ended April 30, 2012 and 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 9pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt"><B>Name&nbsp;and</B></FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt"><B>Base</B></FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt"><B>Stock</B></FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 8pt"><B>Option&nbsp;</B></FONT></TD><TD><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 8pt"><B>All&nbsp;Other&nbsp;</B></FONT></TD><TD><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Principal&nbsp;Position</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Year</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Salary&nbsp;($)</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Bonus&nbsp;($)</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Awards&nbsp;($)</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Awards&nbsp;($)&nbsp;(1)</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Compensation</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Total&nbsp;($)</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">(a)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">(b)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">(c)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">(d)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">(e)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">(f)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">(g)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">(h)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Joel Ackerman (2)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">2012</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 16%; text-align: left"><FONT STYLE="font-size: 8pt">Chief Executive Officer</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: center"><FONT STYLE="font-size: 8pt">2011</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">3,666,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">3,666,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Ronnie Morris, M.D. (3)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">2012</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">13,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">716</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">13,716</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">President</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">2011</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">23,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">3,666,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2,396</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">3,691,396</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Gary G. Gemignani (4)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">2012</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">120,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">377,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">497,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">EVP and Chier Financial Officer</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">2011</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Elizabeth Bruckheimer, Ph.D.</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">2012</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">163,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">10,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">32,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">205,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">VP, Scientific Operations</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">2011</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">163,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">24,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">30,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">217,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Keren Paz, Ph.D.</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">2012</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">153,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">15,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">96,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">264,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">VP, Scientific Innovation</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">2011</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 3%">(1)</TD><TD STYLE="text-align: justify">The amounts shown on the &ldquo;Option Awards&rdquo; column reflect the grant date value of the
stock option awards computed in accordance with Financial Accounting Standards Board ASC Topic 718. For a discussion of valuation
assumptions, see elsewhere in this Annual Report. While these amounts are deductible for federal income tax purposes, for financial
statement purposes, these amounts are charged to additional paid-in capital.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 3%">(2)</TD><TD STYLE="text-align: justify">Mr. Ackerman became a Director and commenced his employment on October 26, 2010.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 3%">(3)</TD><TD STYLE="text-align: justify">Dr. Morris became a Director and commenced his employment on October 26, 2010.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 3%">(4)</TD><TD STYLE="text-align: justify">Mr. Gemignani commenced his employment on November 1, 2011.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The Board of Directors
has the right to change and increase the compensation of executive officers at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Joel Ackerman, Chief Executive Officer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The Company entered into
an employment agreement dated October&nbsp;25, 2010 with Mr. Ackerman to serve as Chief Executive Officer. Under the terms of the
agreement, Mr.&nbsp;Ackerman was also appointed as a member of the Board. Mr.&nbsp;Ackerman received options to purchase 2,500,000
Shares at an exercise price of $0.875 per share (the &ldquo;Non-Contingent Options&rdquo;), which vest and become exercisable in
36 equal monthly installments beginning on October 26, 2010. Mr.&nbsp;Ackerman also received options to purchase an additional
2,500,000 Shares at an exercise price of $0.875 per share (the &ldquo;Contingent Options&rdquo;), which vest in 36 equal monthly
installments beginning on October 26, 2010, but are only exercisable upon the Company meeting all of certain milestones during
the three year period following October 26, 2010. All options were granted under the Company&rsquo;s 2010 Equity Incentive Plan.
All unvested options vest immediately upon a change of control of the Company or the termination of Mr.&nbsp;Ackerman without cause.
All unexercised Non-Contingent Options will lapse and be canceled 90&nbsp;days following the termination of Mr.&nbsp;Ackerman with
cause or by his resignation from the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Ronnie Morris, M.D., President</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The Company entered into
an employment agreement dated October&nbsp;25, 2010 with Dr. Ronnie Morris to serve as President of the Company. Under the terms
of the agreement, Dr. Morris was also appointed as a member of the Board. Dr. Morris received options to purchase 2,500,000 Shares
at an exercise price of $0.875 per share (the &ldquo;Non-Contingent Options&rdquo;), which vest and become exercisable in 36 equal
monthly installments beginning on October 26, 2010. Dr. Morris also received options to purchase an additional 2,500,000 Shares
at an exercise price of $0.875 per share (the &ldquo;Contingent Options&rdquo;), which vest in 36 equal monthly installments beginning
on October 26, 2010, but are only exercisable upon the Company meeting all of certain milestones during the three year period following
October 26, 2010. All options were granted under the Company&rsquo;s 2010 Equity Incentive Plan. All unvested options vest immediately
upon a change of control of the Company or the termination of Dr. Morris without cause. All unexercised Non-Contingent Options
will lapse and be canceled 90&nbsp;days following the termination of Dr. Morris with cause or by his resignation from the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Gary G. Gemignani, Chief Financial Officer
and Executive Vice President</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The Company entered into
an employment agreement dated November 1, 2011 with Mr. Gemignani to serve as Chief Financial Officer and Executive Vice President.
The term of the agreement commenced on November 1, 2011 and is at-will; however, Mr. Gemignani is entitled to six months of severance
payments upon termination by the Company without cause. Mr. Gemignani&rsquo;s compensation includes a salary of $240,000 per annum,
participation in Company employee benefit plans, and an option to purchase 650,000 Shares at an exercise price of $0.73 per share.
The options vest and become exercisable at the rate of 1/48<SUP>th</SUP> each month over four years. All vested options are exercisable
until the tenth anniversary of the grant date. All unexercised options will lapse and be canceled 90&nbsp;days following the termination
of Mr. Gemignani. Each year, Mr. Gemignani is also eligible to participate in the Company&rsquo;s Executive Incentive Plan with
up to 25% of his annual base salary paid in cash, stock, stock options, or any combination thereof, at the Company&rsquo;s discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Outstanding Equity Awards at 2011 Fiscal
Year End</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The following table sets
forth, for each of the named executive officers, information with respect to unexercised options as of the Company&rsquo;s fiscal
year ended April 30, 2012:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number&nbsp;of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number&nbsp;of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Securities</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Securities</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Underlying</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Underlying</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Unexercised</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Unexercised</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Option</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Option</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Options&nbsp;(#)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Options&nbsp;(#)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Exercise</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Expiration</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">Name</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Exercisable</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Unexercisable</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Price&nbsp;($)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Date&nbsp;(1)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(a)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(b)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(c)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(d)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(e)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 52%; text-align: left">Joel Ackerman</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2,500,000</TD><TD STYLE="width: 1%; text-align: left">(2)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2,500,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">0.88</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 9%; text-align: center">10/25/2020</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Ronnie Morris, M.D.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,500,000</TD><TD STYLE="text-align: left">(2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.88</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">10/25/2020</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Gary Gemignani</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">81,250</TD><TD STYLE="text-align: left">(3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">568,750</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.73</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">11/1/2021</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 3%">(1)</TD><TD STYLE="text-align: justify">All vested options will be exercisable over a ten-year period expiring on the tenth anniversary
of the grant date.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 3%">(2)</TD><TD STYLE="text-align: justify">These options vest ratably over three years from October 25, 2010, the date of grant.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 3%">(3)</TD><TD STYLE="text-align: justify">These options vest at ratably over four years from November 1, 2011, the date of grant.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Director Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Under the Company&rsquo;s
Director Compensation Plan of 2010 (the &ldquo;Director Plan&rdquo;), on January 1 of each year, each independent director, other
than the Chairman, will be granted an automatic award of five-year options to purchase 50,000 Shares pursuant to the Company&rsquo;s
2010 Equity Incentive Plan, at an exercise price equal to the last closing price of the shares prior to the effective date of the
grant. The Chairman will be granted an automatic annual award of five-year options to purchase 100,000 shares pursuant to the Plan
at an exercise price equal to the last closing price of the shares prior to the effective date of the grant. All of the options
vest quarterly at the rate of 25% each calendar quarter over that calendar year, commencing on the first day of each calendar quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">In addition, for service
on one or more Board committees, independent directors will receive on the first day of each calendar year either a grant of five-year
options to purchase 50,000 shares at an exercise price equal to the last closing price of the shares prior to the effective date
of the grant, or, at the election of the director, 50,000 restricted shares. The Chairman will receive for his committee service,
on the first day of each calendar year, either a grant of five-year options to purchase 100,000 shares at an exercise price equal
to the last closing price of the shares prior to the effective date of the grant, or, at the election of the director, 100,000
restricted shares. All of these option awards and share grants vest quarterly at the rate of 25% throughout the calendar year on
the first day of each calendar quarter, commencing on January 1 of each calendar year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The Company will also
pay each independent director $15,000 to offset the tax liability in respect of a restricted shares award, paid 25% each calendar
quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The following table summarizes
the compensation paid to directors, other than directors who are also named executive officers and whose compensation as directors
is reflected in the Summary Compensation Table above, for the fiscal years ended April 30, 2012:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 92.5%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Fees</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Earned&nbsp;or</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Paid&nbsp;in</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Stock</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Option</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">All&nbsp;Other</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">Name</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Cash&nbsp;($)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Awards&nbsp;($)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Awards&nbsp;($)&nbsp;(1)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Compensation&nbsp;($)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Total</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(a)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(b)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(c)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(d)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(e)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(f)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 40%; text-align: left">David Sidransky, M.D.</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">86,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">156,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">242,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Abba David Poliakoff</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">81,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Ana Stancic</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">58,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">James M. Martell</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Scott R. Tobin</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 3%">(1)</TD><TD STYLE="text-align: justify">Calculated using the Black-Scholes valuation method (see Note 6 to the Consolidated Financial Statements
included herein).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 12. <I>Security Ownership of Certain
Beneficial Owners and Management</I></B> <B><I>and Related Stockholder Matters</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Beneficial Ownership</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The following table reflects
the names and addresses of the only persons known to the Company to be the beneficial owners of 5% or more of the Shares outstanding
as of July 6, 2012 (the &ldquo;Applicable Date&rdquo;). For purposes of calculating beneficial ownership, Rule 13d-3 of the Securities
Exchange Act of 1934, as amended (&ldquo;Exchange Act&rdquo;) requires inclusion of Shares that may be acquired within sixty days
of the Applicable Date. Unless otherwise indicated in the footnotes to this table, beneficial ownership of Shares represents sole
voting and investment power with respect to those Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Common&nbsp;Stock</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Beneficially</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Percentage</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">Name&nbsp;and&nbsp;Address&nbsp;of&nbsp;Beneficial&nbsp;Owner</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Owned</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">of&nbsp;Class</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">David Sidransky, M.D.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">1550 Orleans Street</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 76%; text-align: left">Baltimore, MD 21231</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">11,276,666</TD><TD STYLE="width: 1%; text-align: left">(1)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">23.2</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Battery Ventures IX, L.P.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">930 Winter Street</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Waltham, MA 02451</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,386,667</TD><TD STYLE="text-align: left">(2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19.3</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Joel Ackerman</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">31 East 79th Street</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">New York, NY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,388,889</TD><TD STYLE="text-align: left">(3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.0</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Ronnie Morris, M.D.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">6039 Collins Avenue, Apt 1429</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Miami Beach, FL 33140</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,388,889</TD><TD STYLE="text-align: left">(4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.0</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 3%">(1)</TD><TD STYLE="text-align: justify">See footnote 1 under &ldquo;Information Regarding Share Ownership of Management&rdquo;.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 3%">(2)</TD><TD STYLE="text-align: justify">See footnote 7 under &ldquo;Information Regarding Share Ownership of Management&rdquo;.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 3%">(3)</TD><TD STYLE="text-align: justify">See footnote 2 under &ldquo;Information Regarding Share Ownership of Management&rdquo;.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 3%">(4)</TD><TD STYLE="text-align: justify">See footnote 3 under &ldquo;Information Regarding Share Ownership of Management&rdquo;.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Information Regarding Share Ownership
of Management</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The following table sets
forth information with respect to the beneficial ownership of the Shares as of the Applicable Date by (i) each of the named executive
officers, (ii) each current director and (iii) all directors and executive officers of the Company as a group. For purposes of
calculating beneficial ownership, Rule 13d-3 of the Exchange Act requires inclusion of Shares that may be acquired within sixty
days of the Applicable Date. Unless otherwise indicated in the footnotes to this table, beneficial ownership of Shares represents
sole voting and investment power with respect to those Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"></TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Shares</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"></TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Beneficially</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Percentage</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">Name&nbsp;of&nbsp;Beneficial&nbsp;Owner</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Title</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Owned</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">of&nbsp;Class</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; width: 41%">David Sidransky, M.D.</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 28%; text-align: left; padding-left: 10pt">Chairman, Director</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">11,276,666</TD><TD STYLE="width: 1%; text-align: left">(1)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">23.2</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Joel Ackerman</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 10pt">CEO, Director</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,388,889</TD><TD STYLE="text-align: left">(2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.0</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Ronnie Morris, M.D.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 10pt">President, Director</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,388,889</TD><TD STYLE="text-align: left">(3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.0</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Gary Gemignani</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 10pt">CFO, EVP</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">135,417</TD><TD STYLE="text-align: left">(4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.3</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">James M. Martell</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 10pt">Director</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,784,829</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.7</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Abba David Poliakoff</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 10pt">Director</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">813,666</TD><TD STYLE="text-align: left">(5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.7</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Ana I. Stancic</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 10pt">Director</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">325,000</TD><TD STYLE="text-align: left">(6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.7</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Scott R. Tobin</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 10pt">Director</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,386,667</TD><TD STYLE="text-align: left">(7)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19.3</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="3" STYLE="text-align: left">All executive officers and directors as a group (8 persons) </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,500,023</TD><TD STYLE="text-align: left">(8)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">62.9</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: left">Includes 576,666 shares which Dr. Sidransky has the right to acquire through the exercise of stock
options.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: left">Includes 3,055,556 shares which Mr. Ackerman has the right to acquire through the exercise of stock
options.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(3)</TD><TD STYLE="text-align: left">Includes 3,055,556 shares which Dr. Morris has the right to acquire through the exercise of stock
options.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(4)</TD><TD STYLE="text-align: left">Includes 135,417 shares which Mr. Gemignani has the right to acquire through the exercise of stock
options.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(5)</TD><TD STYLE="text-align: left">Includes 437,500 Shares which Mr. Poliakoff has the right to acquire through the exercise of stock
options.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(6)</TD><TD STYLE="text-align: left">Includes 233,333 Shares which Ms. Stancic has the right to acquire through the exercise of stock options.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(7)</TD><TD STYLE="text-align: left">Consists of 8,481,857 Shares held by Battery Ventures IX, L.P. (&quot;BVIX&quot;) and 84,810 Shares
held by Battery</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">Investment Partners IX, LLC (&quot;BIPIX&quot;).
BVIX and BIPIX are under common control, as Battery Partners IX, LLC (&quot;BPIX&quot;) is the sole general partner of BVIX and
the sole manager of BIPIX. Mr. Tobin is a member manager of BPIX. Also includes 811,882 Shares which BVIX has the right to acquire
through the exercise of a warrant, and 8,118 Shares which BIPIX has the right to acquire through the exercise of a warrant. BVIX
and BIPIX are under common control, as BPIX is the sole general partner of BVIX and the sole manager of BIPIX. Mr. Tobin expressly
disclaims beneficial ownership over all shares held by BVIX, BIPIX and BPIX, except to the extent of his indirect pecuniary interest
therein which cannot be calculated at this time.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(8)</TD><TD STYLE="text-align: left">See footnotes 1-7 above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Equity Compensation Plan Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The Company has granted
options to individual employees, directors, and consultants pursuant to individual compensation arrangements under a 2008 Equity
Incentive Plan and a 2010 Equity Incentive Plan. The following table provides information, as of April 30, 2012, with respect to
all these compensation arrangements under which shares are authorized for issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 9pt">&nbsp;</P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Number&nbsp;of&nbsp;Securities&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">remaining&nbsp;available&nbsp;for</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Number&nbsp;of&nbsp;Securities</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Weighted-average</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">future&nbsp;issuance&nbsp;under</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">to&nbsp;be&nbsp;issued&nbsp;upon</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">exercise&nbsp;price&nbsp;of</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">equity&nbsp;compensation</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">exercise&nbsp;of&nbsp;&nbsp;outstanding</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">outstanding&nbsp;options</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">plans&nbsp;(excluding&nbsp;securities</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">options&nbsp;and&nbsp;rights</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">and&nbsp;rights</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">reflected&nbsp;in&nbsp;column&nbsp;(a))</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left; border-bottom: Black 1pt solid">Plan Category</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">(a)</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">(b)</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">(c)</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Equity compensation plans</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: 10pt">approved by shareholders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 64%; text-align: left; text-indent: 10pt">2010 Equity Incentive Plan</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">12,158,333</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">0.87</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">17,841,667</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Equity compensation plans not</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: 10pt">approved by shareholders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: 10pt">Directors Compensation Plan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">850,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.79</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 10pt">2008 Equity Incentive Plan</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,857,705</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.95</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">14,866,038</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.88</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">17,841,667</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 13.<I> Certain Relationships and Related
Transactions, and Director</I></B> <B><I>Independence</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The Board has determined
that each of the current directors, other than our Chief Executive Officer, Joel Ackerman, and our President, Ronnie Morris, M.D.,
is independent as defined in Rule 5605(a)(2) of the NASDAQ Stock Market Rules. Furthermore, other than Dr. Sidransky, who received
$141,000 in consulting fees from the Company during the fiscal year ended April 30, 2012 and owns 24.1% of the issued and outstanding
Shares, each member of the Company&rsquo;s three standing committees of the Board is &ldquo;independent&rdquo; within the meaning
of the independence standards applicable to each such committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">During the fiscal year
ended April 30, 2012, we paid one of our directors, James Martell, $18,000 in consulting fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 9pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 14.<I> Principal Accounting Fees and
Services</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The following is a description
of the fees billed to the Company by Ernst &amp; Young, LLP (&ldquo;E&amp;Y&rdquo;) during the fiscal years ended April 30, 2012
and 2011:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"><I>Audit Fees</I>. Audit
fees include fees paid by the Company to E&amp;Y in connection with the annual audit of the Company&rsquo;s consolidated financial
statements, and review of the Company&rsquo;s interim financial statements. Audit fees also include fees for services performed
by E&amp;Y that are closely related to the audit and in many cases could only be provided by our independent auditors. Such services
include consents related to SEC and other regulatory filings. The aggregate fees billed to the Company by E&amp;Y for audit services
rendered to the Company for the fiscal years ended April 30, 2012 and 2011 totaled $174,000 and $154,000, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"><I>Audit Related Fees</I>.
The Company did not incur any audit related services fees for the fiscal years ended April 30, 2012 and 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"><I>Tax Fees</I>. Tax
fees include corporate tax compliance, counsel and advisory services. The aggregate fees billed to the Company by E&amp;Y for the
tax related services rendered to the Company for the fiscal years ended April 30, 2012 and 2011 totaled $39,000 and $13,000, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt"><I>All Other Fees</I>.
The Company did not incur any other fees for the fiscal years ended April 30, 2012 and 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Pre-Approval Policies and Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The Company&rsquo;s Audit
Committee reviews all fees charged by the Company&rsquo;s independent auditors, and actively monitors the relationship between
audit and non-audit services provided. The Audit Committee must pre-approve all audit and non-audit services provided by the Company&rsquo;s
independent auditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt">&nbsp;</P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>
<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART IV</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 15.<I> Exhibits, Financial Statement
Schedules</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>(a)1. Financial Statements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 92%; border-collapse: collapse; margin-left: 0.35in">
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD NOWRAP STYLE="width: 90%; text-align: left">Report of Independent Registered Public Accounting Firm</TD>
    <TD NOWRAP STYLE="width: 10%; text-align: right">F-2</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD NOWRAP STYLE="text-align: left">Consolidated Balance Sheets</TD>
    <TD NOWRAP STYLE="text-align: right">F-3</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD NOWRAP STYLE="text-align: left">Consolidated Statements of Operations</TD>
    <TD NOWRAP STYLE="text-align: right">F-4</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD NOWRAP STYLE="text-align: left">Consolidated Statements of Comprehensive Loss</TD>
    <TD NOWRAP STYLE="text-align: right">F-4</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD NOWRAP STYLE="text-align: left">Consolidated Statement of Changes in Stockholders' Equity (Deficit)</TD>
    <TD NOWRAP STYLE="text-align: right">F-5</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD NOWRAP STYLE="text-align: left">Consolidated Statements of Cash Flows</TD>
    <TD NOWRAP STYLE="text-align: right">F-6</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(a)2. Financial Statement Schedules</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt">All schedules have been
omitted because they are not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>(a)3. Exhibits required to be filed by
Item 601 of Regulation S-K.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; border-bottom: windowtext 1pt solid; text-align: justify">Exhibit&nbsp;No.</TD>
    <TD STYLE="width: 2%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 88%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 9pt; text-align: justify">3.1</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Amended and Restated Articles of Incorporation (incorporated by reference to Appendix A to the Company&rsquo;s Information Statement on Schedule 14C filed March 7, 2011, File No. 0-17263)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 9pt; text-align: justify">3.2</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Amended and Restated Bylaws, as amended incorporated by reference to Exhibit 3.1 to the Company&rsquo;s Current Report on Form 8-K filed February 22, 2011, File No. 0-17263)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 9pt; text-align: justify">10.1</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Employment Agreement dated October 25, 2010 between the Company and Joel Ackerman (incorporated by reference to Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K filed October 29, 2010, File No. 0-17263)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 9pt; text-align: justify">10.2</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Employment Agreement dated October 25, 2010 between the Company and Ronnie Morris, M.D. (incorporated by reference to Exhibit 10.2 to the Company&rsquo;s Current Report on Form 8-K filed October 29, 2010, File No. 0-17263)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 9pt; text-align: justify">10.3</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Employment Agreement dated November 1, 2011 between the Company and Gary G. Gemignani (incorporated by reference to Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K filed November 1, 2011, File No. 0-17263)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 9pt; text-align: justify">10.4</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Agreement dated March 16, 2011 between the Registrant and Cephalon, Inc. [Portions omitted and filed separately with the Securities and Exchange Commission] (incorporated by reference to Exhibit 10.3 to the Company&rsquo;s Amendment No. 1 to Annual Report on Form 10-K for the fiscal year ended April 30, 2011, filed March 13, 2012, File No. 0-17263)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 9pt; text-align: justify">10.5</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">2010 Equity Incentive Plan (incorporated by reference to Appendix B to the Company&rsquo;s Definitive Information Statement on Schedule 14C filed March 7, 2011, File No. 0-17263)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 9pt; text-align: justify">14</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Code of Ethics (incorporated by reference to Exhibit 14 of the April 30, 2008 Form 10-KSB, File No. 0-17263)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 9pt; text-align: justify">21</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Subsidiaries of the Registrant *</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 9pt; text-align: justify">31.1</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer*</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 9pt; text-align: justify">31.2</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer*</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 9pt; text-align: justify">32.1</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 1350 Certifications*</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 9pt; text-align: left">99.1</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Press Release dated July 18, 2012*</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 9pt; text-align: justify">101</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Interactive data files providing financial information from the Registrant&rsquo;s Annual Report on Form 10-K for the fiscal year ended April 30, 2012 in XBRL (eXtensible Business Reporting Language) pursuant to Rule 405 of Regulation S-T: (i) Consolidated Balance Sheets as of April 30, 2012 and 2011; (ii) Consolidated Statements of Operations for the years ended April 30, 2012 and 2011; (iii) Consolidated Statement of Stockholders&rsquo; Equity (Deficit) for the years ended April 30, 2012 and 2011; (iv) Consolidated Statements of Cash Flows for the years ended April 30, 2012 and 2011; and (v) Notes to Consolidated Financial Statements*</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">* Filed herewith</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt">In accordance with Section
13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 45%; text-align: left">CHAMPIONS ONCOLOGY, INC.</TD>
    <TD STYLE="width: 5%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: windowtext 1pt solid; text-align: center">/s/ JOEL ACKERMAN</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">Joel Ackerman</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center; font-style: italic">Chief Executive Officer</TD>
    <TD STYLE="text-align: left; font-style: italic">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; font-style: italic">&nbsp;</TD>
    <TD STYLE="text-align: center; font-style: italic">(principal executive officer)</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">July 18, 2012</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt">In accordance with the
Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and
on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: windowtext 1pt solid; text-align: center; font-weight: bold">Signature</TD>
    <TD STYLE="width: 2%; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 44%; border-bottom: windowtext 1pt solid; text-align: center; font-weight: bold">Title</TD>
    <TD STYLE="width: 2%; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 20%; border-bottom: windowtext 1pt solid; text-align: center; font-weight: bold">Date</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: windowtext 1pt solid; text-align: center">/s/ JOEL ACKERMAN</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Chief Executive Officer and Director</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">July 18, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">Joel Ackerman</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font-style: italic">&nbsp;(principal executive officer)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: windowtext 1pt solid; text-align: center">/s/ GARY G. GEMIGNANI</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Chief Financial Officer</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">July 18, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">Gary G. Gemignani</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font-style: italic">&nbsp;(principal financial officer)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: windowtext 1pt solid; text-align: center">/s/ DAVID SIDRANSKY</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Director,</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">July 18, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">David Sidransky</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Chairman of the Board of Directors</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: windowtext 1pt solid; text-align: center">/s/ RONNIE MORRIS</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">President and Director</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">July 18, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">Ronnie Morris</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: windowtext 1pt solid; text-align: center">/s/ JAMES M. MARTELL</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Director</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">July 18, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">James M. Martell</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: windowtext 1pt solid; text-align: center">/s/ ABBA D. POLIAKOFF</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Director</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">July 18, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">Abba D. Poliakoff</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: windowtext 1pt solid; text-align: center">/s/ SCOTT R. TOBIN</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Director</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">July 18, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">Scott R. Tobin</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: windowtext 1pt solid; text-align: center">/s/ ANA I. STANCIC</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Director</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">July 18, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">Ana I. Stancic</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD NOWRAP STYLE="width: 90%; text-align: left">Report of Independent Registered Public Accounting Firm</TD>
    <TD NOWRAP STYLE="width: 10%; text-align: right">F-2</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD NOWRAP STYLE="text-align: left">Consolidated Balance Sheets</TD>
    <TD NOWRAP STYLE="text-align: right">F-3</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD NOWRAP STYLE="text-align: left">Consolidated Statements of Operations</TD>
    <TD NOWRAP STYLE="text-align: right">F-4</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD NOWRAP STYLE="text-align: left">Consolidated Statements of Comprehensive Loss</TD>
    <TD NOWRAP STYLE="text-align: right">F-4</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD NOWRAP STYLE="text-align: left">Consolidated Statement of Changes in Stockholders' Equity (Deficit)</TD>
    <TD NOWRAP STYLE="text-align: right">F-5</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD NOWRAP STYLE="text-align: left">Consolidated Statements of Cash Flows</TD>
    <TD NOWRAP STYLE="text-align: right">F-6</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD NOWRAP STYLE="text-align: left">Notes to Consolidated Financial Statements</TD>
    <TD NOWRAP STYLE="text-align: right">F-7</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 31; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board of Directors and Stockholders
of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Champions Oncology, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying consolidated
balance sheets Champions Oncology, Inc. (the &ldquo;Company&rdquo;) as of April 30, 2012 and 2011, and the related consolidated
statements of operations, comprehensive loss, changes in stockholders' equity (deficit), and cash flows for each of the two years
in the period ended April 30, 2012. These financial statements are the responsibility of the Company's management. Our responsibility
is to express an opinion on these financial statements based on our audits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audits in accordance with
the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform
the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not
engaged to perform an audit of the Company's internal control over financial reporting. Our audits included consideration of internal
control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for
the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly,
we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures
in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating
the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In our opinion, the financial statements
referred to above present fairly, in all material respects, the consolidated financial position of Champions Oncology, Inc. at
April 30, 2012 and 2011, and the consolidated results of its operations and its cash flows for each of the two years in the period
ended April 30, 2012, in conformity with U.S. generally accepted accounting principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">/s/ Ernst &amp; Young LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Baltimore, Maryland</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">July 18, 2012</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CHAMPIONS ONCOLOGY, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED BALANCE SHEETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS OF APRIL 30</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Dollars in Thousands) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: center">ASSETS</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Current assets:</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 74%; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">4,754</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">10,457</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Accounts receivable, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">584</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">585</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Grant receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">517</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 16.2pt">Prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">205</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">276</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.35in">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,543</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,835</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Restricted cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Property and equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">560</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">146</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Goodwill</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">669</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">669</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.35in">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,922</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12,650</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center; text-indent: -0.1in; padding-left: 0.1in">LIABILITIES, REDEEMABLE COMMON STOCK</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR>
    <TD STYLE="font-weight: bold; text-align: center; text-indent: -0.1in; padding-left: 0.1in">AND STOCKHOLDERS' EQUITY (DEFICIT)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Current liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,676</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,580</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">625</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">302</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 16.2pt">Deferred revenue</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,185</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,618</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.35in">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,486</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Warrant liability</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">555</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">972</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.35in">Total liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,041</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,472</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Commitments and contingencies</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Redeemable common stock; $0.001 par value; 12,533,333 contingently puttable common shares outstanding as of April 30, 2012 and 2011</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,159</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,159</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Stockholders' equity (deficit):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Preferred stock, $10 par value; 56,075 shares authorized; no shares issued and outstanding as of April 30, 2012 and 2011</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Common stock, $.001 par value; 125,000,000 shares authorized including redeemable common stock; 37,740,345 and 36,956,667 shares issued and 34,529,000 and 33,870,000 shares outstanding as of April 30, 2012 and 2011, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Treasury stock, at cost, 3,236,000 common shares as of April 30, 2012 and 2011</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,252</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,252</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,204</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,784</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Accumulated deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(25,143</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,482</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 16.2pt">Accumulated other comprehensive loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(125</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(68</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.35in">Total stockholders' equity (deficit)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,278</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">19</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.35in">Total liabilities, redeemable common stock and stockholders' equity (deficit)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,922</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12,650</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part
of these Consolidated Financial Statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CHAMPIONS ONCOLOGY, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED STATEMENTS OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Dollars in Thousands Except Per Share
Amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended April 30,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">Operating revenue:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; padding-left: 9pt">Personalized oncology solutions</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2,332</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3,382</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Translational oncology solutions</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,817</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,500</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total operating revenue</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,149</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,882</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">Costs and operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Cost of personalized oncology solutions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,356</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,665</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Cost of translational oncology solutions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,543</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,846</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,937</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,910</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Sales and marketing</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,928</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,085</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">General and administrative</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,450</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,611</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total costs and operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">16,214</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">12,117</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Loss from operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(9,065</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,235</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Other income:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Grant income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,465</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Change in fair value of warrant liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">417</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(36</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other (expense) income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(15</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">15</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total other income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">402</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,444</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Net loss before income tax expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,663</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,791</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">(Benefit from) provision for income tax</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">11</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(8,661</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,802</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt">Net loss per common share outstanding, including redeemable common stock, basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.19</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.11</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt">Weighted average common shares outstanding, including redeemable common stock, basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">46,815,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">33,774,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="9" STYLE="font-weight: bold; text-align: center">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS <BR>(Dollars in Thousands)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(8,661</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(3,802</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Foreign currency translation adjustment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(57</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(64</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Comprehensive loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(8,718</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,866</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part
of these Consolidated Financial Statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;<B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CHAMPIONS ONCOLOGY, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED STATEMENT OF CHANGES IN
STOCKHOLDERS&rsquo; EQUITY (DEFICIT)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Dollars in Thousands)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 7pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Accumulated</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Total</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Additional</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Stock</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Other</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Stockholders'</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Common Stock</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Treasury Stock</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Paid-in</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Accumulated</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Subscription</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Comprehensive</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Equity</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Capital</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Deficit</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Receivable</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Loss</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Deficit)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 19%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Balance, May 1, 2010</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">35,780,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">37</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">1,064,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">(219</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">15,193</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">(12,680</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">(750</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">(4</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">1,577</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,133</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,133</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Exercise of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">104,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Cancellation of stock subscription receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(750</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">750</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Purchase of treasury stock from board member and cancellation of accrued stock liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,172,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,172,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,033</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">188</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(845</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Issuance of restricted stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">158,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Foreign currency translation adjustment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(64</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(64</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,802</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,802</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Balance, April 30, 2011</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,870,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,236,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,252</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,784</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,482</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(68</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,323</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,323</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Exercise of options and warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">534,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">97</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">98</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Issuance of restricted stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">125,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Foreign currency translation adjustment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(57</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(57</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(8,661</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(8,661</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">Balance, April 30, 2012</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">34,529,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">38</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,236,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,252</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">21,204</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(25,143</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(125</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(5,278</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part
of these Consolidated Financial Statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CHAMPIONS ONCOLOGY, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Dollars in Thousands)</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended April 30,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">Operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; padding-left: 9pt">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(8,661</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(3,802</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 27pt">Stock-based compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,323</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,133</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 27pt">Income tax (benefit) expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 27pt">Depreciation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">105</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">42</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 27pt">Loss on disposal of property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 27pt">Change in fair value of warrant liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(417</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(493</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Grant receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">517</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(517</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Prepaid expenses, deposits and other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">71</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">217</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Restricted cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(150</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">96</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">636</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">323</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">62</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Deferred revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(433</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">697</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Other liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(77</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,227</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(54</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Investing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Purchase of property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(519</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(85</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Proceeds form sale of property and equipment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net cash used in investing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(519</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(84</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Private placement of common shares and warrants (net of $305 in offering costs)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,095</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Purchase of treasury stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,033</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Proceeds from exercise of options and warrants</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">97</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">21</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">97</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,083</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Exchange rate effect on cash and cash equivalents</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(54</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(60</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Increase (decrease) in cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,703</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,885</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Cash and cash equivalents, beginning of year</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,457</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,572</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents, end of year</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,754</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">10,457</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part
of these Consolidated Financial Statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CHAMPIONS ONCOLOGY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 1. Organization and Basis of Presentation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Background</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Champions Oncology,
Inc. (the &ldquo;Company&rdquo;), is engaged in the development of advanced technology solutions and services to personalize the
development and use of oncology drugs. The Company&rsquo;s Tumorgraft Technology Platform is a novel approach to personalizing
cancer care based upon the implantation of human tumors in immune-deficient mice. The Company uses this technology to derive revenue
for two customer groups: Personalized Oncology Solutions (&ldquo;POS&rdquo;) and Translational Oncology Solutions (&ldquo;TOS&rdquo;).
POS assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained
from drug studies and related personalized oncology services. The Company&rsquo;s TOS business offers a technology platform to
pharmaceutical and biotechnology companies using proprietary Tumorgraft studies, which have been shown to be predictive of how
drugs may perform in clinical settings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The Company has two operating
subsidiaries: Champions Oncology (Israel), Limited and Champions Biotechnology U.K., Limited. For the years ended April 30, 2012
and 2011, there were no material revenues earned by these subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Basis of Presentation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The accompanying consolidated
financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America
(&ldquo;GAAP&rdquo;). Certain immaterial reclassifications have been made to prior year amounts to conform to the current year
presentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 2. Summary of Significant Accounting
Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Principles of Consolidation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The consolidated financial
statements include the accounts of the Company and its wholly-owned subsidiaries: Biomerk, Inc., Champions Biotechnology U.K.,
Limited and Champions Oncology (Israel), Limited. All material intercompany balances and transactions have been eliminated in consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The financial statements
of the Company&rsquo;s foreign subsidiaries, all of which have a functional currency other than the U.S. dollar, have been translated
into the U.S. dollar for the Company&rsquo;s consolidated financial statements for each period being presented. Translation gains
and losses are recognized as a component of accumulated other comprehensive loss in the accompanying consolidated balance sheets.
The Company is subject to foreign exchange rate fluctuations in connection with the Company&rsquo;s international operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Use of Estimates</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The preparation of consolidated
financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements
and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Cash and Cash Equivalents</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The Company considers
all highly liquid investments purchased with an original maturity of three months or less, to be cash equivalents. At various times,
the Company has amounts on deposit at financial institutions in excess of federally insured limits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Fair Value</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The carrying value of
cash and cash equivalents, accounts receivable, prepaid expenses, deposits and other receivables, accounts payable, and accrued
liabilities approximate their fair value based on the liquidity or the short-term maturities of these instruments. The fair value
hierarchy promulgated by GAAP consists of three levels:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 15pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>Level one</I> &mdash; Quoted market prices in active markets for identical assets or liabilities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 15pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>Level two</I> &mdash; Inputs other than level one inputs that are either directly or indirectly
observable; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 15pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>Level three</I> &mdash; Unobservable inputs developed using estimates and assumptions, which
are developed by the reporting entity and reflect those assumptions that a market participant would use.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Determining which category
an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures
each quarter. The Company has one liability measured at fair value on a recurring basis, which are warrants that were issued in
connection with a private placement of the Company&rsquo;s securities that closed during April 2011 and is discussed more fully
in Note 7. As of April 30, 2012 and 2011, these warrants had an estimated fair value of $555,000 and $972,000, respectively, which
was calculated by the Monte Carlo simulation valuation method using level three inputs. The Company has no assets that are measured
at fair value on a recurring basis and there were no assets or liabilities measured at fair value on a non-recurring basis during
the years ended April 30, 2012 and 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The following table presents
information about our warrants liability, which was our only financial instrument measured at fair value on a recurring basis using
significant unobservable inputs (Level 3) as defined in ASC Topic 820 at April 30 (dollars in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif; margin-left: 9pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 74%; text-align: left">Balance beginning of year</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(972</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Transfers to (from) Level 3</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Total gains (losses) included in earnings</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">417</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(36</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Purchases/issuances/settlements, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(936</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Balance end of year</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(555</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(972</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Accounts Receivable</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Accounts receivable represent
amounts due under agreements with pharmaceutical and biotechnology companies for TOS and amounts due under agreements with patients
for POS. At each reporting period, the Company evaluates open accounts receivable for collectability and records an allowance for
potentially uncollectible accounts. As of April 30, 2012, the allowance for these accounts was $14,000. There was no allowance
recorded for open receivables at April 30, 2011. Accounts receivable is also comprised of certain unbilled accounts receivable
for services completed under TOS that have not been billed as of the balance sheet date. As of April 30, 2012 and 2011, the Company
had unbilled receivables of $104,000 and $305,000, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Restricted Cash</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The Company has restricted
cash of $150,000, which is classified as a noncurrent asset. This restricted cash serves as collateral for corporate credit cards
to provide financial assurance that the Company will fulfill its obligations. The cash is held in custody by the issuing bank,
is restricted as to withdrawal or use, and is currently invested in an interest-bearing Certificate of Deposit (&ldquo;CD&rdquo;).
Though the initial CD matures in the second quarter of fiscal 2013, the cash will be reinvested into another CD to continue use
of the corporate cards. The Company accounts for this CD as a non-current asset supporting operations of the business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Property and Equipment</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Property and equipment
is recorded at cost and primarily consists of laboratory equipment, furniture and fixtures, and computer hardware and software.
Depreciation is calculated on a straight-line basis over the estimated useful lives of the various assets ranging from three to
seven years. Property and equipment consisted of the following (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">April 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 74%; text-align: left">Furniture and fixtures</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">58</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">10</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Computer equipment and software</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">287</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">119</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Laboratory equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">167</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">56</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Leasehold improvements</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Sortware in-progress</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">216</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">24</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Total property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">730</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">211</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less: Accumulated depreciation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(170</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(65</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">560</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">146</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Depreciation expense
was $105,000 and $42,000 for the years ended April 30, 2012 and 2011, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Impairment of Long-Lived Assets</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Impairment losses are
to be recognized when the carrying amount of a long-lived asset is not recoverable or exceeds its fair value.&nbsp;&nbsp;The Company
evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that a carrying value may not
be recoverable.&nbsp;&nbsp;The Company uses estimates of future cash flows over the remaining useful life of a long- lived asset
or asset group to determine the recoverability of the asset.&nbsp;&nbsp;These estimates only include the net cash flows directly
associated with, and that are expected to arise as a direct result of, the use and eventual disposition of the asset or asset group.&nbsp;&nbsp;The
Company has not recognized any impairment losses for the Company&rsquo;s long-lived assets for the years ending April 30, 2012
and 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Goodwill</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Goodwill represents the
excess of the cost over the fair market value of the net assets acquired including identifiable assets.&nbsp;&nbsp;Goodwill is
tested annually, or more frequently if circumstances indicate potential impairment, by comparing its fair value to its carrying
amount.&nbsp;&nbsp;The determination of whether or not goodwill is impaired involves significant judgment.&nbsp;&nbsp;Although
the Company believes its goodwill is not impaired, changes in strategy or market conditions could significantly impact the judgments
and may require future adjustments to the carrying value of goodwill.&nbsp;&nbsp;The Company uses a two-step process to test for
goodwill impairment.&nbsp;&nbsp;The first step is to screen for potential impairment, while the second step measures the amount
of the impairment, if any.&nbsp;&nbsp;The first step of the goodwill impairment test compares the fair value of each reporting
unit with its carrying amount, including goodwill.&nbsp;&nbsp;If the fair value of the reporting unit exceeds its carrying value,
goodwill is not impaired.&nbsp;&nbsp;If the carrying value of the reporting unit&rsquo;s net assets, including goodwill, exceeds
the fair value of the reporting unit, then the Company determines the implied fair value of goodwill.&nbsp;&nbsp;If the carrying
value of goodwill exceeds its implied fair value, then an impairment of goodwill has occurred and an impairment loss would be recognized
for the difference between the carrying amount and the implied fair value of goodwill as a component of operating income.&nbsp;&nbsp;The
implied fair value of goodwill is calculated by subtracting the fair value of tangible and intangible assets associated with the
reporting unit from the fair value of the unit. The Company tests for goodwill impairment at the operating segment level.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The Company has not recognized
any impairment losses for the Company&rsquo;s goodwill for the years ending April 30, 2012 and 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Deferred Revenue</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Deferred revenue represents
payments received in advance for services to be performed.&nbsp;&nbsp;When services are rendered, deferred revenue is then recognized
as earned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Warrant Liability</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Warrant liability represents
the fair value of warrants issued in connection with the Securities Purchase Agreement as liabilities based on the certain exercise
price reset provisions.&nbsp;&nbsp;The&nbsp;&nbsp;liability, which is recorded at fair value on the accompanying consolidated balance
sheets, is calculated by the Monte Carlo simulation valuation method.&nbsp;&nbsp;The change in fair value of these warrants is
recognized as other income or expense in the consolidated statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Revenue Recognition</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The Company derives revenue
from its POS and TOS businesses. Personalized oncology solutions assist physicians by providing information to help guide the development
of personalized treatment plans for their patients using our core offerings, including testing oncology drugs and drug combinations
on personalized TumorGrafts, and through other services. Translational oncology solutions offer a preclinical TumorGraft platform
to pharmaceutical and biotechnology companies using proprietary TumorGraft studies, which have been shown to be predictive of how
drugs may perform in clinical settings.&nbsp;&nbsp;The Company recognizes revenue when the following four basic criteria are met:
(i) a contract has been entered into with its customers; (ii) delivery has occurred or services rendered to its customers; (iii)
the fee is fixed and determinable as noted in the contract; and (iv) collectability is reasonably assured.&nbsp;&nbsp;The Company
utilizes a proportional performance revenue recognition model for its TOS business, under which it recognizes revenue as performance
occurs, based on the relative outputs of the performance that have occurred up to that point in time under the respective agreement,
typically the delivery of reports to its customers documenting the results of testing protocols.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">When a POS or TOS arrangement
involves multiple elements, the items included in the arrangement (deliverables) are evaluated to determine whether they represent
separate units of accounting.&nbsp;&nbsp;The Company performs this evaluation at the inception of an arrangement and as each item
in the arrangement is delivered.&nbsp;&nbsp;Generally, the Company accounts for a deliverable (or a group of deliverables) separately
if: (i) the delivered item(s) has standalone value to the customer, and (ii) if the Company has given the customer a general right
of return relative to the delivered item(s) and the delivery or performance of the undelivered item(s) or service(s) is probable
and substantially in the Company&rsquo;s control.&nbsp;&nbsp;All revenue from contracts determined not to have separate units of
accounting is recognized based on consideration of the most substantive delivery factor of all the elements in the contract or
if there is no predominant deliverable upon delivery of the final element of the arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Cost of Personalized Oncology Solutions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Cost of POS consists
of costs related to POS revenue earned from implantations, drug studies, oncology panels, and gene sequencing services, as well
as indirect internal costs, such as salaries for personnel directly engaged in these services. Direct costs associated with implantation
revenues are primarily related to mice purchases and maintenance and shipping of tumor tissue. Direct study costs are primarily
incurred from mice purchases and maintenance and drug purchases. Direct panel costs are primarily related to physicians&rsquo;
honorariums and any panel participation costs such as travel, lodging and meals. Direct gene sequencing costs are primarily related
to costs billed from the gene sequencing service provider. All costs are expensed as incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Cost of Translational Oncology Solutions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Cost of TOS consists
of costs related to TOS revenue.&nbsp;&nbsp;Direct costs include mice purchases and maintenance costs for studies completed internally
and charges from CROs for studies handled externally. Indirect costs include salaries for personnel directly engaged in providing
TOS services. All costs of performing studies in-house are expensed as incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Research and Development</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Research and development
costs represent both costs incurred internally for research and development activities, including personnel costs and mice purchases
and maintenance, as well as costs incurred externally to facilitate research activities, such as tumor tissue procurement and characterization
expenses.&nbsp;&nbsp;All research and development costs are expensed as incurred.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Sales and Marketing</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Selling and marketing
expenses represent costs incurred to promote the Company&rsquo;s services offered, including salaries, benefits and related costs
of our sales and marketing personnel, and represent costs of advertising and other selling and marketing expenses. All sales and
marketing costs, including advertising costs, are expensed as incurred. Advertising costs were $135,000 and $69,000 for fiscal
2012 and 2011, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Basic and Dilutive Loss Per Common
Share</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Basic loss per share
is calculated by dividing loss available to common shareholders by the weighted average number of common shares (including redeemable
common stock) outstanding for the year.&nbsp;&nbsp;Diluted loss per share is calculated based on the weighted average number of
common shares (including redeemable common stock) outstanding for the year, plus the dilutive effect of common stock purchase warrants,
stock options and restricted stock units using the treasury stock method.&nbsp;&nbsp;Contingently issuable shares are included
in the calculation of basic earnings per share when all contingencies surrounding the issuance of the shares are met and the shares
are issued or issuable.&nbsp;&nbsp;Contingently issuable shares are included in the calculation of dilutive earnings per share
as of the beginning of the reporting period if, at the end of the reporting period, all contingencies surrounding the issuance
of the shares are satisfied or would be satisfied if the end of the reporting period were the end of the contingency period.&nbsp;&nbsp;Due
to the net losses for the years ended April 30, 2012 and 2011, basic and diluted loss per share were the same, as the effect of
potentially dilutive securities would have been anti-dilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The following table reflects the total
potential share-based instruments outstanding at April 30, 2012 and 2011 that could have an effect on the future computation of
dilution per common share:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended April 30,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 74%; text-align: left">Stock options</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">14,866,038</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">14,320,948</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,416,667</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,912,019</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Restricted stock</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">25,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">100,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total common stock equivalents</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">16,307,705</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">16,332,967</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Share-Based Payments</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The Company typically
recognizes expense for share-based payments based on the fair value of awards on the date of grant.&nbsp;&nbsp;The Company uses
the Black-Scholes option pricing model to estimate fair value.&nbsp;&nbsp;The Black-Scholes option valuation model was developed
for use in estimating the fair value of short-traded options that have no vesting restrictions and are fully transferable.&nbsp;&nbsp;The
option pricing model requires the Company to estimate certain key assumptions such as expected life, volatility, risk free interest
rates and dividend yield to determine the fair value of share-based awards.&nbsp;&nbsp;These assumptions are based on historical
information and management judgment.&nbsp;&nbsp;The risk-free interest rate used is based on the United States treasury security
rate with a term consistent with the expected term of the award at the time of the grant.&nbsp;&nbsp;The expected holding period
of options are based on the Company&rsquo;s historical experience.&nbsp;&nbsp;The volatility rates are based upon a weighted average
of the Company&rsquo;s volatility and the weighted average of a four-member peer group of companies in the Company&rsquo;s industry.&nbsp;&nbsp;The
Company does not anticipate paying a dividend, and therefore, no expected dividend yield was used.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The Company expenses
share-based payments over the period that the awards are expected to vest, net of estimated forfeitures.&nbsp;&nbsp;If actual forfeitures
differ from management&rsquo;s estimates, compensation expense is adjusted.&nbsp;&nbsp;The Company will report cash flows resulting
from tax deductions in excess of the compensation cost recognized from those options (excess tax benefits) as financing cash flows,
if they should arise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Income Taxes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Deferred income taxes
have been provided to show the effect of temporary differences between the recognition of expenses for financial and income tax
reporting purposes and between the tax basis of assets and liabilities, and their reported amounts in the consolidated financial
statements.&nbsp;&nbsp;In assessing the realizability of deferred tax assets, the Company assesses the likelihood that deferred
tax assets will be recovered through tax planning strategies or from future taxable income, and to the extent that recovery is
not likely or there is insufficient operating history, a valuation allowance is established.&nbsp;&nbsp;The Company adjusts the
valuation allowance in the period management determines it is more likely than not that net deferred tax assets will or will not
be realized.&nbsp;&nbsp;As of April 30, 2012 and 2011, the Company provided a valuation allowance for all net deferred tax assets,
as recovery is not more likely than not based on an insufficient history of earnings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Tax positions are positions
taken in a previously filed tax return or positions expected to be taken in a future tax return that are reflected in measuring
current or deferred income tax assets and liabilities reported in the consolidated financial statements.&nbsp;&nbsp;Tax positions
include, but are not limited to, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 15pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">An allocation or shift of income between taxing jurisdictions;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 15pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The characterization of income or a decision to exclude reportable taxable income in a tax return;
or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 15pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">A decision to classify a transaction, entity or other position in a tax return as tax exempt.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The Company reflects
tax benefits only if it is more likely than not that we will be able to sustain the tax position, based on its technical merits.&nbsp;&nbsp;If
a tax benefit meets this criterion, it is measured and recognized based on the largest amount of benefit that is cumulatively greater
than 50% likely to be realized.&nbsp;&nbsp;The Company has no unrecognized tax benefits as of April 30, 2012 and 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The Company&rsquo;s practice
is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest
or penalties on the Company&rsquo;s balance sheets at April 30, 2012 and 2011, and has not recognized interest and/or penalties
in the statement of operations for either period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Recent Accounting Pronouncements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">During September 2011,
the Financial Accounting Standards Board (&ldquo;FASB&rdquo;) issued Accounting Standards Update (&ldquo;ASU&rdquo;) No. 2011-08,
&ldquo;Testing Goodwill for Impairment&rdquo; (&ldquo;ASU 2011-08&rdquo;). ASU 2011-08 is intended to simplify the testing of goodwill
for impairment by permitting an entity to first assess qualitative factors to determine whether it is more likely than not that
the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform
the two-step goodwill impairment test, which is currently required for all companies that report goodwill. The amendments are effective
for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011, although early adoption
is permitted. The Company does not anticipate that the adoption of this guidance will have a material impact on its financial position
and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">During June 2011, the
FASB issued ASU No. 2011-05, &ldquo;Presentation of Comprehensive Income&rdquo; (&ldquo;ASU 2011-05&rdquo;). ASU 2011-05 provides
for the option to present the total of comprehensive income, the components of net income and the components of other comprehensive
income (&ldquo;OCI&rdquo;) either in a single continuous statement of comprehensive income or in two separate but consecutive statements.
Regardless of which format is chosen, the amendments establish a requirement for entities to present on the face of the financial
statements reclassification adjustments for items that are reclassified from OCI to net income in the statement(s) where the components
of net income and the components of OCI are presented. The amendments in ASU 2011-05 are effective, on a retrospective basis, for
public entities for interim and annual periods beginning after December 15, 2011; however, during December 2011 the FASB issued
ASU No. 2011-12, which defers those changes in ASU 2011-05 that relate to the presentation of reclassification adjustments. The
Company has adopted this standard, which only impacts the disclosures required, but has no impact on the financial position or
results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">During May 2011, the
FASB issued ASU No. 2011-04, &ldquo;Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP
and IFRS&rdquo; (&ldquo;ASC 2011-04&rdquo;). The amendments in ASC 2011-04 were issued in order to align the fair value measurement
and disclosure requirements in GAAP and International Financial Reporting Standards. Consequently, the amendments change the wording
used to describe many of the requirements in GAAP for measuring fair value and for disclosing information about fair value measurements.
However, many of the amendments in ASC 2011-04 will not result in a change in the application of the requirements in ASC 820, Fair
Value Measurement. The amendments in ASU 2011-04 are effective, on a prospective basis, for public entities for interim and annual
periods beginning after December 15, 2011. The Company has adopted this standard, which had no impact on its financial position
or results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 3. Cephalon Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">On March 16, 2011, the
Company entered into an agreement with Cephalon, Inc., (&ldquo;Cephalon&rdquo;), a wholly-owned subsidiary of Teva Pharmaceutical
Industries Ltd., pursuant to which the Company conducts TumorGraft studies on proprietary chemical compounds provided by Cephalon
to determine the activity or response of a compound in potential clinical indications. In April 2011, Cephalon paid an initiation
fee of $1.4 million to the Company, which is reflected within deferred revenue on the consolidated balance sheet as of April 30,
2011. As models, along with required reports, are delivered, the deferred revenue will be recognized on a proportionate basis in
accordance with the Company&rsquo;s revenue recognition policies. Under this agreement, revenue of $918,000 was recognized during
the year ended April 30, 2012. The Company anticipates that the studies will be completed within 18 months of the execution of
the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>



<P STYLE="margin: 0"></P>
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Cephalon will, under
certain conditions, also pay the Company various amounts upon achieving certain milestones. Potential milestone payments that could
be received under the Agreement total $27 million. These milestones are based on the performance of the compounds in preclinical
testing and are dependent upon testing the compound in clinical settings and obtaining FDA approval. No milestones have been achieved
to date. In addition, under certain conditions, Cephalon will pay the Company royalties on any commercialized products developed
under the Agreement. No royalties have been received or earned to date. Cephalon reserves the right to exercise and pay a one-time
fee of in lieu of the milestone or royalty payments. These fees range from $460,000 to $880,000 per compound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 4. Commitments and Contingencies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Operating Leases</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">As of April 30, 2012,
we lease the following facilities under non-cancelable operating lease agreements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">One University Plaza, Suite 307, Hackensack, New Jersey 07601, which, since November 2011, serves
as our corporate headquarters and consists of approximately 3,800 square feet of office space. The lease expires in April 2014.
We incurred $71,000 of rental costs in fiscal 2012 relative to this lease. No rental costs were incurred in fiscal 2011 relative
to this lease.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">855 North Wolfe Street, Suite 619, Baltimore, Maryland 21205, which consists of approximately 1,650
square feet of laboratories and office space where we conduct operations related to our primary service offerings.&nbsp; The lease
expires in June 2014.&nbsp;We incurred $65,000 and $53,000 of rental costs relative to this lease in fiscal 2012 and 2011, respectively.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">17 Hatidhar Street, Ra&rsquo;anana, Israel, which consists of approximately 1,500 square feet and
serves as office headquarters for Champions Oncology, Israel. The lease expires in July 2012; however the Company plans to extend
this lease. We incurred $29,000 and $11,000 of rental costs relative to this lease in fiscal 2012 and 2011, respectively.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Future minimum lease
payments due each fiscal year are as follows (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 82%; text-align: left">2013</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">162,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">141,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">303,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As we intend to extend the lease in Israel,
of the minimum lease payments in the table above, $28,000 and $7,000 relate to anticipated future lease payments in fiscal 2013
and 2014, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Research and Development Materials
Purchase Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">In February 2010, the
Company entered into a research and development materials purchase agreement with a foreign hospital for the acquisition of TumorGrafts.&nbsp;&nbsp;Under
the agreement, the Company made monthly payments to the foreign hospital of approximately $37,000, commencing March 1, 2010 and
ending April 1, 2011.&nbsp;&nbsp;The accrued liability outstanding at April 30, 2011 was $147,000. The Company entered into a Mutual
Release Agreement on December 15, 2011 and reversed this liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Legal Matters</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The Company is party
to certain legal matters arising in the ordinary course of its business.&nbsp;&nbsp;The Company has evaluated its potential exposure
to these legal matters and noted no such exposures. The Company is not aware of any other matters that would have a material impact
on the Company&rsquo;s financial position or results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Registration Payment Arrangements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The Company has entered
into registration rights agreements in connection with a private placement of its securities, which closed during April 2011 and
is discussed more fully in Note 7.&nbsp;&nbsp;This registration rights agreement contains provisions that may call for the Company
to pay penalties in certain circumstances.&nbsp;&nbsp;This registration payment arrangement primarily relates to the Company&rsquo;s
ability to file a registration statement within a particular time period, have a registration statement declared effective within
a particular time period and to maintain the effectiveness of the registration statement for a particular time period.&nbsp;&nbsp;The
Company does not believe it is probable that penalty payments will be made for the registration rights agreement discussed above
and, accordingly, has not accrued for such potential penalties as of April 30, 2012 and 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 5. Licensing Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">During fiscal 2011, the
Company was a party to several different licensing agreements. During April 2011, the Company terminated all of these licensing
agreements with the exception of the agreement concerning Irinophore C, which is described further below. All rights related to
all other licensing agreements that were terminated during April 2011 were returned to the underlying companies and no amounts
were payable under these other agreements when they were terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">In February 2010, the
Company entered into an exclusive option agreement with a Canadian company for which it paid and expensed $40,000 (Canadian) during
the Company&rsquo;s fiscal 2010 year. The option agreement granted the Company the exclusive right to review Irinophore C, a nanoparticle
drug compound, for the treatment of various forms of cancer, including melanoma, prostate, breast, and lung cancer through April
2011. During the option year, the Company performed various TumorGraft testing on the nanoparticle compound. In March 2011, the
Company exercised its option to license Irinophore C, a liposomal formulation of Irinotecan. Under the terms of the agreement,
the Company&rsquo;s exercise of the option resulted in amounts due to the Canadian company of $85,000 (Canadian) comprised of the
option exercise price and reimbursement to the Canadian company for past patent costs, which was expensed in the Company&rsquo;s
fiscal year ended April 30, 2011. The Company satisfied this obligation during fiscal 2012. On the first anniversary of the agreement
(March 2012), an additional license fee of $45,000 (Canadian) became due, which is recognized as a liability as of April 30, 2012.
Commencing with the second anniversary of the agreement (March 2013), the Company will be obligated to pay a minimum annual royalty
of $10,000 (Canadian). Under the terms of the license agreement, the Company will be required to pay up to $3.0 million in development
milestones, if achieved. Upon commercialization, the Company would also be required to make royalty and sales milestone payments
based upon revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 6. Share-Based Payments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Stock-based compensation
in the amount of $3.3 million and $3.1 million was recognized for the years ended April 30, 2012 and 2011, respectively.&nbsp;&nbsp;Stock-based
compensation costs were recorded as follows (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended April 30,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 74%; text-align: left">General and administrative</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3,009</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2,887</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Sales and marketing</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">240</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">105</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">39</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">101</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">TOS cost of sales</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">POS cost of sales</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">25</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,323</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,133</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>2010 Equity Incentive Plan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">On February 18, 2011,
shareholders owning a majority of the issued and outstanding shares of the Company executed a written consent approving the 2010
Equity Incentive Plan (&ldquo;2010 Equity Plan&rdquo;). The purpose of the 2010 Equity Plan is to grant (i) Non-statutory Stock
Options; (ii) Restricted Stock Awards; and (iii) Stock Appreciation Rights (collectively, stock-based compensation) to its employees,
directors and non-employees. Total stock awards under the 2010 Equity Plan shall not exceed 30,000,000 shares of common stock.
Options and Stock Appreciation Rights expire no later than ten years from the date of grant and the awards vest as determined by
the Board of Directors. Options and Stock Appreciation Rights have a strike price not less than 100% of the fair market value of
the common stock subject to the option or right at the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>2008 Equity Incentive Plan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The Company has previously
granted (i) Non-statutory Stock Options; (ii) Restricted Stock Awards; and (iii) Stock Appreciation Rights (collectively, stock-based
compensation) to its employees, directors and non-employees under a 2008 Equity Incentive Plan (the &ldquo;2008 Equity Plan&rdquo;).&nbsp;&nbsp;Such
awards may be granted by the Company&rsquo;s Board of Directors.&nbsp;&nbsp;Options granted under the 2008 Equity Plan expire no
later than ten years from the date of grant and the awards vest as determined by the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">For share-based payments
to non-employee consultants under both the 2010 and 2008 Equity Incentive Plan, the fair value of the share-based consideration
issued is used to measure the transaction, as management believes this to be a more reliable measure of fair value than the services
received.&nbsp;&nbsp;The fair value of the award is expensed over the period service is provided to the Company; however, it is
ultimately measured at the price of the Company&rsquo;s common stock or the fair value of stock options using the Black-Scholes
valuation model on the date that the commitment for performance by the non-employee consultant has been reached or performance
is complete, which is generally the vesting date of the award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Director Compensation Plan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">On February 22, 2010,
the Compensation Committee of the Board of Directors of the Company adopted the Director Compensation Plan of 2010 (the &ldquo;Director
Plan&rdquo;) to replace the Company&rsquo;s former compensation policy for directors, effective for the 2010 calendar year commencing
January 1, 2010.&nbsp;&nbsp;Under the Director Plan, independent directors of the Company are entitled to an annual award of five-year
stock options to purchase 50,000 shares of the Company&rsquo;s unregistered common stock, and the Chairman of the Board of the
Company is entitled to an annual award of options to purchase 100,000 shares of the Company&rsquo;s unregistered common stock.&nbsp;&nbsp;Independent
directors who serve on one or more Board committees will also receive an annual grant of five-year options to purchase 50,000 shares
of the Company&rsquo;s unregistered common stock or 50,000 shares of restricted unregistered common stock.&nbsp;&nbsp;The Company
will also pay each independent director $15,000 to offset the tax liability in respect of any unregistered restricted stock awards.&nbsp;&nbsp;All
unregistered common stock options and unregistered restricted stock issued under the Director Plan vest quarterly at a rate of
25%. For the initial Director Plan year, an independent director could have chosen to receive a cash fee equal to the value of
the unregistered restricted common stock that would have otherwise been granted.&nbsp;&nbsp;The Chairman of the Board was also
entitled to the same arrangement for his services on Board committees at a rate of twice that of an independent director.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Stock Option Grants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Black-Scholes assumptions
used to calculate the fair value of options granted during the years ended April 30, 2012 and 2011 were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended April 30,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 64%; text-align: left">Expected term in years</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="width: 15%; text-align: center">3.0 - 6.0</TD><TD NOWRAP STYLE="width: 1%; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="width: 15%; text-align: center">2.7 - 6.25</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Risk-free interest rates</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">0.4% - 2.3%</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">0.9% - 2.7%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">90% - 108%</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">105% - 122%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">0%</TD><TD NOWRAP STYLE="text-align: left"></TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">0%</TD><TD STYLE="text-align: left"></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The weighted average
fair value of stock options granted during the years ending April 30, 2012 and 2011, was $0.58 and $0.73, respectively. The Company&rsquo;s
stock options activity and related information as of and for the years ended April 30, 2012 and 2011 is as follows (dollars in
thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Average</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Directors</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Average</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Remaining</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Aggregate</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Non-</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">and</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Exercise</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Contractual</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Intrinsic</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Employees</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Employees</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Life (Years)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Value</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; width: 22%; vertical-align: top">Outstanding, May 1, 2011</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,610,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">12,710,948</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">14,320,948</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">0.88</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">8.4</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,780</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">115,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,380,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,495,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.77</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top">Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(50,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(50,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.17</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top">Forfeited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(348,581</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(348,581</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.94</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top">Expired</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(265,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(286,329</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(551,329</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">0.60</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top">Outstanding, April 30, 2012</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,410,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">13,456,038</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">14,866,038</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">0.88</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">7.6</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">0</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top">Vested and expected to vest as of April 30, 2012</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,410,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">13,456,038</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">14,866,038</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">0.88</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">7.6</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">0</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top">Exercisable as of April 30, 2012</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,241,667</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,502,163</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,743,830</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">0.89</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">6.8</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">0</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Average</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Directors</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Average</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Remaining</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Aggregate</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Non-</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">and</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Exercise</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Contractual</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Intrinsic</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Employees</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Employees</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Life (Years)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Value</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; width: 22%; vertical-align: top">Outstanding, May 1, 2010</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,890,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,427,948</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">3,317,948</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">0.77</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">4.4</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">250</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,781,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,851,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.89</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top">Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top">Forfeited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top">Expired</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(500,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(348,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(848,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.58</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top">Change in employee status</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">150,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(150,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">1.18</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top">Outstanding, April 30, 2011</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,610,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12,710,948</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">14,320,948</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">0.88</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">8.4</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">1,780</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top">Vested and expected to vest as of April 30, 2011</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,610,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12,710,948</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">14,320,948</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">0.88</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">8.4</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">1,780</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top">Exercisable as of April 30, 2011</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,533,333</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,461,644</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,994,977</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">0.85</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">5.7</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">597</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Included in the balances
outstanding as of May 1, 2011 in the table above are 10,000,000 options granted to the Company&rsquo;s Chief Executive Officer
and its&nbsp;President at the time of commencement of their employment in fiscal 2011, of which 5,000,000 contain only service-based
vesting provisions and 5,000,000 contain both service and performance-based vesting provisions.&nbsp;&nbsp;The service-based provisions
of these options provide for vesting to occur monthly over a period of three years.&nbsp;&nbsp;The performance-based conditions,
which must be met prior to vesting to occur include: (i) closing of one or more financings of the Company in the aggregate amount
of at least $5,000,000; (ii) bringing in new Company management; (iii) launching of personalized medicine (oncology) business;
and (iv) commencing implementation of the Company&rsquo;s business plan.&nbsp;&nbsp;The determination as to whether these performance-based
conditions have been met was to be made by the Company&rsquo;s Board of Directors.&nbsp;&nbsp;The service-based options, like all
of the Company&rsquo;s service-based options, are expensed on a straight-line basis.&nbsp;&nbsp;Since the straight-line method
is not available for performance or market-based share-based payments, the 5,000,000 performance-based options are being expensed
on an accelerated basis.&nbsp;&nbsp;The Company&rsquo;s Board of Directors determined that in April 2011 each of the performance
conditions under the awards were met.&nbsp;&nbsp;As a result, the awards will be expensed based on each monthly vesting tranche.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Restricted Stock Grants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">A summary of the activity
related to restricted stock grants for the years ended April 30, 2012 and 2011 is as follows (dollars in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Average</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Average</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Grant Date</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Grant Date</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Total</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Fair Value</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Total</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Fair Value</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Per Share</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Per Share</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 48%; text-align: left">Nonvested, beginning of period</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">100,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">0.90</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">33,526</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">0.80</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">205,555</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.90</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Vested</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(125,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.87</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(133,397</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.87</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Forfeited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,684</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.77</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Expired</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Nonvested, end of period</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">25,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">0.75</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">100,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">0.90</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The total fair value
of shares vested during the years ended April 30, 2012 and 2011 was $84,000 and $133,000, respectively. As of April 30, 2012, there
was $19,000 of unrecognized stock compensation expense related to nonvested restricted stock awards. This cost is expected to be
recognized over a weighted average period of 0.3 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Stock Purchase Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">As of April 30, 2012,
the Company has warrants outstanding for the purchase of 1,416,667 shares of its common stock, all of which were exercisable.&nbsp;&nbsp;Of
these warrants, 1,266,667 were issued in connection with the April 2011 financing arrangement and are accounted for as liabilities
as further discussed in Note 7.&nbsp;&nbsp;Activity related to these warrants, which expire at various dates through April 2016,
is summarized as follows (dollars in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Average</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Average</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Remaining</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Aggregate</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">of</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Exercise</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Contractual</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Intrinsic</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Life (Years)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Value</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 48%; text-align: left">Outstanding, May 1, 2011</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,912,019</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">0.73</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">3.7</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">524</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(495,352</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">234</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Forfeited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Expired</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Outstanding, April 30, 2012</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,416,667</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">0.91</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">3.8</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">0</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Average</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Average</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Remaining</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Aggregate</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">of</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Exercise</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Contractual</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Intrinsic</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Life (Years)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Value</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 48%; text-align: left">Outstanding, May 1, 2010</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">748,983</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">0.36</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2.1</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">367</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,266,667</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.90</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(103,631</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(83</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Forfeited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Expired</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Outstanding, April 30, 2011</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,912,019</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">0.73</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">3.7</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">524</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 7. Redeemable Common Stock and
Stock Purchase Warrant</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">On March 24, 2011, the
Company entered into a Securities Purchase Agreement with several accredited investors for the sale of an aggregate 12,533,333
shares of the Company&rsquo;s Common Stock at a purchase price of $0.75 per share, or aggregate proceeds of $9.4 million, $500,000
of which was sold to officers and directors of the Company. As part of this transaction, the Company also issued warrants to purchase
an aggregate 1,266,667 shares of Common Stock at an exercise price of $0.90 per share. These warrants expire five years after the
closing date, which occurred on April 4, 2011. The Securities Purchase Agreement contains certain anti-dilution protections for
the investors and certain registration rights with respect to the shares of Common Stock issued to the investors. Furthermore,
investors will have the right to require the Company to redeem the purchased common shares held by such investors (the &ldquo;Put
Option&rdquo;) for cash for $0.75 per share upon a change of control or sale of substantially all of the company&rsquo;s assets.
The Put Option will terminate upon the achievement of certain financial milestones by the Company, the sale of 25% of the common
shares purchased by an investor, with respect only to the shares owned by such investor, or in certain other circumstances as outlined
in the Securities Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Due to the Put Option
described above, the Company has accounted for Common Stock issued under the Securities Purchase Agreement as temporary equity,
which is reflected under the caption &ldquo;redeemable common stock&rdquo; on the accompanying consolidated balance sheets. The
total amount allocated to these common shares was $8.2 million. This allocation is equal to the total proceeds of $9.4 million,
less the amount allocated to the warrants of $936,000 and is also net of direct and incremental costs associated with the Securities
Purchase Agreement of $305,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The warrants issued in
connection with the Securities Purchase Agreement contain certain exercise price reset provisions. Under these provisions, the
exercise price of the warrants may be adjusted downward should the Company have future sales of its Common Stock for no consideration
or for a consideration per share less than the Per Share Price (as such term is defined in the Securities Purchase Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The Company has granted
demand registration rights in connection with the investment in common shares and the common shares underlying the warrants. These
rights include the requirement of the Company to file certain registration statements within a specified time period and to have
these registration statements declared effective within a specified time period. If the Company is not able to comply with these
registration requirements, the Company will be required to pay cash penalties equal to 1.0% of the aggregate Purchase Price paid
by the investors for each 30-day period in which a Registration Default, as defined in the Securities Purchase Agreement, exists.
The Company may become subject to these penalty provisions if it fails to have a registration statement for the common shares declared
effective, or to maintain the effectiveness of such registration statement. The total amount of potential penalties under this
registration payment arrangement is $41,000 for each 30-day period in which a registration default exists; however, as of the date
of this filing, the Company does not believe these penalties to be probable and accordingly, has not established an accrual for
such registration payment arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The Company has accounted
for the warrants issued in connection with the Securities Purchase Agreement as a liability based on the exercise price reset provisions
described above. This liability, which is recorded at fair value on the accompanying consolidated balance sheets, totaled $936,000
at the time of the close of the Securities Purchase Agreement. As of April 30, 2011, the fair value of these warrants increased
$36,000 to $972,000. During the year ended April 30, 2012, the fair value of these warrants decreased by $417,000 to $555,000.
The change in fair value of these warrants has been, and will be, recognized as other income (expense) on the Company&rsquo;s consolidated
statements of operations. The fair value of these warrants was calculated by the Monte Carlo simulation valuation method. Assumptions
used to calculate the fair value of these warrants were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended April 30,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 74%; text-align: left">Expected term in years</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">3.9</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">5.0</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Risk-free interest rates</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.6</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.0</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">102</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">102</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The Company will continue
to adjust the warrant liability for changes in fair value until the earlier of the exercise of the warrants, at which time the
liability will be reclassified to stockholders' equity, or expiration of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 8. Stockholders&rsquo; Equity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Preferred Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The Company has 56,075
shares of Series A 12% preferred stock authorized and no shares issued and outstanding at April 30, 2012 and 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Common Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">On February 18, 2011,
the Company&rsquo;s Board of Directors approved the amendment and restatement of the Company&rsquo;s Certificate of Incorporation
(or &ldquo;Charter&rdquo;) and submitted the amended and restated Charter to the Company&rsquo;s shareholders for approval.&nbsp;&nbsp;On
February 18, 2011, shareholders owning a majority of the issued and outstanding shares of the Company executed a written consent
approving the amended and restated Charter.&nbsp;&nbsp;In accordance with regulations of the Securities and Exchange Commission,
the amended and restated Charter was filed with the SEC on March 7, 2011. Among other changes, the amended and restated Charter
changes the name of the Company to &ldquo;Champions Oncology, Inc.&rdquo; and increases the authorized shares which the Company
may issue from 50,000,000 shares of Common Stock to 125,000,000 shares of Common Stock.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">As of April 30, 2010,
the Company had executed subscription agreements for the private placement of 1,000,000 shares of unregistered common stock for
$0.75 per share or $750,000. The amount was reflected as a subscription receivable as a contra-equity account on the balance sheet
as of April 30, 2010. In 2011, the Company became aware that the amount was uncollectible in full and the full amount was reversed
against additional paid-in capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Treasury Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">In May 2009, the Board
of Directors approved a stock repurchase agreement with a Board member which obligated the Company to purchase up to approximately
$407,000 of the Company&rsquo;s common stock held by the Board member through April of 2011 providing that the Board member continued
his services under a consulting agreement executed concurrently with the stock repurchase agreement.&nbsp;&nbsp;Under the stock
repurchase agreement, the Company made an initial purchase of $125,000 of the Company&rsquo;s shares of common stock, and may have
been required to make quarterly purchases of $31,250 of the Company&rsquo;s common stock held by the Board member after the end
of each fiscal quarter.&nbsp;&nbsp;The purchase price per share of the common stock for each purchase is equal to the lesser price
of $0.50 or 50% of the average closing price of the stock as quoted on the OTC Bulletin Board for the 30-day trading period ending
on the day before the date of each purchase as long as the consulting agreement remained in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Under the agreement,
the Company has paid this Board member approximately $73,000 and $218,000 for the purchase of 171,883 and 474,289&nbsp;shares of
the Company&rsquo;s common stock for the years ended April 30, 2011 and April 30, 2010, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Effective May 2010, the
Company terminated the consulting agreement with the Board member which correspondingly terminated the stock repurchase agreement.&nbsp;&nbsp;Because
the requirement for the Company to transfer cash in exchange for the shares of common stock ended with the termination of the consulting
agreement, during the year ended April 30, 2011, the Company reclassified $114,000 from accrued stock purchase on the balance sheet
into additional paid-in capital, which represented the remaining amount of the purchase price required under the repurchase arrangement
after the termination of the consulting agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Furthermore, under the
stock repurchase agreement, the Company, at its option for one year following the termination of the consulting agreement, may
purchase all or any part of the shares that have not been previously purchased, up to but not to exceed, 2,250,000 shares of the
common stock, subject to the pricing formula described above. In April 2011, the Company repurchased 2,000,000 shares of the Company&rsquo;s
common stock from the Board Member of the Company, for a cash purchase price of $0.48 per share, or an aggregate purchase price
of $960,000. The Company repurchased the shares using proceeds from the $9,400,000 received under the Securities Purchase Agreement
that closed in April 2011 and is described in Note 7.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The Company has not repurchased
any shares in fiscal 2012.&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 9. Provision for Income Taxes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The components of the
provision for income taxes are as follows (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended April 30, 2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Federal</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">State</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Foreign</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 48%; text-align: left">Current</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(3</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(2</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Deferred</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,523</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(172</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(68</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,763</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Change in valuation allowance</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,523</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">172</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">68</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,763</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended April 30, 2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Federal</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">State</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Foreign</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 48%; text-align: left">Current</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">11</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">11</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Deferred</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,100</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(167</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(68</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,335</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Change in valuation allowance</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,100</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">167</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">68</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,335</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">11</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">11</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">A reconciliation between
the Company&rsquo;s effective tax rate and the United States statutory tax rate for the years ended April 30, 2012 and 2011 is
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 93%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended April 30,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 74%; text-align: left">Federal income tax at statutory rate</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">34.0</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">34.0</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">State income tax, net of federal benefit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.3</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.5</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Permanent differences</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.7</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3.0</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.5</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Change in valuation allowance</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(31.9</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(35.2</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Changes in tax rates</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2.9</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5.4</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; text-decoration: none">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-decoration: none">Income tax expense</TD><TD STYLE="padding-bottom: 1pt; text-decoration: none">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; text-decoration: none">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; text-decoration: none"><FONT STYLE="text-underline-style: double">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left; text-decoration: none">
                                                                            %&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-decoration: none">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; text-decoration: none">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; text-decoration: none">(0.3</TD><TD STYLE="padding-bottom: 1pt; text-align: left; text-decoration: none">)%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Deferred income taxes
reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting
purposes and the amounts used for income tax purposes.&nbsp;&nbsp;Significant components of the Company&rsquo;s deferred tax assets
and liabilities as of April 30, 2012 and 2011 consist of the following (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of April 30,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 74%; text-align: left">Accrued liabilities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">62</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">9</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">State taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stock-based compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,685</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,863</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Capitalized research and development costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">798</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,182</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Foreign net operating loss carry-forward</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">265</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">198</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net operating loss carry-forward</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,478</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">363</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Total deferred tax assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,373</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,611</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less: Valuation allowance</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6,373</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,611</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net deferred tax asset</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Management has evaluated
the available evidence about future tax planning strategies, taxable income and other possible sources of realization of deferred
tax assets and has established a full valuation allowance against its net deferred tax assets as of April, 30, 2012.&nbsp;&nbsp;For
the years ended April 30, 2012 and 2011, the Company recorded a valuation allowance of $6,373,000 and $3,611,000, respectively.&nbsp;&nbsp;The
increase in valuation allowance from fiscal year 2011 to 2012 is due to deferred tax assets generated relative to stock compensation
and net operating loss carryforwards.&nbsp;&nbsp;The Company has established a valuation allowance against its deferred tax assets
as it is currently more-likely-than-not that all or a portion of a deferred tax asset will not be realized.&nbsp;&nbsp;The valuation
allowance reduces deferred tax assets to an amount that management believes will more likely than not be realized.&nbsp;&nbsp;Changes
in valuation allowances from period to period are included in the tax provision in the period of change.&nbsp;&nbsp;In determining
whether a valuation allowance is required, the Company takes into account all evidence with regard to the utilization of a deferred
tax asset including past earnings history, expected future earnings, the character and jurisdiction of such earnings, unsettled
circumstances that, if unfavorably resolved, would adversely affect utilization of a deferred tax asset, carryback and carryforward
periods, and tax strategies that could potentially enhance the likelihood of realization of a deferred tax asset.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">As of April 30, 2012
and 2011, the Company&rsquo;s estimated U.S. net operating loss carry-forwards were approximately $6,825,000 and $928,000, respectively.&nbsp;&nbsp;As
of April 30, 2012 and 2011, the Company&rsquo;s foreign net operating loss carry-forward was approximately $1,138,000 and $790,000,
respectively.&nbsp;&nbsp;The Company&rsquo;s federal and state net operating losses begin expiring in 2029.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The Company files income
tax returns in various jurisdictions with varying statues of limitations.&nbsp;&nbsp;As of April 30, 2012, the earliest tax year
still subject to examination for state purposes is fiscal 2009.&nbsp;&nbsp;The Company&rsquo;s tax years for periods ending April
30, 1995 and forward are subject to examination by the United States and certain states due to the carry-forward of unutilized
net operating losses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">On August 8, 2011, the
Company was notified that it was selected for a tax examination by the Internal Revenue Service (IRS) on the Application for Certification
of Qualified Investments Eligible for Credits and Grants Under the Qualifying Therapeutic Discovery Project program filed under
the Patient Protection and Affordable Care Act of 2010 for the 2009 and 2010 tax years. The examination commenced on September
30, 2011 and was completed during the fourth quarter of the year ended April 30, 2012. The audit resulted in a disallowance to
the net operating loss carry-forwards of $607,000. This disallowance was offset by a corresponding increase to amortizable intangible
assets related to capitalized research and development expenditures of $542,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 10. Related Party Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">Related party transactions
include transactions between the Company and its shareholders, management, or affiliates.&nbsp;&nbsp;The following transactions
were in the normal course of operations and were measured at the exchange amount, which is the amount of consideration established
and agreed to by the parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">During the years ended
April 30, 2012 and 2011, the Company paid one of its directors and former Chief Executive Officer, $18,000 and $143,000, respectively,
in consulting fees and salary.&nbsp;&nbsp;During the years ended April 30, 2012 and, 2011, the Company paid certain members of
our Board of Directors $141,000 and $60,000, respectively, for consulting services unrelated to their duties as board members.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">During the years ended
April 30, 2012 and 2011, the Company recognized approximately $20,000 and $201,000, respectively, in revenues from companies whose
board members were also members of our Board of Directors.&nbsp;&nbsp;Of these amounts, no related receivables were outstanding
as of April 30, 2012 and 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 11. Business Segment Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The Company operates
in two segments, POS and TOS. The accounting policies of the Company&rsquo;s segments are the same as those described in Note 2.
The Company evaluates performance of its segments based on profit or loss from operations before stock compensation expense, depreciation
and amortization, interest expense, interest income, gain on sale of assets, special charges or benefits, and income taxes (&ldquo;segment
profit&rdquo;). Management uses segment profit information for internal reporting and control purposes and considers it important
in making decisions regarding the allocation of capital and other resources, risk assessment, and employee compensation, among
other matters. The following tables summarize, for the periods indicated, operating results by business segment (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; text-decoration: none">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left; text-decoration: none">Year Ended April 30, 2012</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-decoration: none">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; text-decoration: none">Personalized <BR>Oncology
    <BR>Solutions <BR>(POS)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-decoration: none">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-decoration: none">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; text-decoration: none">Translational <BR>Oncology
    <BR>Solutions <BR>(TOS)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-decoration: none">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-decoration: none">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; text-decoration: none"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-decoration: none"><B>&nbsp;</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-decoration: none"><B>Unallocated</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-decoration: none"><B>Corporate</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-decoration: none"><B>Overhead</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-decoration: none">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-decoration: none">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; text-decoration: none"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-decoration: none"><B>&nbsp;</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-decoration: none"><B>&nbsp;</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-decoration: none"><B>&nbsp;</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-decoration: none"><B>Consolidated</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-decoration: none">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 48%; text-align: left">Net revenue</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2,332</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">4,817</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">7,149</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Direct cost of services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,331</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(2,533</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,864</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Sales and marketing costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,752</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(936</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,688</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(2,898</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,441</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,339</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Stock compensation expense (1)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,323</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,323</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Segment profit (loss)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,751</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,550</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(5,764</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(9,065</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; text-decoration: none">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left; text-decoration: none">Year Ended April 30, 2011</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-decoration: none">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; text-decoration: none">Personalized <BR>Oncology
    <BR>Solutions <BR>(POS)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-decoration: none">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-decoration: none">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; text-decoration: none">Translational <BR>Oncology
    <BR>Solutions <BR>(TOS)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-decoration: none">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-decoration: none">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; text-decoration: none"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-decoration: none"><B>&nbsp;</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-decoration: none"><B>Unallocated</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-decoration: none"><B>Corporate</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-decoration: none"><B>Overhead</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-decoration: none">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-decoration: none">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; text-decoration: none"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-decoration: none"><B>&nbsp;</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-decoration: none"><B>&nbsp;</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-decoration: none"><B>&nbsp;</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-decoration: none"><B>Consolidated</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-decoration: none">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 48%; text-align: left">Net revenue</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3,382</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3,500</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">6,882</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Direct cost of services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,665</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,806</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,471</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Sales and marketing costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(980</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(980</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,809</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,724</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,533</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Stock compensation expense (1)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,133</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,133</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Segment profit (loss)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,717</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,115</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(5,837</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(5,235</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">(1) Stock compensation expense
is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as
it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">All of the Company&rsquo;s
revenue is recorded in the United States and substantially all of its long-lived assets are in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 12. Supplemental Schedule of Cash
Flow Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Supplemental cash flow information is as
follows (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 88%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended April 30,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Supplemental cash flow information:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.12in">Cash paid for interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.12in">Cash paid for income taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Supplemental disclosure of
    non-cash investing and financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; padding-left: 0.36in">Stock subscription receivable</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(750</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.36in">Purchases of property and equipment included in accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">192</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 13. Grant Income</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">In October 2010, the
Company was notified that it was awarded total cash grants of approximately $1.5 million under the Qualifying Therapeutic Discovery
Project program administered under section 48D of the Internal Revenue Code, of which approximately $1.0 million related to qualifying
expenses the Company had previously incurred during fiscal 2010 and $0.5 million related to qualifying expenses which the Company
expected to incur during fiscal 2011. In November 2010, the Company received approximately $1.0 million related to the 2010 expenditures.
The Company received a final payment of $0.5 million related to 2011 expenditures on February 13, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">On August 8, 2011 the
Company was notified that it was selected for a tax examination by the Internal Revenue Service (IRS) on the Application for Certification
of Qualified Investments Eligible for Credits and Grants Under the Qualifying Therapeutic Discovery Project program filed under
the Patient Protection and Affordable Care Act of 2010 for the 2009 and 2010 tax years. The examination commenced during the second
quarter of fiscal 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">The IRS expanded its
scope to include the fiscal year 2011 tax return, which was filed in January 2012. The examinations of fiscal 2009 and 2010 were
completed in the fourth quarter of fiscal 2012. The examination of fiscal 2011 completed in the first quarter of fiscal 2013. The
audit of all three fiscal years (2009, 2010, and 2011) resulted in no additional tax due or receivable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 14. Subsequent Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<!-- Field: Page; Sequence: 53; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"></P>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>2
<FILENAME>v316311_ex21.htm
<DESCRIPTION>EXHIBIT 21
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 21</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SUBSIDIARIES OF CHAMPIONS ONCOLOGY, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%">Name</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 55%">Incorporated in</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Biomerk, Inc.</TD>
    <TD>&nbsp;</TD>
    <TD>Maryland</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Champions Biotechnology U.K., Limited</TD>
    <TD>&nbsp;</TD>
    <TD>United Kingdom</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Champions Oncology (Israel) Ltd.</TD>
    <TD>&nbsp;</TD>
    <TD>Israel</TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>v316311_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE
OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">I, Joel Ackerman, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt">1. I have reviewed this
Annual Report on Form 10-K of Champions Oncology, Inc., a Delaware corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt">2. Based on my knowledge,
this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by
this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt">3. Based on my knowledge,
the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt">4. The registrant&rsquo;s
other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined
in Exchange Act Rules 13a-15(e) and 15(d)-15(e)) and internal control over financial reporting (as defined in the Exchange Act
Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify; text-indent: 0.15in">(a) Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others
within those entities, particularly during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: left; text-indent: 0.15in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify; text-indent: 0.15in">(b) Designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: left; text-indent: 0.15in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify; text-indent: 0.15in">(c) Evaluated
the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: left; text-indent: 0.15in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify; text-indent: 0.15in">(d) Disclosed
in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal
control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt">5. The registrant&rsquo;s
other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting,
to the registrant&rsquo;s auditors and the audit committee of registrant&rsquo;s board of directors (or persons performing the
equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify; text-indent: 0.15in">(a) All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: left; text-indent: 0.15in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify; text-indent: 0.15in">(b) Any
fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 30%; border-bottom: windowtext 1pt solid; text-align: left">/s/&nbsp; Joel Ackerman</TD>
    <TD STYLE="width: 20%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">Joel Ackerman</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">Chief Executive Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">(Principal Executive Officer)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Date: July 18, 2012</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>v316311_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL FINANCIAL
OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">I, Gary G. Gemignani, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt">1. I have reviewed this
Annual Report on Form 10-K of Champions Oncology, Inc., a Delaware corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt">2. Based on my knowledge,
this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by
this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt">3. Based on my knowledge,
the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt">4. The registrant&rsquo;s
other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined
in Exchange Act Rules 13a-15(e) and 15(d)-15(e)) and internal control over financial reporting (as defined in the Exchange Act
Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify; text-indent: 0.15in">(a) Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others
within those entities, particularly during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: left; text-indent: 0.15in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify; text-indent: 0.15in">(b) Designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: left; text-indent: 0.15in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify; text-indent: 0.15in">(c) Evaluated
the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: left; text-indent: 0.15in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify; text-indent: 0.15in">(d) Disclosed
in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal
control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt">5. The registrant&rsquo;s
other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting,
to the registrant&rsquo;s auditors and the audit committee of registrant&rsquo;s board of directors (or persons performing the
equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify; text-indent: 0.15in">(a) All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: left; text-indent: 0.15in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify; text-indent: 0.15in">(b) Any
fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 30%; border-bottom: windowtext 1pt solid; text-align: left">/s/&nbsp; Gary G. Gemignani</TD>
    <TD STYLE="width: 20%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">Gary G. Gemignani</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">Chief Financial Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">(Principal Financial Officer)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Date: July 18, 2012</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>v316311_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION
1350, AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE U.S. SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt">In connection with the
Annual Report of Champions Oncology, Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the year ended April 30, 2012, as filed
with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), each of the undersigned, in the capacities
and on the dates indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the
U.S. Sarbanes-Oxley Act of 2002, that to the best of our knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify; text-indent: 0.15in">(i) the
Report fully complies with the requirements of section 13(a) or 15(d) of the U.S. Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: left; text-indent: 0.15in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify; text-indent: 0.15in">(ii) the
information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 30%; border-bottom: windowtext 1pt solid; text-align: left">/s/&nbsp; Joel Ackerman</TD>
    <TD STYLE="width: 20%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">Joel Ackerman</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">Chief Executive Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">(Principal Executive Officer)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: windowtext 1pt solid; text-align: left">/s/&nbsp; Gary G. Gemignani</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">Gary G. Gemignani</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">Chief Financial Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">(Principal Financial Officer)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Date: July 18, 2012</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>6
<FILENAME>v316311_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 75%; padding-right: 0; padding-left: 0; font-size: 10pt; color: #1F497D">&nbsp;<IMG SRC="image_003.jpg" ALT=""></TD>
    <TD STYLE="width: 25%; padding-right: 0; padding-left: 0; font-size: 10pt; text-align: center; vertical-align: bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NEWS</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<HR NOSHADE SIZE="4" STYLE="color: Black; width: 100%; margin-top: 3pt; margin-bottom: 3pt">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #00000A">One University Plaza, Suite
307 Hackensack, NJ 07601 Tel: 201-808-8400</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00000A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00000A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00000A">For Immediate Release</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00000A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #00000A"><B>Champions Oncology Reports
Financial Results for the Year Ended April 30, 2012 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #00000A"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #00000A">Hackensack,
NJ &ndash; July 18, 2012 &ndash; Champions Oncology, Inc. (OTC: CSBR), </FONT><FONT STYLE="color: black">formerly Champions Biotechnology,
Inc., </FONT>engages in the development of advanced technology solutions and services to personalize the development and use of
oncology drugs, <FONT STYLE="color: #00000A">announced today its financial results for the year ended April 30, 2012. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Joel Ackerman, the CEO of Champions Oncology,
stated, &ldquo;Fiscal 2012 was a year of great progress for the company. We demonstrated our ability to drive significant volume
growth in both sides of our business. We continue to evolve our strategic direction to better align the strength of our technology
platform with the needs of the market. Within this new approach, we made significant progress in expanding our customer base and
building a solid operational foundation for the future.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Operating revenues were $7.1 million and
$6.9 million for the years ended April 30, 2012 and 2011, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00000A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #00000A">Total operating
expense</FONT>s were $16.2 million and $12.1 million for the years ended April 30, 2012 and 2011, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00000A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #00000A">Champions
reported a net loss of $8.7 million, or ($0.19) per share and $3.8 million, or ($0.11) per share for </FONT>the years ended April
30, 2012 and 2011, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00000A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #00000A">Excluding
stock based compensation of $3.3 million, Champions recognized a net loss of $5.3* million, or ($0.11*) per share, and excluding
stock based compensation of $3.1 million, a net loss of $0.7* million, or ($0.02*), per share for </FONT>the years ended April
30, 2012 and 2011, respectively.<FONT STYLE="color: #00000A"> </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During fiscal 2012, we modified our POS
business strategy to focus on growing our core technology products, which includes TumorGraft implants and drug studies. As part
of this strategy, we significantly reduced the price of our core technology products to make the products affordable to a broader
patient base and to accelerate the growth of our Tumorbank. In addition, we have increased spending on sales and marketing efforts
to support this strategy. We will continue to offer related personalized oncology services to our customers; however, we expect
future POS revenues to be driven by our core products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the second half of fiscal 2012,
we transitioned the laboratory activities that support the POS and TOS businesses from a third-party contract research organization
(&ldquo;CRO&rdquo;) to our facility in Baltimore, Maryland. We believe that bringing these activities in-house will significantly
reduce the future cost of providing our services and allow us to implement and maintain a more competitive pricing strategy. To
facilitate this strategy and support the increase in current and expected volume, we have invested in the infrastructure and increased
our laboratory staff.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, as part of our modified strategy,
we plan to use TumorGrafting as a platform technology to drive multiple synergistic revenue streams. We continue to build this
platform with investments in research and development, as well as contributions from both the POS and TOS businesses. The platform
is then used to deliver products that serve both the POS and TOS customers in synergistic ways. The result is well-differentiated
products for patients, physicians, and drug development companies. In addition, we are looking for additional opportunities to
utilize the data we are gathering to develop proprietary biomarkers and signatures of response that can predict the resistance
or sensitivity of individual tumors to oncology drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operating Results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">TOS revenues were $4.8 million and $3.5
million for the years ended April 30, 2012 and 2011, respectively, an increase of $1.3 million or 38%. The increases in TOS revenues
were due primarily to increased sales efforts and investments in growing our Tumorbank.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cost of TOS was $2.5 million and $1.8 million
for the years ended April 30, 2012 and 2011, respectively, an increase of $0.7 million, or 38%. The increase in costs was due to
the increased volume of the TOS business. Gross margin for TOS was 47% for the years ended April 30, 2012 and 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">POS revenues were $2.3 million and $3.4
million for the years ended April 30, 2012 and 2011, respectively, a decrease of $1.1 million, or 31%. Panel revenue, a component
of POS revenue, decreased $1.2 million from the prior year, which is primarily attributable to a decrease in pricing per panel.
Excluding panel revenue, POS revenue was $1.8 million and $1.7 million for the years ended April 30, 2012 and 2011, respectively,
an increase of $0.1 million. During fiscal 2012, the Company experienced significantly higher volumes of implants and drug studies
compared to fiscal 2011. For the year ended April 30, 2012, the Company performed 97 TumorGraft implants, compared to 12 in the
prior year. For the year ended April 30, 2012, the Company completed 19 drug studies, compared to 5 in the prior year. The increase
in volume was offset by decreased pricing for both the TumorGraft implants and drug studies, as part of our strategic decision
to accelerate the growth of our Tumorbank.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cost of POS was $2.4 million and $1.7 million
for the years ended April 30, 2012 and 2011, respectively, an increase of $0.7 million, or 42%. Gross margin for POS was -1% and
51% for the years ended April 30, 2012 and 2011, respectively. Gross margins declined due to the strategic decision to decrease
prices to drive increased volumes. Additionally, during the second half of fiscal 2012, the Company transitioned its laboratory
work in-house from a third-party CRO. While this has resulted in increased costs during the transition, it is expected to yield
future savings. Finally, costs related to POS studies are expensed as incurred, so expenses include ongoing costs related to 11
drug studies in progress at April 30, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expense was $2.9
million for the years ended April 30, 2012 and 2011. Our research and development efforts are focused on growing our Tumorbank,
increasing our understanding of our TumorGraft models, their clinical predictability, improving growth and tumor take rates, and
other biological and molecular characteristics of the models. In fiscal 2012, we increased these efforts, but this was offset by
decreased expenses incurred on testing in-licensed compounds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00000A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales and marketing expense was $2.9 million
and $1.1 million for the years ended April 30, 2012 and 2011, respectively, an increase of $1.8 million, or 170%. The increase
for fiscal 2012 is primarily related to employee costs associated with increases in our sales force and marketing expenses incurred
in connection with growing our POS and TOS businesses in the United States and in our overseas operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00000A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expense was
$5.5 million and $4.6 million for the years ended April 30, 2012 and 2011, respectively, an increase of $0.9 million, or 18%. Stock-based
compensation expense relating to general and administrative expense was $3.0 million and $2.9 million for the years ended April
30, 2012 and 2011, respectively. Excluding stock-based compensation, general and administrative expense increased $0.8 million,
which primarily relates to the expansion of our infrastructure, the addition of our corporate offices in New Jersey, and other
costs associated with the Company&rsquo;s growth strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00000A">The Company&rsquo;s cash
position on April 30, 2012 was $4.8 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00000A"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00000A"><B>* Non-GAAP Financial
Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00000A"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00000A">See the attached Reconciliation
of GAAP Net Loss to Non-GAAP Net Loss for an explanation of the amounts excluded to arrive at non-GAAP net loss and related non-GAAP
loss per share amounts for the fiscal years ended 2012 and 2011, respectively. Non-GAAP financial measures provide investors and
management with supplemental measures of operating performance and trends that facilitate comparisons between periods before and
after certain items that would not otherwise be apparent on a GAAP basis. Certain unusual or non-recurring items that management
does not believe affect the Company&rsquo;s basic operations do not meet the GAAP definition of unusual or non-recurring items.
Non-GAAP net loss and non-GAAP loss per share are not, and should not be viewed as a substitute for similar GAAP items. We define
non-GAAP diluted loss per share amounts as non-GAAP net loss divided by the weighted average number of diluted shares outstanding.
Our definition of non-GAAP net loss and non-GAAP diluted loss per share may differ from similarly named measures used by others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00000A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #00000A">Full details
of the Company&rsquo;s financial results will be available in the Company&rsquo;s Form 10-K at</FONT> www.championsoncology.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00000A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Champions Oncology, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Champions Oncology, Inc. is engaged in
the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Company&rsquo;s
Tumorgraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors
in immune deficient mice followed by propagation of the resulting engraftments, or Tumorgrafts, in a manner that preserves the
biological characteristics of the original human tumor. The Company uses this technology in conjunction with related services to
offer solutions for two customer groups: Personalized Oncology Solutions (&ldquo;POS&rdquo;) in which physicians and patients looking
for information help guide the development of personalized treatment plans, and Translational Oncology Solutions (&ldquo;TOS&rdquo;)
in which pharmaceutical and biotech companies seeking personalized approaches to drug development can lower the cost and increase
the speed of developing new drugs and increasing the adoption of existing drugs. The Company&rsquo;s Tumorgraft Technology Platform
consists of processes, physical tumors and information that we use to personalize the development and use of oncology drugs. The
Company is building its Tumorgraft Technology Platform through the procurement, development and characterization of numerous Tumorgrafts
within each of several cancer types. Tumorgrafts are procured through agreements with a number of institutions in the U.S. and
overseas as well as through its POS business. The Tumorgrafts are developed and tested in the Company&rsquo;s laboratory facility
in Baltimore, Maryland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our POS business offers physicians and
patients information to help guide the development of personalized treatment plans. Our core offering utilizes our technology platform
to empirically test the response of a patient&rsquo;s tumor to multiple oncology drugs or drug combinations. The process begins
by implanting a fresh fragment of the patient&rsquo;s tumor, typically received within 24 hours of surgery or biopsy, in a small
colony of immune-deficient mice to grow the tumor tissue. This colony is then expanded by implanting the grown tumor tissue into
subsequent generations of mice until a sufficient number of mice are available for testing. At that point, the colony is allocated
to different groups, and each mouse in a group is dosed with a different drug or drug combination. The response of the tumor in
each mouse is tracked over time and analyzed to determine which drug or drug combination is providing the highest level of tumor
growth inhibition. Our data demonstrates that there is a high correlation between the response to drugs of the tumor in mice with
the response of the tumor in the patient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This press release may contain &quot;forward-looking
statements&quot; (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties.
Champions Oncology generally uses words such as &quot;believe,&quot; &quot;may,&quot; &quot;could,&quot; &quot;will,&quot; &quot;intend,&quot;
&quot;expect,&quot; &quot;anticipate,&quot; &quot;plan,&quot; and similar expressions to identify forward-looking statements. One
should not place undue reliance on these forward-looking statements. The Company's actual results could differ materially from
those anticipated in the forward-looking statements for many unforeseen factors. See Champions Oncology's Form 10-K for the fiscal
year ended April 30, 2012 for a discussion of such risks, uncertainties and other factors. Although the Company believes the expectations
reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are
made, and Champions Oncology's future results, levels of activity, performance or achievements may not meet these expectations.
The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these
statements to actual results or to changes in Champions Oncology's expectations, except as required by law. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #00000A"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #00000A"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #00000A"><B>Champions Oncology, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #00000A; text-indent: 0"><I>(Dollars
in thousands except per share amounts)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00000A"><B>Reconciliation of GAAP
to Non-GAAP Net Loss</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center; vertical-align: top; border-bottom: Black 1pt solid"><B>Year Ended <BR>April
    30</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 72%; font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Net loss &ndash; GAAP</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">($</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">8,661</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">($</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,802</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Less: <BR>Stock-based compensation</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,323</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,133</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt; padding-left: 5.4pt">Net loss - non-GAAP</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">($</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5,338</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">($</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">669</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00000A"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00000A"><B>Reconciliation of GAAP
to Non-GAAP Earnings Per Share (EPS)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center; vertical-align: top; border-bottom: Black 1pt solid"><B>Year Ended <BR>April 30</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 72%; font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">EPS &ndash; GAAP</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">($</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">0.19</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">($</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">0.11</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Less: <BR>Effect of stock-based compensation on EPS</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">0.08</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">0.09</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt; padding-left: 5.4pt">EPS - non-GAAP</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">($</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">0.11</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">($</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">0.02</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00000A"><B>Condensed Consolidated
Income Statements (Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00000A">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="text-align: center; vertical-align: top; border-bottom: Black 1pt solid"><B>Year Ended <BR>April 30</B></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011%Change</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 58%; font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">POS operating revenue</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,332</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,382</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-31</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">TOS operating revenue</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,817</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,500</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">38</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: justify; padding-bottom: 2.5pt; padding-left: 5.4pt">&nbsp;Total operating revenue</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">7,149</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">6,882</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">4</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Cost of POS</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,356</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,665</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">42</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Cost of TOS</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,543</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,846</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">38</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Research and development</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,937</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,910</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Sales and marketing</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,928</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,085</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">170</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">General and administrative</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">5,450</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">4,611</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">18</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: justify; padding-bottom: 2.5pt; padding-left: 5.4pt">&nbsp;Loss from Operations</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">($</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">9,065</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">($</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">5,235</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">73</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Other Income</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">402</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,444</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-72</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">&nbsp;Net Loss before income tax expense</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">($</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">8,663</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">($</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">3,791</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">129</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Income taxes</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">11</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-118</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: justify; padding-bottom: 2.5pt; padding-left: 5.4pt">&nbsp;Net Loss</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">($</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">8,661</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">($</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">3,802</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">128</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">&nbsp;Earnings per share- basic and diluted</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">($</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">0.19</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">($</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">0.11</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">73</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Average Shares outstanding- basic and diluted</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">46,815,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">33,774,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00000A">&nbsp;</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00000A"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00000A"><B>Condensed Consolidated
Balance Sheets (Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00000A"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center; vertical-align: top; border-bottom: Black 1pt solid"><B>At <BR>April 30,</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 72%; font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Cash and cash equivalents</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,754</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">10,457</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Accounts receivable</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">584</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">585</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Other current assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">205</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">793</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">&nbsp;Total current assets</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">5,543</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">11,835</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Restricted cash</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">150</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Property and equipment, net</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">560</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">146</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Goodwill</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">669</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">669</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: justify; padding-bottom: 2.5pt; padding-left: 5.4pt">&nbsp;Total assets</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">6,922</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">12,650</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Accounts payable and accrued liabilities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">2,301</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1,882</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Deferred revenue</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,185</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,618</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">&nbsp;Total current liabilities</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">3,486</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">3,500</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Warrant liability</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">555</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">972</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Redeemable common stock</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8,159</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8,159</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Stockholders&rsquo; equity (deficit)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(5,278</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">19</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: justify; padding-bottom: 2.5pt; padding-left: 5.4pt">&nbsp;Total liabilities, redeemable common stock &nbsp;&nbsp;&nbsp;and stockholders&rsquo; equity (deficit)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">($</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">6,922</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">($</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">12,650</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00000A"><B>&nbsp;</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00000A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00000A"><B>Condensed Consolidated
Statements of Cash Flows (Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00000A">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center; vertical-align: top; border-bottom: Black 1pt solid"><B>Year Ended <BR>April 30</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Cash flows from operating activities:</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 72%; font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Net Loss</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">($</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">8,661</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">($</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,802</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Adjustments to reconcile net cash used in operations:</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">&nbsp;Stock-based compensation expense</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,323</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,133</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">&nbsp;Depreciation expense</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">105</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">42</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">&nbsp;Change in fair value of warrant liability</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(417</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">36</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">&nbsp;Other adjustments</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">12</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">&nbsp;Changes in operating assets and liabilities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">425</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">525</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Net cash used in operating activities</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(5,227</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(54</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Cash flows from investing activities:</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">&nbsp;Purchases of and proceeds from sales of property and equipment</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(519</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(84</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: justify; padding-bottom: 2.5pt; padding-left: 5.4pt">Net cash used in investing activities:</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(519</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(84</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Cash flows from financing activities:</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">&nbsp;Private placement of common shares and warrants (net of $305 in offering costs)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">9,095</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">&nbsp;Purchase of treasury stock</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,033</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">&nbsp;Proceeds from exercise of options and warrants</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">97</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: justify; padding-bottom: 2.5pt; padding-left: 5.4pt">Net cash provided by financing activities:</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">97</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">8,083</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Exchange rate effect on cash and cash equivalents</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(54</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(60</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Increase (decrease) in cash and cash equivalents</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(5,703</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7,885</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Cash and cash equivalents, beginning of year</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">10,457</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">2,572</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: justify; padding-bottom: 2.5pt; padding-left: 5.4pt">Cash and cash equivalents, end of year</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">4,754</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">10,457</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00000A">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>csbr-20120430.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!-- XBRL document created with Ez-XBRL version 5.0.1.0 [07/05/2012 11:39:16 AM] -->
<!-- Based on XBRL 2.1 -->
<!--XBRL Document Modified with Ez-Viewer Version 1.0.5.8 on Wednesday, July 18, 2012 10:32:43 AM -->
<xbrli:xbrl xmlns:csbr="http://championsoncology.com/20120430" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:country="http://xbrl.sec.gov/country/2011-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2011-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:us-types="http://fasb.org/us-types/2011-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink">
<link:schemaRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:type="simple" xlink:href="csbr-20120430.xsd"/>
<!-- Context Section  -->
<xbrli:context id="Context_As_Of_30-Apr-2010">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2010-04-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Apr-2010_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2010-04-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Apr-2010_StatementEquityComponentsAxis_TreasuryStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2010-04-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Apr-2010_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2010-04-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Apr-2010_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2010-04-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Apr-2010_StatementEquityComponentsAxis_StockSubscriptionReceivableMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">csbr:StockSubscriptionReceivableMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2010-04-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Apr-2010_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2010-04-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_30-Apr-2011">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2010-05-01
</xbrli:startDate>
<xbrli:endDate>
2011-04-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2010-05-01
</xbrli:startDate>
<xbrli:endDate>
2011-04-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_TreasuryStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2010-05-01
</xbrli:startDate>
<xbrli:endDate>
2011-04-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2010-05-01
</xbrli:startDate>
<xbrli:endDate>
2011-04-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2010-05-01
</xbrli:startDate>
<xbrli:endDate>
2011-04-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_StockSubscriptionReceivableMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">csbr:StockSubscriptionReceivableMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2010-05-01
</xbrli:startDate>
<xbrli:endDate>
2011-04-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2010-05-01
</xbrli:startDate>
<xbrli:endDate>
2011-04-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Apr-2011">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-04-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Apr-2011_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-04-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Apr-2011_StatementEquityComponentsAxis_TreasuryStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-04-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Apr-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-04-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Apr-2011_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-04-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Apr-2011_StatementEquityComponentsAxis_StockSubscriptionReceivableMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">csbr:StockSubscriptionReceivableMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-04-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Apr-2011_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-04-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Oct-2011">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-10-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_30-Apr-2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-05-01
</xbrli:startDate>
<xbrli:endDate>
2012-04-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_30-Apr-2012_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-05-01
</xbrli:startDate>
<xbrli:endDate>
2012-04-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_30-Apr-2012_StatementEquityComponentsAxis_TreasuryStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-05-01
</xbrli:startDate>
<xbrli:endDate>
2012-04-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_30-Apr-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-05-01
</xbrli:startDate>
<xbrli:endDate>
2012-04-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_30-Apr-2012_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-05-01
</xbrli:startDate>
<xbrli:endDate>
2012-04-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_30-Apr-2012_StatementEquityComponentsAxis_StockSubscriptionReceivableMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">csbr:StockSubscriptionReceivableMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-05-01
</xbrli:startDate>
<xbrli:endDate>
2012-04-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_30-Apr-2012_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-05-01
</xbrli:startDate>
<xbrli:endDate>
2012-04-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Apr-2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-04-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Apr-2012_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-04-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Apr-2012_StatementEquityComponentsAxis_TreasuryStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-04-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Apr-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-04-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Apr-2012_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-04-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Apr-2012_StatementEquityComponentsAxis_StockSubscriptionReceivableMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">csbr:StockSubscriptionReceivableMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-04-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Apr-2012_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-04-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_06-Jul-2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-07-06
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<!-- Unit Section  -->
<!--
I~1\FVPHexeD5678YReqi>XUI~\FVPYwivc444c555cT{h>6<HE<4GG1FH<:18F651FFH;1:=H5=G<6G96I -->
<xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<!-- Element Section  --><dei:EntityRegistrantName contextRef="Context_FYE_30-Apr-2012">CHAMPIONS ONCOLOGY, INC.</dei:EntityRegistrantName>
<dei:EntityCentralIndexKey contextRef="Context_FYE_30-Apr-2012">0000771856</dei:EntityCentralIndexKey>
<dei:CurrentFiscalYearEndDate contextRef="Context_FYE_30-Apr-2012">--04-30</dei:CurrentFiscalYearEndDate>
<dei:EntityFilerCategory contextRef="Context_FYE_30-Apr-2012">Smaller Reporting Company</dei:EntityFilerCategory>
<dei:TradingSymbol contextRef="Context_FYE_30-Apr-2012">csbr</dei:TradingSymbol>
<dei:EntityCommonStockSharesOutstanding contextRef="Context_As_Of_06-Jul-2012" unitRef="shares" decimals="0">47074942</dei:EntityCommonStockSharesOutstanding>
<dei:DocumentType contextRef="Context_FYE_30-Apr-2012">10-K</dei:DocumentType>
<dei:AmendmentFlag contextRef="Context_FYE_30-Apr-2012">false</dei:AmendmentFlag>
<dei:DocumentPeriodEndDate contextRef="Context_FYE_30-Apr-2012">2012-04-30</dei:DocumentPeriodEndDate>
<dei:DocumentFiscalPeriodFocus contextRef="Context_FYE_30-Apr-2012">FY</dei:DocumentFiscalPeriodFocus>
<dei:DocumentFiscalYearFocus contextRef="Context_FYE_30-Apr-2012">2012</dei:DocumentFiscalYearFocus>
<dei:EntityWellKnownSeasonedIssuer contextRef="Context_FYE_30-Apr-2012">No</dei:EntityWellKnownSeasonedIssuer>
<dei:EntityVoluntaryFilers contextRef="Context_FYE_30-Apr-2012">No</dei:EntityVoluntaryFilers>
<dei:EntityCurrentReportingStatus contextRef="Context_FYE_30-Apr-2012">Yes</dei:EntityCurrentReportingStatus>
<dei:EntityPublicFloat contextRef="Context_As_Of_31-Oct-2011" unitRef="USD" decimals="-5">18700000</dei:EntityPublicFloat>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30-Apr-2010" unitRef="USD" decimals="-3">2572000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="-3">10457000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30-Apr-2012" unitRef="USD" decimals="-3">4754000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:AccountsReceivableNetCurrent contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="-3">585000</us-gaap:AccountsReceivableNetCurrent>
<us-gaap:AccountsReceivableNetCurrent contextRef="Context_As_Of_30-Apr-2012" unitRef="USD" decimals="-3">584000</us-gaap:AccountsReceivableNetCurrent>
<us-gaap:GrantsReceivableCurrent contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="-3">517000</us-gaap:GrantsReceivableCurrent>
<us-gaap:GrantsReceivableCurrent contextRef="Context_As_Of_30-Apr-2012" unitRef="USD" decimals="-3">0</us-gaap:GrantsReceivableCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="-3">276000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="Context_As_Of_30-Apr-2012" unitRef="USD" decimals="-3">205000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="-3">11835000</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_30-Apr-2012" unitRef="USD" decimals="-3">5543000</us-gaap:AssetsCurrent>
<us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="-3">0</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
<us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="Context_As_Of_30-Apr-2012" unitRef="USD" decimals="-3">150000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="-3">146000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_30-Apr-2012" unitRef="USD" decimals="-3">560000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:Goodwill contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="-3">669000</us-gaap:Goodwill>
<us-gaap:Goodwill contextRef="Context_As_Of_30-Apr-2012" unitRef="USD" decimals="-3">669000</us-gaap:Goodwill>
<us-gaap:Assets contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="-3">12650000</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_30-Apr-2012" unitRef="USD" decimals="-3">6922000</us-gaap:Assets>
<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="-3">1580000</us-gaap:AccountsPayableCurrent>
<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_30-Apr-2012" unitRef="USD" decimals="-3">1676000</us-gaap:AccountsPayableCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="-3">302000</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_30-Apr-2012" unitRef="USD" decimals="-3">625000</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:DeferredRevenueCurrent contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="-3">1618000</us-gaap:DeferredRevenueCurrent>
<us-gaap:DeferredRevenueCurrent contextRef="Context_As_Of_30-Apr-2012" unitRef="USD" decimals="-3">1185000</us-gaap:DeferredRevenueCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="-3">3500000</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_30-Apr-2012" unitRef="USD" decimals="-3">3486000</us-gaap:LiabilitiesCurrent>
<us-gaap:DerivativeLiabilitiesNoncurrent contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="-3">972000</us-gaap:DerivativeLiabilitiesNoncurrent>
<us-gaap:DerivativeLiabilitiesNoncurrent contextRef="Context_As_Of_30-Apr-2012" unitRef="USD" decimals="-3">555000</us-gaap:DerivativeLiabilitiesNoncurrent>
<us-gaap:Liabilities contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="-3">4472000</us-gaap:Liabilities>
<us-gaap:Liabilities contextRef="Context_As_Of_30-Apr-2012" unitRef="USD" decimals="-3">4041000</us-gaap:Liabilities>
<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" xsi:nil="true"/>
<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_30-Apr-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:RedeemableNoncontrollingInterestEquityCommonCarryingAmount contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="-3">8159000</us-gaap:RedeemableNoncontrollingInterestEquityCommonCarryingAmount>
<us-gaap:RedeemableNoncontrollingInterestEquityCommonCarryingAmount contextRef="Context_As_Of_30-Apr-2012" unitRef="USD" decimals="-3">8159000</us-gaap:RedeemableNoncontrollingInterestEquityCommonCarryingAmount>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="-3">0</us-gaap:PreferredStockValue>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_30-Apr-2012" unitRef="USD" decimals="-3">0</us-gaap:PreferredStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="-3">37000</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of_30-Apr-2012" unitRef="USD" decimals="-3">38000</us-gaap:CommonStockValue>
<us-gaap:TreasuryStockValue contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="-3">1252000</us-gaap:TreasuryStockValue>
<us-gaap:TreasuryStockValue contextRef="Context_As_Of_30-Apr-2012" unitRef="USD" decimals="-3">1252000</us-gaap:TreasuryStockValue>
<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="-3">17784000</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="Context_As_Of_30-Apr-2012" unitRef="USD" decimals="-3">21204000</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="-3">-16482000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_30-Apr-2012" unitRef="USD" decimals="-3">-25143000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="-3">-68000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="Context_As_Of_30-Apr-2012" unitRef="USD" decimals="-3">-125000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30-Apr-2010" unitRef="USD" decimals="-3">1577000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30-Apr-2010_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">37000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30-Apr-2010_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" decimals="-3">-219000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30-Apr-2010_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">15193000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30-Apr-2010_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">-12680000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30-Apr-2010_StatementEquityComponentsAxis_StockSubscriptionReceivableMember" unitRef="USD" decimals="-3">-750000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30-Apr-2010_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="-3">-4000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="-3">19000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30-Apr-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">37000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30-Apr-2011_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" decimals="-3">-1252000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30-Apr-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">17784000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30-Apr-2011_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">-16482000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30-Apr-2011_StatementEquityComponentsAxis_StockSubscriptionReceivableMember" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30-Apr-2011_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="-3">-68000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30-Apr-2012" unitRef="USD" decimals="-3">-5278000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30-Apr-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">38000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30-Apr-2012_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" decimals="-3">-1252000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30-Apr-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">21204000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30-Apr-2012_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">-25143000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30-Apr-2012_StatementEquityComponentsAxis_StockSubscriptionReceivableMember" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30-Apr-2012_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="-3">-125000</us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="-3">12650000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_30-Apr-2012" unitRef="USD" decimals="-3">6922000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="Context_As_Of_30-Apr-2011" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="Context_As_Of_30-Apr-2012" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
<us-gaap:TemporaryEquitySharesOutstanding contextRef="Context_As_Of_30-Apr-2011" unitRef="shares" decimals="0">12533333</us-gaap:TemporaryEquitySharesOutstanding>
<us-gaap:TemporaryEquitySharesOutstanding contextRef="Context_As_Of_30-Apr-2012" unitRef="shares" decimals="0">12533333</us-gaap:TemporaryEquitySharesOutstanding>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_30-Apr-2011" unitRef="USD_per_Share" decimals="0">10</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_30-Apr-2012" unitRef="USD_per_Share" decimals="0">10</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_30-Apr-2011" unitRef="shares" decimals="0">56075</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_30-Apr-2012" unitRef="shares" decimals="0">56075</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_30-Apr-2011" unitRef="shares" decimals="0">0</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_30-Apr-2012" unitRef="shares" decimals="0">0</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_30-Apr-2011" unitRef="shares" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_30-Apr-2012" unitRef="shares" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_30-Apr-2011" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_30-Apr-2012" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_30-Apr-2011" unitRef="shares" decimals="0">125000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_30-Apr-2012" unitRef="shares" decimals="0">125000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_30-Apr-2011" unitRef="shares" decimals="0">36956667</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_30-Apr-2012" unitRef="shares" decimals="0">37740345</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_30-Apr-2011" unitRef="shares" decimals="0">33870000</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_30-Apr-2012" unitRef="shares" decimals="0">34529000</us-gaap:CommonStockSharesOutstanding>
<us-gaap:TreasuryStockShares contextRef="Context_As_Of_30-Apr-2011" unitRef="shares" decimals="0">3236000</us-gaap:TreasuryStockShares>
<us-gaap:TreasuryStockShares contextRef="Context_As_Of_30-Apr-2012" unitRef="shares" decimals="0">3236000</us-gaap:TreasuryStockShares>
<csbr:PersonalizedOncologySolutions contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">3382000</csbr:PersonalizedOncologySolutions>
<csbr:PersonalizedOncologySolutions contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">2332000</csbr:PersonalizedOncologySolutions>
<csbr:TranslationalOncologySolutions contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">3500000</csbr:TranslationalOncologySolutions>
<csbr:TranslationalOncologySolutions contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">4817000</csbr:TranslationalOncologySolutions>
<us-gaap:SalesRevenueServicesNet contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">6882000</us-gaap:SalesRevenueServicesNet>
<us-gaap:SalesRevenueServicesNet contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">7149000</us-gaap:SalesRevenueServicesNet>
<csbr:CostOfPersonalizedOncologySolutions contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">1665000</csbr:CostOfPersonalizedOncologySolutions>
<csbr:CostOfPersonalizedOncologySolutions contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">2356000</csbr:CostOfPersonalizedOncologySolutions>
<csbr:CostOfTranslationalOncologySolutions contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">1846000</csbr:CostOfTranslationalOncologySolutions>
<csbr:CostOfTranslationalOncologySolutions contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">2543000</csbr:CostOfTranslationalOncologySolutions>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">2910000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">2937000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:SellingAndMarketingExpense contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">1085000</us-gaap:SellingAndMarketingExpense>
<us-gaap:SellingAndMarketingExpense contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">2928000</us-gaap:SellingAndMarketingExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">4611000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">5450000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:OperatingExpenses contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">12117000</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">16214000</us-gaap:OperatingExpenses>
<us-gaap:OperatingIncomeLoss contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">-5235000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">-9065000</us-gaap:OperatingIncomeLoss>
<csbr:GrantIncome contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">1465000</csbr:GrantIncome>
<csbr:GrantIncome contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">0</csbr:GrantIncome>
<us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">-36000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
<us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">417000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
<us-gaap:OtherNonoperatingIncome contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">15000</us-gaap:OtherNonoperatingIncome>
<us-gaap:OtherNonoperatingIncome contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">-15000</us-gaap:OtherNonoperatingIncome>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">1444000</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">402000</us-gaap:NonoperatingIncomeExpense>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">-3791000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">-8663000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">11000</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">-2000</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">-3802000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">-3802000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">-8661000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_30-Apr-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_30-Apr-2012_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_30-Apr-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_30-Apr-2012_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">-8661000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_30-Apr-2012_StatementEquityComponentsAxis_StockSubscriptionReceivableMember" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_30-Apr-2012_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_FYE_30-Apr-2011" unitRef="USD_per_Share" decimals="2">-0.11</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_FYE_30-Apr-2012" unitRef="USD_per_Share" decimals="2">-0.19</us-gaap:EarningsPerShareBasicAndDiluted>
<csbr:WeightedAverageNumberOfSharesBasicAndDiluted contextRef="Context_FYE_30-Apr-2011" unitRef="shares" decimals="0">33774000</csbr:WeightedAverageNumberOfSharesBasicAndDiluted>
<csbr:WeightedAverageNumberOfSharesBasicAndDiluted contextRef="Context_FYE_30-Apr-2012" unitRef="shares" decimals="0">46815000</csbr:WeightedAverageNumberOfSharesBasicAndDiluted>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">-64000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">-57000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease>
<us-gaap:ComprehensiveIncomeNetOfTax contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">-3866000</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:ComprehensiveIncomeNetOfTax contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">-8718000</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_30-Apr-2010_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">35780000</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_30-Apr-2010_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="shares" decimals="0">1064000</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_30-Apr-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">33870000</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_30-Apr-2011_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="shares" decimals="0">3236000</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_30-Apr-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">34529000</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_30-Apr-2012_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="shares" decimals="0">3236000</us-gaap:SharesOutstanding>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">3133000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">3133000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_StockSubscriptionReceivableMember" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">3323000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_FYE_30-Apr-2012_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_FYE_30-Apr-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">3323000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_FYE_30-Apr-2012_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_FYE_30-Apr-2012_StatementEquityComponentsAxis_StockSubscriptionReceivableMember" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_FYE_30-Apr-2012_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<csbr:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">20000</csbr:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
<csbr:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">0</csbr:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
<csbr:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" decimals="-3">0</csbr:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
<csbr:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">20000</csbr:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
<csbr:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">0</csbr:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
<csbr:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_StockSubscriptionReceivableMember" unitRef="USD" decimals="-3">0</csbr:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
<csbr:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="-3">0</csbr:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
<csbr:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">98000</csbr:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
<csbr:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Context_FYE_30-Apr-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">1000</csbr:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
<csbr:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Context_FYE_30-Apr-2012_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" decimals="-3">0</csbr:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
<csbr:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Context_FYE_30-Apr-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">97000</csbr:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
<csbr:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Context_FYE_30-Apr-2012_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">0</csbr:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
<csbr:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Context_FYE_30-Apr-2012_StatementEquityComponentsAxis_StockSubscriptionReceivableMember" unitRef="USD" decimals="-3">0</csbr:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
<csbr:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Context_FYE_30-Apr-2012_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="-3">0</csbr:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
<csbr:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">104000</csbr:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised>
<csbr:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="shares" decimals="0">0</csbr:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised>
<csbr:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised contextRef="Context_FYE_30-Apr-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">534000</csbr:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised>
<csbr:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised contextRef="Context_FYE_30-Apr-2012_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="shares" decimals="0">0</csbr:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised>
<csbr:AdjustmentsToAdditionalPaidInCapitalCancellationOfStockSubscriptionReceivable contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">0</csbr:AdjustmentsToAdditionalPaidInCapitalCancellationOfStockSubscriptionReceivable>
<csbr:AdjustmentsToAdditionalPaidInCapitalCancellationOfStockSubscriptionReceivable contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">0</csbr:AdjustmentsToAdditionalPaidInCapitalCancellationOfStockSubscriptionReceivable>
<csbr:AdjustmentsToAdditionalPaidInCapitalCancellationOfStockSubscriptionReceivable contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" decimals="-3">0</csbr:AdjustmentsToAdditionalPaidInCapitalCancellationOfStockSubscriptionReceivable>
<csbr:AdjustmentsToAdditionalPaidInCapitalCancellationOfStockSubscriptionReceivable contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">-750000</csbr:AdjustmentsToAdditionalPaidInCapitalCancellationOfStockSubscriptionReceivable>
<csbr:AdjustmentsToAdditionalPaidInCapitalCancellationOfStockSubscriptionReceivable contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">0</csbr:AdjustmentsToAdditionalPaidInCapitalCancellationOfStockSubscriptionReceivable>
<csbr:AdjustmentsToAdditionalPaidInCapitalCancellationOfStockSubscriptionReceivable contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_StockSubscriptionReceivableMember" unitRef="USD" decimals="-3">750000</csbr:AdjustmentsToAdditionalPaidInCapitalCancellationOfStockSubscriptionReceivable>
<csbr:AdjustmentsToAdditionalPaidInCapitalCancellationOfStockSubscriptionReceivable contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="-3">0</csbr:AdjustmentsToAdditionalPaidInCapitalCancellationOfStockSubscriptionReceivable>
<us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">-845000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
<us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
<us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" decimals="-3">-1033000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
<us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">188000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
<us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
<us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_StockSubscriptionReceivableMember" unitRef="USD" decimals="-3">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
<us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="-3">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
<us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">-2172000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
<us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="shares" decimals="0">2172000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_StockSubscriptionReceivableMember" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="Context_FYE_30-Apr-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="Context_FYE_30-Apr-2012_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="Context_FYE_30-Apr-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="Context_FYE_30-Apr-2012_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="Context_FYE_30-Apr-2012_StatementEquityComponentsAxis_StockSubscriptionReceivableMember" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="Context_FYE_30-Apr-2012_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">158000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="shares" decimals="0">0</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="Context_FYE_30-Apr-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">125000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="Context_FYE_30-Apr-2012_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="shares" decimals="0">0</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">-64000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" decimals="-3">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_StockSubscriptionReceivableMember" unitRef="USD" decimals="-3">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax contextRef="Context_FYE_30-Apr-2011_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="-3">-64000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">-57000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax contextRef="Context_FYE_30-Apr-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax contextRef="Context_FYE_30-Apr-2012_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" decimals="-3">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax contextRef="Context_FYE_30-Apr-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax contextRef="Context_FYE_30-Apr-2012_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax contextRef="Context_FYE_30-Apr-2012_StatementEquityComponentsAxis_StockSubscriptionReceivableMember" unitRef="USD" decimals="-3">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax contextRef="Context_FYE_30-Apr-2012_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="-3">-57000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax>
<us-gaap:ShareBasedCompensation contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">3133000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">3323000</us-gaap:ShareBasedCompensation>
<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">11000</us-gaap:DeferredIncomeTaxExpenseBenefit>
<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">-2000</us-gaap:DeferredIncomeTaxExpenseBenefit>
<us-gaap:Depreciation contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">42000</us-gaap:Depreciation>
<us-gaap:Depreciation contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">105000</us-gaap:Depreciation>
<us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">-1000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
<us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>


<csbr:IncreaseDecreaseInAccountReceivable contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">493000</csbr:IncreaseDecreaseInAccountReceivable>
<csbr:IncreaseDecreaseInAccountReceivable contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">-1000</csbr:IncreaseDecreaseInAccountReceivable>
<csbr:IncreaseOrDecreaseInGrantReceivable contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">517000</csbr:IncreaseOrDecreaseInGrantReceivable>
<csbr:IncreaseOrDecreaseInGrantReceivable contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">-517000</csbr:IncreaseOrDecreaseInGrantReceivable>
<csbr:IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">-217000</csbr:IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets>
<csbr:IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">-71000</csbr:IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets>
<us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">0</us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities>
<us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">150000</us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">636000</us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">96000</us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">62000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">323000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">697000</us-gaap:IncreaseDecreaseInDeferredRevenue>
<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">-433000</us-gaap:IncreaseDecreaseInDeferredRevenue>
<us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">-77000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
<us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">0</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">-54000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">-5227000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">85000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">519000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">1000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">-84000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">-519000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<csbr:ProceedsFromIssuanceOfRedeemableCommonSharesAndWarrantsInPrivatePlacement contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">9095000</csbr:ProceedsFromIssuanceOfRedeemableCommonSharesAndWarrantsInPrivatePlacement>
<csbr:ProceedsFromIssuanceOfRedeemableCommonSharesAndWarrantsInPrivatePlacement contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">0</csbr:ProceedsFromIssuanceOfRedeemableCommonSharesAndWarrantsInPrivatePlacement>
<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">1033000</us-gaap:PaymentsForRepurchaseOfCommonStock>
<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
<us-gaap:ProceedsFromWarrantExercises contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">21000</us-gaap:ProceedsFromWarrantExercises>
<us-gaap:ProceedsFromWarrantExercises contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">97000</us-gaap:ProceedsFromWarrantExercises>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">8083000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">97000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">-60000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">-54000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">7885000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">-5703000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="Context_FYE_30-Apr-2011" unitRef="USD" decimals="-3">305000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="Context_FYE_30-Apr-2012" unitRef="USD" decimals="-3">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
<us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="Context_FYE_30-Apr-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;Note 1. Organization and Basis of Presentation&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Background&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Champions Oncology, Inc. (the &amp;#8220;Company&amp;#8221;), is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Company&amp;#8217;s Tumorgraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The Company uses this technology to derive revenue for two customer groups: Personalized Oncology Solutions (&amp;#8220;POS&amp;#8221;) and Translational Oncology Solutions (&amp;#8220;TOS&amp;#8221;). POS assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug studies and related personalized oncology services. The Company&amp;#8217;s TOS business offers a technology platform to pharmaceutical and biotechnology companies using proprietary Tumorgraft studies, which have been shown to be predictive of how drugs may perform in clinical settings.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company has two operating subsidiaries: Champions Oncology (Israel), Limited and Champions Biotechnology U.K., Limited. For the years ended April 30, 2012 and 2011, there were no material revenues earned by these subsidiaries.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&amp;#8220;GAAP&amp;#8221;). Certain immaterial reclassifications have been made to prior year amounts to conform to the current year presentation.&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="Context_FYE_30-Apr-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;Note 2. Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Principles of Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries: Biomerk, Inc., Champions Biotechnology U.K., Limited and Champions Oncology (Israel), Limited. All material intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The financial statements of the Company&amp;#8217;s foreign subsidiaries, all of which have a functional currency other than the U.S. dollar, have been translated into the U.S. dollar for the Company&amp;#8217;s consolidated financial statements for each period being presented. Translation gains and losses are recognized as a component of accumulated other comprehensive loss in the accompanying consolidated balance sheets. The Company is subject to foreign exchange rate fluctuations in connection with the Company&amp;#8217;s international operations.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company considers all highly liquid investments purchased with an original maturity of three months or less, to be cash equivalents. At various times, the Company has amounts on deposit at financial institutions in excess of federally insured limits.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Fair Value&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The carrying value of cash and cash equivalents, accounts receivable, prepaid expenses, deposits and other receivables, accounts payable, and accrued liabilities approximate their fair value based on the liquidity or the short-term maturities of these instruments. The fair value hierarchy promulgated by GAAP consists of three levels:&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 9pt;"&gt;&lt;/td&gt;
&lt;td style="width: 15pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;i&gt;Level one&lt;/i&gt; &amp;#8212; Quoted market prices in active markets for identical assets or liabilities;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;table style="margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 9pt;"&gt;&lt;/td&gt;
&lt;td style="width: 15pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;i&gt;Level two&lt;/i&gt; &amp;#8212; Inputs other than level one inputs that are either directly or indirectly observable; and&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;table style="margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 9pt;"&gt;&lt;/td&gt;
&lt;td style="width: 15pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;i&gt;Level three&lt;/i&gt; &amp;#8212; Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter. The Company has one liability measured at fair value on a recurring basis, which are warrants that were issued in connection with a private placement of the Company&amp;#8217;s securities that closed during April 2011 and is discussed more fully in Note 7. As of April 30, 2012 and 2011, these warrants had an estimated fair value of $555,000 and $972,000, respectively, which was calculated by the Monte Carlo simulation valuation method using level three inputs. The Company has no assets that are measured at fair value on a recurring basis and there were no assets or liabilities measured at fair value on a non-recurring basis during the years ended April 30, 2012 and 2011.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The following table presents information about our warrants liability, which was our only financial instrument measured at fair value on a recurring basis using significant unobservable inputs (Level 3) as defined in ASC Topic 820 at April 30 (dollars in thousands):&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 95%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 9pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; width: 74%;"&gt;Balance beginning of year&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;(972&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-left: 9pt;"&gt;Transfers to (from) Level 3&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-left: 9pt;"&gt;Total gains (losses) included in earnings&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;417&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(36&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-left: 9pt;"&gt;Purchases/issuances/settlements, net&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(936&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Balance end of year&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;(555&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;(972&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Accounts Receivable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Accounts receivable represent amounts due under agreements with pharmaceutical and biotechnology companies for TOS and amounts due under agreements with patients for POS. At each reporting period, the Company evaluates open accounts receivable for collectability and records an allowance for potentially uncollectible accounts. As of April 30, 2012, the allowance for these accounts was $14,000. There was no allowance recorded for open receivables at April 30, 2011. Accounts receivable is also comprised of certain unbilled accounts receivable for services completed under TOS that have not been billed as of the balance sheet date. As of April 30, 2012 and 2011, the Company had unbilled receivables of $104,000 and $305,000, respectively.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Restricted Cash&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company has restricted cash of $150,000, which is classified as a noncurrent asset. This restricted cash serves as collateral for corporate credit cards to provide financial assurance that the Company will fulfill its obligations. The cash is held in custody by the issuing bank, is restricted as to withdrawal or use, and is currently invested in an interest-bearing Certificate of Deposit (&amp;#8220;CD&amp;#8221;). Though the initial CD matures in the second quarter of fiscal 2013, the cash will be reinvested into another CD to continue use of the corporate cards. The Company accounts for this CD as a non-current asset supporting operations of the business.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Property and equipment is recorded at cost and primarily consists of laboratory equipment, furniture and fixtures, and computer hardware and software. Depreciation is calculated on a straight-line basis over the estimated useful lives of the various assets ranging from three to seven years. Property and equipment consisted of the following (in thousands):&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6"&gt;April 30,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; width: 74%;"&gt;Furniture and fixtures&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;58&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;10&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Computer equipment and software&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;287&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;119&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Laboratory equipment&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;167&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;56&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Leasehold improvements&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;2&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;2&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Sortware in-progress&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;216&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;24&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Total property and equipment&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;730&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;211&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Less: Accumulated depreciation&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(170&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(65&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Property and equipment, net&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;560&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;146&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Depreciation expense was $105,000 and $42,000 for the years ended April 30, 2012 and 2011, respectively.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Impairment of Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Impairment losses are to be recognized when the carrying amount of a long-lived asset is not recoverable or exceeds its fair value.&amp;#160;&amp;#160;The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that a carrying value may not be recoverable.&amp;#160;&amp;#160;The Company uses estimates of future cash flows over the remaining useful life of a long- lived asset or asset group to determine the recoverability of the asset.&amp;#160;&amp;#160;These estimates only include the net cash flows directly associated with, and that are expected to arise as a direct result of, the use and eventual disposition of the asset or asset group.&amp;#160;&amp;#160;The Company has not recognized any impairment losses for the Company&amp;#8217;s long-lived assets for the years ending April 30, 2012 and 2011.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Goodwill&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Goodwill represents the excess of the cost over the fair market value of the net assets acquired including identifiable assets.&amp;#160;&amp;#160;Goodwill is tested annually, or more frequently if circumstances indicate potential impairment, by comparing its fair value to its carrying amount.&amp;#160;&amp;#160;The determination of whether or not goodwill is impaired involves significant judgment.&amp;#160;&amp;#160;Although the Company believes its goodwill is not impaired, changes in strategy or market conditions could significantly impact the judgments and may require future adjustments to the carrying value of goodwill.&amp;#160;&amp;#160;The Company uses a two-step process to test for goodwill impairment.&amp;#160;&amp;#160;The first step is to screen for potential impairment, while the second step measures the amount of the impairment, if any.&amp;#160;&amp;#160;The first step of the goodwill impairment test compares the fair value of each reporting unit with its carrying amount, including goodwill.&amp;#160;&amp;#160;If the fair value of the reporting unit exceeds its carrying value, goodwill is not impaired.&amp;#160;&amp;#160;If the carrying value of the reporting unit&amp;#8217;s net assets, including goodwill, exceeds the fair value of the reporting unit, then the Company determines the implied fair value of goodwill.&amp;#160;&amp;#160;If the carrying value of goodwill exceeds its implied fair value, then an impairment of goodwill has occurred and an impairment loss would be recognized for the difference between the carrying amount and the implied fair value of goodwill as a component of operating income.&amp;#160;&amp;#160;The implied fair value of goodwill is calculated by subtracting the fair value of tangible and intangible assets associated with the reporting unit from the fair value of the unit. The Company tests for goodwill impairment at the operating segment level.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company has not recognized any impairment losses for the Company&amp;#8217;s goodwill for the years ending April 30, 2012 and 2011.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Deferred Revenue&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Deferred revenue represents payments received in advance for services to be performed.&amp;#160;&amp;#160;When services are rendered, deferred revenue is then recognized as earned.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Warrant Liability&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Warrant liability represents the fair value of warrants issued in connection with the Securities Purchase Agreement as liabilities based on the certain exercise price reset provisions.&amp;#160;&amp;#160;The&amp;#160;&amp;#160;liability, which is recorded at fair value on the accompanying consolidated balance sheets, is calculated by the Monte Carlo simulation valuation method.&amp;#160;&amp;#160;The change in fair value of these warrants is recognized as other income or expense in the consolidated statements of operations.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company derives revenue from its POS and TOS businesses. Personalized oncology solutions assist physicians by providing information to help guide the development of personalized treatment plans for their patients using our core offerings, including testing oncology drugs and drug combinations on personalized TumorGrafts, and through other services. Translational oncology solutions offer a preclinical TumorGraft platform to pharmaceutical and biotechnology companies using proprietary TumorGraft studies, which have been shown to be predictive of how drugs may perform in clinical settings.&amp;#160;&amp;#160;The Company recognizes revenue when the following four basic criteria are met: (i) a contract has been entered into with its customers; (ii) delivery has occurred or services rendered to its customers; (iii) the fee is fixed and determinable as noted in the contract; and (iv) collectability is reasonably assured.&amp;#160;&amp;#160;The Company utilizes a proportional performance revenue recognition model for its TOS business, under which it recognizes revenue as performance occurs, based on the relative outputs of the performance that have occurred up to that point in time under the respective agreement, typically the delivery of reports to its customers documenting the results of testing protocols.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;When a POS or TOS arrangement involves multiple elements, the items included in the arrangement (deliverables) are evaluated to determine whether they represent separate units of accounting.&amp;#160;&amp;#160;The Company performs this evaluation at the inception of an arrangement and as each item in the arrangement is delivered.&amp;#160;&amp;#160;Generally, the Company accounts for a deliverable (or a group of deliverables) separately if: (i) the delivered item(s) has standalone value to the customer, and (ii) if the Company has given the customer a general right of return relative to the delivered item(s) and the delivery or performance of the undelivered item(s) or service(s) is probable and substantially in the Company&amp;#8217;s control.&amp;#160;&amp;#160;All revenue from contracts determined not to have separate units of accounting is recognized based on consideration of the most substantive delivery factor of all the elements in the contract or if there is no predominant deliverable upon delivery of the final element of the arrangement.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Cost of Personalized Oncology Solutions&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Cost of POS consists of costs related to POS revenue earned from implantations, drug studies, oncology panels, and gene sequencing services, as well as indirect internal costs, such as salaries for personnel directly engaged in these services. Direct costs associated with implantation revenues are primarily related to mice purchases and maintenance and shipping of tumor tissue. Direct study costs are primarily incurred from mice purchases and maintenance and drug purchases. Direct panel costs are primarily related to physicians&amp;#8217; honorariums and any panel participation costs such as travel, lodging and meals. Direct gene sequencing costs are primarily related to costs billed from the gene sequencing service provider. All costs are expensed as incurred.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Cost of Translational Oncology Solutions&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Cost of TOS consists of costs related to TOS revenue.&amp;#160;&amp;#160;Direct costs include mice purchases and maintenance costs for studies completed internally and charges from CROs for studies handled externally. Indirect costs include salaries for personnel directly engaged in providing TOS services. All costs of performing studies in-house are expensed as incurred.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Research and Development&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Research and development costs represent both costs incurred internally for research and development activities, including personnel costs and mice purchases and maintenance, as well as costs incurred externally to facilitate research activities, such as tumor tissue procurement and characterization expenses.&amp;#160;&amp;#160;All research and development costs are expensed as incurred.&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Sales and Marketing&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Selling and marketing expenses represent costs incurred to promote the Company&amp;#8217;s services offered, including salaries, benefits and related costs of our sales and marketing personnel, and represent costs of advertising and other selling and marketing expenses. All sales and marketing costs, including advertising costs, are expensed as incurred. Advertising costs were $135,000 and $69,000 for fiscal 2012 and 2011, respectively.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Basic and Dilutive Loss Per Common Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Basic loss per share is calculated by dividing loss available to common shareholders by the weighted average number of common shares (including redeemable common stock) outstanding for the year.&amp;#160;&amp;#160;Diluted loss per share is calculated based on the weighted average number of common shares (including redeemable common stock) outstanding for the year, plus the dilutive effect of common stock purchase warrants, stock options and restricted stock units using the treasury stock method.&amp;#160;&amp;#160;Contingently issuable shares are included in the calculation of basic earnings per share when all contingencies surrounding the issuance of the shares are met and the shares are issued or issuable.&amp;#160;&amp;#160;Contingently issuable shares are included in the calculation of dilutive earnings per share as of the beginning of the reporting period if, at the end of the reporting period, all contingencies surrounding the issuance of the shares are satisfied or would be satisfied if the end of the reporting period were the end of the contingency period.&amp;#160;&amp;#160;Due to the net losses for the years ended April 30, 2012 and 2011, basic and diluted loss per share were the same, as the effect of potentially dilutive securities would have been anti-dilutive.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The following table reflects the total potential share-based instruments outstanding at April 30, 2012 and 2011 that could have an effect on the future computation of dilution per common share:&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;table align="center" style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap"&gt;Year Ended April 30,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; width: 74%;"&gt;Stock options&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;14,866,038&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;14,320,948&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Warrants&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,416,667&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,912,019&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Restricted stock&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;25,000&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;100,000&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Total common stock equivalents&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;16,307,705&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;16,332,967&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Share-Based Payments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company typically recognizes expense for share-based payments based on the fair value of awards on the date of grant.&amp;#160;&amp;#160;The Company uses the Black-Scholes option pricing model to estimate fair value.&amp;#160;&amp;#160;The Black-Scholes option valuation model was developed for use in estimating the fair value of short-traded options that have no vesting restrictions and are fully transferable.&amp;#160;&amp;#160;The option pricing model requires the Company to estimate certain key assumptions such as expected life, volatility, risk free interest rates and dividend yield to determine the fair value of share-based awards.&amp;#160;&amp;#160;These assumptions are based on historical information and management judgment.&amp;#160;&amp;#160;The risk-free interest rate used is based on the United States treasury security rate with a term consistent with the expected term of the award at the time of the grant.&amp;#160;&amp;#160;The expected holding period of options are based on the Company&amp;#8217;s historical experience.&amp;#160;&amp;#160;The volatility rates are based upon a weighted average of the Company&amp;#8217;s volatility and the weighted average of a four-member peer group of companies in the Company&amp;#8217;s industry.&amp;#160;&amp;#160;The Company does not anticipate paying a dividend, and therefore, no expected dividend yield was used.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company expenses share-based payments over the period that the awards are expected to vest, net of estimated forfeitures.&amp;#160;&amp;#160;If actual forfeitures differ from management&amp;#8217;s estimates, compensation expense is adjusted.&amp;#160;&amp;#160;The Company will report cash flows resulting from tax deductions in excess of the compensation cost recognized from those options (excess tax benefits) as financing cash flows, if they should arise.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Deferred income taxes have been provided to show the effect of temporary differences between the recognition of expenses for financial and income tax reporting purposes and between the tax basis of assets and liabilities, and their reported amounts in the consolidated financial statements.&amp;#160;&amp;#160;In assessing the realizability of deferred tax assets, the Company assesses the likelihood that deferred tax assets will be recovered through tax planning strategies or from future taxable income, and to the extent that recovery is not likely or there is insufficient operating history, a valuation allowance is established.&amp;#160;&amp;#160;The Company adjusts the valuation allowance in the period management determines it is more likely than not that net deferred tax assets will or will not be realized.&amp;#160;&amp;#160;As of April 30, 2012 and 2011, the Company provided a valuation allowance for all net deferred tax assets, as recovery is not more likely than not based on an insufficient history of earnings.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Tax positions are positions taken in a previously filed tax return or positions expected to be taken in a future tax return that are reflected in measuring current or deferred income tax assets and liabilities reported in the consolidated financial statements.&amp;#160;&amp;#160;Tax positions include, but are not limited to, the following:&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 9pt;"&gt;&lt;/td&gt;
&lt;td style="width: 15pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;An allocation or shift of income between taxing jurisdictions;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;table style="margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 9pt;"&gt;&lt;/td&gt;
&lt;td style="width: 15pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;The characterization of income or a decision to exclude reportable taxable income in a tax return; or&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;table style="margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 9pt;"&gt;&lt;/td&gt;
&lt;td style="width: 15pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;A decision to classify a transaction, entity or other position in a tax return as tax exempt.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company reflects tax benefits only if it is more likely than not that we will be able to sustain the tax position, based on its technical merits.&amp;#160;&amp;#160;If a tax benefit meets this criterion, it is measured and recognized based on the largest amount of benefit that is cumulatively greater than 50% likely to be realized.&amp;#160;&amp;#160;The Company has no unrecognized tax benefits as of April 30, 2012 and 2011.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company&amp;#8217;s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties on the Company&amp;#8217;s balance sheets at April 30, 2012 and 2011, and has not recognized interest and/or penalties in the statement of operations for either period.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;During September 2011, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No. 2011-08, &amp;#8220;Testing Goodwill for Impairment&amp;#8221; (&amp;#8220;ASU 2011-08&amp;#8221;). ASU 2011-08 is intended to simplify the testing of goodwill for impairment by permitting an entity to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test, which is currently required for all companies that report goodwill. The amendments are effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011, although early adoption is permitted. The Company does not anticipate that the adoption of this guidance will have a material impact on its financial position and results of operations.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;During June 2011, the FASB issued ASU No. 2011-05, &amp;#8220;Presentation of Comprehensive Income&amp;#8221; (&amp;#8220;ASU 2011-05&amp;#8221;). ASU 2011-05 provides for the option to present the total of comprehensive income, the components of net income and the components of other comprehensive income (&amp;#8220;OCI&amp;#8221;) either in a single continuous statement of comprehensive income or in two separate but consecutive statements. Regardless of which format is chosen, the amendments establish a requirement for entities to present on the face of the financial statements reclassification adjustments for items that are reclassified from OCI to net income in the statement(s) where the components of net income and the components of OCI are presented. The amendments in ASU 2011-05 are effective, on a retrospective basis, for public entities for interim and annual periods beginning after December 15, 2011; however, during December 2011 the FASB issued ASU No. 2011-12, which defers those changes in ASU 2011-05 that relate to the presentation of reclassification adjustments. The Company has adopted this standard, which only impacts the disclosures required, but has no impact on the financial position or results of operations.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;During May 2011, the FASB issued ASU No. 2011-04, &amp;#8220;Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRS&amp;#8221; (&amp;#8220;ASC 2011-04&amp;#8221;). The amendments in ASC 2011-04 were issued in order to align the fair value measurement and disclosure requirements in GAAP and International Financial Reporting Standards. Consequently, the amendments change the wording used to describe many of the requirements in GAAP for measuring fair value and for disclosing information about fair value measurements. However, many of the amendments in ASC 2011-04 will not result in a change in the application of the requirements in ASC 820, Fair Value Measurement. The amendments in ASU 2011-04 are effective, on a prospective basis, for public entities for interim and annual periods beginning after December 15, 2011. The Company has adopted this standard, which had no impact on its financial position or results of operations.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
<csbr:CephalonAgreementTextBlock contextRef="Context_FYE_30-Apr-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;Note 3. Cephalon Agreement&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On March 16, 2011, the Company entered into an agreement with Cephalon, Inc., (&amp;#8220;Cephalon&amp;#8221;), a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd., pursuant to which the Company conducts TumorGraft studies on proprietary chemical compounds provided by Cephalon to determine the activity or response of a compound in potential clinical indications. In April 2011, Cephalon paid an initiation fee of $1.4 million to the Company, which is reflected within deferred revenue on the consolidated balance sheet as of April 30, 2011. As models, along with required reports, are delivered, the deferred revenue will be recognized on a proportionate basis in accordance with the Company&amp;#8217;s revenue recognition policies. Under this agreement, revenue of $918,000 was recognized during the year ended April 30, 2012. The Company anticipates that the studies will be completed within 18 months of the execution of the agreement.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Cephalon will, under certain conditions, also pay the Company various amounts upon achieving certain milestones. Potential milestone payments that could be received under the Agreement total $27 million. These milestones are based on the performance of the compounds in preclinical testing and are dependent upon testing the compound in clinical settings and obtaining FDA approval. No milestones have been achieved to date. In addition, under certain conditions, Cephalon will pay the Company royalties on any commercialized products developed under the Agreement. No royalties have been received or earned to date. Cephalon reserves the right to exercise and pay a one-time fee of in lieu of the milestone or royalty payments. These fees range from $460,000 to $880,000 per compound.&lt;/p&gt;</csbr:CephalonAgreementTextBlock>
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Context_FYE_30-Apr-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;Note 4. Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Operating Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;As of April 30, 2012, we lease the following facilities under non-cancelable operating lease agreements:&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 9pt;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;One University Plaza, Suite 307, Hackensack, New Jersey 07601, which, since November 2011, serves as our corporate headquarters and consists of approximately 3,800 square feet of office space. The lease expires in April 2014. We incurred $71,000 of rental costs in fiscal 2012 relative to this lease. No rental costs were incurred in fiscal 2011 relative to this lease.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; margin: 0pt 0px 0pt 27pt; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 9pt;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;855 North Wolfe Street, Suite 619, Baltimore, Maryland 21205, which consists of approximately 1,650 square feet of laboratories and office space where we conduct operations related to our primary service offerings.&amp;#160; The lease expires in June 2014.&amp;#160;We incurred $65,000 and $53,000 of rental costs relative to this lease in fiscal 2012 and 2011, respectively.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; margin: 0pt 0px 0pt 27pt; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 9pt;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;17 Hatidhar Street, Ra&amp;#8217;anana, Israel, which consists of approximately 1,500 square feet and serves as office headquarters for Champions Oncology, Israel. The lease expires in July 2012; however the Company plans to extend this lease. We incurred $29,000 and $11,000 of rental costs relative to this lease in fiscal 2012 and 2011, respectively.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Future minimum lease payments due each fiscal year are as follows (in thousands):&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="width: 75%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; width: 82%;"&gt;2013&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 15%;"&gt;162,000&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;2014&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;141,000&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;303,000&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;As we intend to extend the lease in Israel, of the minimum lease payments in the table above, $28,000 and $7,000 relate to anticipated future lease payments in fiscal 2013 and 2014, respectively.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Research and Development Materials Purchase Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;In February 2010, the Company entered into a research and development materials purchase agreement with a foreign hospital for the acquisition of TumorGrafts.&amp;#160;&amp;#160;Under the agreement, the Company made monthly payments to the foreign hospital of approximately $37,000, commencing March 1, 2010 and ending April 1, 2011.&amp;#160;&amp;#160;The accrued liability outstanding at April 30, 2011 was $147,000. The Company entered into a Mutual Release Agreement on December 15, 2011 and reversed this liability.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Legal Matters&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company is party to certain legal matters arising in the ordinary course of its business.&amp;#160;&amp;#160;The Company has evaluated its potential exposure to these legal matters and noted no such exposures. The Company is not aware of any other matters that would have a material impact on the Company&amp;#8217;s financial position or results of operations.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Registration Payment Arrangements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company has entered into registration rights agreements in connection with a private placement of its securities, which closed during April 2011 and is discussed more fully in Note 7.&amp;#160;&amp;#160;This registration rights agreement contains provisions that may call for the Company to pay penalties in certain circumstances.&amp;#160;&amp;#160;This registration payment arrangement primarily relates to the Company&amp;#8217;s ability to file a registration statement within a particular time period, have a registration statement declared effective within a particular time period and to maintain the effectiveness of the registration statement for a particular time period.&amp;#160;&amp;#160;The Company does not believe it is probable that penalty payments will be made for the registration rights agreement discussed above and, accordingly, has not accrued for such potential penalties as of April 30, 2012 and 2011.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<csbr:LicensingAgreementsDisclosureTextBlock contextRef="Context_FYE_30-Apr-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;Note 5. Licensing Agreements&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;During fiscal 2011, the Company was a party to several different licensing agreements. During April 2011, the Company terminated all of these licensing agreements with the exception of the agreement concerning Irinophore C, which is described further below. All rights related to all other licensing agreements that were terminated during April 2011 were returned to the underlying companies and no amounts were payable under these other agreements when they were terminated.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;In February 2010, the Company entered into an exclusive option agreement with a Canadian company for which it paid and expensed $40,000 (Canadian) during the Company&amp;#8217;s fiscal 2010 year. The option agreement granted the Company the exclusive right to review Irinophore C, a nanoparticle drug compound, for the treatment of various forms of cancer, including melanoma, prostate, breast, and lung cancer through April 2011. During the option year, the Company performed various TumorGraft testing on the nanoparticle compound. In March 2011, the Company exercised its option to license Irinophore C, a liposomal formulation of Irinotecan. Under the terms of the agreement, the Company&amp;#8217;s exercise of the option resulted in amounts due to the Canadian company of $85,000 (Canadian) comprised of the option exercise price and reimbursement to the Canadian company for past patent costs, which was expensed in the Company&amp;#8217;s fiscal year ended April 30, 2011. The Company satisfied this obligation during fiscal 2012. On the first anniversary of the agreement (March 2012), an additional license fee of $45,000 (Canadian) became due, which is recognized as a liability as of April 30, 2012. Commencing with the second anniversary of the agreement (March 2013), the Company will be obligated to pay a minimum annual royalty of $10,000 (Canadian). Under the terms of the license agreement, the Company will be required to pay up to $3.0 million in development milestones, if achieved. Upon commercialization, the Company would also be required to make royalty and sales milestone payments based upon revenues.&lt;/p&gt;</csbr:LicensingAgreementsDisclosureTextBlock>
<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="Context_FYE_30-Apr-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;Note 6. Share-Based Payments&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Stock-based compensation in the amount of $3.3 million and $3.1 million was recognized for the years ended April 30, 2012 and 2011, respectively.&amp;#160;&amp;#160;Stock-based compensation costs were recorded as follows (in thousands):&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap"&gt;Year Ended April 30,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; width: 74%;"&gt;General and administrative&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;3,009&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;2,887&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Sales and marketing&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;240&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;105&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Research and development&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;39&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;101&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;TOS cost of sales&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;10&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;40&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;POS cost of sales&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;25&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Total stock-based compensation expense&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;3,323&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;3,133&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;2010 Equity Incentive Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On February 18, 2011, shareholders owning a majority of the issued and outstanding shares of the Company executed a written consent approving the 2010 Equity Incentive Plan (&amp;#8220;2010 Equity Plan&amp;#8221;). The purpose of the 2010 Equity Plan is to grant (i) Non-statutory Stock Options; (ii) Restricted Stock Awards; and (iii) Stock Appreciation Rights (collectively, stock-based compensation) to its employees, directors and non-employees. Total stock awards under the 2010 Equity Plan shall not exceed 30,000,000 shares of common stock. Options and Stock Appreciation Rights expire no later than ten years from the date of grant and the awards vest as determined by the Board of Directors. Options and Stock Appreciation Rights have a strike price not less than 100% of the fair market value of the common stock subject to the option or right at the date of grant.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;2008 Equity Incentive Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company has previously granted (i) Non-statutory Stock Options; (ii) Restricted Stock Awards; and (iii) Stock Appreciation Rights (collectively, stock-based compensation) to its employees, directors and non-employees under a 2008 Equity Incentive Plan (the &amp;#8220;2008 Equity Plan&amp;#8221;).&amp;#160;&amp;#160;Such awards may be granted by the Company&amp;#8217;s Board of Directors.&amp;#160;&amp;#160;Options granted under the 2008 Equity Plan expire no later than ten years from the date of grant and the awards vest as determined by the Board of Directors.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;For share-based payments to non-employee consultants under both the 2010 and 2008 Equity Incentive Plan, the fair value of the share-based consideration issued is used to measure the transaction, as management believes this to be a more reliable measure of fair value than the services received.&amp;#160;&amp;#160;The fair value of the award is expensed over the period service is provided to the Company; however, it is ultimately measured at the price of the Company&amp;#8217;s common stock or the fair value of stock options using the Black-Scholes valuation model on the date that the commitment for performance by the non-employee consultant has been reached or performance is complete, which is generally the vesting date of the award.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Director Compensation Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On February 22, 2010, the Compensation Committee of the Board of Directors of the Company adopted the Director Compensation Plan of 2010 (the &amp;#8220;Director Plan&amp;#8221;) to replace the Company&amp;#8217;s former compensation policy for directors, effective for the 2010 calendar year commencing January 1, 2010.&amp;#160;&amp;#160;Under the Director Plan, independent directors of the Company are entitled to an annual award of five-year stock options to purchase 50,000 shares of the Company&amp;#8217;s unregistered common stock, and the Chairman of the Board of the Company is entitled to an annual award of options to purchase 100,000 shares of the Company&amp;#8217;s unregistered common stock.&amp;#160;&amp;#160;Independent directors who serve on one or more Board committees will also receive an annual grant of five-year options to purchase 50,000 shares of the Company&amp;#8217;s unregistered common stock or 50,000 shares of restricted unregistered common stock.&amp;#160;&amp;#160;The Company will also pay each independent director $15,000 to offset the tax liability in respect of any unregistered restricted stock awards.&amp;#160;&amp;#160;All unregistered common stock options and unregistered restricted stock issued under the Director Plan vest quarterly at a rate of 25%. For the initial Director Plan year, an independent director could have chosen to receive a cash fee equal to the value of the unregistered restricted common stock that would have otherwise been granted.&amp;#160;&amp;#160;The Chairman of the Board was also entitled to the same arrangement for his services on Board committees at a rate of twice that of an independent director.&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Stock Option Grants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Black-Scholes assumptions used to calculate the fair value of options granted during the years ended April 30, 2012 and 2011 were as follows:&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap"&gt;Year Ended April 30,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; width: 64%;"&gt;Expected term in years&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; width: 15%;" nowrap="nowrap"&gt;3.0 - 6.0&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; width: 15%;" nowrap="nowrap"&gt;2.7 - 6.25&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Risk-free interest rates&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;0.4% - 2.3%&lt;/td&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;0.9% - 2.7%&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Volatility&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;90% - 108%&lt;/td&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;105% - 122%&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Dividend yield&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;0%&lt;/td&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;0%&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The weighted average fair value of stock options granted during the years ending April 30, 2012 and 2011, was $0.58 and $0.73, respectively. The Company&amp;#8217;s stock options activity and related information as of and for the years ended April 30, 2012 and 2011 is as follows (dollars in thousands):&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left; vertical-align: top;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Weighted&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left; vertical-align: top;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Weighted&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Average&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left; vertical-align: top;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Directors&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Average&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Remaining&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Aggregate&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left; vertical-align: top;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Non-&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;and&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Exercise&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Contractual&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Intrinsic&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left; vertical-align: top;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Employees&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Employees&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Life (Years)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Value&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left; vertical-align: top;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; width: 22%; vertical-align: top;"&gt;Outstanding, May 1, 2011&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;1,610,000&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;12,710,948&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;14,320,948&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;0.88&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;8.4&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;1,780&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top;"&gt;Granted&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;115,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,380,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,495,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.77&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top;"&gt;Exercised&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(50,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(50,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.17&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top;"&gt;Forfeited&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(348,581&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(348,581&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.94&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top;"&gt;Expired&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(265,000&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(286,329&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(551,329&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt;"&gt;0.60&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top;"&gt;Outstanding, April 30, 2012&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1,410,000&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;13,456,038&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;14,866,038&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 2.5pt;"&gt;0.88&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 2.5pt;"&gt;7.6&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 2.5pt;"&gt;0&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top;"&gt;Vested and expected to vest as of April 30, 2012&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1,410,000&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;13,456,038&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;14,866,038&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 2.5pt;"&gt;0.88&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 2.5pt;"&gt;7.6&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 2.5pt;"&gt;0&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top;"&gt;Exercisable as of April 30, 2012&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1,241,667&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;6,502,163&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;7,743,830&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 2.5pt;"&gt;0.89&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 2.5pt;"&gt;6.8&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 2.5pt;"&gt;0&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;table align="center" style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left; vertical-align: top;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Weighted&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left; vertical-align: top;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Weighted&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Average&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left; vertical-align: top;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Directors&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Average&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Remaining&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Aggregate&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left; vertical-align: top;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Non-&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;and&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Exercise&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Contractual&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Intrinsic&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left; vertical-align: top;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Employees&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Employees&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Life (Years)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Value&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left; vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; width: 22%; vertical-align: top;"&gt;Outstanding, May 1, 2010&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;1,890,000&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;1,427,948&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;3,317,948&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;0.77&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;4.4&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;250&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top;"&gt;Granted&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;70,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;11,781,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;11,851,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.89&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top;"&gt;Exercised&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top;"&gt;Forfeited&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top;"&gt;Expired&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(500,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(348,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(848,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.58&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top;"&gt;Change in employee status&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;150,000&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(150,000&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt;"&gt;1.18&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top;"&gt;Outstanding, April 30, 2011&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1,610,000&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;12,710,948&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;14,320,948&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 2.5pt;"&gt;0.88&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 2.5pt;"&gt;8.4&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 2.5pt;"&gt;1,780&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top;"&gt;Vested and expected to vest as of April 30, 2011&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1,610,000&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;12,710,948&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;14,320,948&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 2.5pt;"&gt;0.88&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 2.5pt;"&gt;8.4&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 2.5pt;"&gt;1,780&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top;"&gt;Exercisable as of April 30, 2011&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1,533,333&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;2,461,644&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;3,994,977&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 2.5pt;"&gt;0.85&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 2.5pt;"&gt;5.7&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 2.5pt;"&gt;597&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Included in the balances outstanding as of May 1, 2011 in the table above are 10,000,000 options granted to the Company&amp;#8217;s Chief Executive Officer and its&amp;#160;President at the time of commencement of their employment in fiscal 2011, of which 5,000,000 contain only service-based vesting provisions and 5,000,000 contain both service and performance-based vesting provisions.&amp;#160;&amp;#160;The service-based provisions of these options provide for vesting to occur monthly over a period of three years.&amp;#160;&amp;#160;The performance-based conditions, which must be met prior to vesting to occur include: (i) closing of one or more financings of the Company in the aggregate amount of at least $5,000,000; (ii) bringing in new Company management; (iii) launching of personalized medicine (oncology) business; and (iv) commencing implementation of the Company&amp;#8217;s business plan.&amp;#160;&amp;#160;The determination as to whether these performance-based conditions have been met was to be made by the Company&amp;#8217;s Board of Directors.&amp;#160;&amp;#160;The service-based options, like all of the Company&amp;#8217;s service-based options, are expensed on a straight-line basis.&amp;#160;&amp;#160;Since the straight-line method is not available for performance or market-based share-based payments, the 5,000,000 performance-based options are being expensed on an accelerated basis.&amp;#160;&amp;#160;The Company&amp;#8217;s Board of Directors determined that in April 2011 each of the performance conditions under the awards were met.&amp;#160;&amp;#160;As a result, the awards will be expensed based on each monthly vesting tranche.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Restricted Stock Grants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;A summary of the activity related to restricted stock grants for the years ended April 30, 2012 and 2011 is as follows (dollars in thousands):&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap"&gt;2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Weighted&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Weighted&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Average&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Average&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Grant Date&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Grant Date&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Total&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Fair Value&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Total&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Fair Value&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Shares&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Per Share&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Shares&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Per Share&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; width: 48%;"&gt;Nonvested, beginning of period&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;100,000&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;0.90&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;33,526&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;0.80&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Granted&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;50,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.75&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;205,555&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.90&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Vested&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(125,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.87&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(133,397&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.87&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Forfeited&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(5,684&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.77&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Expired&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Nonvested, end of period&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;25,000&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 2.5pt;"&gt;0.75&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;100,000&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 2.5pt;"&gt;0.90&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The total fair value of shares vested during the years ended April 30, 2012 and 2011 was $84,000 and $133,000, respectively. As of April 30, 2012, there was $19,000 of unrecognized stock compensation expense related to nonvested restricted stock awards. This cost is expected to be recognized over a weighted average period of 0.3 years.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Stock Purchase Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;As of April 30, 2012, the Company has warrants outstanding for the purchase of 1,416,667 shares of its common stock, all of which were exercisable.&amp;#160;&amp;#160;Of these warrants, 1,266,667 were issued in connection with the April 2011 financing arrangement and are accounted for as liabilities as further discussed in Note 7.&amp;#160;&amp;#160;Activity related to these warrants, which expire at various dates through April 2016, is summarized as follows (dollars in thousands):&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Weighted&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Weighted&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Average&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Number&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Average&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Remaining&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Aggregate&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;of&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Exercise&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Contractual&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Intrinsic&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Shares&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Life (Years)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Value&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; width: 48%;"&gt;Outstanding, May 1, 2011&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;1,912,019&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;0.73&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;3.7&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;524&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Granted&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Exercised&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(495,352&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.20&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;234&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Forfeited&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Expired&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Outstanding, April 30, 2012&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1,416,667&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 2.5pt;"&gt;0.91&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 2.5pt;"&gt;3.8&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 2.5pt;"&gt;0&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;table align="center" style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Weighted&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Weighted&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Average&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Number&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Average&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Remaining&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Aggregate&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;of&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Exercise&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Contractual&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Intrinsic&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Shares&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Life (Years)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Value&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; width: 48%;"&gt;Outstanding, May 1, 2010&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;748,983&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;0.36&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;2.1&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;367&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Granted&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,266,667&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.90&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Exercised&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(103,631&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.20&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(83&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Forfeited&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Expired&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Outstanding, April 30, 2011&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1,912,019&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 2.5pt;"&gt;0.73&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 2.5pt;"&gt;3.7&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 2.5pt;"&gt;524&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
<csbr:RedeemableCommonStockAndStockPurchaseWarrantTextBlock contextRef="Context_FYE_30-Apr-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;Note 7. Redeemable Common Stock and Stock Purchase Warrant&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On March 24, 2011, the Company entered into a Securities Purchase Agreement with several accredited investors for the sale of an aggregate 12,533,333 shares of the Company&amp;#8217;s Common Stock at a purchase price of $0.75 per share, or aggregate proceeds of $9.4 million, $500,000 of which was sold to officers and directors of the Company. As part of this transaction, the Company also issued warrants to purchase an aggregate 1,266,667 shares of Common Stock at an exercise price of $0.90 per share. These warrants expire five years after the closing date, which occurred on April 4, 2011. The Securities Purchase Agreement contains certain anti-dilution protections for the investors and certain registration rights with respect to the shares of Common Stock issued to the investors. Furthermore, investors will have the right to require the Company to redeem the purchased common shares held by such investors (the &amp;#8220;Put Option&amp;#8221;) for cash for $0.75 per share upon a change of control or sale of substantially all of the company&amp;#8217;s assets. The Put Option will terminate upon the achievement of certain financial milestones by the Company, the sale of 25% of the common shares purchased by an investor, with respect only to the shares owned by such investor, or in certain other circumstances as outlined in the Securities Purchase Agreement.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Due to the Put Option described above, the Company has accounted for Common Stock issued under the Securities Purchase Agreement as temporary equity, which is reflected under the caption &amp;#8220;redeemable common stock&amp;#8221; on the accompanying consolidated balance sheets. The total amount allocated to these common shares was $8.2 million. This allocation is equal to the total proceeds of $9.4 million, less the amount allocated to the warrants of $936,000 and is also net of direct and incremental costs associated with the Securities Purchase Agreement of $305,000.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The warrants issued in connection with the Securities Purchase Agreement contain certain exercise price reset provisions. Under these provisions, the exercise price of the warrants may be adjusted downward should the Company have future sales of its Common Stock for no consideration or for a consideration per share less than the Per Share Price (as such term is defined in the Securities Purchase Agreement).&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company has granted demand registration rights in connection with the investment in common shares and the common shares underlying the warrants. These rights include the requirement of the Company to file certain registration statements within a specified time period and to have these registration statements declared effective within a specified time period. If the Company is not able to comply with these registration requirements, the Company will be required to pay cash penalties equal to 1.0% of the aggregate Purchase Price paid by the investors for each 30-day period in which a Registration Default, as defined in the Securities Purchase Agreement, exists. The Company may become subject to these penalty provisions if it fails to have a registration statement for the common shares declared effective, or to maintain the effectiveness of such registration statement. The total amount of potential penalties under this registration payment arrangement is $41,000 for each 30-day period in which a registration default exists; however, as of the date of this filing, the Company does not believe these penalties to be probable and accordingly, has not established an accrual for such registration payment arrangements.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company has accounted for the warrants issued in connection with the Securities Purchase Agreement as a liability based on the exercise price reset provisions described above. This liability, which is recorded at fair value on the accompanying consolidated balance sheets, totaled $936,000 at the time of the close of the Securities Purchase Agreement. As of April 30, 2011, the fair value of these warrants increased $36,000 to $972,000. During the year ended April 30, 2012, the fair value of these warrants decreased by $417,000 to $555,000. The change in fair value of these warrants has been, and will be, recognized as other income (expense) on the Company&amp;#8217;s consolidated statements of operations. The fair value of these warrants was calculated by the Monte Carlo simulation valuation method. Assumptions used to calculate the fair value of these warrants were as follows:&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6"&gt;Year Ended April 30,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; width: 74%;"&gt;Expected term in years&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;3.9&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;5.0&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Risk-free interest rates&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.6&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;2.0&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Volatility&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;102&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;102&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Dividend yield&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company will continue to adjust the warrant liability for changes in fair value until the earlier of the exercise of the warrants, at which time the liability will be reclassified to stockholders' equity, or expiration of the warrants.&lt;/p&gt;</csbr:RedeemableCommonStockAndStockPurchaseWarrantTextBlock>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Context_FYE_30-Apr-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;Note 8. Stockholders&amp;#8217; Equity&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company has 56,075 shares of Series A 12% preferred stock authorized and no shares issued and outstanding at April 30, 2012 and 2011.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On February 18, 2011, the Company&amp;#8217;s Board of Directors approved the amendment and restatement of the Company&amp;#8217;s Certificate of Incorporation (or &amp;#8220;Charter&amp;#8221;) and submitted the amended and restated Charter to the Company&amp;#8217;s shareholders for approval.&amp;#160;&amp;#160;On February 18, 2011, shareholders owning a majority of the issued and outstanding shares of the Company executed a written consent approving the amended and restated Charter.&amp;#160;&amp;#160;In accordance with regulations of the Securities and Exchange Commission, the amended and restated Charter was filed with the SEC on March 7, 2011. Among other changes, the amended and restated Charter changes the name of the Company to &amp;#8220;Champions Oncology, Inc.&amp;#8221; and increases the authorized shares which the Company may issue from 50,000,000 shares of Common Stock to 125,000,000 shares of Common Stock.&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;As of April 30, 2010, the Company had executed subscription agreements for the private placement of 1,000,000 shares of unregistered common stock for $0.75 per share or $750,000. The amount was reflected as a subscription receivable as a contra-equity account on the balance sheet as of April 30, 2010. In 2011, the Company became aware that the amount was uncollectible in full and the full amount was reversed against additional paid-in capital.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Treasury Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;In May 2009, the Board of Directors approved a stock repurchase agreement with a Board member which obligated the Company to purchase up to approximately $407,000 of the Company&amp;#8217;s common stock held by the Board member through April of 2011 providing that the Board member continued his services under a consulting agreement executed concurrently with the stock repurchase agreement.&amp;#160;&amp;#160;Under the stock repurchase agreement, the Company made an initial purchase of $125,000 of the Company&amp;#8217;s shares of common stock, and may have been required to make quarterly purchases of $31,250 of the Company&amp;#8217;s common stock held by the Board member after the end of each fiscal quarter.&amp;#160;&amp;#160;The purchase price per share of the common stock for each purchase is equal to the lesser price of $0.50 or 50% of the average closing price of the stock as quoted on the OTC Bulletin Board for the 30-day trading period ending on the day before the date of each purchase as long as the consulting agreement remained in effect.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Under the agreement, the Company has paid this Board member approximately $73,000 and $218,000 for the purchase of 171,883 and 474,289&amp;#160;&amp;#160;shares of the Company&amp;#8217;s common stock for the years ended April 30, 2011 and April 30, 2010, respectively.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Effective May 2010, the Company terminated the consulting agreement with the Board member which correspondingly terminated the stock repurchase agreement.&amp;#160;&amp;#160;Because the requirement for the Company to transfer cash in exchange for the shares of common stock ended with the termination of the consulting agreement, during the year ended April 30, 2011, the Company reclassified $114,000 from accrued stock purchase on the balance sheet into additional paid-in capital, which represented the remaining amount of the purchase price required under the repurchase arrangement after the termination of the consulting agreement.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Furthermore, under the stock repurchase agreement, the Company, at its option for one year following the termination of the consulting agreement, may purchase all or any part of the shares that have not been previously purchased, up to but not to exceed, 2,250,000 shares of the common stock, subject to the pricing formula described above. In April 2011, the Company repurchased 2,000,000 shares of the Company&amp;#8217;s common stock from the Board Member of the Company, for a cash purchase price of $0.48 per share, or an aggregate purchase price of $960,000. The Company repurchased the shares using proceeds from the $9,400,000 received under the Securities Purchase Agreement that closed in April 2011 and is described in Note 7.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company has not repurchased any shares in fiscal 2012.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<us-gaap:IncomeTaxDisclosureTextBlock contextRef="Context_FYE_30-Apr-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;Note 9. Provision for Income Taxes&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The components of the provision for income taxes are as follows (in thousands):&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="14" nowrap="nowrap"&gt;Year Ended April 30, 2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Federal&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;State&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Foreign&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; width: 48%;"&gt;Current&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;1&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;(3&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;(2&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Deferred&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(2,523&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(172&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(68&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(2,763&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Change in valuation allowance&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;2,523&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;172&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;68&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;2,763&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;(3&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;(2&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="14" nowrap="nowrap"&gt;Year Ended April 30, 2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Federal&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;State&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Foreign&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; width: 48%;"&gt;Current&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;11&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;11&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Deferred&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(1,100&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(167&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(68&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(1,335&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Change in valuation allowance&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;1,100&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;167&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;68&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;1,335&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;11&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;11&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;A reconciliation between the Company&amp;#8217;s effective tax rate and the United States statutory tax rate for the years ended April 30, 2012 and 2011 is as follows:&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;table align="center" style="width: 93%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap"&gt;Year Ended April 30,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; width: 74%;"&gt;Federal income tax at statutory rate&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;34.0&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;%&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;34.0&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;State income tax, net of federal benefit&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;2.3&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;4.5&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Permanent differences&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.5&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(0.7&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Other&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(3.0&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;2.5&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Change in valuation allowance&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(31.9&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(35.2&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Changes in tax rates&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(2.9&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(5.4&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom; text-decoration: none;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; text-decoration: none;"&gt;Income tax expense&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; text-decoration: none;"&gt;&lt;font style="text-underline-style: double;"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; text-decoration: none;"&gt;%&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; text-decoration: none;"&gt;(0.3&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; text-decoration: none;"&gt;)%&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.&amp;#160;&amp;#160;Significant components of the Company&amp;#8217;s deferred tax assets and liabilities as of April 30, 2012 and 2011 consist of the following (in thousands):&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap"&gt;As of April 30,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; width: 74%;"&gt;Accrued liabilities&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;62&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;9&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Depreciation and amortization&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;80&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(4&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;State taxes&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;5&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Stock-based compensation expense&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;2,685&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,863&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Capitalized research and development costs&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;798&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,182&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Foreign net operating loss carry-forward&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;265&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;198&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Net operating loss carry-forward&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;2,478&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;363&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Total deferred tax assets&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;6,373&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;3,611&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Less: Valuation allowance&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(6,373&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(3,611&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Net deferred tax asset&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Management has evaluated the available evidence about future tax planning strategies, taxable income and other possible sources of realization of deferred tax assets and has established a full valuation allowance against its net deferred tax assets as of April, 30, 2012.&amp;#160;&amp;#160;For the years ended April 30, 2012 and 2011, the Company recorded a valuation allowance of $6,373,000 and $3,611,000, respectively.&amp;#160;&amp;#160;The increase in valuation allowance from fiscal year 2011 to 2012 is due to deferred tax assets generated relative to stock compensation and net operating loss carryforwards.&amp;#160;&amp;#160;The Company has established a valuation allowance against its deferred tax assets as it is currently more-likely-than-not that all or a portion of a deferred tax asset will not be realized.&amp;#160;&amp;#160;The valuation allowance reduces deferred tax assets to an amount that management believes will more likely than not be realized.&amp;#160;&amp;#160;Changes in valuation allowances from period to period are included in the tax provision in the period of change.&amp;#160;&amp;#160;In determining whether a valuation allowance is required, the Company takes into account all evidence with regard to the utilization of a deferred tax asset including past earnings history, expected future earnings, the character and jurisdiction of such earnings, unsettled circumstances that, if unfavorably resolved, would adversely affect utilization of a deferred tax asset, carryback and carryforward periods, and tax strategies that could potentially enhance the likelihood of realization of a deferred tax asset.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;As of April 30, 2012 and 2011, the Company&amp;#8217;s estimated U.S. net operating loss carry-forwards were approximately $6,825,000 and $928,000, respectively.&amp;#160;&amp;#160;As of April 30, 2012 and 2011, the Company&amp;#8217;s foreign net operating loss carry-forward was approximately $1,138,000 and $790,000, respectively.&amp;#160;&amp;#160;The Company&amp;#8217;s federal and state net operating losses begin expiring in 2029.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company files income tax returns in various jurisdictions with varying statues of limitations.&amp;#160;&amp;#160;As of April 30, 2012, the earliest tax year still subject to examination for state purposes is fiscal 2009.&amp;#160;&amp;#160;The Company&amp;#8217;s tax years for periods ending April 30, 1995 and forward are subject to examination by the United States and certain states due to the carry-forward of unutilized net operating losses.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On August 8, 2011, the Company was notified that it was selected for a tax examination by the Internal Revenue Service (IRS) on the Application for Certification of Qualified Investments Eligible for Credits and Grants Under the Qualifying Therapeutic Discovery Project program filed under the Patient Protection and Affordable Care Act of 2010 for the 2009 and 2010 tax years. The examination commenced on September 30, 2011 and was completed during the fourth quarter of the year ended April 30, 2012. The audit resulted in a disallowance to the net operating loss carry-forwards of $607,000. This disallowance was offset by a corresponding increase to amortizable intangible assets related to capitalized research and development expenditures of $542,000.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="Context_FYE_30-Apr-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;Note 10. Related Party Transactions&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Related party transactions include transactions between the Company and its shareholders, management, or affiliates.&amp;#160;&amp;#160;The following transactions were in the normal course of operations and were measured at the exchange amount, which is the amount of consideration established and agreed to by the parties.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;During the years ended April 30, 2012 and 2011, the Company paid one of its directors and former Chief Executive Officer, $18,000 and $143,000, respectively, in consulting fees and salary.&amp;#160;&amp;#160;During the years ended April 30, 2012 and, 2011, the Company paid certain members of our Board of Directors $141,000 and $60,000, respectively, for consulting services unrelated to their duties as board members.&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;During the years ended April 30, 2012 and 2011, the Company recognized approximately $20,000 and $201,000, respectively, in revenues from companies whose board members were also members of our Board of Directors.&amp;#160;&amp;#160;Of these amounts, no related receivables were outstanding as of April 30, 2012 and 2011.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
<us-gaap:CashFlowSupplementalDisclosuresTextBlock contextRef="Context_FYE_30-Apr-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;Note 12. Supplemental Schedule of Cash Flow Information&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Supplemental cash flow information is as follows (in thousands):&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6"&gt;Year Ended April 30,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Supplemental cash flow information:&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-left: 9pt;"&gt;Cash paid for interest&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-left: 9pt;"&gt;Cash paid for income taxes&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in;"&gt;Supplemental disclosure of non-cash investing and financing activities:&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-left: 0.25in; width: 74%;"&gt;Stock subscription receivable&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;(750&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-left: 0.25in;"&gt;Purchases of property and equipment included in accounts payable&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;192&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
<csbr:GrantIncomeTextBlock contextRef="Context_FYE_30-Apr-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;Note 13. Grant Income&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;In October 2010, the Company was notified that it was awarded total cash grants of approximately $1.5 million under the Qualifying Therapeutic Discovery Project program administered under section 48D of the Internal Revenue Code, of which approximately $1.0 million related to qualifying expenses the Company had previously incurred during fiscal 2010 and $0.5 million related to qualifying expenses which the Company expected to incur during fiscal 2011. In November 2010, the Company received approximately $1.0 million related to the 2010 expenditures. The Company received a final payment of $0.5 million related to 2011 expenditures on February 13, 2012.&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On August 8, 2011 the Company was notified that it was selected for a tax examination by the Internal Revenue Service (IRS) on the Application for Certification of Qualified Investments Eligible for Credits and Grants Under the Qualifying Therapeutic Discovery Project program filed under the Patient Protection and Affordable Care Act of 2010 for the 2009 and 2010 tax years. The examination commenced during the second quarter of fiscal 2012.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The IRS expanded its scope to include the fiscal year 2011 tax return, which was filed in January 2012. The examinations of fiscal 2009 and 2010 were completed in the fourth quarter of fiscal 2012. The examination of fiscal 2011 completed in the first quarter of fiscal 2013. The audit of all three fiscal years (2009, 2010, and 2011) resulted in no additional tax due or receivable.&lt;/p&gt;</csbr:GrantIncomeTextBlock>
<us-gaap:SubsequentEventsTextBlock contextRef="Context_FYE_30-Apr-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;Note 14. Subsequent Events&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;None.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
<us-gaap:SegmentReportingDisclosureTextBlock contextRef="Context_FYE_30-Apr-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;Note 11. Business Segment Information&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company operates in two segments, POS and TOS. The accounting policies of the Company&amp;#8217;s segments are the same as those described in Note 2. The Company evaluates performance of its segments based on profit or loss from operations before stock compensation expense, depreciation and amortization, interest expense, interest income, gain on sale of assets, special charges or benefits, and income taxes (&amp;#8220;segment profit&amp;#8221;). Management uses segment profit information for internal reporting and control purposes and considers it important in making decisions regarding the allocation of capital and other resources, risk assessment, and employee compensation, among other matters. The following tables summarize, for the periods indicated, operating results by business segment (in thousands):&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom; text-decoration: none;"&gt;
&lt;td style="text-align: left; font-weight: bold; text-decoration: none;" nowrap="nowrap"&gt;Year Ended April 30, 2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; text-decoration: none;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold; text-decoration: none;" colspan="2" nowrap="nowrap"&gt;Personalized &lt;br  /&gt;Oncology &lt;br  /&gt;Solutions &lt;br  /&gt;(POS)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; text-decoration: none;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; text-decoration: none;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold; text-decoration: none;" colspan="2" nowrap="nowrap"&gt;Translational &lt;br  /&gt;Oncology &lt;br  /&gt;Solutions &lt;br  /&gt;(TOS)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; text-decoration: none;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; text-decoration: none;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold; text-decoration: none;" colspan="2" nowrap="nowrap"&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif; text-decoration: none;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif; text-decoration: none;"&gt;&lt;b&gt;Unallocated&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif; text-decoration: none;"&gt;&lt;b&gt;Corporate&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif; text-decoration: none;"&gt;&lt;b&gt;Overhead&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; text-decoration: none;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; text-decoration: none;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold; text-decoration: none;" colspan="2" nowrap="nowrap"&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif; text-decoration: none;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif; text-decoration: none;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif; text-decoration: none;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif; text-decoration: none;"&gt;&lt;b&gt;Consolidated&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; text-decoration: none;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; width: 48%;"&gt;Net revenue&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;2,332&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;4,817&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;7,149&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Direct cost of services&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(2,331&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(2,533&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(4,864&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Sales and marketing costs&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(1,752&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(936&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(2,688&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Other operating expenses&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(2,898&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(2,441&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(5,339&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Stock compensation expense (1)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(3,323&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(3,323&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Segment profit (loss)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;(1,751&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;(1,550&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;(5,764&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;(9,065&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom; text-decoration: none;"&gt;
&lt;td style="text-align: left; font-weight: bold; text-decoration: none;" nowrap="nowrap"&gt;Year Ended April 30, 2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; text-decoration: none;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold; text-decoration: none;" colspan="2" nowrap="nowrap"&gt;Personalized &lt;br  /&gt;Oncology &lt;br  /&gt;Solutions &lt;br  /&gt;(POS)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; text-decoration: none;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; text-decoration: none;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold; text-decoration: none;" colspan="2" nowrap="nowrap"&gt;Translational &lt;br  /&gt;Oncology &lt;br  /&gt;Solutions &lt;br  /&gt;(TOS)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; text-decoration: none;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; text-decoration: none;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold; text-decoration: none;" colspan="2" nowrap="nowrap"&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif; text-decoration: none;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif; text-decoration: none;"&gt;&lt;b&gt;Unallocated&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif; text-decoration: none;"&gt;&lt;b&gt;Corporate&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif; text-decoration: none;"&gt;&lt;b&gt;Overhead&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; text-decoration: none;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; text-decoration: none;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold; text-decoration: none;" colspan="2" nowrap="nowrap"&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif; text-decoration: none;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif; text-decoration: none;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif; text-decoration: none;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif; text-decoration: none;"&gt;&lt;b&gt;Consolidated&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; text-decoration: none;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; width: 48%;"&gt;Net revenue&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;3,382&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;3,500&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;6,882&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Direct cost of services&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(1,665&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(1,806&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(3,471&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Sales and marketing costs&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(980&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(980&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Other operating expenses&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(2,809&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(1,724&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(4,533&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Stock compensation expense (1)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(3,133&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(3,133&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Segment profit (loss)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1,717&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;(1,115&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;(5,837&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;(5,235&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&amp;#160;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px 0pt 0.25in; font: 10pt times new roman, times, serif;"&gt;(1) Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;All of the Company&amp;#8217;s revenue is recorded in the United States and substantially all of its long-lived assets are in the United States.&lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>

<!-- Footnote Section -->
<link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>csbr-20120430.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Viewer Version 1.0.5.8 on Wednesday, July 18, 2012 10:32:43 AM -->
<schema targetNamespace="http://championsoncology.com/20120430" elementFormDefault="qualified" xmlns:csbr="http://championsoncology.com/20120430" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:country="http://xbrl.sec.gov/country/2011-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2011-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:num="http://www.xbrl.org/dtr/type/numeric">
<annotation><appinfo>
<link:roleType roleURI="http://championsoncology.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
<link:definition>001 - Document - DOCUMENT AND ENTITY INFORMATION</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://championsoncology.com/role/StatementOfFinancialPositionClassified" id="StatementOfFinancialPositionClassified">
<link:definition>002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://championsoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical" id="CondensedConsolidatedBalanceSheetsParenthetical">
<link:definition>003 - Statement - CONSOLIDATED BALANCE SHEETS [Parenthetical]</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://championsoncology.com/role/StatementOfIncomeAlternative" id="StatementOfIncomeAlternative">
<link:definition>004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://championsoncology.com/role/StatementOfOtherComprehensiveIncome" id="StatementOfOtherComprehensiveIncome">
<link:definition>005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://championsoncology.com/role/CONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" id="CONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT">
<link:definition>006 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://championsoncology.com/role/StatementOfCashFlowsIndirect" id="StatementOfCashFlowsIndirect">
<link:definition>007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://championsoncology.com/role/ConsolidatedStatementsOfCashFlowsParenthetical" id="ConsolidatedStatementsOfCashFlowsParenthetical">
<link:definition>008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS [Parenthetical]</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://championsoncology.com/role/OrganizationAndBasisOfPresentation" id="OrganizationAndBasisOfPresentation">
<link:definition>009 - Disclosure - Organization and Basis of Presentation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://championsoncology.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
<link:definition>010 - Disclosure - Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://championsoncology.com/role/CephalonAgreement" id="CephalonAgreement">
<link:definition>011 - Disclosure - Cephalon Agreement</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://championsoncology.com/role/Commitmentsandcontingencies" id="Commitmentsandcontingencies">
<link:definition>012 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://championsoncology.com/role/LicensingAgreements" id="LicensingAgreements">
<link:definition>013 - Disclosure - Licensing Agreements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://championsoncology.com/role/ShareBasedPayments" id="ShareBasedPayments">
<link:definition>014 - Disclosure - Share-Based Payments</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://championsoncology.com/role/RedeemableCommonStockAndStockPurchaseWarrant" id="RedeemableCommonStockAndStockPurchaseWarrant">
<link:definition>015 - Disclosure - Redeemable Common Stock and Stock Purchase Warrant</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://championsoncology.com/role/StockholdersEquity" id="StockholdersEquity">
<link:definition>016 - Disclosure - Stockholders' Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://championsoncology.com/role/ProvisionForIncomeTaxes" id="ProvisionForIncomeTaxes">
<link:definition>017 - Disclosure - Provision for Income Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://championsoncology.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
<link:definition>018 - Disclosure - Related Party Transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://championsoncology.com/role/BusinessSegmentInformation" id="BusinessSegmentInformation">
<link:definition>019 - Disclosure - Business Segment Information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://championsoncology.com/role/SupplementalScheduleOfCashFlowInformation" id="SupplementalScheduleOfCashFlowInformation">
<link:definition>020 - Disclosure - Supplemental Schedule of Cash Flow Information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://championsoncology.com/role/GrantIncome" id="GrantIncome">
<link:definition>021 - Disclosure - Grant Income</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://championsoncology.com/role/SupplementalCashFlowInformation" id="SupplementalCashFlowInformation">
<link:definition>022 - Disclosure - Subsequent Events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="csbr-20120430_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="csbr-20120430_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="csbr-20120430_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="csbr-20120430_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
</appinfo></annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<import namespace="http://fasb.org/us-gaap/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/invest/2011-01-31" schemaLocation="http://xbrl.sec.gov/invest/2011/invest-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/country/2011-01-31" schemaLocation="http://xbrl.sec.gov/country/2011/country-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/currency/2011-01-31" schemaLocation="http://xbrl.sec.gov/currency/2011/currency-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/exch/2011-01-31" schemaLocation="http://xbrl.sec.gov/exch/2011/exch-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
<import namespace="http://xbrl.sec.gov/dei/2011-01-31" schemaLocation="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<element name="DocumentAndEntityInformationAbstract" id="csbr_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="BalanceSheetParentheticalAbstract" id="csbr_BalanceSheetParentheticalAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PersonalizedOncologySolutions" id="csbr_PersonalizedOncologySolutions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TranslationalOncologySolutions" id="csbr_TranslationalOncologySolutions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CostOfPersonalizedOncologySolutions" id="csbr_CostOfPersonalizedOncologySolutions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CostOfTranslationalOncologySolutions" id="csbr_CostOfTranslationalOncologySolutions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="GrantIncome" id="csbr_GrantIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WeightedAverageNumberOfSharesBasicAndDiluted" id="csbr_WeightedAverageNumberOfSharesBasicAndDiluted" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockSubscriptionReceivableMember" id="csbr_StockSubscriptionReceivableMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" id="csbr_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" id="csbr_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AdjustmentsToAdditionalPaidInCapitalCancellationOfStockSubscriptionReceivable" id="csbr_AdjustmentsToAdditionalPaidInCapitalCancellationOfStockSubscriptionReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>

<element name="IncreaseDecreaseInAccountReceivable" id="csbr_IncreaseDecreaseInAccountReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IncreaseOrDecreaseInGrantReceivable" id="csbr_IncreaseOrDecreaseInGrantReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets" id="csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ProceedsFromIssuanceOfRedeemableCommonSharesAndWarrantsInPrivatePlacement" id="csbr_ProceedsFromIssuanceOfRedeemableCommonSharesAndWarrantsInPrivatePlacement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CephalonAgreementAbstract" id="csbr_CephalonAgreementAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CephalonAgreementTextBlock" id="csbr_CephalonAgreementTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LicensingAgreementsAbstract" id="csbr_LicensingAgreementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LicensingAgreementsDisclosureTextBlock" id="csbr_LicensingAgreementsDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RedeemableCommonStockAndStockPurchaseWarrantAbstract" id="csbr_RedeemableCommonStockAndStockPurchaseWarrantAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RedeemableCommonStockAndStockPurchaseWarrantTextBlock" id="csbr_RedeemableCommonStockAndStockPurchaseWarrantTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="GrantIncomeAbstract" id="csbr_GrantIncomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="GrantIncomeTextBlock" id="csbr_GrantIncomeTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>csbr-20120430_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Viewer Version 1.0.5.8 on Wednesday, July 18, 2012 10:32:43 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="csbr-20120430.xsd#StatementOfFinancialPositionClassified" roleURI="http://championsoncology.com/role/StatementOfFinancialPositionClassified"/>
<calculationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/StatementOfFinancialPositionClassified">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="loc_us-gaap_GrantsReceivableCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_GrantsReceivableCurrent" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_Goodwill" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DeferredRevenueCurrent" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_TreasuryStockValue" order="30" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" order="50" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="60" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount" order="20" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" order="30" use="optional" weight="1"/></calculationLink>





<roleRef xlink:type="simple" xlink:href="csbr-20120430.xsd#StatementOfIncomeAlternative" roleURI="http://championsoncology.com/role/StatementOfIncomeAlternative"/>
<calculationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/StatementOfIncomeAlternative">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueServicesNet" xlink:label="loc_us-gaap_SalesRevenueServicesNet"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_PersonalizedOncologySolutions" xlink:label="loc_csbr_PersonalizedOncologySolutions"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesRevenueServicesNet" xlink:to="loc_csbr_PersonalizedOncologySolutions" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_TranslationalOncologySolutions" xlink:label="loc_csbr_TranslationalOncologySolutions"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesRevenueServicesNet" xlink:to="loc_csbr_TranslationalOncologySolutions" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses"/><loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_CostOfPersonalizedOncologySolutions" xlink:label="loc_csbr_CostOfPersonalizedOncologySolutions"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_csbr_CostOfPersonalizedOncologySolutions" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_CostOfTranslationalOncologySolutions" xlink:label="loc_csbr_CostOfTranslationalOncologySolutions"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_csbr_CostOfTranslationalOncologySolutions" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_SellingAndMarketingExpense" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" order="50" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_SalesRevenueServicesNet" order="10" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" order="20" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense"/><loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_GrantIncome" xlink:label="loc_csbr_GrantIncome"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_csbr_GrantIncome" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_OtherNonoperatingIncome" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit" order="20" use="optional" weight="-1"/></calculationLink>




<roleRef xlink:type="simple" xlink:href="csbr-20120430.xsd#StatementOfOtherComprehensiveIncome" roleURI="http://championsoncology.com/role/StatementOfOtherComprehensiveIncome"/>
<calculationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/StatementOfOtherComprehensiveIncome">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_NetIncomeLoss" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" order="20" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="csbr-20120430.xsd#StatementOfCashFlowsIndirect" roleURI="http://championsoncology.com/role/StatementOfCashFlowsIndirect"/>
<calculationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/StatementOfCashFlowsIndirect">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetIncomeLoss" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_Depreciation" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="50" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" order="60" use="optional" weight="-1"/>


<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_IncreaseDecreaseInAccountReceivable" xlink:label="loc_csbr_IncreaseDecreaseInAccountReceivable"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_csbr_IncreaseDecreaseInAccountReceivable" order="80" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_IncreaseOrDecreaseInGrantReceivable" xlink:label="loc_csbr_IncreaseOrDecreaseInGrantReceivable"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_csbr_IncreaseOrDecreaseInGrantReceivable" order="90" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets" xlink:label="loc_csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets" order="100" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" order="110" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable" order="120" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" order="130" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" order="140" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" order="150" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities"/><loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_ProceedsFromIssuanceOfRedeemableCommonSharesAndWarrantsInPrivatePlacement" xlink:label="loc_csbr_ProceedsFromIssuanceOfRedeemableCommonSharesAndWarrantsInPrivatePlacement"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_csbr_ProceedsFromIssuanceOfRedeemableCommonSharesAndWarrantsInPrivatePlacement" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" order="20" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" order="20" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="40" use="optional" weight="1"/></calculationLink>



</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>csbr-20120430_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Viewer Version 1.0.5.8 on Wednesday, July 18, 2012 10:32:43 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
<roleRef xlink:type="simple" xlink:href="csbr-20120430.xsd#DocumentAndEntityInformation" roleURI="http://championsoncology.com/role/DocumentAndEntityInformation"/>
<roleRef xlink:type="simple" xlink:href="csbr-20120430.xsd#StatementOfFinancialPositionClassified" roleURI="http://championsoncology.com/role/StatementOfFinancialPositionClassified"/>
<roleRef xlink:type="simple" xlink:href="csbr-20120430.xsd#CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://championsoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical"/>
<roleRef xlink:type="simple" xlink:href="csbr-20120430.xsd#StatementOfIncomeAlternative" roleURI="http://championsoncology.com/role/StatementOfIncomeAlternative"/>
<roleRef xlink:type="simple" xlink:href="csbr-20120430.xsd#StatementOfOtherComprehensiveIncome" roleURI="http://championsoncology.com/role/StatementOfOtherComprehensiveIncome"/>
<roleRef xlink:type="simple" roleURI="http://championsoncology.com/role/CONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" xlink:href="csbr-20120430.xsd#CONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"/>
<roleRef xlink:type="simple" xlink:href="csbr-20120430.xsd#StatementOfCashFlowsIndirect" roleURI="http://championsoncology.com/role/StatementOfCashFlowsIndirect"/>
<roleRef xlink:type="simple" xlink:href="csbr-20120430.xsd#ConsolidatedStatementsOfCashFlowsParenthetical" roleURI="http://championsoncology.com/role/ConsolidatedStatementsOfCashFlowsParenthetical"/>
<definitionLink xlink:type="extended" xlink:role="http://championsoncology.com/role/DocumentAndEntityInformation">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityRegistrantName_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityCentralIndexKey_3" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_4" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityFilerCategory_5" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_TradingSymbol_6" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_7" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentType_8" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_AmendmentFlag_9" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentPeriodEndDate_10" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_11" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentFiscalYearFocus_12" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_13" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityVoluntaryFilers_14" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityCurrentReportingStatus_15" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityPublicFloat_16" order="150" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://championsoncology.com/role/StatementOfFinancialPositionClassified">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AssetsAbstract_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="loc_us-gaap_GrantsReceivableCurrent_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_GrantsReceivableCurrent_5" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_AssetsCurrent_7" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_8" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_Goodwill_10" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_Assets_11" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_AccountsPayableCurrent_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_14" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_DeferredRevenueCurrent_15" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_LiabilitiesCurrent_16" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_17" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_Liabilities_18" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_CommitmentsAndContingencies_19" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount_20" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_StockholdersEquityAbstract_21" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_PreferredStockValue_22" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_CommonStockValue_23" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_TreasuryStockValue_24" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_25" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_26" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_27" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_StockholdersEquity_28" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_29" order="90" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://championsoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_3" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_5" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_6" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_7" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_8" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_9" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_10" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_11" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_TreasuryStockShares_12" order="110" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://championsoncology.com/role/StatementOfIncomeAlternative">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLossAbstract" xlink:label="loc_us-gaap_OperatingIncomeLossAbstract_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OperatingIncomeLossAbstract_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_PersonalizedOncologySolutions" xlink:label="loc_csbr_PersonalizedOncologySolutions_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingIncomeLossAbstract_2" xlink:to="loc_csbr_PersonalizedOncologySolutions_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_TranslationalOncologySolutions" xlink:label="loc_csbr_TranslationalOncologySolutions_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingIncomeLossAbstract_2" xlink:to="loc_csbr_TranslationalOncologySolutions_4" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueServicesNet" xlink:label="loc_us-gaap_SalesRevenueServicesNet_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingIncomeLossAbstract_2" xlink:to="loc_us-gaap_SalesRevenueServicesNet_5" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_CostOfPersonalizedOncologySolutions" xlink:label="loc_csbr_CostOfPersonalizedOncologySolutions_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6" xlink:to="loc_csbr_CostOfPersonalizedOncologySolutions_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_CostOfTranslationalOncologySolutions" xlink:label="loc_csbr_CostOfTranslationalOncologySolutions_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6" xlink:to="loc_csbr_CostOfTranslationalOncologySolutions_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6" xlink:to="loc_us-gaap_SellingAndMarketingExpense_10" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_11" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6" xlink:to="loc_us-gaap_OperatingExpenses_12" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OperatingIncomeLoss_13" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_14" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_GrantIncome" xlink:label="loc_csbr_GrantIncome_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_14" xlink:to="loc_csbr_GrantIncome_15" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_14" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_16" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_14" xlink:to="loc_us-gaap_OtherNonoperatingIncome_17" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_14" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_18" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_19" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_20" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetIncomeLoss_21" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_22" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_WeightedAverageNumberOfSharesBasicAndDiluted" xlink:label="loc_csbr_WeightedAverageNumberOfSharesBasicAndDiluted_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_csbr_WeightedAverageNumberOfSharesBasicAndDiluted_23" order="90" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://championsoncology.com/role/StatementOfOtherComprehensiveIncome">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetIncomeLoss_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease_3" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_4" order="30" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://championsoncology.com/role/CONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_9_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_9_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_StockSubscriptionReceivableMember" xlink:label="loc_csbr_StockSubscriptionReceivableMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9" xlink:to="loc_csbr_StockSubscriptionReceivableMember_7" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9" xlink:to="loc_us-gaap_RetainedEarningsMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9" xlink:to="loc_us-gaap_TreasuryStockMember_4" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9" xlink:to="loc_us-gaap_CommonStockMember_3" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockholdersEquity_10" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SharesOutstanding_11" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_12" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:label="loc_csbr_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_csbr_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_13" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:label="loc_csbr_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_csbr_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_14" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_AdjustmentsToAdditionalPaidInCapitalCancellationOfStockSubscriptionReceivable" xlink:label="loc_csbr_AdjustmentsToAdditionalPaidInCapitalCancellationOfStockSubscriptionReceivable_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_csbr_AdjustmentsToAdditionalPaidInCapitalCancellationOfStockSubscriptionReceivable_15" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_16" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_17" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_18" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_19" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax_20" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetIncomeLoss_21" order="120" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://championsoncology.com/role/StatementOfCashFlowsIndirect">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_NetIncomeLoss_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_us-gaap_ShareBasedCompensation_5" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_us-gaap_Depreciation_7" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_8" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_9" order="40" use="optional"/>


<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_11" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_IncreaseDecreaseInAccountReceivable" xlink:label="loc_csbr_IncreaseDecreaseInAccountReceivable_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_11" xlink:to="loc_csbr_IncreaseDecreaseInAccountReceivable_12" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_IncreaseOrDecreaseInGrantReceivable" xlink:label="loc_csbr_IncreaseOrDecreaseInGrantReceivable_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_11" xlink:to="loc_csbr_IncreaseOrDecreaseInGrantReceivable_13" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets" xlink:label="loc_csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_11" xlink:to="loc_csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets_14" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_11" xlink:to="loc_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities_15" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_11" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_16" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_11" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_17" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_11" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_18" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_11" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_19" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_21" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_21" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_22" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_21" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_23" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_21" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_24" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_25" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_ProceedsFromIssuanceOfRedeemableCommonSharesAndWarrantsInPrivatePlacement" xlink:label="loc_csbr_ProceedsFromIssuanceOfRedeemableCommonSharesAndWarrantsInPrivatePlacement_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_25" xlink:to="loc_csbr_ProceedsFromIssuanceOfRedeemableCommonSharesAndWarrantsInPrivatePlacement_26" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_25" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_27" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_25" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_28" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_25" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_29" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_30" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_31" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32" order="60" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://championsoncology.com/role/ConsolidatedStatementsOfCashFlowsParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_2" order="10" use="optional"/>
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>csbr-20120430_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Viewer Version 1.0.5.8 on Wednesday, July 18, 2012 10:32:43 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2008-03-31.xsd#negated" roleURI="http://xbrl.us/us-gaap/role/label/negated"/>
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_DocumentAndEntityInformationAbstract" xlink:label="loc_csbr_DocumentAndEntityInformationAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_DocumentAndEntityInformationAbstract" xlink:to="lab_csbr_DocumentAndEntityInformationAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xml:lang="en-US">Entity Well-Known Seasoned Issuer</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityVoluntaryFilers" xml:lang="en-US">Entity Voluntary Filers</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityVoluntaryFilers" xml:lang="en-US">Entity Voluntary Filers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityPublicFloat" xml:lang="en-US">Entity Public Float</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityPublicFloat" xml:lang="en-US">Entity Public Float</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement Of Financial Position [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, At Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents, beginning of year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents, end of year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, Net, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivable, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="loc_us-gaap_GrantsReceivableCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GrantsReceivableCurrent" xml:lang="en-US">Grants Receivable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GrantsReceivableCurrent" xml:lang="en-US">Grant receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantsReceivableCurrent" xlink:to="lab_us-gaap_GrantsReceivableCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid expenses and other current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xml:lang="en-US">Restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current, Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current, Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xml:lang="en-US">Deferred Revenue, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xml:lang="en-US">Deferred revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xml:lang="en-US">Deferred revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent" xlink:to="lab_us-gaap_DeferredRevenueCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xml:lang="en-US">Derivative Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xml:lang="en-US">Warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xml:lang="en-US">Warrant liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Common, Carrying Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount" xml:lang="en-US">Redeemable common stock; $0.001 par value; 12,533,333 contingently puttable common shares outstanding as of April 30, 2012 and 2011</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount" xml:lang="en-US">Redeemable common stock; $0.001 par value; 12,533,333 contingently puttable common shares outstanding as of January 31, 2012 and April 30, 2011</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders Equity Attributable To Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' equity (deficit):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock, $10 par value; 56,075 shares authorized; no shares issued and outstanding as of April 30, 2012 and 2011</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $.001 par value; 125,000,000 shares authorized including redeemable common stock; 37,740,345 and 36,956,667 shares issued and 34,529,000 and 33,870,000 shares outstanding as of April 30, 2012 and 2011, respectively</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockValue" xml:lang="en-US">Treasury Stock, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TreasuryStockValue" xml:lang="en-US">Treasury stock, at cost, 3,236,000 common shares as of April 30, 2012 and 2011</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel" xlink:label="lab_us-gaap_TreasuryStockValue" xml:lang="en-US">Treasury stock, at cost, 3,236,000 common shares as of April 30, 2012 and 2011</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_TreasuryStockValue" xml:lang="en-US">Treasury Stock, Value, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_TreasuryStockValue" xml:lang="en-US">Treasury Stock, Value, Ending Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_TreasuryStockValue" xml:lang="en-US">Treasury stock, at cost, 3,236,000 common shares as of April 30, 2012 and 2011</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid In Capital, Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit), Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit), Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net Of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated other comprehensive loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated other comprehensive loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable To Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders' equity (deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders' equity (deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities, redeemable common stock and stockholders' equity (deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities, redeemable common stock and stockholders' equity (deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_BalanceSheetParentheticalAbstract" xlink:label="loc_csbr_BalanceSheetParentheticalAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_BalanceSheetParentheticalAbstract" xml:lang="en-US">Balance Sheet [Parenthetical] [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_BalanceSheetParentheticalAbstract" xml:lang="en-US">Balance Sheet [Parenthetical] [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_BalanceSheetParentheticalAbstract" xlink:to="lab_csbr_BalanceSheetParentheticalAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xml:lang="en-US">Temporary Equity, Par Or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xml:lang="en-US">Redeemable common stock, par value (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Temporary Equity, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Redeemable common stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par Or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued, Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par Or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued, Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockShares" xml:lang="en-US">Treasury Stock, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TreasuryStockShares" xml:lang="en-US">Treasury stock, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_TreasuryStockShares" xml:lang="en-US">Treasury Stock, Shares, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_TreasuryStockShares" xml:lang="en-US">Treasury Stock, Shares, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLossAbstract" xlink:label="loc_us-gaap_OperatingIncomeLossAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLossAbstract" xml:lang="en-US">Operating Income (Loss) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingIncomeLossAbstract" xml:lang="en-US">Operating revenue:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLossAbstract" xlink:to="lab_us-gaap_OperatingIncomeLossAbstract"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_PersonalizedOncologySolutions" xlink:label="loc_csbr_PersonalizedOncologySolutions"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_PersonalizedOncologySolutions" xml:lang="en-US">Personalized Oncology Solutions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_PersonalizedOncologySolutions" xml:lang="en-US">Personalized oncology solutions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_csbr_PersonalizedOncologySolutions" xml:lang="en-US">Aggregate revenue during the period from personalized oncology solutions.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_PersonalizedOncologySolutions" xlink:to="lab_csbr_PersonalizedOncologySolutions"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_TranslationalOncologySolutions" xlink:label="loc_csbr_TranslationalOncologySolutions"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_TranslationalOncologySolutions" xml:lang="en-US">Translational Oncology Solutions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_TranslationalOncologySolutions" xml:lang="en-US">Translational oncology solutions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_csbr_TranslationalOncologySolutions" xml:lang="en-US">Translational oncology solutions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_csbr_TranslationalOncologySolutions" xml:lang="en-US">Aggregate revenue during the period from translational oncology solutions.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_TranslationalOncologySolutions" xlink:to="lab_csbr_TranslationalOncologySolutions"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueServicesNet" xlink:label="loc_us-gaap_SalesRevenueServicesNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SalesRevenueServicesNet" xml:lang="en-US">Sales Revenue, Services, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SalesRevenueServicesNet" xml:lang="en-US">Total operating revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_SalesRevenueServicesNet" xml:lang="en-US">Total operating revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueServicesNet" xlink:to="lab_us-gaap_SalesRevenueServicesNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Costs and operating expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_CostOfPersonalizedOncologySolutions" xlink:label="loc_csbr_CostOfPersonalizedOncologySolutions"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_CostOfPersonalizedOncologySolutions" xml:lang="en-US">Cost Of Personalized Oncology Solutions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_CostOfPersonalizedOncologySolutions" xml:lang="en-US">Cost of personalized oncology solutions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_csbr_CostOfPersonalizedOncologySolutions" xml:lang="en-US">Total costs related to personalized oncology solutions during the reporting period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_CostOfPersonalizedOncologySolutions" xlink:to="lab_csbr_CostOfPersonalizedOncologySolutions"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_CostOfTranslationalOncologySolutions" xlink:label="loc_csbr_CostOfTranslationalOncologySolutions"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_CostOfTranslationalOncologySolutions" xml:lang="en-US">Cost Of Translational Oncology Solutions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_CostOfTranslationalOncologySolutions" xml:lang="en-US">Cost of translational oncology solutions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_csbr_CostOfTranslationalOncologySolutions" xml:lang="en-US">Total costs related to translational oncology solutions during the reporting period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_CostOfTranslationalOncologySolutions" xlink:to="lab_csbr_CostOfTranslationalOncologySolutions"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xml:lang="en-US">Selling and Marketing Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xml:lang="en-US">Sales and marketing</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xml:lang="en-US">Sales and marketing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total costs and operating expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total costs and operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other income:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_GrantIncome" xlink:label="loc_csbr_GrantIncome"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_GrantIncome" xml:lang="en-US">Grant Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_GrantIncome" xml:lang="en-US">Grant income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_csbr_GrantIncome" xml:lang="en-US">The aggregate amount of other income amounts, resulting from grant income.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_GrantIncome" xlink:to="lab_csbr_GrantIncome"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xml:lang="en-US">Gain (Loss) On Derivative Instruments, Net, Pretax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xml:lang="en-US">Change in fair value of warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xml:lang="en-US">Change in fair value of warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xml:lang="en-US">Change in fair value of warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xml:lang="en-US">Change in fair value of warrant liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xml:lang="en-US">Other Nonoperating Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xml:lang="en-US">Other (expense) income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xml:lang="en-US">Other income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncome" xlink:to="lab_us-gaap_OtherNonoperatingIncome"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total other income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total other income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (Loss) From Continuing Operations Before Income Taxes, Extraordinary Items, Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Net loss before income tax expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Loss before provision for income taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Net loss before income tax expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">(Benefit from) provision for income tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Provision for income taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">(Benefit from) provision for income tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable To Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Net loss per common share outstanding, including redeemable common stock, basic and diluted (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Net loss per common share outstanding, including redeemable common stock, basic and diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_WeightedAverageNumberOfSharesBasicAndDiluted" xlink:label="loc_csbr_WeightedAverageNumberOfSharesBasicAndDiluted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_WeightedAverageNumberOfSharesBasicAndDiluted" xml:lang="en-US">Weighted Average Number Of Shares Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_WeightedAverageNumberOfSharesBasicAndDiluted" xml:lang="en-US">Weighted average common shares outstanding, including redeemable common stock, basic and diluted (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_csbr_WeightedAverageNumberOfSharesBasicAndDiluted" xml:lang="en-US">Weighted average common shares outstanding, including redeemable common stock, basic and diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_csbr_WeightedAverageNumberOfSharesBasicAndDiluted" xml:lang="en-US">The average number of shares or units issued and outstanding that are used in calculating basic and diluted EPS.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_WeightedAverageNumberOfSharesBasicAndDiluted" xlink:to="lab_csbr_WeightedAverageNumberOfSharesBasicAndDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xml:lang="en-US">Statement Of Income and Comprehensive Income [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xml:lang="en-US">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net Of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" xml:lang="en-US">Foreign currency translation adjustment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" xml:lang="en-US">Foreign currency translation adjustment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive Income (Loss), Net Of Tax, Attributable To Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement Of Stockholders Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Statement, Equity Components [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Statement, Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockMember" xml:lang="en-US">Treasury Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-In Capital [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_StockSubscriptionReceivableMember" xlink:label="loc_csbr_StockSubscriptionReceivableMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_StockSubscriptionReceivableMember" xml:lang="en-US">Stock Subscription Receivable [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_StockSubscriptionReceivableMember" xlink:to="lab_csbr_StockSubscriptionReceivableMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Adjustments To Additional Paid In Capital, Share-Based Compensation, Requisite Service Period Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Stock-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:label="loc_csbr_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xml:lang="en-US">Stock Issued During Period Value Stock Options and Warrants Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xml:lang="en-US">Exercise of options and warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_csbr_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xml:lang="en-US">Value of stock issued during the period as a result of the exercise of stock options and warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:to="lab_csbr_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:label="loc_csbr_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xml:lang="en-US">Stock Issued During Period Shares Stock Options and Warrants Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xml:lang="en-US">Exercise of options and warrants (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_csbr_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xml:lang="en-US">Number of share options (or share units) and warrants exercised during the current period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:to="lab_csbr_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_AdjustmentsToAdditionalPaidInCapitalCancellationOfStockSubscriptionReceivable" xlink:label="loc_csbr_AdjustmentsToAdditionalPaidInCapitalCancellationOfStockSubscriptionReceivable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_AdjustmentsToAdditionalPaidInCapitalCancellationOfStockSubscriptionReceivable" xml:lang="en-US">Adjustments To Additional Paid In Capital Cancellation Of Stock Subscription Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_AdjustmentsToAdditionalPaidInCapitalCancellationOfStockSubscriptionReceivable" xml:lang="en-US">Cancellation of stock subscription receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_csbr_AdjustmentsToAdditionalPaidInCapitalCancellationOfStockSubscriptionReceivable" xml:lang="en-US">Aggregate adjustment to additional paid in capital for cancellation of stock subscription receivable.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_AdjustmentsToAdditionalPaidInCapitalCancellationOfStockSubscriptionReceivable" xlink:to="lab_csbr_AdjustmentsToAdditionalPaidInCapitalCancellationOfStockSubscriptionReceivable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xml:lang="en-US">Stock Repurchased and Retired During Period, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xml:lang="en-US">Purchase of treasury stock from board member and cancellation of accrued stock liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xml:lang="en-US">Purchase of treasury stock from board member and cancellation of accrued stock liability (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net Of Forfeitures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Issuance of restricted stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net Of Forfeitures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Issuance of restricted stock (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax" xml:lang="en-US">Foreign currency translation adjustment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement Of Cash Flows [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-Based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Income tax (benefit) expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Gain (Loss) On Sale Of Property Plant Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Loss on disposal of property and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Loss on disposal of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>





<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xml:lang="en-US">Increase (Decrease) In Operating Liabilities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_IncreaseDecreaseInAccountReceivable" xlink:label="loc_csbr_IncreaseDecreaseInAccountReceivable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_IncreaseDecreaseInAccountReceivable" xml:lang="en-US">Increase (Decrease) In Account Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_IncreaseDecreaseInAccountReceivable" xml:lang="en-US">Accounts receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_csbr_IncreaseDecreaseInAccountReceivable" xml:lang="en-US">The (increase) decrease during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_csbr_IncreaseDecreaseInAccountReceivable" xml:lang="en-US">Accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_IncreaseDecreaseInAccountReceivable" xlink:to="lab_csbr_IncreaseDecreaseInAccountReceivable"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_IncreaseOrDecreaseInGrantReceivable" xlink:label="loc_csbr_IncreaseOrDecreaseInGrantReceivable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_IncreaseOrDecreaseInGrantReceivable" xml:lang="en-US">Increase Or Decrease In Grant Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_IncreaseOrDecreaseInGrantReceivable" xml:lang="en-US">Grant receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_csbr_IncreaseOrDecreaseInGrantReceivable" xml:lang="en-US">The (increase) decrease in amount due during the reporting period in Governmental, corporate, or foundation grants.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_csbr_IncreaseOrDecreaseInGrantReceivable" xml:lang="en-US">Grant receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_IncreaseOrDecreaseInGrantReceivable" xlink:to="lab_csbr_IncreaseOrDecreaseInGrantReceivable"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets" xlink:label="loc_csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets" xml:lang="en-US">Increase (Decrease) In Prepaid Deferred Expenses and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets" xml:lang="en-US">Prepaid expenses, deposits and other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets" xml:lang="en-US">Prepaid expenses, deposits and other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets" xml:lang="en-US">The (increase) decrease during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets,or income taxes.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets" xml:lang="en-US">Prepaid expenses, deposits and other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets" xlink:to="lab_csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" xml:lang="en-US">Increase (Decrease) In Restricted Cash For Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" xml:lang="en-US">Restricted cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" xml:lang="en-US">Restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" xlink:to="lab_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Increase (Decrease) In Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Accounts payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Increase (Decrease) In Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Accrued liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xml:lang="en-US">Increase (Decrease) In Deferred Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xml:lang="en-US">Deferred revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xml:lang="en-US">Deferred revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xml:lang="en-US">Increase (Decrease) In Other Current Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xml:lang="en-US">Other liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Investing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments To Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchase of property and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchase of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xml:lang="en-US">Proceeds From Sale Of Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xml:lang="en-US">Proceeds form sale of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash used in investing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash used in investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_ProceedsFromIssuanceOfRedeemableCommonSharesAndWarrantsInPrivatePlacement" xlink:label="loc_csbr_ProceedsFromIssuanceOfRedeemableCommonSharesAndWarrantsInPrivatePlacement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_ProceedsFromIssuanceOfRedeemableCommonSharesAndWarrantsInPrivatePlacement" xml:lang="en-US">Proceeds From Issuance Of Redeemable Common Shares and Warrants In Private Placement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_ProceedsFromIssuanceOfRedeemableCommonSharesAndWarrantsInPrivatePlacement" xml:lang="en-US">Private placement of common shares and warrants (net of $305 in offering costs)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_csbr_ProceedsFromIssuanceOfRedeemableCommonSharesAndWarrantsInPrivatePlacement" xml:lang="en-US">The cash inflow associated with the amount received from entity's raising of capital via issuance of common shares and warrants in public placement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_ProceedsFromIssuanceOfRedeemableCommonSharesAndWarrantsInPrivatePlacement" xlink:to="lab_csbr_ProceedsFromIssuanceOfRedeemableCommonSharesAndWarrantsInPrivatePlacement"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xml:lang="en-US">Payments For Repurchase Of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xml:lang="en-US">Purchase of treasury stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xml:lang="en-US">Purchase of treasury stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xml:lang="en-US">Proceeds From Warrant Exercises</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xml:lang="en-US">Proceeds from exercise of options and warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xml:lang="en-US">Proceeds from exercise of options and warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by financing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xml:lang="en-US">Effect Of Exchange Rate On Cash and Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xml:lang="en-US">Exchange rate effect on cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xml:lang="en-US">Exchange rate effect on cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Increase in cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Increase (decrease) in cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Proceeds From Issuance Initial Public Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Offering costs (in dollars)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xml:lang="en-US">Business Description and Basis Of Presentation [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_CephalonAgreementAbstract" xlink:label="loc_csbr_CephalonAgreementAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_CephalonAgreementAbstract" xml:lang="en-US">Cephalon Agreement [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_CephalonAgreementAbstract" xml:lang="en-US">Cephalon Agreement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_CephalonAgreementAbstract" xlink:to="lab_csbr_CephalonAgreementAbstract"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_CephalonAgreementTextBlock" xlink:label="loc_csbr_CephalonAgreementTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_CephalonAgreementTextBlock" xml:lang="en-US">Cephalon Agreement [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_CephalonAgreementTextBlock" xml:lang="en-US">Cephalon Agreement [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_csbr_CephalonAgreementTextBlock" xml:lang="en-US">The entire disclosure relating to cephalon agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_CephalonAgreementTextBlock" xlink:to="lab_csbr_CephalonAgreementTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_LicensingAgreementsAbstract" xlink:label="loc_csbr_LicensingAgreementsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_LicensingAgreementsAbstract" xml:lang="en-US">Licensing Agreements [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_LicensingAgreementsAbstract" xml:lang="en-US">Licensing Agreements [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_csbr_LicensingAgreementsAbstract" xml:lang="en-US">The entire concept related to several different licensing agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_LicensingAgreementsAbstract" xlink:to="lab_csbr_LicensingAgreementsAbstract"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_LicensingAgreementsDisclosureTextBlock" xlink:label="loc_csbr_LicensingAgreementsDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_LicensingAgreementsDisclosureTextBlock" xml:lang="en-US">Licensing Agreements Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_LicensingAgreementsDisclosureTextBlock" xml:lang="en-US">Licensing Agreements Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_csbr_LicensingAgreementsDisclosureTextBlock" xml:lang="en-US">The entire disclosure related to several different licensing agreements.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_LicensingAgreementsDisclosureTextBlock" xlink:to="lab_csbr_LicensingAgreementsDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Disclosure Of Compensation Related Costs, Share-Based Payments [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_RedeemableCommonStockAndStockPurchaseWarrantAbstract" xlink:label="loc_csbr_RedeemableCommonStockAndStockPurchaseWarrantAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_RedeemableCommonStockAndStockPurchaseWarrantAbstract" xml:lang="en-US">Redeemable Common Stock and Stock Purchase Warrant [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_RedeemableCommonStockAndStockPurchaseWarrantAbstract" xml:lang="en-US">Redeemable Common Stock and Stock Purchase Warrant [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_csbr_RedeemableCommonStockAndStockPurchaseWarrantAbstract" xml:lang="en-US">Equity-based compensation plans and award types, including multiple equity-based payment arrangements.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_RedeemableCommonStockAndStockPurchaseWarrantAbstract" xlink:to="lab_csbr_RedeemableCommonStockAndStockPurchaseWarrantAbstract"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_RedeemableCommonStockAndStockPurchaseWarrantTextBlock" xlink:label="loc_csbr_RedeemableCommonStockAndStockPurchaseWarrantTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_RedeemableCommonStockAndStockPurchaseWarrantTextBlock" xml:lang="en-US">Redeemable Common Stock and Stock Purchase Warrant [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_RedeemableCommonStockAndStockPurchaseWarrantTextBlock" xml:lang="en-US">Redeemable Common Stock and Stock Purchase Warrant [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_csbr_RedeemableCommonStockAndStockPurchaseWarrantTextBlock" xml:lang="en-US">Equity-based compensation plans and award types, including multiple equity-based payment arrangements.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_RedeemableCommonStockAndStockPurchaseWarrantTextBlock" xlink:to="lab_csbr_RedeemableCommonStockAndStockPurchaseWarrantTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingAbstract" xml:lang="en-US">Segment Reporting [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SegmentReportingAbstract" xml:lang="en-US">Segment Reporting [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xml:lang="en-US">Cash Flow, Supplemental Disclosures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xml:lang="en-US">Cash Flow, Supplemental Disclosures [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_GrantIncomeAbstract" xlink:label="loc_csbr_GrantIncomeAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_GrantIncomeAbstract" xml:lang="en-US">Grant Income [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_GrantIncomeAbstract" xml:lang="en-US">Grant Income [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_GrantIncomeAbstract" xlink:to="lab_csbr_GrantIncomeAbstract"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_GrantIncomeTextBlock" xlink:label="loc_csbr_GrantIncomeTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_GrantIncomeTextBlock" xml:lang="en-US">Grant Income [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_GrantIncomeTextBlock" xml:lang="en-US">Grant Income [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_csbr_GrantIncomeTextBlock" xml:lang="en-US">The entire disclosure relating to grant income.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_GrantIncomeTextBlock" xlink:to="lab_csbr_GrantIncomeTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain"/>
</labelLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>csbr-20120430_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Viewer Version 1.0.5.8 on Wednesday, July 18, 2012 10:32:43 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="csbr-20120430.xsd#DocumentAndEntityInformation" roleURI="http://championsoncology.com/role/DocumentAndEntityInformation"/>
<roleRef xlink:type="simple" xlink:href="csbr-20120430.xsd#StatementOfFinancialPositionClassified" roleURI="http://championsoncology.com/role/StatementOfFinancialPositionClassified"/>
<roleRef xlink:type="simple" xlink:href="csbr-20120430.xsd#CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://championsoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical"/>
<roleRef xlink:type="simple" xlink:href="csbr-20120430.xsd#StatementOfIncomeAlternative" roleURI="http://championsoncology.com/role/StatementOfIncomeAlternative"/>
<roleRef xlink:type="simple" xlink:href="csbr-20120430.xsd#StatementOfOtherComprehensiveIncome" roleURI="http://championsoncology.com/role/StatementOfOtherComprehensiveIncome"/>
<roleRef xlink:type="simple" roleURI="http://championsoncology.com/role/CONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" xlink:href="csbr-20120430.xsd#CONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"/>
<roleRef xlink:type="simple" xlink:href="csbr-20120430.xsd#StatementOfCashFlowsIndirect" roleURI="http://championsoncology.com/role/StatementOfCashFlowsIndirect"/>
<roleRef xlink:type="simple" xlink:href="csbr-20120430.xsd#ConsolidatedStatementsOfCashFlowsParenthetical" roleURI="http://championsoncology.com/role/ConsolidatedStatementsOfCashFlowsParenthetical"/>
<roleRef xlink:type="simple" xlink:href="csbr-20120430.xsd#OrganizationAndBasisOfPresentation" roleURI="http://championsoncology.com/role/OrganizationAndBasisOfPresentation"/>
<roleRef xlink:type="simple" xlink:href="csbr-20120430.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://championsoncology.com/role/SummaryOfSignificantAccountingPolicies"/>
<roleRef xlink:type="simple" xlink:href="csbr-20120430.xsd#CephalonAgreement" roleURI="http://championsoncology.com/role/CephalonAgreement"/>
<roleRef xlink:type="simple" xlink:href="csbr-20120430.xsd#Commitmentsandcontingencies" roleURI="http://championsoncology.com/role/Commitmentsandcontingencies"/>
<roleRef xlink:type="simple" xlink:href="csbr-20120430.xsd#LicensingAgreements" roleURI="http://championsoncology.com/role/LicensingAgreements"/>
<roleRef xlink:type="simple" xlink:href="csbr-20120430.xsd#ShareBasedPayments" roleURI="http://championsoncology.com/role/ShareBasedPayments"/>
<roleRef xlink:type="simple" xlink:href="csbr-20120430.xsd#RedeemableCommonStockAndStockPurchaseWarrant" roleURI="http://championsoncology.com/role/RedeemableCommonStockAndStockPurchaseWarrant"/>
<roleRef xlink:type="simple" xlink:href="csbr-20120430.xsd#StockholdersEquity" roleURI="http://championsoncology.com/role/StockholdersEquity"/>
<roleRef xlink:type="simple" xlink:href="csbr-20120430.xsd#ProvisionForIncomeTaxes" roleURI="http://championsoncology.com/role/ProvisionForIncomeTaxes"/>
<roleRef xlink:type="simple" xlink:href="csbr-20120430.xsd#RelatedPartyTransactions" roleURI="http://championsoncology.com/role/RelatedPartyTransactions"/>
<roleRef xlink:type="simple" xlink:href="csbr-20120430.xsd#BusinessSegmentInformation" roleURI="http://championsoncology.com/role/BusinessSegmentInformation"/>
<roleRef xlink:type="simple" xlink:href="csbr-20120430.xsd#SupplementalScheduleOfCashFlowInformation" roleURI="http://championsoncology.com/role/SupplementalScheduleOfCashFlowInformation"/>
<roleRef xlink:type="simple" xlink:href="csbr-20120430.xsd#GrantIncome" roleURI="http://championsoncology.com/role/GrantIncome"/>
<roleRef xlink:type="simple" xlink:href="csbr-20120430.xsd#SupplementalCashFlowInformation" roleURI="http://championsoncology.com/role/SupplementalCashFlowInformation"/>
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<presentationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/DocumentAndEntityInformation">
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_DocumentAndEntityInformationAbstract" xlink:label="loc_csbr_DocumentAndEntityInformationAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_csbr_DocumentAndEntityInformationAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityRegistrantName_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityCentralIndexKey_4" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_CurrentFiscalYearEndDate_5" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityFilerCategory_6" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_TradingSymbol_7" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_8" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_DocumentType_9" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_AmendmentFlag_10" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_DocumentPeriodEndDate_11" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_DocumentFiscalPeriodFocus_12" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_DocumentFiscalYearFocus_13" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_14" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityVoluntaryFilers_15" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityCurrentReportingStatus_16" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityPublicFloat_17" order="140" use="optional"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/StatementOfFinancialPositionClassified">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_AssetsAbstract_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="loc_us-gaap_GrantsReceivableCurrent_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_GrantsReceivableCurrent_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_AssetsCurrent_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_Goodwill_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_Assets_12" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_AccountsPayableCurrent_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_DeferredRevenueCurrent_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_LiabilitiesCurrent_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_Liabilities_19" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_CommitmentsAndContingencies_20" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount_21" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_StockholdersEquityAbstract_22" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_PreferredStockValue_23" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_CommonStockValue_24" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_TreasuryStockValue_25" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_26" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_27" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_28" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_StockholdersEquity_29" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_30" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_BalanceSheetParentheticalAbstract" xlink:label="loc_csbr_BalanceSheetParentheticalAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_csbr_BalanceSheetParentheticalAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_PreferredStockSharesIssued_7" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_8" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_10" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CommonStockSharesIssued_11" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_12" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_TreasuryStockShares_13" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/StatementOfIncomeAlternative">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLossAbstract" xlink:label="loc_us-gaap_OperatingIncomeLossAbstract_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_OperatingIncomeLossAbstract_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_PersonalizedOncologySolutions" xlink:label="loc_csbr_PersonalizedOncologySolutions_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingIncomeLossAbstract_3" xlink:to="loc_csbr_PersonalizedOncologySolutions_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_TranslationalOncologySolutions" xlink:label="loc_csbr_TranslationalOncologySolutions_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingIncomeLossAbstract_3" xlink:to="loc_csbr_TranslationalOncologySolutions_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueServicesNet" xlink:label="loc_us-gaap_SalesRevenueServicesNet_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingIncomeLossAbstract_3" xlink:to="loc_us-gaap_SalesRevenueServicesNet_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_OperatingExpensesAbstract_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_CostOfPersonalizedOncologySolutions" xlink:label="loc_csbr_CostOfPersonalizedOncologySolutions_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_csbr_CostOfPersonalizedOncologySolutions_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_CostOfTranslationalOncologySolutions" xlink:label="loc_csbr_CostOfTranslationalOncologySolutions_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_csbr_CostOfTranslationalOncologySolutions_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_us-gaap_SellingAndMarketingExpense_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_us-gaap_OperatingExpenses_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_OperatingIncomeLoss_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_GrantIncome" xlink:label="loc_csbr_GrantIncome_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_15" xlink:to="loc_csbr_GrantIncome_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_15" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_15" xlink:to="loc_us-gaap_OtherNonoperatingIncome_18" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_15" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_19" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_20" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_21" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NetIncomeLoss_22" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_23" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_WeightedAverageNumberOfSharesBasicAndDiluted" xlink:label="loc_csbr_WeightedAverageNumberOfSharesBasicAndDiluted_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_csbr_WeightedAverageNumberOfSharesBasicAndDiluted_24" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/StatementOfOtherComprehensiveIncome">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NetIncomeLoss_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/CONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_CommonStockMember_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_TreasuryStockMember_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_RetainedEarningsMember_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_StockSubscriptionReceivableMember" xlink:label="loc_csbr_StockSubscriptionReceivableMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_csbr_StockSubscriptionReceivableMember_7" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_9" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockholdersEquity_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_SharesOutstanding_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:label="loc_csbr_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_csbr_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:label="loc_csbr_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_csbr_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_AdjustmentsToAdditionalPaidInCapitalCancellationOfStockSubscriptionReceivable" xlink:label="loc_csbr_AdjustmentsToAdditionalPaidInCapitalCancellationOfStockSubscriptionReceivable_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_csbr_AdjustmentsToAdditionalPaidInCapitalCancellationOfStockSubscriptionReceivable_16" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_17" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_18" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_19" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_20" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax_21" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_NetIncomeLoss_22" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockholdersEquity_23" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_SharesOutstanding_24" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/StatementOfCashFlowsIndirect">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_NetIncomeLoss_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_ShareBasedCompensation_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_Depreciation_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>


<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_12" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_IncreaseDecreaseInAccountReceivable" xlink:label="loc_csbr_IncreaseDecreaseInAccountReceivable_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_12" xlink:to="loc_csbr_IncreaseDecreaseInAccountReceivable_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_IncreaseOrDecreaseInGrantReceivable" xlink:label="loc_csbr_IncreaseOrDecreaseInGrantReceivable_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_12" xlink:to="loc_csbr_IncreaseOrDecreaseInGrantReceivable_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets" xlink:label="loc_csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_12" xlink:to="loc_csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_18" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_19" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_20" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_21" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_22" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_22" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_23" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_22" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_24" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_22" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_25" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_26" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_ProceedsFromIssuanceOfRedeemableCommonSharesAndWarrantsInPrivatePlacement" xlink:label="loc_csbr_ProceedsFromIssuanceOfRedeemableCommonSharesAndWarrantsInPrivatePlacement_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_26" xlink:to="loc_csbr_ProceedsFromIssuanceOfRedeemableCommonSharesAndWarrantsInPrivatePlacement_27" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_26" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_28" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_26" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_29" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_26" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_30" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_31" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_32" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_33" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_34" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/ConsolidatedStatementsOfCashFlowsParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/OrganizationAndBasisOfPresentation">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/CephalonAgreement">
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_CephalonAgreementAbstract" xlink:label="loc_csbr_CephalonAgreementAbstract_0"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_CephalonAgreementTextBlock" xlink:label="loc_csbr_CephalonAgreementTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_csbr_CephalonAgreementAbstract_0" xlink:to="loc_csbr_CephalonAgreementTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/Commitmentsandcontingencies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/LicensingAgreements">
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_LicensingAgreementsAbstract" xlink:label="loc_csbr_LicensingAgreementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_LicensingAgreementsDisclosureTextBlock" xlink:label="loc_csbr_LicensingAgreementsDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_csbr_LicensingAgreementsAbstract_0" xlink:to="loc_csbr_LicensingAgreementsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/ShareBasedPayments">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/RedeemableCommonStockAndStockPurchaseWarrant">
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_RedeemableCommonStockAndStockPurchaseWarrantAbstract" xlink:label="loc_csbr_RedeemableCommonStockAndStockPurchaseWarrantAbstract_0"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_RedeemableCommonStockAndStockPurchaseWarrantTextBlock" xlink:label="loc_csbr_RedeemableCommonStockAndStockPurchaseWarrantTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_csbr_RedeemableCommonStockAndStockPurchaseWarrantAbstract_0" xlink:to="loc_csbr_RedeemableCommonStockAndStockPurchaseWarrantTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/StockholdersEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/ProvisionForIncomeTaxes">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/BusinessSegmentInformation">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/SupplementalScheduleOfCashFlowInformation">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_0" xlink:to="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/GrantIncome">
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_GrantIncomeAbstract" xlink:label="loc_csbr_GrantIncomeAbstract_0"/>
<loc xlink:type="locator" xlink:href="csbr-20120430.xsd#csbr_GrantIncomeTextBlock" xlink:label="loc_csbr_GrantIncomeTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_csbr_GrantIncomeAbstract_0" xlink:to="loc_csbr_GrantIncomeTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/SupplementalCashFlowInformation">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X``02D9)1@`!`0$`>`!X``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!E`2X#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MHH`**BN;F&TMWN+B58HD&6=S@`5YKK_Q+ED9[?14\N/I]ID7+'_=';\:WH8>
MI6=H(Y<3C*6&C>H_EU/2I[B"VC,EQ-'$@_B=@H_6L>;QEX>@)#ZK`2/[F6_D
M*\1N[VZOYC+=W$L\A_BD8FH:].&51M[\ON/$J9]._P"[A]Y[>GCKPVYQ_::#
M_>1A_2M2SUG3-0_X]+^WF)[)("?RKY\H!*L&7(8=".HJI95"WNR9$,^JI^]%
M,^D:*\3T7QSK.D,J/,;NW'6*<Y('LW45ZEH'BC3_`!#!NMGV3J,R0/\`>7_$
M>XKSL1@ZE'5ZKN>QA,RHXGW5H^S-JBBBN0]`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"H;JYAL[66YN)!'
M#&I9V/0"IJ\L^)'B%KB\&C6[_N8<-.1_$_9?P_G]*WPU!UZB@CEQF*CAJ3J/
M?IZF'XJ\5W'B.[*J6CL8S^ZB]?\`:;W_`)5SM%'4^I-?3TZ<:<5&*T/B*M6=
M:;G-W;"D)%=]X;^',M[&EWK#O!$W*VZ\.P_VCV^G6N^LO#&B6"A8--MQC^)D
MW$_B:XJV8TJ;Y5JSTL/D]>K'FE[J\SP/(]:6OH272--F0K)I]JRGL8E_PKF=
M9^'.E7T;/8`V4_;;RA/N.WX5G3S2G)VDK&M7(ZT5>$D_P/(:FM+FYM+R*>TD
M>.X1AL9.N?3W^E6-4T>^T>_-G>0LLO\`!MY#CU4]Z])\$^"AIH34]3C!O",Q
M1'D0CU/^U_*NJOB:=.GS/6^WF<.%P5:M6Y%I;=]CJ]'FOKC2;>74H%ANV3,B
M*>A_I]*OT45\RW=W/MHKEBE>X4444B@HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@"KJ-XFGZ;<WCXVPQL_Y"OGR>>2
MYN);B5BTDKEV/N3FO9?B#<&#P?=@'F1DC_-A7BU>YE4$H2GW/E\]JMU8T^B5
M_O"O0?AUX82Y;^VKQ-R(VVW1AP6'5OP[5Y\`3P.IX%?0FDV2:=I%I9H,+%$J
M_CCG]:TS*LZ=-1CNS+)L-&K6<Y;1_,N4V26.&,R2R*B#JS'`%*[*B,S'"J,D
M^@KQOQ#K]QKM^[L["U5B(8L\`>I]S7S%:LJ2\SZ:O75)7ZGJT.N:7/+Y46H6
MSOTVB09-7Z\"Q7H'@/Q#/-.=)NY#(-I:!V.2,=5K&CB^>7+)&%'&<\N62L=O
M-9VUQ+#+-!'))"VZ)F7)0^HJ:EKD_&/C`>'D2VM8UEOI1N`;[J+ZGU]A7HTZ
M<ZLE".IT5JM.A!U)Z(ZRBO+_`+5\1&@^W!9/+(W>7L3./]WK79>$]5U'6-'6
MYU*T$$FXJI''F`?Q;3TK2KAG3CS<R?HS&AC8UI\G*T_-&]1FN#\-^(]4U#QK
M?:=<W`>UB\W8FP#&&P.:T_'>L7NBZ+%<6$HCE:8(25#<8/K0\--5%3ZL:QM-
MT95M;*_X'4T5E^';R>_\.V%W<,'FEB#.V,9/TK*\=>()="TB,6D@2\N'VQG`
M.T#DG!_`?C41I2E4]FM]C2>(A"C[9[6N=317&^`?$MSK5O=6U_+YEW`VX-@`
ME#[#T/\`.NIU"5X--NIHSAXX793Z$`XHJ4I4Y^SEN%'$0JTO:QV+-&:\P\)^
M/;Z?6([76)T>&?Y$?8%V/VZ=CTK=\=>*Y="@BM+!U%]+\Q8@'RT^GJ:UE@ZL
M:JI=6<\,QH2HNM?1?>=E17,>!=7O=:T)[F^E$LHG9`0H'``]*Y?4_$GB>3Q=
M>:3I4X8K(1%'L7H!GJ:4<+.4Y0NM-QSQ].%*-6S:EMW/3Z*\O;Q=XJ\.WL(U
MVV5[>0]"@!([[67C(]#78^)=6FM/"4^I:?*%?8CQO@'@D=C[&B>%G&45H[[/
MH.GCJ<XRE9IQW3W-^BN=\%:I=ZOX<CN[V023&1U+!0.`>.!6)XF\;W<.J?V/
MH,(EN@VQY-N[YO[JC^9-3'#3E4=-;HJ>,I0HJM+9[=SO:*\MN-2\?:+%]NO%
M,D`Y<,B,H'OMY%=MX8\20>)-.,Z)Y4\9VS19SM/J/8TZN&E3CSW37D30QT*L
M_9M.,NS5C<HKS?Q=XOU;1/%7V>UE0VJ(CF)D'S9ZC/6NTM=8AU/P^VI63\&%
MF&>J,!T/N#2GAYPA&;V9=/&4JE25-;Q-2BN+^'VO:CKL-\VH3B4Q,@3"!<9!
MSTJKXG\5ZM_PD"Z#H2*)^`TA`)+$9P,\``=ZKZK/VKI]5]Q'U^E[%5M;/9=3
MOJ*\[LM1\=:=JMM;7UJ+J.=PN64;0.YW+TP/6O1*SJTG3:U3OV-</B%63LFK
M=U8****R.@****`.0^)*D^$G([3QD_G7CM>Y^,[,WOA+4(U&76/S%_X"<_TK
MPNO?RN2=%KS/D\\BUB%+NA\3!9HV/0."?SKZ-0AD5AT(!%?-YY%>Z>#M675_
M#=K+NS-$HBE'<,O'ZC!K+-8-QC/L;9#42G.F]V:][$T]A<1)]YXF4?4BO"2C
M1L48$,IP0>Q%>^UQOB3P.NI7+WNGR)#</S)&WW7/K[&OFL51E42<>A[6,HRJ
M)./0\SKH_`]O)-XIMW0';$K.Y]!C']:EB\`:W)*%D6"),\N9,_H*[WP_X>MM
M`M"D9,D\G,LI&"WL/05S4,/-S3DK)'+A\--S3DK)&S7E&L;!\6(C?8\GSHL;
MNF-HV_AFO5ZY3QAX/3Q$B7%O(L-]$NU6;[KKZ'^AKWL'4C";YM$U8WS"C.K3
M3@KN+3MWL=50"#TKS!=.^(:P?8!._E`;=_FIT_WNM=EX3T2[T+2?LUY>FXD9
MMVWJL>>P)Y-35H1IQOSI^A5#%3JSY?9M+NSS*U766\9:B-#;;=^;+GE?N[N>
MO'I4WB>/Q:FG1G7G+6OF#;RA^;!QT_&NJ\.>&M4T[QG>ZE<PHMK+YNQA("3N
M;(XK3\<Z->ZYHT5M81J\JS!R&8+Q@^M>B\5!5HK2VFO_``3R5@:CPTY-R3N]
M.C^1=\(?\BCI?_7NM>=^(M:L]1\>1O>R-_9UDX3Y!NW;>3Q[MQ7H%E::EIW@
MJ*S@B4ZC%;>6J;Q@/TZ^W6L/PGX%BM;.=]=LX9[F23Y5<[]J_7U)S7-1G3IR
MG5D_)6WUZG7B*5:K"E1@NB;OMIT.6M]>L;#Q^-3TYW^PW#XE#+MP&^]Q['FO
M5]5(.BWI!R#;O_Z":Y?Q3X&M+S20-&L8(;M'!`7Y=Z]""?U_"MC3;;4F\(_8
MK^,+?"W:'[X(;@A3GZ8I8B=*HH3B]5IKN/"TZU&52E-:/5-;:[H\LT7P\VL^
M&=0NK92;NTD5E`ZNNWD?7N*L6FEW6LZ+JWB/4G>7RH"L+/\`Q,`!GZ`?K7;^
M`=`U#0;2]CU")(VE=2FUPV0![5LZ]IC7/AB]T^PA17DB*QQC"C).:Z*F-M5<
M4]+K7RZG+1RQ.BIR5G9W7=ZV,+X8_P#(L2?]?+?R%<C>ZJVB_$B^OUMS.8Y7
M'E@XSE<>]=[X'T>]T30WM;Z-4E,S.`K!N"!Z5EV?AG4X?B)-K$D*?8F=R'W@
MG!7`XJ(U::K59/5-/YFDZ%5X>A&*:::Z;'-ZQJ>K^/+BUL[72VABC8G/)`)X
MRS$``"NR\76HLOA[-:AMPAACCSZX(%=6`!T&*QO%>GW.J^&[NSM$#SR!=JEL
M#@@]:P6(4IPBERQ3.IX.4*=23ES3DOT,OX<Y_P"$/CQU\V3'YURWP],8\97P
MNL?:BDFS=UW;OF_'']:[;P9I5WHWAV.SO45)A([$*P88)XY%8GB?P-<W.IG5
M]#F$-V6WO'NVY;^\I[&M8U:;J58-V4NIA.A55&C4C&[ANCMKGRA:S>?M\G8=
M^[IMQSFO,OA>&_MS43%G[/Y7_LWR_IFG3:-X]UF(65]/LMSPY>10"/?;R:[?
MPUX<M_#FF_9XF\R9SNFE(QN/]`*A\E"C*',FY=C1>TQ6(A4Y'&,;[[LX3Q5:
MQ7OQ-MK6<%HIO*1P#C@@U6AGO/`FLWFF71:33[J-@&QU!!"N/?L172ZMX;U.
M[^(%IJT,*&SC:(LYD`(V]>*W?%'AZ'Q%I30'"W"9:"0_PMZ'V-;+$P2A"6L6
MM?(YW@ZDI5:L%::DVO-=CE?A1Q;ZG_OQ_P`C5KQ5X*O;[5SJ^CW*QW1P60MM
M.X<!E:K7@'P_J.@Q7RZA$L9F9"FUPV<`YZ?6JOB#PYXE_MR35]'U(NS@`1EM
MA11_#CH14RJ+ZU*4)I?DRX46L#"%2#=NVZU>ID1^+/$_AF\B@UV%IH&_YZ`;
MB.Y5AU_&O4(I$FB25#E'4,I]0:\S?PMXK\2WL']O3+';1'J2N0.^`O<^IKTR
M*-88DC081%"J/0"L<9[/W>6W-UML=&7>VO+GOR].;<?1117$>F%%%%`#719(
MV1QE6!!![BO`=>TI]&UNZL7!VH^8SZH>0?RKZ`KD?'?A@ZWIXN[5,WUL#M`Z
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M--704E+10,0D*"20`.2:Y<^*[RY\VXTS1I;JQB8AIMX4OCKM'>NEGB$T$D1.
M`ZE21[C%<=IMUK'AW3SI)T6>Z>(L()H<%'!.1GTK&K)IK6R,:LFFNB-B?Q-`
M/##:U;1F5!@>63M(.<$'Z5%+XKM_[&L]1MHO-6XG6!D+8,;'KGZ5ES:#>VG@
M&XLO+,M[-)YK1Q#."6!P/H!5?6O#5Y#<VD^G1.UM/+$]S;H/N.N/FQ^>:RE.
MJM;=$92G56MNB.DUC7CIUU!8VMH]Y?3`LL*'`"^I/84[3]7N98+I]3T][#[,
M-S,S!E88SD&L_6+:^T_Q'#KEG:/>1&'R9H8_O@9R"*L+)>^(]+U"UN-/EL(I
M8RD32GYF)'<=JTYI<S_(OFES/\BG_P`);>O;G4(M#G?3!SYV\!BO]X+Z5HZA
MXBAM=*L]0MX_/BNI4C7YL8#=_P`*Q8;_`%NVT4:,="G>Z6/R%F!'E$8QNS]*
M75-%N['PCIEE!#)=36TZ.ZQ#)."2<?G6?/.SMV[=2%.=FUV[=3L994AB>61@
MJ(I9B>P%<O\`\);>RP/?6NASRZ:A/[[>`S*.K!?2KD=[<:];7=A/I=W8K)"P
M$LP&"3QBLFTOM;TW1AHQT*>6YC0PQS(1Y3#H&)JYS>EG9>A<ZC;5G9>G4WKG
MQ'8V^@IJX9G@D`\M5'S,Q_A^M5]/UG5KB\ACN]"EMX9<D2B0-LXS\P[5F7/A
M>\B\(65G`5DO;247&S/RLV22OZU6E34=9UVRN8M,U&SD25#<F67$6U>H`[U+
MG--7\O\`@DNI--7\O^";Y\11V^KW=A?Q"V\F+SHY"V1*@ZD>_M5K1-1EU;3U
MO)+4VZ2$^4I;)9>S'TS63XSTIM2@L#%:M/(ERH;8.1&?O9]NE=,BK&BH@"JH
MP`.PK6//SM/9&L>?G:>R%I:**U-0HHHH`****`"BBB@`HHHH`****`.#\9>!
M1J3/J.E(JW9YEAZ"7W'HW\Z\LEBD@E:*:-HY$.&1A@@^XKZ/K&UKPSI>O)_I
MD'[T#"S)\KC\>_XUZ6%S!TUR5-4>)CLHC6;J4M)?@SP>BN[U+X7ZA"Q;3KJ*
MY3LLGR-_A_*N?G\'^(;8D/I4[8[QX<?H:]>&*HSVDCP*F!Q%-VE!_F8E%:L?
MAG796PFDW>?>,C^=:UE\.]?NV'FPQ6J'J99`3^0S52Q%**NY(B&$KS=HP?W'
M*5TOACP;>^()5FD#06`/S3$<O[+Z_7I7<Z+\.=+T]EFO6-],.<.,1@_[O?\`
M&NQ5510J@*H&``,`5YN(S-6Y:7WGLX/)7?GQ'W?YD%C8VVFV<=I:1".&,851
M_/ZU9HHKQVVW=GT:22L@HHHI#"BBB@!**6B@`I*6B@!**6B@`HHHH`****`$
MI:**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
(B@`HHHH`_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001144204-12-040031-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-12-040031-xbrl.zip
M4$L#!!0````(``:*\D#V0-\G?GL``(2X!0`1`!P`8W-B<BTR,#$R,#0S,"YX
M;6Q55`D``YPG!U"<)P=0=7@+``$$)0X```0Y`0``[%U[;^,XDO]_@/D.O!RP
MF`/:#]F6'^G'PIU'=W:Z8R-)STSC[M"@)=KFCBQY*2F)YX#][%>D_)!DV91L
MRG8<]V`Z'8ED_:I8+%:11>K=WY]'%GHDS*6._?Y,*Y;/$+$-QZ3VX/W9MX?K
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MJ>FGJBBKM5JMDG@[+^K2I(+0J%;ZX^N7>V-(1KA`;=?#MA'!0M=@CY>GKE.K
M:(UU-8(2LPJV8]O^*+F\Z;&2-QF3$A0J0"G"J#&O)Z\4K6"2,2,&5\F5X%HE
MS`SF6*34QX97(,]C"]O8<]CD&GZ?-<1(?V4+]1*\G4,DWAI2@@X4B?2ZE]CK
M>M#K\Z*&X]L>FT3+NL0H#IS'TO0E5T*M4-8*56U>S6<,!N^J>M.W"15-0I/K
MP(N$XN39&":7YV\2*E#[D;A><I7@74(E&U/#3:XC7B54<:F17`%>)!7WQFQ%
M>7B34,%W"P.,Q_,Z?>SV1!].7ZRN4L">M[H:O&2TYWO$#57C.NXFUA%O$F@]
M6VN&Y1]?N*W@%H\;C7-7F(,[TD?"B)Q/!\9Z4U,:,V=,F$>!?,BHB08XJ/=G
M+AV-K?FSH1A*W*`69B:S^.R:9Z69[;]P;(\\>^B>&!XWX1&;;$Q?4AC0TX(_
MVNZ/3O]'M5QHCT6;Y;-%>9@CJ#=9_$Y-_@1F#(8$MU'F9EU]<?/KV8<R_&DT
MM*9>?U>*5^8-EI(I@"RH8X8H"F/IP0,.K5"N%:KE1>W%V]F31?U2A.6,,OAQ
M[X'9XW/DU;]\`'CAC,:.#;^Z[6?J_H!?1XY][SG&GU_)J$?8;F06/'/)@`.;
M/3"!)%A=:E`OP(),"N\#[V,Z',[7LG/V859LB:]WI402(?F&T+SH+GT`W\OU
MV>3X.C6!L]?3K6W3I-P.8JN+J7EC7^`Q];!U5!V\EL?7T]5WQ,/4)N859C;$
M6NY1]7$R<Z^G<X7QNO=[KL'HF"O['3$(?<0]BQQ%/W./[ES*Y.OI[[9A^"/?
MXK%GQQL2QE\S,N12?20WMN&,CJ/?YS8\+;\O5P6NOU^%%$`[J#`#.&3>)4A_
M+@,=`L&03$/OYZ#-104M+K3%6Z5".\4E^8V"(]&!4R!STH-3Y'/2C5.HE'NH
M="3:<(JM3@IR"L8.)1@[6)V)A_"'%<%%8M@E&>2UC'$*R':UHW`P77J*KXZR
M6T_ATJOIZE/T<\2=>PIF7E=_GV*3?6T4Y:T"6J%C>`<?:$"`5M74RR`:H%<.
M2@*Q"%7+&J%6=K.J43G%9CM;I7BI.G`*YDYZ<(K^3KIQ"A=WO5GV4K7A%%^>
M%.04D!Y*0'JP.A-?QCBL""X2PR[)(*^EG%-`MJM=E8/ITE-\=93=>@J77DU7
MGZ*?(^[<4S#SNOK[%)OL:[,L9Q4HUPO_\*W##S0:A7)]4QGPVRV^V73I:@O^
M_.>?;OZM_<_U;]W/Y)E<ZO5&\_L=^1?]\,>WFW_SQ]^?Z*-1J]4,7=>-A_\;
M?JB_^WSUKO;IDW;]^=VYUKRNZ]KU]>>WVOG[S_K[3^_JGUKUF\C5&3ZGS`7O
M#C$CH&/3YR/A!I(/4RT1+V?@9^]FO_,V$EK\=G^YU-STRI]S>)>]M1\@QA_W
M',J\79,^0@=^"!6^Y7?]\)MZ-B2]5)\_O"2V,Z)V4K-I!11IHA1%'^.<]_R5
M)>Q`1"G>F82>7PG5O",#ZGH,M.P6CPB:JM,=OT1EY5;KQ>?VU^Y-Y_8>=6XO
M.E\ZG[Z_03>W%\5WI57M<C"+=Q>`AV'KQC;)\Z]DDHYH>,"M;&I&YT)</.1=
M4]?`UG>"V56P;)&.5"&P10&=54U%6;JF%EA/>#QP6$J&[D?8@DKHCHP=YH%W
MA;CUQ?8DS%^DW1G)!X;Y96GWDU'/L=(1XQ-]T&ZD<JQ?%G&X&!QNQ_>X`>+E
M$\DLVU;$54^4F9H!9!*#`J?N^[/RV8=:H]RHM6J52!>NH3K#-[N0[6$R3MF'
M6KGP:T`E7'?67AL>F/SAM86365MJL`\\D*#%2.TXQ*ZPT)GT;3']11%'FHK3
M"10R*'(-S]QTM*Z_1VDL-9-,ARM^!BK\[R0Z\V:BBO<[L:Q?;>?)O@=[!WZ*
M>>.Z/@R-5+1NG;`VK6@J2N\WQ_)M#[-@>*7D*4HGUD1L(`4V8SZRN3>65G3?
MN?67-14EU_5[X)-=6P[VU@S3<+[08ICRN34T1@LZ#)UF@QO;<AA&B`2G/5^Y
MP^ZP;9O\!W<T'[$E?$SO`C,V`;2_8<M/'@3+MVJMQE0%A=(;%0$I$^5\H*X3
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MA@9M;TA-QENK4I$1F\[G73Q1/$UK>K.<Z#I$22D"([,+]=B,F`H,\XGYA>(>
MM2B_F%>A<*KE2AQ.,C%UB&2Z4EER0.6(+DF?P$/SCCP2VU>J/76M&<&33$H1
M&)GV:#'O7`XF)[71R]$QM;Y[\M&4:JU9SP#BDC"8;3WZ2$+EU#HIK5C0+"&I
M&IW4M8LK3VITH0(JY%2KQ005:G\;LK+HNUS3TI#E*Z34&XE('#PU(`:1.+&-
MC;E_=NFY3:WW9QZ8LN!J=%6TEEA>0^N.F(2,1*S,OW5A>\RQ+"!W`TTS<%#G
M>Y<CQYXM0+1'?'I2T>E-36_%?.)-X>R0*8E*Y<041*"!81?+],J6RJ(Q;IR"
M"@#I%RDD`$*[%,K8K\:6"6,DMB8OFZ^:J<E'DOG4K916]*C972:C`(3,A\D&
M8D766TAX2B33:,37%Z5T<T`I6Z?BW]?8`F4\NRR4C0*.),\R42'+@E:O-2LQ
MHR@CG`-,B3`+%5V++75E@YDBE^>+X[JWQ.OT'_"S$M'6F_'8*`N$O-'+)*XM
MAW:;PA>Z/70LDS`WF%)5['II>B,Z12R340$B\[&#++/:7B`GI=5+1I_6VC_L
M]6GC$E716M7]<[`B&UHV#NNQ);&]8)<G^ZYGHZ$?`!/I,UC7,U/+GQ69#[2#
M`9G]>L*]F[Y-KM^33H.5_>/>QO8M><M[X6`SV[?DG.X%^Y:V;]_P55F]F#^;
M"R\RKU2O-':!0K'E.P#(AVKYMCLLF#$"WPL'&UF^Y7AW+]@/W/*I.[&4+19>
MSTQHHZ)MFSGY?TLI`3*JRA%F32/(`O"!0#\RS";!JRYF'2:ZVA1KCEW"1#;\
M)I(,'6\)(>;*6BR7M=!*9SH(>:&N[`MUEL,-R4)./-P`0ZC*_ZR$FGB\02E&
MZ0&,[3!&]TCR5UD.>.4639J.5P@XE;8J!AQT1MOWA@ZC?Q%3C9[J]7)#7P4R
M3E(Q.*F"*@4GSGXHDMK*;@V34@A(*BDE@)0;00FJ5(8E)]NW&;10(+2/.3H%
M^3S0;C@W;XXV'U,7>+6KMKG7F9-MH:69B55!4VGFJO667J_7&VM0+5N6;1!)
M!55M-&KE:DW?#I%R0U>M!L?DUL"26Y2<+!U(J]+:"%MD#24HJ4A<E6HT.3*!
MD@H@<MFD!"*N1@&CY?*%&3X$.Q!,6\Y@<N]8/E\G2'.>4Y8`5)VN_<J)*8,D
MR^FH5C-#>F#8=BT<K&'E(:99=F\*:NI`R9(WF]/C=BE!S1=6L$7<:7[T/6&/
MU"#NJF,JF:14;\8W$I(IJ0$CD4Y#J[72@A$"O'!<K]//>;QI];J^Z+,4)!7#
MDXX]O;X-O+S'H=:L+>%+.1H5`90)<'98,!/`1;J52S`S^&FX2U!4RQ%'NJ:G
M+K>77J6E+9W!6TU/)3"9U%JQ?>O4P.Z)R"6&<E\Q^Y/P5'%EXM+*L;,EJXDI
M@R055*6Y`:1/Q"8,6U"J;8ZH+:[%X:<<E(FJ5M>BYP@D%-6"DYWRJ,56\3.`
MZXSY#4H+J:JP814M=DQ^B<BV"*1'[BI:;0,$BP3$[:50T"NQ$]T)9+9'(=OJ
M;I7KJ5`(<RYN$0B>*U"#6M@3"#6](3GY.8,D0O,A@:G->>W8BS-0-S8,#'%U
M#O>3NHQX*[)>LW5\+/A)2SDGM#(?.WZCQ09HQ:[HK6,[4=52H$(QU4VFHP:*
M-),Y,Y;EM^IF[EHM:M]6TE(%2'K.KI(=S\("73-GQ.E2VX<*4Q,%ON-'TG?8
M=(_]`3\3]^H9IC*'F=3&;'+CD9&;?.9*Q3!NM*)3?HYP#T<JLF'0K->K^Y,*
M5)_JT4=P<?HKCH5D&TI)G;Q$1PT4Z?F4K%#`'"OU6:K-^#@.$]B*LMIDN'U`
MS)S\M@^06V2Z[0/N1FEM^]-21:E@>4!/8;BU?(2F.,]U'Q`/8FCGF,2Z#[@;
M#>W]::FZ)-7=*<3NK-&L$V<I!A^Q2PV^>$DMWUNQ#;W6]4A.=^`W0Y>+6BC=
M04)8+<94*1E3C*U,&,72Q.^$#H;PH/T(KO&`W/J\;SK]8$-T.XFNV#_G^_KS
M)9@LY//"++^^NM[4],TQ1\+SA/%P#9$('=C!74'&1.Q<8'%K.[03VL=HF__T
M76]ZWYPXBAS<WPRM\*F"7)+@IP*?NUY;7EC8`?(#E9;TZ$YC[])*(+?VS'S6
M$*P>73]<0TX=*JGWV-"6KC))@VJS[)MMCLLG6T*]$3_^O"Y%)Q_4ZYW,Y`RV
M<LPZY`![F\@\9=K6'E!O(.REM*4<8&\3*Z7,0]L#ZMR%O3#3[H.S(@X2#?3`
M5IL<'1@F''CQ`-BEWBPC)C#OX-L[`UNTLOJ6HVP)5%HU=HERSI`/33RY+0*<
M!*ELJ>(D2E4+*J?AKG[QYR3-_->F3H+->07ME0E8=O\EN'FOV4SFN>]P$J6R
MR?RDI:?)?&?2/$WF>5F`%SF9+[X/'ARQO/09C+&@O"@DWG6$IO`K3W['3'SK
MZ^J9,(.ZF^R]+27=AXY^;8-D9^PH7VLX&M8W<2B.AOEM;ODZLB&PX91]-/QO
M/\D>C2C438LO1B22J+35?%F#77&"G79<W!_UE)=CU-MJ')<>'/N4EW]<>32B
M>$%37K#MO>>@:$7N24UJ(-*A/Q@9;)"G\+($H#R]1*^^."7((5E%K0#2K"I=
M8-L@5I"CV.FO,>W;K_[,F%,*:W_,YK,V]#J$L[$K_3K$LX6S/?]RS2L2US8.
M^>N0T)8N^RO4*<6>O7*AS;-9>;$[,O:9,>1[0^`0P'"@+"&"4'!FH%E+^+)`
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M"92L%VG)H5R2/@$9FKOZ<I*$GEIHV;ZDE`D:**1!%6E0+8YCT?@61&5?ORSK
MJ:@N/O7'OQS=Z7<9_V2;-^E:.#`%XINT"E9J8E].344V%Z#I=W=3@^3_!:GR
M\2OC;VRPG(YO>RH/:]5:H:\OIZ#X02TZZ4<2MP/788O2XCN>*D6GAS\FGX*B
M8G320&Q;>(N274;&X.#.K-[LD[=M.YC`VZY+/!5?BZLD0<X(8P=LR"3?6*NU
MJ;F8F8[E)A9KZQ?8'8*#,_\&;]OPZ"/$)(JS/#>#L!,F9'-7[$O6>7`RM4-N
M%T_46)9Z["I[*4G5^&3WW:B&QWQB?J&X1RU%NEM?^O*EE&@.(&4^>&7IRZ=;
MHIP9E3OR2&P5)\'JK88$8HRD:GPR6UNKRF28"6`01(I0T5.JD(6&3)`K2.>%
M-[WKNA'46^)Q<PIN[B,UB?EQ\LWEX5(N$U5!CWV[.C7MW!!+G;-*I:$`,]C7
MV5E3`V((1B)A!;@4"J.N9C0(3$\Z-\`2(>M:2P5BYAB$F.)CU`FAFUH91P/;
M#*3S0YS>3FP(=X7FW]B/X)BIMA3-5)8B@79NB.5A7&L+R"(&"7<,3]?AY\\[
M_3MB$C+B[MET6TND[80NFN&A"H2&'H'N,X@:!6^56Z&/,2H#MA=6Y2-#/9-Q
M6P;ARN($8:<?VJ!488QBOI6<J'*(&:Q/-G"A3IE*?':OD@(S4UEMQ^/$%(*2
M!6V-C4"ML#?7U`9%5FR>F^5F-8VQ2R">&^1L4MT,\%6_3PROT[]Z!JVU!^0.
MAGW'Y@V!0>`_^,3Y"%.JK629K1Y=$LE"/4?4THFPI@1U<HEN3A_C;31C;G,6
M\CG"3I'%4U6".VGVN^%?+,!6U^]9U.A`/[)5WXW,MKL:VZ9*33HOO)NYSJFA
M?O1=:A/7O23S!`/H(?X-:Y>[WL2%'A)[=`\`[:.5=L+]\#?+>SM&KC>QR/LS
M7J2`+3JPSQ'?+:?]R5LTPFQ`X4%Y[,'_SV]1']HZ1QK_W:,CL*LV>4+`"[;?
M!`_>(!?P]]^>_6W@O>4$>OP?MXY'D%9$'3;`-OTKV*[$MHD$$\CIHS`;O%JI
M-VN@-.;_^OFG_-'BT?CM?VKU\H[)SH3$_T'Y/SYBX\\!<WS;%$#H7!(O1R;B
M(;5-PHFUQM[60"Z&@(1?D(DZMN%8SF#R!H$Y*J)?O"%!`<QFI5)^RY,:L#V9
M/]'>_M<;!#I&[`$>$!-1&_$:)GDDEA/$QJ!^V'SD0]$$X,;0%NTCU[%\<2>G
MT%0W^!R+BSP'0:SK\F0P^A=9:HR7]<$T0Z/.%"DRF3]PB^@!BL;@:8VW+GKP
M1PX;,-SWT,."/(0#7M]A(PX>(]L!$@B/Q\S!QC`*0A@I#I_!#T:0^*8,\L=.
MP"H=C7E8'@PZ@#7T0<;(XT1=+@XZ&ODV*9BD3PW*61@!GQ&TG"%@?`A(0O(!
M#"9TT"-!;+K*"W"1]^0@`]3`&0$<KL5C]QQU%P(SYQV([N<"_B74@=W.?;CS
MA$!#N3S8DC7P$&V@B*!%A%TP-.">C(<3%]B$YCCKTX[C`AR'(7HPO7F!;@37
ML@:L#0EE,TF/`8UP>+PA,#D8!@)%[AA,/P@2F=C#R.D%27*H#XHMU`!&C6]R
MAY2SQ8A(CHK2GFO-3./6*`XPUIM.#M"S,'-P50EUT7BF0UQ?(/`<080)$C-`
MB)Q^CSJAPH:@P+'Q)D$BS!DS2CS,)F$5G3+P!CT-*6CB$(,"]`BQD3MTGFQ.
MJ4>@+C$I=X'%0(`7P1@`*S#AW`9Z;2/#HK9`XQ*/KVFXQ==IW<)C#<)9,8B<
MV8HP<OV>2TV*H3-@+"U;0O3+C<LPL<#0?:$CRC6*]^ZBX,=(/W\K_EJ<ERRB
MZT"ST81@QLTD1#,(?`1JH6KY#>*>@FB-NV5O>$$P,$_\+]L!KCW@`;IO:@"@
M.F9<W7L37A*L8!CZR^C;'&;S52[.:6*?JCXV`MLSF;K;,/-24UC&?A!/<PLQ
M2S5U0R9GS%,L6#"K\T:8R8TS>J+>$`V(#0/(LB;\#1F+41'L5@?&C4*[8XNX
M,X_@FRU&CDAI%?W5AAD,C%-D;OG4;G>CD\L%8=S&\UET,1H,B\\W,`W@8/98
M(!YADPAK#/$4$V,.X9'80N=/@?>9N>:0C&#G+2@V#JE/:"@M8HOL84(D_Q3Z
M62"VO?9<3%WH"/`)W,,.+"I%=.^#^&&>@FX+,8(6G*`9*R]LO"DW1]V%XH.P
M+N:#[6248D9);H=`D)9O!B'`U+0(H7JAV9Q/G10>/PT=,$4%\)"@M>B$#K,S
M6)H_@WCF3;II.S;!K_8$BJAM68N)FL*(95-C"W&"Q<UEX(MZW,7&1MQ>$0O:
ML84,J!V22=0(O3;=2%2':,]''/5^<#0ATO%O$$Q.O%+(C\:H[]O&-,PQI@<9
MD,.]+F@;3R>JXGWQ_]M[V^:VD>-?]'VJ\AUP?;UUY2J(RP=1#W:2*J^]SG%J
M=^UC>9/*JQ0(#D6L08#!@V3FT]]^F!D,2(`21$H$R:GS/UE9`@8]/=T]/3V_
M[G;&($Y>XAHKE<DS$JV4W$",1]4)II*^^V4=WQ9X\IQ3)!`^R;LH[2HH9L81
MS;F!#9&E*HQ3/#KBJ33A%J9XQ/'PF.*K9!$Z?Q>I(G*ZOIG@0>.HC;K>6Y`"
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M,>2U+3J-]T'L=.`/QLV05>ZJ(`Z*>#"F>!QL\M/@9@KGT#``MN'NC`@>%G1=
M$YKU&G;X.`F`"(]\-I#I;,%:DPCAS("<*>A`XH#W#M_F4)N/"R**!0%QSYQ;
M<#'B/%549DOQ):U.&`*=QVF0H9X6J@C;=Q9DN=X(89OD$*,S$6-YJH9G<CQZ
MHX.8M4EE=JLH'[P@<:BTFM6,TG'*2Q+RV&ZI]C[N'<JD+$NP6YRF$IVUY/+&
M&10VWU6RRUL!NXW%"^8P<TY/<'DW9*Q]>9?"BY7O9/UEF'^"Z\BT\GV*O$UA
M)2:]9'\ZG<)N<PH.X$RI;"#480`V%52E))^Q9M+9H1AX&H`N@0%88*P=W-\;
M]F(7O+^3#4G5P0(-0(C7%>GKUJI:1EDGDAC^RFD6S^E+;\#"C;,I?J;[0X-/
M2FI/1W&6Q3,>ZH6#?772N8=(&RQ61O^>>^.Q_+=!4J+HN14)W7PH!@%A;\P'
MQ^I!22>R2NOXC]EXS:.]H?DL3DT]@#^?3KQ9$"Y>.^EB-HK#$A,O!SP\/G?/
MMZH6]T7)]/R"X@%R:E@>?3/:Z[]Q_F\>HWP!0[^)#".0/D<_/;ZHX=_S42]`
M<>%[(G;K<-,I]&65SA^SQ/P'"H*5BU;)1787U\C%QVB>XQ(7889021*(!_V-
M3PUPBA<!/36&@X>?A60$P;;H?XWPTA)7^PV:6BLE^R<EN-'4R,GO4;&^2C#D
M#3KB#>C2N/;@J>Z+48B*E_BBT#BRH=G)%O)V?!+R*14/9ZMG6&W(/%R:8(X!
M_SLZVN6IZ#23O>/PP]X+=%,"K-<C5\.'I;J)$V0X6WK3T"_`5P%%H:.)C+T5
M'HN./J3&?<L?^?@&79URZ$V@MT,R@;Y:,8092Z#8XG]S6$J1E-_&\PI:HH*J
M&56EPJA`9GI3""E#_R]/*!0PPHLO4^KN).">Q8?NL`.J:5H5ZO-P?T14/F(H
M9*;`F@!OBI]ESX]&QWG!P#(JP=?I>(/.]P$I33U/\9%9#'1,<CY1.72?=0%'
M.+Z!7',-GQH3FGIX(:!U;USBRL1Y.1P.W6ZW2P.\O+KHXS]<#(?,!6W]X4+Q
MZ0Z8#5;.EZ%8J9Z_XD4?G/R3,(;EIC@M,HJ7%7^:"5!290+"PI!(*[&ZH%&L
M'`N]LS18514?,J`(E6[*VC&C.#I='M>((CT`#K&O9]ZGN1*)PS"^(^[1_B"O
M!M#!Q-"EA'R.XAST*$\*V=5J;8H@/A%'H!+ED`2?HQI)"HND::/RBEWLA#>_
MP2N\FD`@7,16X>WU.^=K/`]\Y[+?Q<\I27!.^%9%7DK$>0I"D;[:DZ.9\E&&
MX$J-XF0LDE,?IS-/Q6M'_?0(+RL4$SF1K?A8[+15NUDF/_&SE?.O=H4D%=HG
M["'CR=6Z$\'--,,/A^,&`TH6JO%&L&%\PU$=BG++99:T^GA=EE1^#SD/'(O^
M^J)/WT9;\YS3V".^])Y^&B5W\=ED],&\K>#="J,V^U)K2*E9B9%&R:/QBI/7
MSO_K^Y.)[[]Q-EHD==*\./N!W_A)WBJ/!-@X\IW!IT+WX`%'NQ\:J$LM)6J4
MEP]\.4$Q-T[,\O43\/PV^?RK/9OOZ2;?WH8\@C^3B4VE49DS8V\EEPOA%@3X
MSF+G!"\Q7SG2B=F6+C?<5E=7I/DJ/)&!;.%,GMNHU8E1G(%OS7B=$P;KO%*X
M-O*`A2SOVZZE..M='(Q8G0S.&W]OU12WPBA]EK?9Z8^!S&U,?\3,CI!A'2X<
M(+*&GMO3>)L-5Z[)T(\U&,YFLS\TWIU<-5.+>O9MH"O;L;VMMCY/]=F#F])N
M#*R2YGY'7Q*IXXA`S,.]!Y$U`SU>?6D09QSG=-%7S<IUSGO#04VS,!P.-S(+
MQOS7G6<.C6U-CWZ-V+9_-VM;1WVI.JA.46:9*++P+Y,Y!3@+;WSY@D!C$<>Y
M<,",BL3Q;A(A@<!T%]<@<QFQ*Y@539?/]P^L<KCQM<^?K@DZ23>1RQCB,H2R
MN-",YR*J0JO1B!A)%WZFKBWY3AN3%%.Z;L7[$K+D^.P<YA-A&9!P`<3*-P,<
M28U>?2G(A)7'XMM!315>J+SLG>&E'UW$T54H7\'IUY@NO#F$]VE2!I#.O/AP
M^>;+J5I3O)@+TYA3-P+"S$T<7^9'YA&P(2R2,%>XI0LLX.NAP.M'7C5<3[HE
MI%R7*,XXWT4-IQ-O2MD?!#A_R#VJ<2TY+H@T9X\WJ+WN67&#.N@.5V]0CS37
MHRBJ3<AP:_3J4OJ3@E&$=R6I&G99D/CF$_1')0ZK)*DHCE02,-UPHP('JX.A
M[J">IGQ[ER%$6YJ@!`P9PAA\K,B0(0QWS#5,N'*9<<.*")N$-(BTS=2-.]`*
M!"E,\+\(XHA'P#^9Y.0PO#>E"4Q%R'@*+`$R7B@$`<8#^%(V^D;E6(P9>$0/
M&N1QXMUA`E6""!Y7824D`P@@@<AYF>X=<=H5_.)T!#XPCHZYV)QU3;B']Q+:
M;B9POWM?3M_^.N7B'4@CUV%RWKUG(&^1&IZ"=01:)#R%8/!!BEL16)$!6Q&:
M/[%IA-;4H!3FYD6,K8.1.<D;=A;<E%(C)4:O$RY0&3"A+28;=V`)#*3$X[0D
M'TZ:S]7.5>2A:0LI,\2?V5:M&(TE)=VIO5@A3M6R)?'3A6QW3VA;#%N)/T(7
M&":=EDX$`J#BE&LAP=8+'PS"10G/'GHC%'=$GNDA7+`P240-H^G-2?"=M)`-
M`7H%.6H?.(/C.T\^D\:3#/_1<4J=D((2BHF`(6!N/#P0G8:@`A(<$M\*QO`7
MR"G02;!S3AC<:A"_3J:1&".PD3>H7S)S#&%.H-4IIJ4Q:JCCU/!(<H`=HZP$
MFCG9*QP)$?#7%WS;^V(95M+=$JS$@D@V`4N<\]E+N;Y//Y?=(";V9T$LJL>B
M>BRJIRVHG@^5OL8:AK01XC*\W.3C#YI"&Z?=ZS[1M)_UDH>>>J?<VL)+-/W:
M;6GP=F[6^I>'`[OH]:ZV^;U=W"G_4G&(:AF3SP]'8(;-83JMLC2_8,7V:8SA
MN1D&__@BI%T\;G1)V6IIV>I,=@467,'27,<);4M.$)V"#-V`Q[3.93HT4%*_
MMR5,TE%"NOIG3\Z\Y[>J;;4_%M?53MMJH*[GE4'B=O'\8M#HJ-5J^>FO#3"U
MVX.KMX:_P!;\&N$8NG[FV+@).:+MY:1WT2PLT``Q?,!<.]\,3VEAUG8[/ARK
M:L!<JZ]PFZ:P[#EN>'B^F4EM.OT#8U_O;+/SXL.FOT/X=:C`,V7J'H&.V3J$
MH80'D24C)12V:U3#.:-B.+HX^H.:X.P0]AGN%93JXVSN!8FJG?1+#*+]"W`-
M6$M(FMU3W!9,E<$HHV(^U_<UZN;?344DT8:RF"ICW*EF-[R)&9G$7\8"!BFA
MI7$`V"8)N(-5_+]3!TJ"<1;5<SH&+_1/]46\EK\EJT86TT!2!<*K$!;%A9FX
MTC[7,P\2.*^D&;>?P`*"/E=>I;IN2Z5BL6<8H[[-J=Q+,/6L*\K1(6@SI_M>
M@FI.POC.`(`E8N9Q730-`)L(@ZV.R5>8"_]`[>VX#QX75A-R,$DEX_XEUHOQ
MNS54F]7'N?*1V5P$?`Z3:EUN$8:,T<3)\M&NK(NE2C5^1RN%W>QB^'=`-?1@
M/ORV+(8.Q#%^%;&HY.G@<F&Q]'&0$GI6EJG7,UB:_;W+P-6^LE+[!VS'L"+Q
MZ_I35(M;R6`7==8VK=-U*-#\O\?Q&!')ULPJ0A1'BNRCE.&?NKPY8['3K+`,
M9")EI4E=44\II>IYX%,MQ+%46A1%+J`["1@N28]5JHHFB7IKIMS:)\HQ#\A%
M5>/R@%AL44+@)W7&4V<0&;KE(OZ>LJ,('U\V^6@7\#=+FTFM1BLCIUM7@(TG
M6#N0B1I^8TR%22".W,;A;5V9R*I/O0VS`I.OK,A(A(&XE9N/^2'\L/J8:VXQ
MB/?-Q`U5J)7+AR#^@`'QW`+"H"EDDR2;8B@"N=(@;D"RW*7:0[PQ2BD_HIJU
MK10X5W0^;*ORL$+O*4C`'"/#))`X,L@$&;MBTGIU:\>=!$F*161AJ(!&2?T$
M4Z9*B68E,8'3="C,7`=Z61;:8R4I7`W95%:_##()LW@(-?+EBKGP1%E4Y0?+
M12R7TO*PWS8G\56(L&LHXMI%^#BI^%*Y("U]R/29RNOLUDKCN@^NRLKJ1TL;
M8&%LJN;F:@(?,AO:\*.2>FG_)=4=@X.5,J(/X62]$I1XN/H!211F]90.#?IU
M*@/K4[(+=S\K/TH-HKCZ;]EG5HX"MWL17,@KNQ,UGK3J/+.>!14=K(IVK;`^
M\:S>/[UGY&"Y`&N:C\"4^9DJ3+JTO)B,0'M,1,E&^I]R9RI[B%6R+=,8JN0&
M_UY.14(M3>OLD>KU8W2N%3>\.EB9:C_<L"=/!-S8&=:<MS[PO3[P>P%*CQ;C
M"W>-LKYP$1^3G%'-VPV?>.XMV+7A-&B9<#F^U1GF.E=;=OOFCMXU>]Z_T+#K
M-[@5("9VH\,V7J8B2'DC*'<+Y+;21RK#_^)2R<XOJE*R%6)%B&)-41M^Z617
MWM-TT>GZNN_XTG51S%U5-'/>JM(1*(YFB?%2<R!5[$!\%XF/$1=JLH*Q%FJX
M$M\&*?>%K/8-JGZ]4A][*=&R7`"[27],=]77:%#LO=:_D0TU@0LK#H59LUY.
MH]!Q3I%FYXGCE!RSESG8I8F4NZX>?<--N;EA\1EDJ.WE7.=_P:Y#B;UJMR'?
M%P\DGV7-&*PUHK+D!2;RBB3%IJXDI+'JL@R"*'OC8;4&.+?.IXLT`#\;?C-:
MR-(*?!0H:M_#5CD5X=RYR0,9UI5M4-119VY^*TN$1_$%[#\1:8<0%$H7K>'2
M]E@JW\<@48SG&RS5:9X0T5^GIQ3IXR2_D9T\X2<\PHQD1(>Z`99H^)K/XN3O
MB3?)4A5:3B@RPZJJMO12[U\LW[#*)J*->FH(/PPB*N-3C(Y3S%3?^P;%?I@!
M"*-+`I%A^W=CS#0##@C=`*3HDYQ.X[M(.2Y8%(.[7\$"P!\D?S#B(YT:VB04
MS5C,$EE\;T1'F[9"UO3E39'T/<'%PU1TW_%AP\$6W;(5!LCW2?"*SI@1G?[H
MZ,`=N:GJA:PL441`L-[&#%;O#;P(;XX%ALN31?G<;+INR@G38<#2"#`$T2K(
M)9L$W^6I6P<!^9")IQG>2*6-)F*I^1.,<OMJN08267T/16S$]Q=Y7:2D%!_+
M@I!XZ=%JX^F5)$TND:Q@I-Q8;0.=60QLX)LIF*"IVZZL+22WU*QJP6!VY@>(
MB?!B:<-/!(H]BD^><1,M/CF;+Q:UB_0Z\*T1_6$>!U@](2++):GBD=4E<U&V
M"LS;8HZ"&"ZD`9&+3&UQD2_IRFHZX]BGMAE%>USN@HN42NL`3,UBS.W<C_US
M^VXDA9YH$U#UP]!+D3V5=0@;?*$LF(/<"UW0ED)%X(JDI:+)Y(49(YS(A:)Z
M4J_X<DY>IX[+UX<JI`[_8_BR0"NUC.:(3"H;IF.\"E;O7NV1LIARZ1A1.'(R
M7`.4B[F*Z6-A,H-R;N+%P5><9]7LL&\.SZ]&E?\N(NX96RZX52IKXSD&CYP3
M^@U?KP)19?8I9M!M"-M)0QEP!8#0$W@031]>DXR]$!M(Z4L/,E52/UQIJF"0
MH-3>B=Z^"6Y5G%`^CV3Q=!CHPZJ7Y4E4V`+YB56"5'"QT-ND;&)4V&WUU<)R
MX[^`Y:"S(T\%_M)\A!.5]>."4G"W%#LB"QU7AW#?TL68X1@I<YX6`CJF\!6Z
M,FC/UHGEDH.OK:;JC.R9-\LSO'+3D[@U.#2![\=4<@D;*=-E75CT13<W'6I%
M.)%MH2@63]M[C)L52*DI7OF<&A\7QI.V.NJZ+$?75]Z%G.^';=Q^XV^Z#9V4
M/>%/RL6[5BZ>/6\H0C3#8!LQ2Q[AM7+*1H*M/CZ@](T#7/(\,D.7/_-DVT3R
MT[4WJYUK4&T12K\<+1*0@'?$/H?=V<=ST7;?";ZO4&TZN6P:RCI1!+3GV"`/
M3*47>HDJHLD'`?A$@381T8UWHS>X5!@'@/<\,D]Q^<[!G(^:,,<!B]I0!EMF
M&#%1?='5!2S2')&-)',W#>9SV8@E0Y<?E@$C.IH09-="D5/Z4!!)%XQ8_8!O
M$?OU(_H+Q/[*+QA3*8Z%AA&&8T84)_!L/I--,B.YFD4G2V(5#ZY6!VP<G!9=
M)XS'5'V*:!5>6)"T+`7W$,=_EO4N]250C2BI<H%)Q\%MHAA:1FG&+&',VR.W
ME.73L#65]YO*K_>9RJ^%J:QT74KV1R'G[E%N?IAN,]BX&H5GE8D,&?X/(R0(
M*R$M>??E4_FU*3R".@3<D2]UG(_*V)9):F!BBR`23KXPM87Z<<@(G4=25$E-
M$)UB&3EAM7,Y1IH*;#M+"_J^B+Q9;52$E#ADQB:5.JK3Z"B&75T+-F^GAL:@
M;"=U8U&O>;HY,<.4A2K(G05U=:WZEER;)5H*143;`2<(C#WA,:6@RJ!";["&
M(T$(K#PISL!H`>`E8-;_2AD%U9%`/DFMY6:]=NY(8=JBI]=>*%?[5T+M@7A8
M%56$7(/`:^=/L4?+HJ&B2QK!]9YG<2;6=+"6<6&*U>/=?*&>:MMRG1&XAY-`
M:JC:H/5VA.'L5*]?0:!6;U>^5R83#_=C2N1+U>34#<.ZZ?)>6/4]>;`I)F`.
M+_]8JX#.V^6'N<GTR][`R!LZO])Y0T4MZ"TE"6U=;%JCW#_170?MP`%ZP[?"
M^06!>Y^Q.'8\FX%AO9ZJLF=6XS7'"-TX1XV8>AS=*M_;CP/I*]*#WJT7A!3H
MHF,>L95>Q.I/>"4@;_JY<B:*/P;&;H03Y;,1US<WWTJQ.+'2)-`0(68TN'HF
MB_UOK_`"A&*M?*]5`--J_'58??CP^GF9%RW/0JOKS,,\E7!1*9\"S*&?F=_!
M,;1CH@$-KOQ#/)<WPV3H=)%[_B/'2?G>$K^"M[QIGBSDG]<@*]Y1T?@;F02`
MW?6HGS?/F2LRE>\?%"-EE)5O&54W1X/G="WIT:%"?L''8P101>G6BE+5T$\%
M1HTOST0!FS4)8HP-1F4EN4\RL6*A5N=F]`8Q>_>60;#<X,4))JZZ$)&=M:H>
M<S=C50IDI]3=`=BBT<K%;^45Q!H">"]:>JB@9R$?J]:ZXOH#\>1+4-,'I;Z.
MM`$?5ZNP)B_U9NRD$ZU:B<P^-WKIT@)PQ4PI;NOQ/N!4/;@?1]<G0;`4H(%,
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M]4P`0R.,KTLRE&Y%RQG6WATU]Y9_&\LNV#=X6'I8"2I\[2=4P--K?QHCKH*C
M`)3&CI<&G%"7Q;I8X4,J2%:.:*23TYA8F56BI&31GIQSO^67JJO?I-,XR4ZS
MQ,,`K[IY+?+MHMBYE2ENZBI6W\UZ5,R+,&*(UYW<4U6RDA&R*%A:RALRN:/J
M`7P3G.PXDR0JS)DNT8CE)EWG-L9[34[V3X+T&Q9^$[K-N9-0=4B^?$,P-ORP
M"+#?^DH%RF4N%7+$,K*F#*5))O)(R]LT@#T\H318,ZV9D3>1)Y/!UI9V0T;B
MO$Y7YX7+3=W>2_+]>Q0@=ZXSFGEQ6\[WA0M^DY(,/`?GKSLL1UE1SJ&H@XE/
MJ,0>Y(.Z\*742U6;;*VZZ+$02F'<RE(5@@JFU:&M#&;BD$F`A:EJOUK(A9(!
M_0U*9?)6X1'QI/;;QFCJVK[J=8_2DT]G@G`6<P'_HQ/RBASL-;EF8#?!CB;U
MA>%T5GXLN"P27O92^H-`>T>WE%K4508ZB`P('R@+*+=>C25]0&."\G3$]\6Z
M;*_"!E9N)KK*I11C,IU:/=*5,K)H3:D$/E7DTTW384$F@IJI5EN6CY@82%5E
MC2=E13:9B*,M2$F$=$U<ET0.9E*NYPWV@BLQ/B")7!7^A!W#+*;+Z=!%/W?O
M.]C2<2YW"JKE4BX.:I!!E4+-6G.<11.G0EN#$_DZCJO`DZ_0]&.ZH<S3T<2X
M$@"RP(T-K]^I;.]^2/'VBX=S)9BOWG=A'<C5LEVR4$Z&[#'P,C)/B[05*UTL
MP6\R,9MC\MG"J(>8E@HBFO434,F5_6"D*\FL+,M14&"BE/)D'BN\OCDN*8`'
MFS/M+;(Z830V:REI$Q\D<D3<D6:<)%Y5!JB@IR@(5&V`(OIDJH%WX$F$P?^,
M"MVZ$!G2J2IMEK+5Z7WIZX7!-Q$&TUB9S(JWV=X4-<M%43X%'\*4R(CS=JA.
M+>ZEL32&$EX#CQ$ZA?DLF1-+EX9<'/JV''^AZH\2;91:KE.A@RC-)Q/86BFS
M65=G9"<$?$W/<,<]Q!D1?"T@^PLD!.GT`?:5#3'SIW*XR-QI#)?1*#X:4#4!
MJGDLIP%3C#CG'.>*.T\MKQ%2A__5M>(Y6;DZ0X/$L!;F9BZ\UJAJ+E'Q`OQJ
M-6D$@5M>HLH):I\1"YN:"R:7B8O@,L9Q7P'EVW=U4)5DF7J9ZZK_E7G?1$25
M"[$0P&T0YREF)P6A7"!9MH%J(JMW3&=G),PA"J54+^I"^Q*+QQ!5KIE,^SKF
M$T14EV"\:K5K;&!A^#8R>&6^2`BMZXQRIICMQ"S@F;KELD3/#->K%27&YLE/
M\U=.LWA.7S(NNA&>]^!/2FIU\`^'V@HN#PBK#IDK%*&.,=;'*M64AN:S.#7U
M`*%Z)MXL"!>OG70Q&\5AB8F7`QX>G[OG6U5+24.]9>/F2U@G1J&""?D.4G;U
MINY]1RG_`X0]'<O(2L.XJ5WA7:RP+-)8SF<LUE<6X_&I5"5%L[YS\C);)LXK
M*;DF;"`+R_@&QK""T'Y!>%M:9C_$8H:3!2XE1D0]4FD7Z\V1CYS(I#S=%69I
MU0GK#_\2W^&,(:OEM.0&I37>2JE"H`+P&Y$!V?IG<J\C?"?T^4(E>J5`MA<4
MARVU3D;%.OP"55*DP.,,"*L[+TWDTDK"X%F1R0)BLE(A#BRIY"X18YGRM%KR
MB4Y,5$$A,[I(J*%I/C@N-["EA$GG!LM?4FP*9CWL_J"Y$-_KVIM,YGKK3AX9
M9)7X[:T[!^Q'X.4II;04C)M3%P(^&,(Z:)86@7Q@W(]4V"+R0NG,ZA(>AN<[
M\[(,TQ"#R/RMC#24^PU,/:PXAF7%$AD^++Y6^M*:6'NYZO&:Q!<^8E?4Z*^?
MH-0W[8V7RQ$3O2)@LRGSLO9!I)Z@^`8"I;%+M:H.]SF)(_C9%_:"N!S?X[/C
MM9AG?/%2!"0^Z,.?P<=KJF^(L?J?8KS1.E&BW^^^^?#V^B?]S]Z;5RHEL_+U
MW^=T86R^__;Z]]+KO\4=(N>T>^DZQG-?Y1WKW\W&%$5+0V.,Y>'5<.9G.H[Q
M!XY>99R5F%%!\GF(3@KM<JJX\:3<$\-HIS&BA$@XZ&9<1T!Y,U@7A-H2<5C/
M^2]8%ZP1@MF(7'(PK2[,>=_&7'$KO]QP!=X/Z4H`7ZSH7L3-93A6.J'@`1.!
M3Y3)B`3>+6`T%PL\R'K%Q!G52:JNTY)13%Z&*4+=XVJL8UK%-9^,--+EB>X#
M1);:@S''LE=6HD+-Q$8<A%J9J=XT(.6S6HITL5WY?5E5@;-2B_1=;X)NP7N8
M.&E';^@JTZW:AL$+6+9I+&_L@U1)`-9VN._:L;@`4^_3O0\,@F6[:1N1W8@P
M+Q)W,BS:'*K>8=+'*L(TVEF6Z>"J\NZC2]8?;BA/6KY_Y*!MAM$#&Z;M%MB%
MP@8-2S;H,U<4T8=97.1$3,&C0%GDNZ3[#=&PSA`-51BXR)>6\D&E5;B:29&*
M*Z_("P)4#%]=(5+;*)($C!M++TC=QI<?X%-7U7"E27QZ][%DK*7;08<TO/8(
M59IX'N=IV6&I')L\+30D1957C!YB.%+X,FV[B$$Z7\0-;".AO"EEX\(@$;(Q
M>"<:\?0-@Z&O%\A(DO$AFLAM0D,=<(L9Q6"->BJ2ZZLBHNBZ\6$VD&$LLUT?
MEP,7L]0,X*KGU24N<!,_;"S.LJ>'97COIBK;O>&:XO!<F)$FIBR3P1KXG"E]
M)=/JTBT!'KN36!<)I_W"Y<)R.3#5+SBHO68POUQPDJPR>Z0/,*Y8LO(.F_FZ
MSIB55#\B\\77Z&FOK_8:"H*G\G[<Z-1HSE/N,R'98K[KFB]I]KK%73X\I&S'
MZ>XM4,6@D[&BB$_;9+I5U8_4#V/N>:AV0XZ:RY-D8>?+PE>TRDVLF7^(F?_5
M6SS(RI^5K/S;0D%`.M[Z4VP*JBH'?4"WZY_D=OW*(0E=ONV]7E<P5-K.D/3]
MWKGN.']_^_8S/?CQPY?K^FWBG2*JO$U4J:Y^E"MB%`V'".Y,+9F1T\O^XFR)
M\$(@30-)WRAHYM)[LMYH<4KXHMU.[>5W@%=1JIK)KMACV;J'$&%`9\#ML"6^
M,/638(3=N"-=,KN2)+0VQ268,3>DE?Q9GM-R?Q1O%.=9#2^`\/^C3)!)P!JN
MJYM@V>>:]L&B-1&]/(>CA.\57M[JA'#$RW[7K9&M]5;[K-)JSY_'9C>TA#+.
M<J\;^P#S]I<?\_3TQO/FKZ^+]KK%D?-S'.*]=OH5#,M/8>Q_^]N?__07/QTE
MK]^)^10K]>M66_H1\ES@'U_$Y*\OWO'/__GP[Y__,^B>OITGIQC%>?&WYXMK
M_(:%]`:@3)+BHCO8L8<O/D58MA$$JG?N.JM8BE+O&FPUH;NJ$5I7\=-%A[WC
MEJRO^IMI>A&Y<C>-PW!Q&M]A_71L(1",`X_1$E_%K>=\+O<3^LB@5%2Q7[(Q
M?&.>)UBNB9H:L"Z8!&,OY!R]@]7.0M0NR>@]Y$_%C#Y!KEX>C=,".C):%+*R
M`M:6Q4@74KGF:*$Y<*!&HGK`NKJ/[D8D6W^3_L'$9%B3N:X_!X=L[I6+F"XV
M=MC4!\9_V>N<.3.PD_(88\R[U&M.@1MPB8)HM65C7`%4*,5<JZ+L8*#>I@RC
M1XP,4'K#,J"#$+*A#5=JU`TQ6)Y6:##!5C)HJZRM:A>427M+6X&/#?3D<3XK
M+7DI=%S55&@N#5C'^5TVZT$4:M&B1[,%.'S5NZ0RD7=>J1F&]*)5U:W*HEME
M`UZ$*-(B1J$$44V^J%\MEZIW"1R.LJE&KXKO='8K-CQ-M_5/54URI3C<6)L;
M,JD\CJ*#/,IL&B.2NF0O;KT$<48:M<CP?/)3"1(DQP&M@[,OG`>QQ9Q6;/W;
M`J!ME.)BZ>9VK$6;J*(O)4<>7O8OE$Z3!*7"^-AJ;D)%]YG"?%$5\J)AFPJW
MJNR9L9@+8CS/4OW9'*.R>1H7>!TA(_#Y#^_?HBL&IM(+.^#YF_0:=>#8UV=?
M%-2`#![>V_,59_TRE=9S9;V2>%%<(+'!G\VP=Z=L=`)DL?TO<I,J>$]D%T,5
M5.L%PX`&M_C0]&O"\'R;W$ID*3<5(M2%;"&*W$*R/2!1G%*JBC3@,-,P$+EN
MHJ/%!S<2HF:A)4D)`[P*IHC<8`ITO#P[IUQV_.3+RTO^619PHR4L>7;W^&GH
MRBGG#P]E`9_*WT9C7>41+6=Q&FNWAW?6<8Q9T$*4YK%GSM[6;_4^:23Q+P)K
MM-M;/$5(%;S81=!&B(PJPRU5@7KJ:$FV)8JC4Q]-,A?Q+0#;_+;>LU.+U-PM
M?*O;Z0^#:'<`KD\1I4C"#%,\/WP.O?]YKG.=!W@\[5ZXSO_Q_&^8K>1_<YW?
M@-'_@"?%PNE>G'=[TL=W\78`=O_?XEOSPEEN2>BY<X-93!N!8:?"&_\W]Q("
M<%!G!*-O"VWCWREC*UPX`_<2]I(4GZ9]A\$1"&L'68$UE%`/%FKQ?4Z9M(%Q
MC`'[^R]1%+%_>=&CW8EBP%&F&EA1IVFC!'NY#1]=MGH(*\$MVGR-XW)%_PIC
MD%[=($\(:J/_]B]4\3ZKEONKEI?#(4A;`N?*?\7A1#C7&1CL3"GF>>_*=7Y"
M5W%&>:R_>LDB)`A2KX^7FGSRKE>KGGL^7%$KV"E0/V,*;)!_;>B9O*>Z$RJ<
M84*4#(@6:CJW"EOHOE^ZJ[2!M:M66W5Q>V8\65+?<Z-]PG!0J<K5:K>LX>N:
M+%CEM,JY5CE[%[`K9L%XZB5:,;]X1M3'B^#_N<['-/&P8<G]ZCA<VN6H0V&Q
M?;(BEO9-#.Z_F\(G20-5ASCUS9IM\1]Y2%=F?7T=6TY3HS;Q='!$N%1IZRNI
M8?^J4,->]8[:5C7<V_/`!TX>0Q#7+)])=NH@SY@:@")@HL`\.;)_`1\3J*T%
MWISG*7`]?=4NQW]M^?2+X2[+IS]UT=S+OJR0"HHP>$"^1ZMJQ`Y5C=CS?N-R
MABTM$%M?9A$]DS4S/+@2E6>]=I6HW([>V8J.SZP_R_4<&ZC0H=09''0'&ZN2
M+3*X633U3L@T@)*'*PK'5+GK^BZDTM/2Z7'DMHQB1.6\[%\6#O$%_5@`$(M[
MU[&J`+`Z9.$4#Y13?+91`\!#7LQ5XNHZ\SJ_2G1]ZGQ6W=;*0!M[UW"#=9*<
M#V*4Y!BU`<GKKD/<U'>EG6E>Z\YV2^`<K`>7",0L3N-T'F0R'8\1+/_-@U37
M#"JP,M79I;_K&U0#-F$2/?.P?3<B%\*%<1<>RXN3)2I6CN0O!Z3&+E_F<I$M
MB4JBJQC6=<%]L#C:W).@E+J$4DI`%$6ECL7:7EH]`GR\[)T1'64DQ]*"_)I3
M7;0O@LU*<9T/K%P!]<DL$HSW*R"?)LB:F#7$_2)N@,F_<M[I[NEKB^DPY1+S
MI+R$4^,4CB(DMJET72Q&QZ!=SG]!@#`!W^(\8<0:@D9'V-U2I+4E1DN85,$5
ME5`=,`%,(V'$]SF#GEGG4[%,2H1P57POBKF8JGIC*05`%ES"<H:,J4/L,"7&
MJ*$XG=YH=E>5U%6'#]NG!(!5C:W2@[9@"[Z(FX!*HR%/91UIYVU"R!6;,ERK
MQ:14Y@Z3F'RD0XT!5B3OU<?.W%3K0^WSL)7=4@U6."/I)#%4T*)/IXZ+AW%:
M`!H+`"JG?*:$]<]3?(129KG@,GR4\#47-3:"4*=KR":P$-@G";!-BZK/,V^!
M_6$+S\0HRHP8JE+BOD:+!8F?SW`S]VOJEZZ2))T2QRLD4EZ=!91(&S)2,ZZU
M',J-H$1D/(R4QR_R\R24TR/K'&#GVX3K%:N&M-)JU;P^QFPIE(8B,?>>$56=
MP1GP1A<4T6]'1BW4FD]2XF_-X`^O!3P2(27W<*8S+/2("YW@,O,R&JZA0L"2
MXZC6?KT,%9))YT"<M2MQP9@MN7!U(0CE^U%)=MQKBGVJD*>'%A(ILB.:`>1T
MEL0O@8^)FM&-=A7W!D\W[#B:^L+3W3<8W5-EQ!GPD_)IZ([J`6CG+$7_'QY4
M!5RQDI]B:F'9.\[[99M<'I4S$,CW0H/)*HV.5L5@9BUU7\PK`>0H<6!1"=+[
M$;X<SZ=H\=\9J00JAPQ#*0DY8:#D\5W'>8N5F5E!#3@"D46/5=(DZR"ADUA,
M974CHB>X0I70]5,)9Q=2S86BQ@$[E1JZ32^"A2&SHT&_Z.@2329WIESC=K%,
MSGY4>WD25W-/`B(15[>CQ'>9T+\2]GCG1=XX\"(I*@O:"*109RJ_9JSJ%XV=
MEV>,HCY1+[XR$SZJCQ%*];MT^<MGF!5ZJ#6!&)?5F)523D&CQ['>*?"HK(B>
M`Z>5F#=FD.EQDM]HF+>KMTWLLI`IKT_E,V"2`.UPA$M-7%E2E%IA@,9&L!8N
MI3:B%^`Z(^S4D'$]I3"G&N?XFJZ`7.BGME-&205DP5(-7ET:1!%DY&/I,C#L
MJI3FJ%'LF"[`,:"*K#0)M>=3:%'7@<V.6.%B&,!I#V9,;B87+6.#2`]F`B9;
M)`>Q/4A7[*5;*PT:^2]?D03QJ9*ABLI&(7)`.9G+4HKY1Y?#94FD6@\TU_+H
M^J/8X43(0%,P&^'17J:75'^&DE=AL1T,DM,VD&;Z>'#GI85>K&D580(?*I*A
MEK)9L?I^2K4:*`06C\"B\!J,E[?2?L?YI'+UJ=Q/Q'!9F2%8WL%.M(#T,;6P
MR"^!L90LJ-RYLQ7.CF#=P<^%)2EES^FD+]K%B_AAE</(^08R8JGW7#AUQ9P!
M_!#2!Z^6O`?I&DLN\1[(^23JDD3F%JN4$4H-7#9AM0*M&%,3RBT2\V1:G_QZ
M/J>,DT&GJU,0*;?0B$CK-"!JBZ`2@("0.;5>*/)T/,X!*GV6VR=@BM;2QV?>
M-Z&G2E`M#]L25>1>&0U69$Y?NIH,\S!WW$R,*?[\:?+.Z";QA3V?=Z@_U$2+
M>FBI%EKM]NS/.TYMWZ\C]NRID[;LN5)J'*(J$.ABF*`(`ZT(=!,YZ/3T+Y;2
M1]5.S;6QJI)':[%Y%:?O6B(-F#Q^/!FS$=M[1-I5=Y>(M,W@+W!`N4N\^5]?
M\'\?#G^HPO;03$^Y]Q,2$HXW^$`3G!*O2_7W81V`H[!XYY6T_!M=A)_+(O_\
MTZ[!Y-BU?>#:]BMI0<NURVD>$!][1ZL3CUV;"M[?R^@M4[*OI#]WSVF%+#^3
MX.._BX@BHE288(RG&@[[WXHU3'L21/;+![Z\!,3NRM<19WBUR?<?-(LVSKSO
M7EXV:^/<4@`Z^_UTI.3.J,DW@=&IBKD]GOD;(Y7[9XW@K*U&7?>:M5-OF3%[
MP6"':E1>NQ@]:&2:6BXSZQRD=D/T&?/QZ9J[CV)[9[0V;>/OP8C*=BWE<[M*
MM2D]GQ\@0(>:&]5OM&$\*BWJ<)EW^N2\>WYKVE;;\U2?/;@I[=JL+F?)P9LU
M075Y&]K`8#Q;&MVZ(]P&V7/NH+\N,WI;N7,'S,#>X#D8:),/'T@<P71^_F^.
MM_@?(PRX(?3F<^A%NR>V+3>?GPP,5N]2E8).\8YX&H=C3+R([[A^.7SJCSB1
M;=CQ6E/6RJ<J1D:2%;VL80<&=L?/"<3HW"78Y"?B%B6(S::BH@I;5+]JI3+3
MYF.TI"N5_F6'>T7(\@NR.QYAM9R3`+MF1:<(B\JIB3?=MCJ?YMPN%QZ`)^#X
MGR4!U5CF/[^]PV+];X@%\`0\(G\_QWJLLHKS%P9,GN#%I;K@=6LWGE?4@P][
MKLSF8;P0N%[C`$:C5E<,?8Q.]1]AJL4^1NDSX]2H?+HR:5@<66\?$:+P[0$!
M2`A$4BR<SXT::-".8@)]O'Y^7`$'@9EAT1$2EYEOOZF(*96$QHP%[`1&C%=M
M5R3EM]2\+RT*;U-);GR`NZ;!>^\5,QY*F,3=X])]4[`IZJNM>WMA]2;=IP8;
M"'`TL&@-)DOE:IY@_?(_@`H%ME(MJ!()[)-UGTM3W7E>45LRAOK=[J4UR\U2
MA>:($XWSE#JN,KAT;TV6-$^>4R\(S@FJ3\G:%X^N6/M*L`SF?TBC@LE&(Z$9
M-UK4PALKC$S5X,KNJ!%->UNF<P=6\3@5Y@/F_!"RC>733$8WI8^<CCP$7R53
M@@C>][38+!F052>8[G(?(+DYF)^F$G1CF4ZJ&PJEND./;)<C,=Q&`V\/137R
M9)::S*N2S9RYG[+'V7F)0'AJJ#OO(!4&32QC!$BEVI"I+F]>F]6U.B,2/21;
MPX)C5<E.II^IRI.!T3^CG$AG]"/C[+`<BVER[G_1C)KW2MZ7RTYC23=+^Z\$
MUI7)EG^2RIFGRJ/\"<]PI]<^.+3`"\YDQJ6AIA8*C3XN=97T=<X7XZ:-ZOM2
M\VJ$BJRU+"GO^5.N*&^^'J2Z_8,!/[[AF_&0Q[Z50'EE%/1Z[(=R;]UC4,;-
M,6&XUF.H/<CU^^Y20HUF&B<S9D++U>H.LGQR*_I1":=^)?`M,J#+6[=^97G?
MYO07REVNSS?`9)*D')FCOBX+V:%,TNPN];/5YMSW0H$-M#AEP:@S\@\OXD,O
ML^J>^B>E26!23=%38US+-VPJAFW"0IDF%^DVNW>2YQ.@]Y0H*]LNQ-ZKZB[#
MY<-9':_RB!-I*6O*M):N]B?>3;&3KQ>M++Y)=Y#>1W85F;V50V1C.BO7X&,E
MJ^^F,9=N1?,M.VG0UL@S\I64RXQCRB^0FZ`Q(7:V2NOP-"N`Y*V,DA2N>3.6
MF(>#8GJ8K$'%2:N$TWG9&ZKN(?%DD@K9!-?[;F2Z!)$"H:L*'"6Z#'K-:$,E
MB9@HNH8;QKE]_2>D]Y17*R([QK):+_:2SC"_7FZ:_>$/'>>#M`7<5"M<>IWS
MUZCG5@7+_*+6"+?%98,EA0@L2SJE+".!/<F5YU/RH>KF5F+&<ET3REJ]PPPO
M<B/D&:->$"I5FE*142I,32:7$%.?S&((:"VIT:#R%8&P%24J,3:["WSI*I&8
M5'*ODMZ]V)FW[KV8QW+G[[B<MB:*)J3LFWN@[C/MO[/4P@Z.U2DR4>'QQTL'
M\:5^;??DW'#*3)$I8U-C;&J,38VQ:VM38UK!QT-)C7D:E$]5_LCF7VH-*3M*
M53E7J2H_?Y]S,UV,N./)B/R)-0QI1^,`I7%FYX`J'<!T_E/GO//H7@*/MA_;
M&.-I*'L,'_N="^)C0Z1JFW-BO@3IM]-)(KB0-YY:Z>37!N"Z-C05*]'MG/T`
M2]'O#'YH1,ANLO\V])8>SI0K9LI%,Z:TRSC34_^,L7P/QJE:+HAP-`.6][J7
M5@[U8+WND)C2[^]&#K=F'-\'>,\9C9U%(,)QRR6QNP4)W&^Y:\B!RADWA]LJ
MY^%08G089N9C%5[78U'+F_57[^O"<475QXH:.%2-O]L97G)IG6[G8K!4&,>L
M+U:Z>UFZ6<#G`UDX2I6J#"*ZA>=B?=PA,&I4I`>OQLS".F.,MR6R6\DC"^P\
M(\[OL..**]:=>F$^VL1L,V:RI9C(L]-M>6!Y8'G06A[\2^[)Q\N!9Z+[*<+"
M=KNR`FIY<"P\L*;Z+9\;CY<!=J^RB]-J'F@`^/&RP(J!-=1OO@CLJ%5="O!(
M6/#VYB81V(3`;E6M6QO,^3U>R?2B(_:A[?:$P"SN?W.\',!>(HGG8SOJXV7"
M1^!!$*6!?^P[U*$`?G]6Y2%V.5?+3,O,%5JHP))EY.:,_(PE'BPC-V?D+\%$
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M'AW(@H`Z6'-]=%,Z%*_[0YQ,1-`ZO_N`K-S@[-(=7C;O0MLR,W<H\^AVKAK%
M(%HM7-9<'Z%WC?U@UF%8#ZT/[4G_O/$!O[X=;5.\PWYS[O+<'?0;=7.WG..S
MR;"W#YQK0,1C8_BU`W8[YUO2R4=CA?:#43LAL%W4M)1=SWN*J]W3C\L7LU.R
M4[)3LE,Z^*-:"<U5K@C88.-^MJ;V3S%Z^:+V$5BP3;EQL-P<N&?#<[<[:(8H
MLNRL8>>9>WF^?^S</D4/<-2-(1LCVHZ=81>=\\/E5T.0W#JY>@8FV;.?]5?M
ME.R4[)3:,Z7#.?O]4Z14[#X:.T)W@HJYWRR7CK<'0GL@M`?"UK+3'@CM@=`>
M".V!\*D.A%OP,8[+-[13LE.R4[)3.OBCH\R?XEY;]JC(1\7^6<\]/V^4:+-S
M7ZFMW#QWA]V^VSL?6&YN@9L7[L79P+T<[%<88]?G'C@H;@:N/3:&G7<.^&"]
MQP?%9VWH"N./*H@;J3_:9IV'4Z#ZV>FV/+`\L#QH+0]L![AGHKO-576/?G$L
M#RP/6L\#:ZJ/O@><W:OLXK2:![99IQ4#:ZAML\X;VZRSS6MCFW4>[>3M]F2;
M==IFG?0MVZRSYE9V7QNFV?Z2EIGM9*9MUKDE1MIFG5MBI&W6:9MU-O(N[F7X
M)NY;B;V;?\F28DG9.U+V+M=@D^:3ZQ"5K6XVUW,OKVSS24RS[U_L;\_%;;%A
MX`YZ>\R&C5M/-NLIUIZ);VO]SXZT]61_:!M/[F'CR8L#Z]*('5![AS:ER^%A
M3:EI4E:K)_-4GSVX*>W=:6;?.D\>3C,S.Y/VS<3:N>.=TJ&XX+8+I9W)T<W$
M6KGCG=(A^=QU_2AWN&@GP^Y!]!:GIKN',(_+PYA'MS-L=']PA);M`*=T*%[V
MNZD7W0@GB!PA$8-`A9?E37&#3X/HV4;!KOL;N_:&FY<<?\Y&G.WCX,E667A,
M384;'5V.MOUKK]/;K-+9L3!J)P2VBYJ6LNNY3W>V0KB=DIV2G9*=TC$<X^K;
M"O<:;-R'4GZYYY[;+E+;XV;?O0!V-H7)6G;6L//,'?3WCYV-*-IB[6;;/*H9
MPRX;8IKWBE_;DRO$GK:J@90]]EE7U4[)3LE.R1[[GJJCL#T+[HM7U%INVK.@
M/0O:LZ`]"^Z>7_8L>!^56W`PCLLMM%.R4[)3LE,Z\%/C/<V$C_.4.!P,W,'`
MMK_=!C?[[MDYG+O/]LO[;"LW!^[5U9E[U;!8SZZYN;LSXO!P^?0$9\1AQ\K5
M0]AT]1QLVH\NPI6$_)&G63!9+#DH5^BR;$C;Q\@/\[$88Y)*-A7.R`N]R(>W
MX@+T)/V8HD)A3STM6QZ/XEOXWT0X'`S&_^_$\RR(H]2YX6)/&#G'-][%L[D7
M+9@3E_W>Q9O4>3<-Q,0!Q\G/LP!&^C29!+Y(*/(>9&G!M<^)2`.<N^-E_'V8
M#Y+FQ[.9`+)G^#?X-_PM2&32#?T.Z)T$*?AK1+Z+SX`?Z4^=H2;8![YY\%P<
MA0ODT"W0<#KR4J`=0_[(AWD2WP8I30MI6WT7!'*JWJ5'YB*9Q,D,65H[5L<0
M"_W35YA=F0CCXSS#5&@FT]_&`M8^T1\`AL>^GR?.#(B;PIQ@D8"G2%(0CWF,
M1`AG@76.:VE8G0#,=1S09UW)PQE(IS,2SDQD0$D`-,AKDA(9`4O::^<D>.7X
M89SB7X&*.()Y()4@/Y,@@B_!']0<E;PH@?-4YQS'F\&A@!8;9"$4'I#P4B_(
M&_@(?&64P%#X&7@;M4`-!M/Q;DA8Z$%X,O3RR)]*BF#.:1R!ZOT/ICL3XP`H
M$LY)'.$)Y&8!X^9`O$C3-[3&)\'M*R6!]#$0.QK<0RXM3:0D^&H<9PY*5[L$
M8P%&:`:<H>%`%X&E=U,!@R92#-8MDC/U0*5&0D2T/G?\/JZ6!P(S6M02]U/L
M)20FNG'9`P55"J7KA,$W[(<>KF-!S:MH3/#2+:+?PJS!*B8>;B2G(2X&/!Y4
MTW,-<B;H<^4W8/)3$/L`[&$,]N/6"T(R7J@R!O](%+WDF\@D2>D4:%$JZ)$U
M`?IP_$+]5_FO%!/G,1(H%:79P/_YO@A%XJ%IK)_,UP>OC982-+53CRP>'SS)
M7@L/]%0N@SE;0T[@B,T"Y7AW,'KJW(F$V%9)V5N8FP/F.`\SM_12`.L],A9/
M\B-B$I0MTM8!=@=_*CH[W@67-N8'$[(UQP!^"/"'+\"7)*"KYNLLAD,,U4KD
M?-%`NPN/<!QVQ*"MK]1;)\UG,,9"2;/G@\\09`L0QM"3CD92<#$E+I(3DI*N
MXSNTY3DB0K^G%)WIDT%G#R=%4SN)PS"^2YV3,?R`+]$^%.<I/)>^>MV2-9!N
M&'[NKR_8:7VA*)'E1:^Z/[QQY#'9Q[G,4]B*U4]-2`&O.,3"WKC7_?5%E_\M
M/7+\=U44;Z-@W3$U4#BOI`4E<Y?3/"`^-HF_MK@/Q2-8O<6.8AMVTCN@/FG/
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M]J0$/K_+U-9M^0`]#3NEXYW2KOTIHT:"<7$BHO&#KDP.M?Q+\V#*L=;H:!IM
MW3F?VBIRC[G@VS4O=R9S#>\#;6&8K25:8^F!#)&9S@0!BK<(4,2M@NHAI`YO
M(,XX3RB-_X%)U5A]XN7E&15-P%^^Q,`I5E'`E&TLL1[<BG#1<=ZN%L[K4YF!
M1/`8O2LN,C-Q\B@1?GP34;$.SO;VXQD6'^!Z&;(0@9D>'JG];S51G*L8=)RO
MTR"%<=(,\\#-ZN\C'$E_3Y94N9.)9(['225&C95N9Z`JK#1:ST,I:,!5##[G
MB3_U8!7^Y26VH$&YH$&=J.MJ-<`X$'KF6ZDLDRIG,%?<A8%Z[EGOW#T_OU"*
M"K\+LI3JTX`VD)2[JB@+E^^A.A^B*%M96>_CDRHYI"AQX5/]<_X4C1"D:<YU
MI/PXBE"7X7MW038E&HU:)+K(CT-#<2$>,@=8+<7S?2SL`R/A]&#J8>"-@C#(
M`L$5&?*$*M^,@]3/TY2_^%N<">>BNE!)17V(Y9DP'P0%&K&<T*T'ZINGSAA>
M2+%,4IS?3(LIG+MH%;@.!9D!6RABSPM%M#`MX-GIMCQH)0^>J\)`>SGP3'2W
M*T'F>->AU3RPVOA,-0_:RP!KCMJQ#K_ELY%(CE<.CUX1OXB9%V#2Q_&RX*TJ
MAVM-T2Z7(9X<KPC*?B=';(?>P2N)YV?Y,5<Q^`@\"*(T\(_($AU*CK/-%M]:
MMG@2^+:`P188^4LP$<[)O_'BK`IG;?G9D)_WU9?9IQ(&1U5!S9)N2=]8WYZM
M),.GXG;:-?L%K6%9J]/Q>^Y5K^]V>U=/3DP[,_(OFK5L;,W$M[7^@X;]VUK#
M@`U7?MAOUEW2EF)HB#$_G(30PYF)365H9RI#*<S8,CT^.;L:NH/ANNXL>Y(]
MW#^<PC`'J,C]0?,$]5;MPK8P@YW)\:KO0>S#MD2#S9MOEC=ON?00+NV$P'91
MTU)VV6(,=D^V4SK`*>W:<S+RDDM7)N4TP`;F^V"2XU7ZXD:V_7C2X]?=K.TY
MG[;E.!A##CJ7A\NO+<K5,S!I/VHNV'S9:BEH(0#UV>FV/&@E#VR&WC/1W1)L
MW]&O0ZMY8+7QZ-/TK#EJQSK8?-DC5T2;+VOS9=NQ##9?UN;+VGQ9FR^[I\ET
M-E_6YLNVC)$V7];FRS[O]?Z!-[>VI+0!-_'`_-)U%Y:MSB^\.+MTKR[W-,ER
MX^S2P9XVNM[6ZO<[S>`;K6'`ABL_:`COL=FE#4%SNC+[=K^ZPQEMNYWT3B=C
M89KMA&F6XG,M4^F37G?@G@\:;1CTHDTTW3>IWZV<-?-&:T3,YI<>7%;FX<SD
M`+7V(+9?FU]J\TMM?NGVN;03`MM%34O99?-+[9YLIW2`4]JUY_2@_-)UL83#
MS2]]3$'/8\T#;%K_<Z_XM"W'H91?:O.6'\"FIM5%MYIA^I<?\_3TQO/FK]\'
MJ1_&:9Z(3Y-W1LOH+]PH]EV<9BE!O7[R4C'^["VP3VWZ%<C[*8S];W_[\Y_^
MXJ>CY/47,19BAN._HR:[U/+X;32F_ZK.Q[+QL7X;F^3B3+^(R5]?O..?__/A
MWS__9]`]!2M]BOG_+_Z&I#]/PV;90=<I)N/P;!SNX(SM>:M[.1-[1VJP%C2Y
M?>8&SI\BYU</6.+TSWA;+7=O)A0&=2G.8L=SKH6?)]S,6#/R[4TBN`DRM4M.
M!68JA-@)&5[$F":\C`W+XR35/9]3+Z1^SU[D>`K4[L#6-AP,W,%@8'1_-HAA
MGEWV>Q=OTJ7ES8`VW4=ZCK`\?/<E;`%#[&;.X[D.MF36GYLGL2_$F+[R\JIS
MYLR",`0%<IV7PVY7-6B73::]%$,>U'XYGDQ@?)@,"M4X2(1/4RO32DW@YUZ2
M\>^#U,E`VE*/^DJ76>R%::S:3^M&V?`=/9\RDW3;ZH)'*[R(5$/L,C.NN@4S
ML$F\V49:]8^>!+>"6[X[W@36GDA%0X,=K[&CM.HW'?L@"B@:\&5VS*0`T<CW
M2`J:#R^(4@<8B3\`R5EP.@["G/INP])DW(*[$)E"B)#OZCW@2I`":^DULMTI
MBR&P!MO>RW[9=<R2;)</Z4]TG`_<IWL6H]@4G[X#$7&F'K`(GZ?OX<N)^&^.
MS#.7E7Z-UJC4Y'RL6YDS05,!0C5:.&D.+"V^<X+O*'GO=]]\SC/GTQPGJ7_9
M>_.*>.-[Z91^6))V)Y_#9SP'/AO=D`0@TY,X1"U0^I?F(W2OL\`+PX7JJTXK
M7J%R7IJ*+.7E+0ABGH"DS(((!90^BT-X_C0`6T#KC5^7*R;[IX.%`'W#Z4;`
M!N"`P3NW9"/ZPQ\,J@S>%3R%UT'F%?O<L@3$4;A8%H.[2*RRG>P#-H"7E,;4
MJ=T/$C^?(9=\;N$>YUD81-RY/;M/TCL[-N^MV6?>YT(M@B$[8Y'Z23#")O2C
M^%:4#2-P$G<1.'#B)H(B7J6[<!R55FJ]R8'!,C&;QXF7P+8&^IHME"D#ZYR(
M20C"4AK/]YA(0P^3PK]0LHBT&$KI:.F7*H1V$S2/`N;HF#DC+T19`ED46IVR
M.,,M<X9S136,?7J4&98N"S[N1B\O.WVU8^$8,`?Y'I(,_X(IPI"2Y3Q^_8X'
MBI@RV=4D%-L$O3HXI^T1#3%]%S:P2)"6\W[(?XG``4#6PY=]]$;1@,2@^3@L
M:>C]BX9?&W2'^#6K29*0K^9R2"5`JQ5'$>^9#V6NW(2UO5OR&4#28$U!9FZ#
M%'?BCO.[4@UZ1OV>E7;5X2B)S<Q;.",0KS'R!0@>@PF&/\*Q:1KGZ%>5]![V
MUTF>P=&&-@$2NB!;\OG0'D0QJ58`9+'<P^_P]][2KXM-40JZQTKZ&7Y/9R2'
M4CF<$W3S<$O`[0Q%>RPF#S;UKZR$&A)J&O$;1AD"-V=H&*I\MAH!YJV9I)6>
M,*T@#K7J%)#Y#LGJF@*HW%W].3_,Q]*+8^=-V9LE'VX2H*VO\C;!)<CH+?8X
MT8EUT.,()@':3>`*RET0CYG26/N-2$;-0&/AAQXZU6(R05[`"^O'[C@?RR2#
MT$8Q&&#<HK*8_#AP?Q1#ES]MS#TM;[[DU8TT=V@"<U!B<C?G(O)"4@.]R_0Z
M7>VF%:<5K26L7W,O&"M?KWPH%.`M.H/NZ1@^(;D&D^;MV8-CO4'S>S'Q\C!S
M<4=OHI\NV"@81>ZX:IYLF(!-`IWA/XHC`YHRFN;"L'5.@);(F7A!F.HE]6J6
M4Q]=RA*ZNL;D>,)HF.!.<D8&5?TU0I-%OKH_K?E2A1,!+\SA$$6NO;%>RKLA
ME\<8:L[Q(8?4Y8;)AV=>GO5HI[]_B4JCC7F)),/?.-/X#J,"M&121M`7TF=C
M4#(*\)L".(X%B_)(A'B.**T)3@48-J)]:,1ESD#)T.E*,-@6@F^'E@??!RF#
M!P)PM\9TE/;]!&46I[3*T@H^I-:NU]CULG.>;<LOP9&=,/!&(!6@?2,ZXDFW
M^AX?9?E`(3UC/5C)XT=9P0=)GQ/G%I/FFKKO+FL=_+[PBC-VN=%(JW-K&*?Z
M'^O/BQ@W@@?+5UVL&2:5$ZD.!</1VR9.O91T@'Z\O+KHD^_LO(=/RBT1@SN.
MB'#JY8*M#_@*V"[Y%;#B8!PN])>&0_;2R1+)F`.>]M>-AC(T$@)D#957[C@N
MK<Q-%/P/UR:5IW"8'IKH$_$=`]WBE5JGJM!@:;F,S14(B.?2)92[P%KR\)CE
M>Z&?A[SPO&_]BM%NYYV7A+&3!C/\(\HV#L(_S40VQ8WY+:C`;,Y!K#SE'50/
M=S^K[P2XI1[NCG`6NTM?M]8(<97)<L+.ULI*2K)/\2H%:.\,@V@7I28W`@Y5
M9=9N=EF\2<;P.7T;<ZV=G\M&X.FGM9L$X?U9&TYQ;5@\>^-I[!%?FH`^]DI&
M'W7I;=.UGR)=^^+L!XW;YI`P1X,BOA9;PY!6I^L..GO:!GA;#!AVFE4&;W/>
M[I<@_78Z@3,#7LR#HYAF#OBUE55]'K\06\B6:Y0B3^_\T*XI])L)3<T4=I$)
M^L\83R9XZ&T71WO=YNU&6R84VYG"\UN-]\%M`"?"L;,(1-BR5,-MJ-G>3V`_
MVDKL,.I(,2*\MPPBQA/PA:(9>S0BAP2/H5!4NA2+RF&$D`.*7A(&(E'!.1U?
M7+K`=#&LQ[%#"NSAWXH/%9<E?NBEJ;REB1D<,(53ATC2_T^##C"6CF`K>659
M_I`1;/[+CX\':"*\4R%%KPTJ?B8:$"Y9X$?;C>J\[#CF!(Q(G\.3>:R@[B@J
MOS5-A1\"_.%S(B:"D'C$)Z(FT.S8'\8\^77%\-SM7@P-*.`U/`L_O75Z_1^<
MN69CRCC*/)O&"4>A8<N,8O6BO-K`7\9%=@K:AW(XG9X@0.2.^=`:237Q&U9,
M#03V!S%*<L2E]2XK0-BERXV?8D3-@/"^U\AC;XX78&(L`5S@X/$U&D$MBMOH
M=6!J="TG@2_O9#]&?IP@4HXVJ!/8KPP(W#O0`G`Y2CA4_%2:CV9!EIED2"V1
M1(P=^:K"E%510CHF33U#>6AR7M@QUDO_5,VZTACQ743:":OT!Z@S;-:2#S5J
M7(D\1[?`SW$*GG.7X"SI7C,E-A.!ZG)MW;PKI_`QDK?6=*DH@:LW\E8IK;@S
MQ)%__BYOV%"C8"(:4[Z6[7B?A7`6$WWW\SN\2>,,@`N%WWX+6GJCX*_L/SU@
M>.5IX8.15UQ^&F":LAC-YC3%3Q&><V[`,0*YZYA02HTB!`='PA,+HZRPD.R3
M+2$Z:'&=">B<,R0H/]U3UH#`$;W2'][S5.7B':?!JKBA[BXC=\>%RB#&W$\"
MQM)ZZJ*[`/;#.+>4CQ%ZOK94O8KER".&:E!"B@F_K82_XZ\N>/'YKE<"8U`+
M"K0O80U*%()5%4`004I21A)FB7?*SKN"/*CKYQ(80*);RHSI@%17Y-6,A(\J
MXMUYE#8@,0,&B3EJ!1(9("5X>LGAC*$P;_P/<T*W8.QP/C>85@&DC,<!3@?!
M/UXP/D4@AC</,C2D^R"T6_<]OJ(5R6&?L-Y'B9"/$56B[7>[5RRAZQP,3^I;
M(HKDI'+VER??GPELUZ-2A48P"T^Y!L9^H$?)YW28Q^]\#V;P:(CPDNZ%RL*J
MAWH85D#ETA2SD%1DTR3.;Z92,S&E!/2144-CWKBE_I7>4F&&L8,0(F#9;>!K
M!!TCC/,P(^="\T`;/?@KI4=%F8&^7,.]RNU%XZW7O.@N[7UCP:DP`0/_U/,(
MI)>;W#I^%L;6Y"SC<W!?);PC0G9*N-"9]TTX_\W)#8#IJH]RLL"@Y_:'6UC$
M(AL-(Y@P'.$1)T'JPSSEQRNY^-5(OY*P,6.7*"<6Z=V$!M=O+:=3((H<AC!S
MZW"*"3@;!0B6&S;IW+D2+EX>,5,@/,X*=-NGK^^<G\"T"Q`K.7NU2TK@)6Q%
M)+(2@"G8:96OCPG+"F^($L2R/!?X:(CNG9?*F5>(<4*]EAB_QSC4_=@UMFX=
M"PVL43B,*Q"JF7"L98$M6[.+@<Z9>=F'PXJ"U6:F>*+G<]%S+R\'].#9Q9G;
MO[RJDNK[,V179%J!_](J]%^//KCLU,D<NN`6IG"D(O"S1N+S/KGLZ^K,QW&]
M/ND-H&)SA+,?<CF.&+>\/%[#+>,G\"OS=#6Q0:V_L?E20O)$R`Q2RO^1ITJ=
MI5VY&TCIT7-2!!O!["HFN,[X?@SJDI=<BJ>_[/7.6&OP6$<P;AVL*Q2HRB_G
MY/5:CUB!@H')B">.%.L3U7'.P-1GJYN)W@F+S$%SN0Q`?;&%/9!G1ZIRI>3K
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M=D0K7-U^[X/`R@/KVL/:3H8/;5::K6]W;1GY4)F$PQ2,85FY.2N_8L;OT=KJ
M+7:>OI?36Z;$DFY)WUC?GJU;Z#N^/US#H39V1VS6U*(U268;SOHX.V&>;-3Z
M=5VG[U;.ME'2S_VSW4'^CT0X5\SC\5S>.''FI.\.^]MHV[;;6?0NFB>%M6T.
MYY=[/X6^>W'^K#T`G[I[V#M=2Z<H,8/E.>_P@K/A*>1ICE+/TU.LL978:0NH
M]O&OH7VRW"MQKYEEM,Q;4MV&-MFV(VMA5R@[)3NEG4QIUZZ8T;"G:>CWV1J/
MK3O;/K[?V&8=2I^['U3+F-<L)F295S[';:UUV[HPTZ$Q;3,/?RW3FI<FL4@9
MBZ-X(J3,-LI`[N?MZ]ZNL$7*6*3,?C#2(F4L4L:6\+6D/!TI%EGRF/OWXT26
M'.>LUWKX=MI[4*&ZI5B3GMOK-J_4VC:00^_\8N_G<`!8DYX[&`RW,(M=7W!8
MK,ERZ+ZIE;`7_F7^-;-/EGL6:[(]U6UHDRW6I(57_G9*=DH6:V*Q)A8N89GW
M]$`=B]1I._=VB#X)V]L9YRVU2H[\(`SXK#X2V1T6'*LKV*5[RF,]'.H8IRM*
M_QX%&;40P39R#I9VS[,X610/WEM!LFAX@66O'MVY^#G7ZR$`HH$%$.W!_?/Y
M@_%#SS]M"QUZ"FS!;@HF'20?CQ=.MZ^U*?:8]%UW=9:00Z,P(-:++1R>9#V,
MKM4MC@=GF_4XKFJI>:03?_X(+[G>AEBZX$I2<>&)E-B1B,0DJ(+M[#`,U^\T
MS[9O:TCQK-/\-K<]EHZ>^BP2.'I@8>)Q`(>]1$1^V[J"][;+Y=U"`+J=;2`Q
MGM_8?,("ZRWCY>`1O=9;!@GI[[\%:8H!V:G$]#I7^RXR)X-A9QN5@Y[5AMP'
M(:(*[BIT6+7_'"K\X*3?3"+K&=DD;W7ON3;LG#T5UW9A0]OJKE@8P+8WWO7&
ME.5]+'S92_FU$\61V,3&KAOQ8Q'1$-_G(DH;IP.N&?QI+,NS?E'&#M9]$L;&
MV&9I3:@33!A$XI1^^UI=B!H7[_B.>G\C&[:.N!\>'Y8^]G6%8]KF]:?6?>#5
M/0&D!UU9JR#^D]Z`EG^WN[MKE1]2;M`B&S-S#W&1L2VC2VMN[R)FV)8^69C1
MC=*MM^\ER:)HV49O>6DJ,FZ<'@;>*`BYF1->:$^""(XUV"DU$3`RM?V:Y\D\
M3F6G]:(K,[:/$N.EGC+ZX<IF?-?`PV`"^P)8E-4^-547]&/%%0I+5]-=T67:
MN'K'_F5!JIN2%?W.-FIVL_7EKY=#6]3C4.X;J^_DE[K'/_^,6W+UN+?+:J_C
M[77\#H^-MC;`DUZ/OY5]=0V/8PTWVIA$?;Y1G?X'3:&-TVX6=FQWZO@\$;Z$
MM*)C"PXXC/D_^D6[HD^7S6^LVAI(.VD4@6U1L)5Q$YENB-H:CA[.-7>C])+V
M&11J%7PZHB;#>`X74<K&I3Y,ND-F]]WSR\,1G9Y[^8A^'.UQD/A2TYL'&?SV
M?R!`B4B%E_A3VIG&XE:$\9PZ@?MQFK7,`EU<-2^RT5Y!ZETVOR=OE1V2E049
MUS<7&$:.;IPP3E..6YY.XN3.2UI6,Z=_?D#6:+L*L>ML87WM_5MSB3I4+$'?
M/;NP!30>S[^!;=6R]_"%`YS2+MP^JL!0=2?7+H:?NX.+PP'A#]SS9BGEK3(V
M]>;P%Y&FKYU_'G5=M9/&HFKQD<2WQDIA$9)MVKP.<$J[M:I&U1`\^JQNT0V,
MPY[77[&E?UK.O`UJUSPC[.J9"?G5B[P;07'3J9<Z@G.-A`3<W7I!2#`P<1N,
M$>3G>*,XSYQ)GN6)!-Z%7A1AL"/-,,?D)L`/P!_H-0G0PPAMC(ENSCQ.TP#_
MDL9Y@IC!>.(D`B.Z[(S!/^N@=T1>BLL6I%/XLP=4A&%5<I3CW7A!E&9.D*44
MXZL<LH`_N1J^5XD>_/#P@CNN"2BDHD#)F$BMHA(^_Y+\,+?;[=(0+\F]P'^Z
M&-Z><XV@<%%)UM<I\1>XE]9EB3D36'=G$J1@[XE\AB9F,5,=I,XX%_C/*@;=
MB`CC6!1I#STN5A3#*L>@TZ7+&Z2\+I(JPU[5L,RO!J]65_>^A:U9U"##>?G<
M62%<.+,X$:=A\`W8>)I-O>@TBA'6ZF4XK`-+ZSD$.&7A\RJ&=>X">!)?&PDI
MK&)<.Z$JLF&X'(6]BF3@J1=):"O3-2M4<B3"0-S"FT0"3L7AJ>"3T8-H,O+`
M*DA+641@Y8)XC+3(G[R$A"O,QX0,)K$F;4_BVR#%(>0OY?/`.I\^5$G#QPBF
MGHED%I"EN)L*,@;5:QP@^OB_>0!\*JM3YGVC>2#'?)_XA4NH3=-=D$WAU1N0
M-YP)OIIG@6E:*E>7ITF`8P]$"[0$B4R=:9!B'0J7+B=]U`-I]=033!U,._'@
MSPGIP1]Y$J3CP%=?3'-_:KR01_#%+,3KSR#Q\QD(/"T"KKOK!!-X8.+=Q@FH
M`9H/.(S<(A?NXCR$-1F#[Y;BXGN$Q'[([%Q60_0&B3Y3*>7:`5D$L(97"A/.
MDNC3=^=Q!K(8`*\78/VFM$@X<Y+$8!KS\B]9\2IB.LWVND/98M^NPXF[]37B
M@)X9V=_?.]>=>^^JP$8($$YO#BKZG5Z$Y8+]Y;(_+/:7J_[E`W>71Q(]>>#-
MFG,'IGJ)UI[;&UP6M%Y<=1OLA)7$R'H=.%Q*X)15LBAM`587M3Q(\+?P<[_;
MOSI2837WY$D0DL'521:)``,8R;T$;$>>E@Q>RB88_K1@A]#+<G;QPF`69&0;
MJCV!*FEC(0/;"5M@RADHY,+`S,'JI_GH#TI0B6'E/-A8V/)@5@@OM<X>@?U$
M>D#];O>JD0"I;W*.BC27Z`'B]`IJ>U=70Q(R)=RX>]80.%I45'DDRPSG<G!N
MF'KMF.E4&JTX,6X2;/E%E=^%*3"[%:'6R/*GR'F;W\#PSJ5;X9ZC"0(/*I@$
M=-SQT*VD7\(>*S=\<@\YCW-E"3\BYC@"L?H"'EH$RW4MDML`]L:3CU^N7SDQ
M^T=OY_,P\`OA?(?AEXGZ#2SF_\V!#T3"QP@\O6Q&J4D_`V_HG$3OP"X:R%/0
MWQ,/__X[YD+2!_A]4C@0X\2;"Q`.WWD/(A^#O[!P/B<Q"2+8VIO$FY%6CYU<
M#_`92$%?$Y[+A*\]^K<3^/283G'O4)[?^I3+!&SLZA*DJ%!J4^@6VM)!2DHL
M`PLR0Q]MC&RY%O-,S$;P>=5%EL9`SN.Y(A3(^G%.QIA3I_($S,I_<R]!-TLF
M5)$MJ#J,\=<]<.DRW#KR,&,7%CR2("W<3*E<]V^K=$SK7N!>A$/CH<D<YXX.
MDA/T)$$P/)A"@AM6S$9"']#0:97H63X8@^?'*RS/`73($N2Y^@]!.1%D#N8(
M'BG3.#SK$XV%TOWEQSP]O?&\^6O.2/[J?4>Q@$G"2U]!VWX*X3#WMS__Z2_J
MN2],Q&?@].(K2%KJL6&O>`T3W%!COXC)7U^\XY__\^'?/_]GT#V%!3G%I7CQ
MMZ??.$.99/D;2"^\U7'D'!R:A&/.@C@S4F\=W]ZN.#,GSF0&9]19K_S+BBK&
M)(9HBU(X]HAI'((5@8\41U:7CM23"95"KDG'_%K*ARQ]DGQ8>;2,XF0&YA4.
M(7#J01&7>HK/D<'`9V>@73F>,CQ.5A7?^1PJ3]0NAKU!>X+4R""ETRJF9X[E
M>.7(`P+=;Q+!NBB-/;(L:+RU'HK@O"^,<>,@V-P+T.K3`E+8!@[V/ARL4^4Q
MS<"FOYL&8N+\_%WX.06:/H$`@4/DPJ'`.!'TS@:K)P(7Q057$PP]$CD1TJ$"
M&PV.:*4`/G@^56X#34AY:S/:R,@`@Y@Z/\7217NO9PE4]XHIG%><:5S:3XTI
MI.Q(I+!)&[L"T!`DL"^JW.,1?4L24#E-*ZR/B=C>1+3Q+AU.^]UB$>&]&CE,
MV!64436?1L7ENIO"4:2\8O*X'J;Q_4)4N;J?R`]*=5J\"P93>Q'PH@ANT=60
M'XKS#(--Y)2L35RO]!\:^`6F._'.2Z<?P,Q?Y^`%T_;@A<4K:<M]"?`D3<*=
M:Q^VASPD2X8S<W!JX+6C#2M2HO;'O]CPLR7>^,B/"?(C*/A1;C^P6>&#)RYS
M4,XGW%I=`TGV*5Y;`NV=81#MH-9!=165BF3E1]\^;SS@$]0\P,\\4=^!QT$R
MG@C/=B`+QAG;6ZI><(A\V48U@FUAB;:9-7KO-O+Z&&!<!SBEW2#3>*N]TF50
M4:+HR,8%HT#AX+"_??8W*QJP_63>O9_`KE*X[I&7HB9:NU2V7<+3FIG8A":[
M3;7<\)0"7J?=3@_.A$O6B'^YZAZ-=>P$8Q!1')V2PQ30Q2%%=C"DRJ44\5\8
MFJ+*0=:%VL\I[=*%ZG;Z&*Y8*4Q%13P0WI#Z23"G.$\1;5PS^5;W+6J&/V]-
MJ:IM3?_D8KA1VZ:=YS)5RRZ]^SE/_*F7\BWY/,%+Q(SO,1%ERI?I)M158DM3
M&')1(]([M#.]JZW6WCA0SZ_([BCN,!YZ&8$7&'XZ2EX3U$8B)]I]4S'H,"[(
M86J)`_MS#['U&\"/D?/)SV)$&"$PZ8&H+P_A/G35JB-1-PRV0CCS$E2U,W1F
M01CBYI<_'HKEC1$1GV),0B&R4@G!.KM\KY!.*T"S=_%8N/A7QC:LT-;5M!G7
MQ_\MB)/5MM(27Z;>&.@2MXCJA&'`(N:$WI9`+`VA[,E+T*[!@GL^PV2:'].0
M>GB#OK3ZF5X')N[\!HR;52\D.QVK-[4U\V>\&E!O`J<8*[8Z(CG1(>X`M#T@
MO*IFO@1?*V.Q(N>#&"4Y5D?O#51>T4,T@G>R0]'"%?2E!5_N&GQI@"I3;%@_
M-D&5A>H]4%R?$$&\X\^W185P)4&>T;YX=(E)R#L?7%AI.!FSAW"ZE1P_#==7
M$#A4+A8_<'+_X45DH`K`K"$Q:4D<3"DC*$D!TI5`O56`KBE+*_)8^GNO8K@@
M`:-1.=K`!/?BMAR&\$HB2@Q(G1.DVI5[A@*VO"JA@:/8P1,#$@2O(;<0<0^J
M59QE2TB86H_0Q+M<PZ$8#A6P_C_?HB5IN=MXA@`71;'#)#_6=WP2&Z#I""K4
M,M!$MH'<W^)(5$*G:F6B)#CB!K>>+ZKWR=[@K<%+^RE/@TBDJ2,GT09$5+BN
M\\[N;;IR@AC0+)LTWL7P&'$07OC\Z9H,U]=/U]+D<52"TE1C<&H"L;9_C1J)
M4I%HO_<P#Q]=?D0BC@4&[T9L"FDE^V576-4!2#'KB9939JS3#J0&YTJ^8-+!
MO9F@14XX@X+0CP9:>R0P+[`J=UR>$5R@:$VM<5=?W!8OZ-_P'9WK8&HXTI)Z
M#-'CO`K@_5Q08R%,U,5$:"!2-O"6F:^EQD<GBHW][ALY3SD[_8?>FU<=QZB;
MD.,9I_QL"06G+YZC4GLC2OH"T4GBL-SJ2$'3.9<=&RUE'L6H0/2^X9MCF%!*
MC.5L9^7385)*X=O*+!*C^`(F%%/5!==)@O0;<2A-&;5/\3#8B..%$*4E<G$E
MX`,\!$PI$\K)-##\C#1-\QEH1_`_X6HO527-@0JAWXW9S$6Z#6_(*3KU(V5%
M%"/WJTU2.<A[.6QA7Z3->B"N@HGJQJOJ>%*%PW.V@_5J0L8S(KAJR;JG[<QG
MT"YT20F#3OM8XC@_\GD:(^8WB_)OK^,P9R-;^O4);"!-"[,]!W./<U$),A]Z
M\K"QP:I^M:O:GE5=LQ%MWD'RONZHF[FWST3?[Y%T2<2XG02^BQ/L8YDUO3)Y
M)O(^P58^%=X:YK5,(:TAL(;`TO<4=BHB25YO25NAE#OJFW=V*:$H6(94IF&N
MX4D;&\?UW<'@.%OFG;F7O8NCG/F>XLXVG/6%VSL[H#:)E*9-;:>HY)_,WJ^8
MW^,78&.LU0E:E^;E_*M.FQO.XA&))D#\<-"\L\(3$-\:N-MNA0D,]OG>MJGT
M0AEH!Z?MFZ!`=`M;QIWTW(MA<ZQG2Q3V:G#>!M*MNDKS>7[9O-_:!NJZM;WU
M$]TZ%3=&"E/8+@:W2U0>M\%>/J(C7\LT%F9Q=M8*'V>C60S!4VOD';=C<ZVO
M4'%=>^_OG/2.J7W09ETNVM\.L7%O$,NRIQ2WDX$[Z-LN7RWC6VL:-EV7(4LG
M"-UJLLQ[WG*(#EB;]7(S.'!<C!LV3!>UC).>W46SL(EEG`PGN-UFS<^;,6Z#
MSF#/B52V4,,-H(9;*)]V8+`%"S4\P$6U4,-#7-4U.Y%%R!`M%FIHH8;6$%A#
M8.FS4$,+-;P/@#5P!Y?'"34<N,/N1J7.]G;FQPDU/'<OGTS2+=2P+CY\WBQ:
MU\IK^)Y[V;4@IM;,Y&3@GEUL`]QA,8='("V',Y.3J\M&_DH;K="6YF#AAP<O
M['W8=+>!?=NUZW#1WP8\?K>S.-M2TH7%(;8-X&1!=99W.P+6]9J9%`M(?'J^
M64!B.U!.X#4TS(+>E`$'QD#PNWJ])X2)'2[CAN[E8&NB=UR,ZP^.!IBX<3'5
M)9KXO[+-4#/RP%]WUKCS0>JDT_@N@E?F7L*-`:C49PJ/R%8O5*1T7`344S.B
M[E(9T<J0G6M4U%R-#+A89!7K=J;P'I8(I?JH'A7U5->J6#<U2!5!44PE1,=8
M!7-65!7-8EV$5172K*O#VK!<^P$7UWT;ANNJXLK+6N1Z@I?/XZ+H^.]1@"MS
MG5'16UP:['"%A5<#+T3IX9&1[6&,?8:X4035F*4BNU7C5!>$OK_6\]_^_*<_
M_^DO_\_IJ?,ACK,(Z_->R^X`IZ=8-SH,HF^O)_)OO\`_G._TJVPQ!U[#,`(!
ML"_D;Y,85V":9?/7/_YX=W?7^3Y*PDZ<W/S8[W8'/^*??\0'7^#0/ZZ,3;_%
M5X+7^+_PS_\?4$L#!!0````(``:*\D#<%)0./PD``%IU```5`!P`8W-B<BTR
M,#$R,#0S,%]C86PN>&UL550)``.<)P=0G"<'4'5X"P`!!"4.```$.0$``.U=
M6W/;MA)^[TS_`X_Z6EF6G9Y)/'$[BB\9G7$BC^RD?<O`Y$K""06H`&E+_?5G
M09'6A00(R@H%>L[DP8Z,!7:_#Y<%=@&]_V,^#;U'$))R=M[J'AVW/&`^#R@;
MG[>^W%^WW[;^^/WGG][_J]W^Z\/PQKOD?CP%%GF?L,R(0N`]T6CB7?W3_DKA
M"83W=5F7AU4=_7;TUL-?_X2`@0S(XE?O/W&X\+IO?_5.CKLG7O?X[/3D[,VI
MU_ODM=NJF9"R[P]$@H=J,7G>FD31[*S3>7IZ.IH_B/"(BW'GY/CXM),5;"U+
MGLTEW2C]=)J5[7;^^G1SYT]@2MJ4R8@P?R6EJBF2Z[Y[]ZZ3_!6+2GHF$_D;
M[I,H`:I4+T];0OVOG15KJX_:W9/V:?=H+H.6PD#P$(8P\I+FSZ+%#,Y;DDYG
MH5([^6PB8'3>\N6#:"L<C]^<'BOI7^XB$H%B9S"ZI@P-I22\Y9(JG2]"(F7"
M6,M3+7P9]I_-\"=D.L,RDB/U(1\OCGP^[:A2'<LJ.TIQGX1^'"8(W:":&P;`
M/`(6J,:7GZK*]]A^TG>XO]%DJ-CB8A.TM,6$DA&1#PDOL6R/"9DA/]UN!\)(
M9I\H>+OMXVY*SR_IQ]]Z4D(D+V(A4+.L@9`\0)@T^ZVX7*=F+2^(G/18H'Y<
M_1W31Q*B%K(771`A%CC`OY(P!H/V=O+;U/?$IH%$^%D;^.L&[_G!D9;HR'@Z
M36IK4Z0_DQ\)/C4!G+7+=['#XR(`@7,@3H&Q1"7Y3"E`PI;W!'0\B?!/M5/8
M\WT>H[)#\`$5?PCA,T06_<XDYCYA9JM3GDY<XNFC(!OZEE.DDW"?':VM*3&G
M+A%S*V!&:'`UGP&3@+/`()J`L)V_;:3=)\P*@Y2\-RZ1MU2Q='U%O0Y,@'8B
M*\2X9(6I$^$AR$A0/X*@>)'\C!Y9Z2BI4(FS3%4!PFX!JG>6XS,0T>(VQ*D9
ME5>*SY37C.NF<7HSB#E+E=E8NT6H5M^`\^")AJ')&<B*.`OZR@B[A:).@&\H
M>:`A;@G!8DDO*%ROMIES>TL6=IZB1N"`744/N,Z3WS;6O940-14Q!)7ZDEZF
M*>3H3'9OB;N$$:!RP1`>@<46PT8CT`AF=,:ZM[BMV60WZ3I"@`YYPV!P:+*Z
M!(&.:40?84U?*U^]3-)M=DKM=F_>NHNX_WW"0]1+*D\U6AC8*2A<]T8BG7D2
M3<H.B(M*'[`#Z:$N.!')F^G>,+_@TREG5E3DBC:"A[R![@W@>P%$QF)A14-!
MX480461DN;/1KMU)#P*Z5.*6T*#/+LB,1B1<ZT8F;[U<N!%<V8#@WB9]"!&A
M#((K(AAE8XF;CWBJ@(8`O5WJ4_,)8ZEP(ZBS`2&E[C=WJ%O3,HD<8$^;"9@`
MD^B(]9G/IW##I?P,T6!T3^;F#7.EFAI!:F5X4H;_[0[#:]YTCP657-9243=V
M%$:S#)M`%]W"(00`TR0LKA)F6(2@8"/C/HM`@(R6QBW7@RS'H3=5YW#&*7;G
M2AO(\$L@M'11FP9)44G+\Z;.5N;7[S__M/JWGWRVY3S:"Y$>EAP`[)K%EJ^H
MCMRU?*LUA]+O2`@R/4Z\`_%(?9#FX*!.PCX)($^H^N3;+78PU8GH/[A@IJ#=
M\3!6V!<=(EH('30'HP3:;)S9V+[?%#0-_O>",+G$B836!)1(-8:!,NM=S"X;
MS$"@QFR<IO"8CMKS96V=$TUWN>`2)["=!JV-Z`%72BVL&QW&ROY].HE&'G8;
MO%:R#6%B/P.XYB0K0$145M$E3E(A3[)54E/->54&.9?ILK3<O7#F'23;`-3W
M$Q'?8<U&DZ>D%VH"22:;W3M'_`@,[0I1VUXPI8S*2"0.=3E-99)-X*K4>O=.
M#Y]M6QV%V;@O:Z5=(":O?&X8Z9Q02]^@`286=-/RU;;V(-%GSOBF3>5S@U[F
MA5Y;<EEB6:/..5LO<L!^4`K;AB^V89=[1Z0?"66J)P_8*F6DSW"V3"ZOJG%Y
M*R`RQBJLJV@"9]5Q<<^-3H(K>8M-BXE&HDF,::UVSWG&WF.UQF^6JU?'5</7
MR,T%9PAIC*BF2QON(#_`B(LT;G=/YB"OYNAD(=J4$;'H([NR.&9@L/A'MGK(
MSEQ$^'8'_J&(N[?R/)N1CNL/Z+&/C,D-.HEF$%M@J:U/:`@;[2=HI`O'[QH[
MTM971PA)VWC=KPKD5;#(_#!)U7V<ONLZ=<`(AP7HV\-SRTH77S?0=>EK7`[H
MF"T3\/U%<N)+_`1T%JR=__:"_\8R2J_^)6#<HE?+`ZQ%Y3/")2Q_EKF(=:C0
MM.Y3'S?6$;>"]6(_ZX2ZZWL=\B?99P$5X$>[+A#YBNI8&?*MUC^A*AUN!7^D
M:,J'Q1<)2/3S<5$/^\=CV1VA"I7\?\&P\>`J4M+`]>-N0@1\P$DD4!,5SE()
M,J9(3;%`PYG2P>!B*D-VL['Z-JE,LN$DE@+CXNLZEX#N@4_+AMU&L<;SM&ZR
MBZ_FK,YX54AJ,-IX+^/YL0RKDV]C!0TGTA:F\HAJ^Y`<UQ'?>"4\6X8\#/<R
M4J:3$ZJ71`6W-T%]ECZ4L7I531<MM!%M*&/VT*1,O=W3F"QA:2!6RB1Q3WN6
M3**O@24C-"E+[^IA::5(^MY=YE%ER0J;#]_9CR^[ZEX#FY4A?-X4.K4XYLW9
M?-WMFHMJ1Q,[5MC0+O%2&+-.83@J<*)3;+U-58G_;=E71W4.G(Q5ITX3"O7>
M>M.J*J_;XJ^1VAQ$&;M.G2[D5=]Z%ZL2M=NRKX[7'#@9J4Z=3N3U7D::EB\X
M[3IN=76\.I*U8&5DEV1^.Q$8ZK-']"1>&!@JJJ3FQ[+((CE"N.<]_^^8"M"^
M3&NPKD(EATT(JDAD[LFM"F"5QYIJ3RI';7V`(,EA*S@OM"6[0BW-9KL*7.ZE
M&FL`2+^!YF7S5E$E+[QDL(YV7\I8?<718+1ZXR)]&DJ%"=46_D\BDJ]P4-M\
M=2`*R(D/FJZ[YP;<Z]4&4C>O[N\/9/>R5K/9&??T0YC%PI^HP[V1W<-J%L*-
MI+T*.`[>@UKOL&EOO)J#\*GY`0&C6+-Y-`+BWGV*XF^BJ)SB6*F:`Q*\B[D%
M24O66R['[V7^0#@*'3G'G[7Z@7`43B'N30=7HQ'XT6!T-<<%B(UAB$[%@!7C
M8I@.*E73<,*K06;YV('VVLK[YV__Q(_^!U!+`P04````"``&BO)`)M#'R>D1
M``!!`P$`%0`<`&-S8G(M,C`Q,C`T,S!?9&5F+GAM;%54"0`#G"<'4)PG!U!U
M>`L``00E#@``!#D!``#M75MSVS86?M^9_0]:]W5E67+3)IEF.XHNB3:.Y4I*
MTCYQ(!*RL*4(%2!MJ[]^`5*4=0%`D*($,./I3.,X`'B^<PC@W/G+KT\+O_8`
M"44X>'?1O+RZJ,'`Q1X*[M]=?)GTZZ\O?OW//__QR[_J]=_?CVYJ7>Q&"QB$
MM<]LS`Q!K_:(PGFM]W?]*X*/D-2^)FO5V%*7KRY?U]B/WZ`70.J!U;]K_XW\
M5:WY^M^UUE6S56M>O;UNO?WQNM;^7*O7^6-\%/PY!136&%D!?7<Q#\/EVT;C
M\?'Q\FE*_$M,[ANMJZOK1CKP(AGY]HFBG=&/U^G89N/WSS=C=PX7H(X"&H+`
M?9[%EQ'-:[YY\Z81_RL;2M%;&L^_P2X(8T9ETE63CN!_JZ?#ZOQ7]6:K?MV\
M?*+>ABXVQ@LWC]E>X%4C^<<+SBY`7()].(*SVOK'+Z/!X304A`T/+1KK,0W@
M^^Q)G(:WX6H)WUU0M%CZ,/W=G,"9%&+Z?$[Y*T[S#WRUQA'4L)]AP-^9N@=G
M(/+#$FD[7+LD2O$"H.`TA"9+'T5GO$1]`1=32,HD<F?=8RB<,V*(&TUA?0.\
M1#I%JQ]#;8##=JE;9KU@3%-*4-;B+IV2.C\VKWZ\OHI72<_B=N#U@A"%JT$P
MPV01'U$7M7UT[APLENQ?*&;GNX_O5Y<N7C1B?,J%CB1R'((0\L6'LSX*V.&+
M@'^'*>)K=WQ`:7R+Y")7<\DC">_@P&/O#O0ZG`@?>>RAWGO@\_MC/(<PI'>`
M,"+F,$0N\',AR+MV>3(8,%H6L.V'D`1,O@^P*.</%RJ/R"$#3CIXL21PSK?O
M`TR>5I16Z7J9).>1Z?!V/+P9=-N37G<\8?__W+N=#/N=C^W;#[WQX'8\&78^
M?1S>='NC<>^W+X/)']U>?]`93#)?Q,(+ER>1#J#SOH\?Z2#P$(%N6%04APL=
MOTTW.VCS'+KUH*-V:9ZE8R!,S4!!?!+=,*IW\,"G$+)M[Z6(^#../IUCI1F[
M.P_RN9J*B?!NBN^E&:#3^'**:/T>@"6[I)K-!O1#FOZ&\[A9OVJN]=(?UK]V
M-FQ@Z."`_4C3I_A@"OWXV8Y\L'.5<,D$Q1,P?7Z;5-3&`YWFOCS;9)=FIARD
MJZWUA%R*]XS@A0:[TD?B#&)KF'B0O+M@,R+**,%+3C-_X1/=XZV+@Y"]@3T_
MGL9V%[SG/SS_NX_9??3N(B01+"@D"MW+>_S0\"!*Y,-^V!<+^Y63O,4C>(]H
M2$`0WH*%2#"RH4[K%*(1ZLS%A*0@/!53\T!.YV!YA]%-@,^.7OCT":Z4/-\;
MZUQ7ANF'E*=<;YV9ZYV(\`NBCRB['_Z`@/0"K\N@2!@O&^[\6`'>*XA/V7]M
MY*7O(Y\I?XR2>TS4K_S.2.=5!9@NICOE]X]GYO>$`.XW'*\64^Q+.+TSQOFI
M`CS>ISCE[BLS1SA>+'`P#K'[YWC.U$\ZC$+NT^0DJL]SQ43GYPK(00M&*IR?
MSBR<5$>?L&4E8M@>XKRN`,/W"$Y9^_.96=MF-'B<CKX/9*_XSACG3068NT]Q
MRMW7AE[<.T@0]M3ZB7"LT[RJ`+NEI*=\?V.([XF^E)#59[\3V=/*\4[S));J
MB?@O)/_9*#(J!*ZTZHM@,]II5L$>51"_8;\9H_0;]/U/`7X,QA!0'$!O0&GT
M#%FHS$CF.,WJ6*D*"!N!G-M>32C[BOTH"`%)[`K9;A".=9I5,%6EI&\8;\92
M79O0([C$).0F!\,C/8U44YQF=8Q7.8*--,YMQR:$W453'[E]'X-0*8*M<4ZS
M"@:MD.P-LR5F;6,WL'&B4(=F9/<EZ/$2]+`EZ%%<2&U*84C;4QX@<$5GC'B@
M]>$/*=EE!S^*LYY'<-N!Q__H_16A!^#SR&X[[`!"5NP2^@K\2+5MM.8;#9D<
M,E\L)%TDTJUV]EWCNICI;70$7<C(90?!+0S72H1J#RFF&8VOZ`HJ`X`]>^L#
M#W=ND9DM&\D,HQ$87;'(:2\[Z%A<(G<$+@'R>D]+GG/&=GN<#Y4@S):.QFRC
M<1Q=2>GA*#M6>:QZH'&R[2`P&<G1/LKV*"X[7EF<YR/(:$=N"#WQO7C+3)9,
M@>@O8C0,I"NM7'#*#HX><^CA)23,SO5!DCK'*%YRS95=F\K33C[-:&!)_YA3
M`B@[0'J$GH"Q]XA\4:+`_A"S,29M56"+VK*#I<=>(YGWA]DP4KZ;8SMF5%:\
MM#B#;Q"8(I]Q#%*VW>+,A#GV&7&4;[UPI6'@ZRYA?ZBI"")[%.74QKH#*SW+
M13S!;!@J%^O5MN8A+)O<`"2"WA98+6F)YY@-6Y4C,#DR>UP#73B#C"QO!!]@
M$&GL+_$$L^&M$L0EAV7/69AK9XE>/),^@1)D)(9DCWN@"PFSP'CAW1:E6O9I
MQDRG:=*'4,KNRL1GC\=ABT2]_>4T33H-RMU8'(L]'@.>6HS"N,:/>SEPP-,1
M8."J1:.8Y31-.@Q*$%4&-GM\"2/H0;B(@R(\J2`(&:/80^X'00@)I&&".,D=
M3R-;[077<95^O**+.BV3_HH2!'\<='N<'X6L<07'6B:=)"7(50W-'I_*'5EK
MR#'!6=%XP6BG9=93HF2S-#XE0F&-Q;U5>9.9'K$WU&F9S<LM(`T1!'L,Z0F!
M@$9DI26-P\%.RVR:;@%YB$'88RZW/0\EC[X#R!NP6W&)0N!OO48JQU3F9*=E
M-J.W@,3T0-EC4(]@R'@!O1X@`5-G:-MUHT7D\^8?7<9T%ZEUQ:S)3LML;G`!
M">J!LL>6WJ)/UO'G!E-Z"\/A;`*>U)[B/"LY+;,%M$5V9WZ$]ECJAXASJ?-.
MRVSY;0%QB4'88X!GV29'!#^=5L6]*#H`,\I0SU-]D;<KW4L9AB[%+V48]I9A
M3.!BB0D@JV0WLE=\2&*(7FQFW$$2-YI0&5AZ*U2F<$,?CT46\2[-.KU1=*=:
MW_HJ!Q![#.9==U>!7:>W@/6]LW+#L<=BWB4Y>=W:43C'!/W]K'UDBFY_HO6=
MM[1AV&,:BTB-&P[D%5,RR?K&75H0[#%H163J75X9,ZWO[*6/PQYC=\N%6>#>
MTIAM?7NP?%CLB0<?=(_3NJX4LZSO-::'P9[([P&=F;>49(;]?<DT`)3=G:Q$
MN>A=3\IVC=9W+M-%47H#LY(BPPFQNJ'A9'1U:DPDQ&>U,SM[)YO#+V6\.$Y?
M'*?5=YP.EY"`,,X*3,.%&MEUBEF5<9"J,93A%#W\S@G_C<.4:LI7XFK;<'WF
MC+$?\?5%FSI[DE'G9@8?=YFOA:6$;#D)ZR<$!-0'R7+:O%?/,NJ<S,_\3##V
MA`/&P(=T75XUAN0!N9"J"_\E,XPZ(W.)*!N(/<[_#;!U-Y9<%\?^G,HX(U4(
MRI"-Y.3J8,JTT$)7A\94HQY&)4<%)Y@>GM-=(LGSBUTE.G.-.@Z+"2,3D#V7
MR@A2R'C">^!TV?GJX[BORAJMXN12SC/J0<PA,ETP]EPR8QC7+#%"/P/R)]R"
MJ5(#I)/,.A0+2$H-Q9XP\@<8,&P^H[/M+1AG.2[N)LD65L9,LP[&`A+3P&-/
M2/D`7Q[=S:R7L8!HA`CL"2`++(5\/AC[/YV00;P]Y]DM#O`NC6G/R6PC)W.N
M_5]8R`6EC.-,HFO'G5G3[T:+5>JM(69[RNCQ2J!#[R&PIECT`T/-=^8P>.[&
M,0@8EO@C--P?<4=@J*S!T5W";*>9(I(K@M`>*R@N%SJ$K;INQ#/,-IHY1G`*
M0/:8/U*`1:X?LUUGCI&5$I(]2L.S,M-G\)-6*Q$C>:WMX("^AS-,UJ5Y$_`$
M:>^)86<`4`#(*KZ,Q<TZ%/(^X5/--K_)HZB<F`GV&`D;`.L=\)Z9FS-E6;-D
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M-SZM53X'T?@3Y8^EXJA[.U0II"+CML3M(,'RO0F'?^L#1'YX8B&M'W(F*6U`
M62,MC7:&GW>TH&)-'Y,UC&;92C>.6()Y0)TN[SDIT8RFU"4H7O3Y@[E2L>A-
M-)I^KBD+;23V6-K[K5\S-X]X@M'2C)P[18K`'K-3TE(Y^V13S3-:X93W-,L`
M8D\\?Z<X/5-`@M%&/0(YQ2(FWYY4Y:W^#9FB.!AKU!.74Q`BXNW)/SBV;7-E
M.KJ(:;?G=L_3P:7";5N4O5ILN,U3SS>=8,G-%D.8@K@G\X)GL(!$=60O%45A
M6M^;>,R90HGO$X%D?1+DU(^N3A.9<W"B#*U$95@E_:*Z$6&O>$)%_.CXWX;Q
MHWCC\6^`\&1QVGN"Q$54GD]QS)KVEY&4`O&$90L2TI*SK&21ZBUJ?\E).1C+
M4)0D0M4Y93J\S;Z?!$6',X6[0";D4A]BMAY&6^BE8[8G*S0F=`27$7'G_.YA
MK^T(AH@(CJPL-5IO%;.%-+GU:WU0]N2;ZA&>V;8OSS)FJVS*E^HS*GN:EJK4
MB1&D(4%NN.YLW'X$Q(LS)OJ8S"`*(PU1'[&TV<*=W.(_$JD]_5*5VLAIW@G]
MM:M3FU,*5(O:L^;)EMO/CU,GEQVY<G5*>DH`FM4BUOY4XJJXX*2U/TV)_^WL
MI0H=0.=]'S_20>`Q7<,-7[(`7[(`OX,L0+;S^*M]1_`#8COD_>H+HV40;+JG
MM-T0/20?)=1H2Y)[L2I5.^2'9D\HI]C]8=))6XSA.M=+*>U_3Q#;X3&!P$4^
MW"%W@LO;GZ=XG-$$A#)?DA,QQYXS(*W;W8U/9<5T#R88300ZE9`4D6$1`ZPY
M0+KKSV'E[]F0,=-H2MYYI9S-"7OV<!<R>]9%63MW>YC1U-=S2W('MCTY',\M
MO'C;]>&,H67XPM6=#Y)<^^7:(I`)5&\!HQGGYQ6U-D/LR?4\9[,[DXY;4R]"
M)DO4Z1C\OS.W6=JI7-["?X/`%/FZ6GV^A<SFY9WWW<C/F3+B^I+DCD-BVJZ+
MHR#,3MG0F&HVE:X`HP59&IHP3U=_E!(P),\DQ*U3]46DF&HVZ:U<$67`/.&W
MK0YQL/-]"9"7JO&;9MU!4LK6IA2&TL]E%%S.;++;J;:;-G1[-.M#$,_AWCAF
M@XG@ZLAUF^HL:#8/[NCWX7CP]JC9TEN$WH%51B0J<Z[9Y+<3REF`TY["+"&Y
M)(+>%NJ\4MV;;C;_[;2"%4"UI]KKD.+T^EE_G"Z78/?FFDUK.Z%4!3CM24D6
MX(Z3<>*4F[#HGI6L839)[80B5N"U)U-9/P!72MJ`V?2SDD/2.3#;HV]+Z!X$
M#TQ1+"E?1+%8I5+:"F"S1]!,$4SK9=R_(D3@CH>=F80Z80O]1<QVPBXH++'D
M\X&V)I3,J'0A].*O&PAB*KH2UU_%;)/M<D6>#[4]\61]+I1RC#LM"[.%BHD\
M'VA[SG4)W7T4@,`MZ0)7+.:T;"\8/0[;"8OXMP\97NO"ZU6'LQ'T(%QPG\VZ
MJTM<\[)5O,S=NCPN"ME1Y$+)\5WN`YR6T6^M%1.<P$->*D/LN>C7^DD?D^<R
MRN%LJRF0AD8GG^RTC'ZOK0SAYP-KSVV^_;ZN7\:T=8'J_E9-<UI&O^A6JC0S
M8%;QCB[E;G9:)EUHI<HX'VA[@E:]V0RZX7#6>V)G3'`/1^SV&`8<"KM7^!_<
M?GA@ED4@#&476<:YKDHI9UY4]@2NQ#3F_II(GF6<ZZIXR/*BLB=F)::\S8X>
M0E;LE,GJMJ(UW[FN2FV<-IR,$-69OOO!?^LC#\0-`=8HZ5:%[QW@(9<Y#)'+
M*'LI\]6E^*7,U]XR7Y$E.^!L!_Y=-/61.V1W+%&W^-1>HS)%O7D095AY@K.K
MP9_)^T&RO_P?4$L#!!0````(``:*\D`PFE?@ORD``.=@`@`5`!P`8W-B<BTR
M,#$R,#0S,%]L86(N>&UL550)``.<)P=0G"<'4'5X"P`!!"4.```$.0$``.U=
M>6_EQI'_?X']#KVS`3P&GF8T(U_CQ%[H=)3,S--*LIW`"`R*;$E<\Y'/))]&
MRJ??/GB3??'H:F4706"-U-6L:OZJNJM85?VG_WK<1.@!IUF8Q-^]>/-J_P7"
ML9\$87SWW8L?K\_VOGGQ7]__^[_]Z3_V]OYV=/D>G23^;H/C''T@8VY#'*!/
M87Z/3O^Y]U.(/^$4_<3G0F2J5U^^^@:1'W_&08RSP'M:H;_LHB?TYIL5>KO_
MYBUZL__MP=MOOSA`AQ_0WAY]3!3&O]UX&4:$K3C[[L5]GF^_??WZTZ=/KQYO
MTNA5DMZ]?KN_?_"Z'/B"C_SV,0M;HS\=E&/?O/[;A_=7_CW>>'MAG.5>[-=4
M=)HANC?OWKU[S?Y*AF;AMQFC?Y_X7LX62LD7$HZ@_]HKA^W17^V]>;MW\.;5
M8Q:\H&N0)A&^Q+>(/?[;_&F+OWN1A9MM1-EFO[M/\>TP#U&:OJ;TKV-\Y^4X
MH/-_LT<>P>?_S^+7+Q`=]./E>34+FV&7O=YE>W>>M^631-X-CLJI7KS^'BW`
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M9"4Q79+7VGK1/&7<>MD-DZ8\:Q!]>?,:1WEU^J`:]&9O_TUY:BE^_2O9?'),
MN;KV;FH+TU`8P4`+VB%DL0N::@#ZA0VQCOCY.+6!8OFK+R$K?>\`^"0[#SXG
M/V8Z&*T'0^"TR:H$`7088N/@`3N=91#D]D`A1&\7$:8(SK#_ZBYY>!W@D(.7
M_-#%+/G5K]RR7^*[D!KT./_H;8:LJG"H!;Q*V.R^^F('KL<A.M`V6F=GV`96
M56`HD:I`PK(X/2::D7K1.3G!/_X5/TF!VAUK%:E]1@5OOAB(V$A$AL*!=3Z>
M[>)5`(H^8(<1L11BCW=I2AYX%F:^%_T=>^EI')P0ZRX`K7"X)=Q*V.W"H!B*
M^%A$!Q/?)T!T.`1\%V+=%HI50&D"68&29:WO61CA])@\[2Y)Y;:W/=*JY>TR
M*;!A;!@JQ\$9W5G8M6MO!V'0M[9#&%@*G]>I1S]773UM;I+>>A?,M\=8PF27
ML>[K+?Z.^``(&$[CT!;R!E]P$W-#;W?ALVBRV23Q59[XOUW=>^3MK'<Y_;1(
MV9`?3&6$=D^I<A%$QS]&A1C9"G%"U*`$/,%:D<?RZ58#9@-'737&EM*.,FQ\
M3:85Z$%KB"7$=]@2!O+IWR$0/(4_6X@<>K5-[`V\UZ50=DB>$]!GG46>R-RV
MQUC"69>Q[HNL_H[H``BD3>/0%M8&7W`3;$-O=VF;5J5M2!SYX;&6K5R74:$Y
MX0-!W?>Y>;9M#0=!,606AQ"Q-&)YI(`_^8S\;NASE'R\9>0.,2Q$0A'&*0#!
MAD,B>&[>;2-9")8A-(N08@?1-/:EC^=Z-`B:F\RJ\,!"DHX@>1Z^85#<`X@8
MPUUT+!LW^!E'T5_CY%-\A;TLB7%PGF4[G`IP+*>Q&BT0,RYPK"G!'J-`)0GB
M-'`A@G%"_*8CA-VX@`)&_9"`'$/+8OZG)-K%N9?RH+#(9@^/M8KQ/J,"6%0#
M>6@>Q%C/S+)=_`H@T<?M,!X6CNWRSVR7>)ND.0TKYUXN/&I(2>S&<T5LBR*?
MQ=?0B@!Q"L`([D(26([92N$S$*V586=9I%_L;J+0/XL2;RC[?'B<54RW&13`
M@`]";!0<>">S:A>E`Z^^#\W^>P?(I5W?GH6Q%_LA\3>3+%243!B10^3;RL41
MI[.N;U%%B$I*P,*)V01+#`4#R=W5`*$PFU>-0'M:=9AE.,\T]*<ST**F]%CL
M?:)@`QR`OIK3JZO3ZRM(``^_[RY4!U^V/5`>>]G]81S0_YS^O@L?O(AH37:8
M'WMI^D1.1#]YT4Y6[:-';Q'"N@+U$A0)`2LF8S\T2%?H,$<E-6+D4*"?+)M/
M?\`UZ>R"Y(V"X6<LQK97KVU/F!6ZP7=A'%.TD?WY"7OS1^VVG1IZF])A\EN!
M7#:MLY'AZQIM$ZMG\8#A^\F.\'&)?4QXNHGP1YP7+J[LN"$CLWGXD+/?V^"+
MX:@>OT*$8E7&)L".)B/E2!MRQ'A^]K5L\W3F08]<&AK0.X"IX6]/A7^@55T-
M5M3:*Z*PJ+ABIKMPX2-;&@NLK(:\.X)S!4RZ$)=CQ!ZZ+U*\]<+@]'&+XPR3
M#72=W^.4>T!JI.M06T2]GC!=%!54J"!C9R1&B#@EN$),$PMSLHS)E3"Y_.)+
M@<>F@-G5+`METQ08Z%37+.@KE.T@F<:A%4KM5:!Q1(U5;++^7$[HYAR<V@_K
MJ0Z5H$ITB;,\#?T<!\..ZD<BJ5+##":QJ'Y&HG6A5!,C2;BOG@)*>><2D@9?
M(%7%'(==/3(&H<W#;++%:?YT05:?M>HB7&WI-R?B/DI/L1(RJ\=7*?O]LQ`?
MOD*,@+==*TE8W`7NP#I*$"8!KB4`B[@XS+]!&'QV.*W0414&/_(BVCD8+@R^
M@'2GK"14))I=#T)MR/JN@]**60R:)4GP*8R&^@_TAM@,B]5L]6))Q9_`HEX`
MK&D90PC&#*R<!GM.V2TM?MVQ1%U%[L4QVUIL.RJA#$?8CT,(`Q"P<0>A&P\?
M:#!DS7YD01Y2L`[]]Z%W$T9A'N*,[/.LL<5]$@4XS>B>GS]IY+-I3V%1?0S$
MZL*E05J=[,AY'#XG;HI,YX='Y^_/K\]/KU;H\O3D]/3#X='[4W2\_O!A_1%=
M7:^/_XH./Y[PG_Z\?G]R>GGU&3K][Q_/K_^.7IZ<GIT?GU]_#JD]ID#MZI<A
M2NVG=5QX3WJ?A`4$`*D</9:%^0/%2/BXN3'G6SX2-EUC_$*O$-O^7,C:&`:X
M*%]C$-U6M3+=X:!A-;044T!C5S>%C`^@AHY%C<$N:*@Q_U$]&$Q/9UET-[15
M#OP!A96BWI[.GN!;3)X<7.(''.\T=E(!@45M%;+<:PM1#$3%2'`]-><\Y2-A
M-'0V=FWJHAS07464HAG$HU1K(.Q>J66O7=H<M1AN9U2`[XWS\@SD<BI4SXG-
M+PT?O#Q\P`UFM#)!5)16MT.5$'US75*T#U3P61[FLOSLI2P)N83__.W3-;?*
MV1FWNVEJ*4)_]]31`I!M5&__!-HXY3NF`QNE<+=Q:6<<PR305JBQ!]HO<TXV
MFS#?L"J].#A.8MKM!<>^7'ED5#9+FJ7,]THOZ]$\P;$Y'JQR>9((ODP$JT6C
M:ACU2D65&+*9%QQ@O&$E;D1>P@J1G3SD[CS.,7GY.?_0P5O8EZ6LAQL:;94H
MR81)K>8-3Q"]GV);3H;:LZ%RNE7Q57!57'*PJCL(\%GA4HN760>?W^60T<]F
M?T1_V'^UO_\&;;T4/=!2Z#^B-V]77QX<K`X.#FIMSJ,GM-WE>6L"?@M$4M^:
M@+R,UHL?;M,P0@?[*T2O>&9F@:(<9F-^MJOX%R_>T4:$!V\:Z]A:VMZ*VDT8
MGVJ@^@GD$ZV3S:Y;(W(KW,BF,,HU:`XNDR<.\SP-;W8<Q-<)NO!8G`<^IV*T
M9)^QY&PBVLL`WX9^F'_^+6PW+=-\"(<R("[2(G+->%*U)!H:;;<N>(#9@=K2
MXC-"<?T1&[CB'8X#P.)?(]XSSOL?WNPW=ZDOOUKM?_UEN0EYN_P^2<-_XN"/
M*$[*WX9,3EY1Z_9>/\?[%'RVG2R`48'&'&(XE-L\CT#N)#]+C-Q`X;;`PMF-
MJ!07G2E[Q'6'6HZ==-@<BC;4U]`Y88?UN2XM<-]3^'*UO[]/_]\WQ"B,_6C'
M@)^*G(^#KU=??[&_.OCB2V9_#[Y:O2-V_:NOOAZPX`=?K+Y\^XX]B_WS8/7-
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MA$Q-`8I/!5`?-1WEWN#TM22JG#J?+2NH.VZSOL7K?_G5-'=6:P9+%EBK3;*5
M;%-\C^.,N%/G,3EIXO=)EGW$^?KVVGN4G8$,9[);7V@HI,RF\-ZXK3D0GP2]
MI--\SMHIT1N:R%R`)8DSBEQTF&V)'!%RL,K%YRB;P9X!`MB$`=:I+05T'=S9
M<48:Z8&JUQ$6&C+;R"C+"#:[2)E[(TTK<B>7:"@BQ;+Z,VDF$<Q.X"[[!L9>
M2PAP4SR%2]BL,I$Y%%H0=SI92>R?DM2ASE4#2!GN6.5`Z96N`+U2IY4H<8')
MYZ+U=$UJEUISB8R&IMKIF!`_NTFI87B[_\7!/C,+]#>_%C;TZA[CG!\.[G$>
M^EXD2;W6)+1@$K1%$&P=B!&A7UID_P#,NK8ND`TM,`-:J0-&*+.8'8(WVR3U
MTB>N@82I=<IN6P[8E\0+G%[1#Z6RE!'-&6SFD6@+U3/1)655[T6(T3I%G)Q_
M$4=D`L1F`$L[&2V@H#AI5><:HI=AC((DBKPT0^2$R[^4@^XWAB#M?2`W0BB8
M[C$FLG6=6JFO='U2.&T;$D.M9IP*-<@<T2T=<81*U4^7=4B-A'A3Z(\(;%#U
M0R/V+,T)P*J,#`QZKR#"R0UK!O&>P3YEADMY%8@SNU2;+:[\AU7I@;:2]0C!
ME&M`!*52%=M33>2&(AF)TMZ3/*$H<!HC`I=<4P3(@M407K!@J!T%$;!F5*SK
M:H5+-:[:(K2U(5Q&A!$%J9/>@0/MA-7*H*/-+4V`U60]ATQ%":S3<O]%!"H'
MO+$IPF@[838_6"[R=IS*.UE(0G<R2C2MA(Z=@_2B&XGO(UQH'6J8NG`#[[)=
M:^JDYSQ)L&?@,QN@4%):ZXRWW.#)P%664<$HD89GV58>9SSD44*XZ!MK0$FB
M$>!><8\7I4LLHH#4`*$C-H1^A]J,Z''OCA,\S\([X/\J8*_46"#/M\>'GMLK
M)8/46[G#,8PA!]S=<7(XZ>C._4J<\G'G%\X=]U;'%"C-&*1CVVJ(P-F1I5(,
MC(;J>5,QJ^K,P0<ZT?5&S7/+/#G3R\5PK9TR/],$<<?42#15VN6DI:;V#`LO
M\V)A!GH!@$8[9Q&%10,C9KJ+EZ*<KQKJ0+OF19BWB7`%9+HHE^/%'M+7Q!1Y
M.>NK7E8V:J!=1F41\7+FN\"I1K?+61T`_U@YBHLL0?N3:P"HBWTU>B84AES@
M-*.M?V@H;$WFCY*[IZLDVM&&0$.G0PTB6P4A*M9[7],:XU%)@"H*D!J023(D
MI0S98C($B;^C!M>CT\\EQ.'=7<IZVY4:B8)=2A4TO\>(G_40U1SZLTS:5V!5
M+EI:TZIPT5&9"6I\G7IQ%GF\C9>V'BNH;"FRDOG^`;Y!X(HJ3Y3"@C)+`\[/
M1`8M@V0LAK9%RA7RPIDD/0O0LDE:ZF^Q4X<7X:RXL_L*IP^ACVG;$,FY6D1A
MLV>'D.E>XPXZLKZUOAS,VL.`=>K0YI[7:"?=LS10AXZYV;;:2T(.\UY#"2G&
M`3S?T\<MCC-LY/?V:""\W@'&Q;YB.=@E=U=#@.,D*^X2K3&/"S(W_%X1?(1>
MKP`[$P[+=)'6MZ,\7QU26\=F/3&&$$+;"+KH#4^0*+E5>8LP1]%Q(O%MRV?*
MG&+>:"Y/5!(V#ZTIWB8I4W]^?(4[F!IH6^MTJJ]JDTW!..]9B]:N,3!V?$IK
MX*1'/44F8@]4OAJD03!WM(<M@DI&ETW""(_50.5L-JO/,)'^_C`.3L@Y/4JV
M%`3%L45R.I;366U1+Q>@W]:!CV?GS`9%>6B&:TL_08Z@IH!J2[\,]W:[F&NH
M0K^!N5H/+$:A,+LWFS#SP4M_PPT/1!:($A/9C$7)6.^%H_A@AIYJ.+0&FTG`
M`FJ4_TTY&"@<-3/75J-12KCW`E(JK-O3U1]PC%,O(JP<!ILP#FF`@-[8IE98
M%:5%K54+T8500<%`U*:!UM]ILG@M&AA=7E("FWJMJ1I=Y=;3"\"HLTFT&33*
MK!5==B:DK/`XAP/*,!JZ#.^@L7#M&+@+^8XZ&M@8#9O?*-7"5EXCN"I*F::_
MYAD(!92MYX?,SR]PVJ52Z7H@MJ=V'Y,X:;-16`"-CZYJ6HLJJ2-(%SM-FDI'
M"S(7TH_'R,1O"0K9:-#OL-K(ZJJ%+JPF?(SY(?7BG,\M^N;2'&+KTTJ;K=[Q
MG_ZU@"G(5Q(=]L)EV-/ZX"'G[_H>(Z_*OO,VR2YF'V^2AL(4OV;70F2[B-D%
MMK?<-82#^YHQ`-O61XL^9BU&2+PPICO8.C[!:?C`?+GSF"@L>V\TD>@BQ;GT
M"D;M*6S&3/3%ZBD$(2U+6=8QJNE18P*6E+="?)+YSUDXU0BEC!?Q^)[\"Q.]
M0+=>6'8X(CKUR4N9PI0WK8#=C/,L9=,+'STKR=YQR6)F?)7%M1"R60V9&=K*
M7NS,S%!:=.+I7MH_O\D<>0&%36=>R/3PV7K`:P!SZ0U9?XE+YV:A<YJ>8V_(
M]3"O5IUZ.:Y[CKT4U`XX]V.<>B><>5,GWCG/71A"3B10MZ.6\_+L1*C!.,0`
MU-"";N9G1*SC)"8L[0A7ZRJ8>81OD[2XW_C:>\39Z6.>>DD:A+&7/IWG>)-]
MI.EX<4Z6+&("D6,_SM1-,99YJO7&&DLMGJ"_1>'1T2>B^I&H?B;B#RUM$7OL
M"K4>C-B35ZC];%0^'+;7AZWUI)>5TYOJT0U?KR($0\ZMY;<S&#MH=Q7>-U9@
MFR8/84:>@,@_&^LQYP=0,T_,=438;R2SJ*D>;D:SI)VVO=,1'HNM]@C'^#94
M[U)]"NL[S!#3@MV!#"US+M#+8C38*52?^Y)5%NW^7&B((`VRCA@7CAK0!5^!
M?0LH5.%AZR727XMN,,ZUDDK:XVRZNQT&A_;%]NGS,,_3\&:7LQLOKQ/$KS*&
M^7Z@PSW=U<%\<2C^]+SND=Q9]:^'%*CG4P]HCST=/_52VA@T*Z^=./*RT*=U
M'F&TRZ4][U64%NV`6H@N.DJ*^I:4%6)4O&**TT$IGKDXE0-`;T;QB];:E+39
M4GM%=\-H%_`N&X)[?V^J10CXTS0O7K&C]$ZM#*1ET53;KJW1T]D)"4(_X_#N
MGLQT2*#NW>&/N\T-3M>WO.NMVK:8SV$KQ<A0L"X,2W)4T",^`2WL+JZ?`;<^
MLXKI%6(V-2Z;R1CQR2Q;H.>P.C#98Q,7A:67%>L1<Z5(;JLE2=$N#O/R@A=>
M*5`O$\KOO1Q18[[+R%\)-GPO\G<1_Z;51\_IQ15<$MH8T]C*4AMA%RT6Y9:-
MG]>W_#1+>#E.-ML4WQ,7EN59L-^JLZ--9[)9OFLL9*^VM&KR32Q_X9I2A+9F
M*?\`GT@]7>#C]<>K]?OSD\/KTQ-T=4W^\^'TX_456I^AX_6'B\O3/Y]^O#K_
MZ12]7U]=@9;9C@-PK_9V%'HM9QH-,'26I,2\Q,>[-,6Q_\0:>!#^B-TG`C3:
M>1P&_[/+<BH@.5FO;Z^]QPO6JH3,0J\YP">8_U>5NF2#!=NY4':6=3C79]"`
M\*#7"A5<H)(-U."#F9\&)ZAFA>78LMY#"T2P33*U8!:V7#6_7+5&*Q_D5?,"
MYH(]JW6QGG=FT<H-)K+9,W%6+]OKRE1R*+'X,BJ[5^U)F!^X^4QL46O#N++U
M34'_'K[10L)%\^?FVO*M<RJ=&+AT3J$0()X;NZ'J/HD"G&:GO^_"_,G,7Y/0
MPWAI4H&DOEF3$G%2M_RQD:(E;=$^4\L&Y(2IL2AQO91`!%`OS@?5_"2FU2:'
MCZ'LH[J<#D*=!`((L;8JL563$)@1(GCU64X4$&V104NH)1)<@5S>_`'3>*;\
M%-D9"W--<\6H[*Y<]`L?!@H0X>I*+L%M+2W0S;=**`R-AKKY5@B']B6F3@!"
MLLK26TN!0'$8!"'O(7SAA<3Y/?:V(7$FE/"0TUD$BDJ`WBU'U7A$"?;.8U20
M.`$?K??1!9+.R[#9"CKWPA@'92:$$DL"`JO-GP4L]_L-\X&HRFYR`33R%>^W
M&I8L]X3$%'[Y\NXF\]-P2^%XB7T</M"8C1`"FH2V4E!T1.B?8.G6TR1"-14H
M/,S>2NM#N.XKL;A1^?YNLV,]_T6A7_6FI3V'S0W,0+#>9E;3(N5'*B=,E?%K
M[.UUAN_08AB"98FLZ]P96>BA-]9FN&&`T9Y58V-6J#$*+*2@P>Z11_[IXT63
MU_B%(<2Y3_/GQ?)IK*P%FHEAJZ$9D;KUPC$"7;/I9)7?&K/K1'!89US>>!EF
MN2S$G'E\V_U]%V9A7MYZR+]1DLTXN8O9+#_1+D)2/VWA1UMU]19?QKZW6#V2
M?G?L.(^H=AY7/,EX[X@^&C6?O4+5T\O[3A%_/FHP`&5<`=:4G2WWV'PTW;::
M$-;MMJ.A?<_=BGI.]>K.66[P";M&BS^(S<[^MF;^0788!S_S1F;9Z2-._3`3
MEQ],FM.J+SA>\&$WD<^'^(2E&6!3%B',8E*6,E9.BZIY00H69EZ(\F^LP6E#
MVJ(-'M"-=#,+^5/9W(\5$I2Y]?W[U#TB>]'0E=W61_Z"&^O#J8=6"2[)?@Z#
MT(\U3+,&\]LW?FB<V<!I3@ILX;1%-S!Q1076<[-QHY="9>06]?JF&+S1$G]L
M%Q954K],BGI67F;T>7L92F/7LHT\ZS4'OZ%S%M.@8^J,[,($6Z=SVCRF/G[$
M<V2++)_A.+#(]LW[$%NV<.ZE&>U(HN93JC0YT?<%$&.Y]%JU5J`Z!67-%4B7
M6P$MZ[DX7.K;`*HGT:N.O1HW6XH;5H_)<4-[\?@F*P=G6!>Q0RU#NX01LIG0
M2'BYQ%L"W7OJ]Y/=X!+G83IP0)9]8S"8Q6JRHXEPPV?,!CD[3Q03M`^=*^Y8
MPV5"3I'SHB#C=[@764Y<G=FM'S>)EP9HP[YTL27HJK[G^RD]AW,:)WK+CX!U
M/[72%-.N:2T_ZTU6VV(:Y_2V$F^2XO)9W-9<H:1+J:XS']Y&X'R<'K=`;EF1
M!0&I2YSE:>CG.&"C#HDG&["ZHK,DO<5AOM-0[BE3VU;X:<N@'R$J-FOZL:R<
MN?!\V-Q5.6!C?E#S,.^ZT-G8MW6B_6F]`,P`@*OZ#)HPJ/[3U0#<)'`#M8Q-
M,)@;WB@8+82)52CSD)ZM69BT,C*[X-1Q8`[5T#02QGKA9N>7;A<">7G_U)D=
M[=,RO`BSM5\9:+?R3/JLZ"W,OUB;$(E*3.G^(=8'D`X`QUYV?Q8EGS*SPO\^
M&4R]_Q#[TC)_2H`8A5O5_6:"))J"`)7R"T$EJ>`7(<IJ]WO*!+L:(<#!T=./
M&0[.X^KR^4,_#Q_"/,0ZNC)B,KM]],U%'>JTS%!83H..GM!+.A/9#S]'U62H
MGLT!G9M%]%HVKQH.>X?\:.P.=*<?!UR@!'::8QK[881;;?6OD_E4>9''026J
MS[=<BIR"ZD&H?RD'^?/S,QP`RY@G]`-YL8QQV=B>_);^[-,5+-L@)ZX9I"5U
M5)JV/J^"6J[7.^KFU<M.X\,$MBOWAE@>+-\;*$:!N89'GVU!:<ABMRZ:E"`Z
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MHXP>W<@1X"Y)`FYG,M[DI-_V8.FCS;)@L%9Q9V!I6G5T^F9F!C.X3NO'_$!K
MG_7-H(S4MAF4BR$T@^L4E734#C)*5ZR@F4B<=5=,H!GO(A/8-G,*@_A#0A8W
M9AQ&*^0G*1E"C,R*7K9Z2R8)>(#C;KB3BU63-N^;M6[/-$S&H#U3VXM9CW47
M!"5>&)2!UR+>2KL\L$3&0W:@UC_JZ4T'=_S3%5?S2%A,AZJO"N6$[&C`LX/Y
MG(X<%<?*7PI:1#ZS%;$_VR0+"V<KH<0`=W(_<P%''IC'RCCR$$U__U!V#=MV
MUJE>G=+YCA-R3":#Z+X2/='`F1\E16H*G2IK9JZRQ)5;FNJY8D=M_.AMMA&F
MJU]H5/U"0K)0\5U(>Y?S1ZT(05A]`'/G"&X3@X#G=*.M0W%V-]DW(...=7$/
MRU%.TH&T(:/XH]:$H'%(39$U=\Q&M1S/6B<Z/)3DYTY<<J3\#4&ID8/Z\&%+
M'MB0JHE:JD.K!CH):8O**,Z%]R0(1.C3@EJ8OB!F$=D,%93N&`VU2!7OVX5X
MU\IZ6()S6%,@T`JUU@^K!+""TVXKC0\\ICK>)8=6\[XX^IK.&L\TB)U2=K5@
MI031@A*,5_E9^`=7?(&V:.G^L*I`JG_I#%WB!QQ+^^FI:4$5OR^(IM978;6"
MTAV55XM4\9XNQ/M(99_..:R:"[1"K>/#*@&:Q,1:!?"6TF,W>=$<L*E+0L%T
MLY9X7XVBV[:3F[Z^C%P89_=-!0HU,I&D$'2Q9E^B80:3.%FC/X"_$;7Y[A?D
M"^14%L+";,/VY7*SX8#(J!AK';A5.8\?<#97)Q#99/!61BZJH;6I)G.KH'\6
MT6O9'"F\'X]=3055`]>>HEYX3V57??_W79CB5AG#81SH%!T93&)1,8U$ZWU5
M+HC9Y1Z<O*H\6O'2HQ7[O@Q>?S1-S$9O:[=JCRR+9=/`F.M<U[`8*YQ%@Y(F
M/L9!=D;$'BB,TK4H!K/8-"E&PO4S53@UHN2]>D;'K,H\DMXFZ:9*_W=0$\W!
MVE-%8Z2Z>`J?Y?3MYJE[GM.V^T=L'1\X'#AK.^7;+RB7FR[$=-?!%:MR%L9>
M[,_DV\LF@[<R<E$-K4TUV;/P[<U$KV5SV[?7P*ZF@JJ!.Z$0I7G6**\26-]>
MX@#C#<V^.4XVFR3F#?4;-X[21.'P@3A=Y$3B8\')>^8'V"I6F7-)Y.?UZNX&
M<F:OYT?\`>6%R*TKD%FI"WL*JAX#4M&R[")Q";?E&%:@P!<EJQ>EOBB9=MXD
M0_YPL/\E"\O?WF)62.$G60YU>?*2"T3K1]AA)8QIR0:MPDAH>R%B_FEU-:ON
M*$H1>2$>^0,KIR;3A?G39QE*O3"C*\0J/_CEH`^AQRZA+R\3D2PX6>/M[B8*
M_?H5P=T4.KL%:U5(S&V^[(=ASY*TOD5M?5LP3+LX:H1?)<0`85>I*,)P*ZUL
MJ,G8?0.%@1VZ.\MVC-5,)N&]@=`QU87$@(BAJA5&%#M5:@M,S+0P2N4M\;+(
MC)0,*"HZP+[\6%40H(K"A8BGB11\KRY&4B5)V'73[5T8)LAB522HN*U(862!
M6H&VN!A#F25VXF;,9)Y8B?L!$ED$<UO*>?.$;@>B)4Y%9Q>6S<U`T/0`D'7K
M<DI\:C]?WYX^^JS?WR4Y'*YCRBWQ>NA_Z">I!R^BQR")?3&:QJ*%,12OBT].
M3EV+<@)$9Z`]9IGIH9L<^Z$Q#921F2IJ*2!M*X$P%YPX4WXI)_L!+RBGEKF!
MEM*FX1FCFUW3,T(Q[1F?83;X7:_=-'B)\3&:QJ+Q,12OUX!59&%6Q17):*"X
M`\KZ3)2UDB1TSN+,)=G+H"K`,1'2IL$9HX]=@S-"&6&B)V74]SPF)R\ONF"!
M[W7QB4$SE"*?`RBNHA),\]M508XX/2HG<"'F8BKANO7AB-V>'B11Y*6PUZ<;
MHU$6I]"!HL5;(WFO!WIS>T+XT+S[44QD\P9'&>N"5AT46^5H!Q(R%A3!ZK6&
M2A#U+B=4(<B>!AP5;:]/<.:G(0N*DFWQR,O"C.9]XJS\T'R-'_.C2/[9;L1D
M%C5FE*A=&):3H,8L[(#$YN'9S_5,Z!<Z%V*3@:F9#;D3`[EMZN9X>'=U=C2V
M+5X7&M[%X6WHTR3MGH71T5_-"6Q>)ZHK4N^>R)H0#6X=#B@FB'!6+\0T`F3O
M@DP3-$[(03S&VWLO(NI\EV*6*R,Y`RH(;.4(RECNQ6>*L:@:#'CT6Y9[:TE?
M2LBTDKA4>)D3NS(SKZ(`0Z_,U@T!`-!VNR^`5GJHD00TWY.F;J:X[.*]2VF+
M\(@WG\@3Y)<R>N5\<`F9:I60*R?<^8TF;(7\SGH:FDS8AH=CNMV=5.NN$:`P
MF\?FEP9#`7NJ5-/S+P[-&5`]A0.Q#0=$M1J2'P/=7DQ^!&X=TTX=+\MP(M?T
M4[K7::/6`??+#6F=TU*E7S8*OQ/.N.]#'\>T7*3:HF51>B6)K5.NG.W>_<+E
MZ/J8"!FB?P82:)USS41H''0+C>*G7!S00VZ&R:)Y$3D#T\]5]!P?52)7YUZ0
M#^.Z:M(Z^*IU9%Z=U=LD3:@!-5EO@QA4"4=VP6<LV5C-UQ--XNV:V`$X!]A,
M]U0V8=J6/L_1N^:!5371.Z'8N[_D+^68IDNP&L@;+\-!60ZEX2E/G-CBT7SR
M$O2Z>]?8YB6)U92HF!.Q25>\$'SOB,Z+JJI&>`][R15)=%;D1G=%;![QYU&5
M[I%_%CUQT%X<-=G5\=VGSNRBQ1`NPMPFPP&??]%%&64U'`D-S*0RHPV'5%\F
M."*]5@FT'/HP#MA_RT+PHGA2%548-9<M)V6DH/WK_7I]8.@$++[%?ZJJY\LZ
M9^`HQ;^DX%HNSDR2T_SW_*DP3'[3@&W).![:]#YY*7%^B#SL`EX_V@74W=GL
MHCS<DB7#S3FV7(T1>_(=M#LTQ0*TG*,)ZF_)@"D#*^,F<]&$R;;D,:H,'8GY
M5Y5]=D,F$_[_+9G8%(PV98#YK)2;^R0*<)KQ5_LQR742(!2$-O-752+T4CL;
M!)\A3H(HC0,1%RO"6,U/U0)8+R]5!UW06F*6DJ`_![CNZ`7QF[0MX#GR]65N
M&3\;(R2\JAED'9A"U.J%CLD&7WN/1DEZ,BJ[ES9*F!^H$B>C$1GN5K;=LE)8
MOI=1!::!FQ@52`+5!9W]1TH&JPTR"RP`D@/[RN*"`.N$<KO00)0]K2BBW1=>
MFC]=$Y\JHQW#DECG"[62U*)V:(C1#T?P3R",!C6)'-@U;,EC4U=TH=;5%TV<
MP>N,V<9B,HL#FJ1GK24@=&P;@I;3!<TSV+3,T6HQS(#O:/CS$F^3E%W7HQ&&
M$Y'8#"*(V>[YTWPHJL8ZL$4MQ+Y5SU\!G)ZC+T<-'.(-0VH:U(!ZH!EBZF'*
ML0W&LEB0>F,2*]/&GD5MVFVW$?N"YD6TZ]Y9E'PZC93E/$;D-O5)3YP>\AID
MO&$F)40EI0L[CFW!K.J4`0A[2J6/0+NM:2DC3>9J;==*:=6>PG)+6DVQ!MO1
M4MH5:F&R0>[$S@4HHNU>K28`'>K3:H#."8E6/]!D!QXV5"6"#@VUE20US&87
M(FP4*L*ZP`F:LW)L+=E&`H=6*HT8"_-@49G3-S@6`(TRB]5^N="Y=LXQK94D
MI\FUNEG/'9,K9#/!);/)("Y2,$COY2;#O^_(PIX^:'LL`A*K7HJ0[?X!OAR*
M^%@G?!$#]I^'_R&'4=_GD&((#O]:$3`A#:`&2,-"?15PP%%83@)(Y*MC6`KT
M6+Q[BF6;T>JU)":<G"0;+^SMTLW[<`;'V[Q-2L#P<+H\J@:B7_A04*!(5[MW
M;9!XJ;D([PG5]^1G\A^:T4_^\+]02P,$%`````@`!HKR0/`,'+WN%@``A&H!
M`!4`'`!C<V)R+3(P,3(P-#,P7W!R92YX;6Q55`D``YPG!U"<)P=0=7@+``$$
M)0X```0Y`0``[3UKD]HXMM]OU?T/W-ZOV^F&SLPDJ<UNT3PR[)"&!3+9^>12
MVP)TQ]B,9'<W\^M7LGD8D&3)-@A[J:W:9(C.\7GI=5[ZVS_>%F[M!6*"?._S
M3?W=_4T->K;O(&_V^>;;I'O[X>8??__?__G;_]W>_OMQU*^U?3M<0"^H?:5C
MI@@ZM5<4S&N=/V]_1?`5XMJO,:X:1?7NAW<?:O2OWZ'C0>*`U5]K_PS=5:W^
MX:^UQGV]4:O??WIH?'K_4&M^K=W>LL^XR/O]&1!8HV1YY//-/`B6G^[N7E]?
MW[T]8_>=CV=WC?O[A[O-P)MXY*<W@O9&OSYLQM;O_OVU/[;G<`%ND4<"X-D[
M*(:&!U?_^/'C7?2O="A!GT@$W_=M$$2"2J6K)AS!_NMV,^R6_71;;]P^U-^]
M$>>&R0#[+AS!:2WZ_*=@M82?;PA:+%U&=O3;',/IYQN;/.-;)L?[]P_W#/HO
M&^4T/:?C!2A8];RICQ<1S3<UAO?;J+<EWIZ#Q9+^"_&IPEU_MGIG^XL[-NI.
MBN@N'Y'C``20(1],N\BCVD#`'?H$,=PM%Q`2F946N8HH<Q+>\CT'>@0Z+4:$
MBQSZ4><1N,R@QG,(`S($F!(QAP&R@:O%@2[NXG30H[0L8-,-(/:H?E]@5LD?
M(RJ.R`%E'+?\Q1+#.14311Y_+2NM0GRI).OH=/`T'O1[[>:DTQY/Z/]_[3Q-
M!MW6S\VG+YUQ[VD\&;1^^7G0;W=&X\Z_OO4FO[4[W5ZK-TDUQ,R(B]-("Y!Y
MU_5?2<]S$(9VD%45QXCR3]/M#-I^AR0^E&N6ZJ#.R<@`SX"'_HP67;H0/P*"
MZ+>&&!+Z#?TU70%=7O,(%PN`5X/I&,T\NN3:@.X@MNV'=`OQ9D,J.1M!HF<H
M:BCSF@Q<SH%+Q3+#,-*IGE4<0>>VX,4"!9%M`<^Q_8A7>BK3%9X,3TX2^\AF
MZZ8WVS*M1QH//J_US>GDHU8-G2%8Z5/$`<])T`@ZE#7P[$*F"-\;![[].YUY
MT9_#$%-B"/P.,`::!J>%./>23W'.?=>AQ_K.'R$]"FHN]$?@.0D:8O\%L1M&
MU\?QICT!;YH30X0CM\)=MC/032!83:CP";#9LJI'FQ!)3N(>0SK=("%C.&/6
MG?5F($&3>_=8TE$,*7#9=<T)7;C;6K/2JXXU)_E?V&S+<"I-PA4HP2+EEEM:
MO+NPBW'\)0_.F,&SF_!'=A.N_Q@QL_ZY#YXAYY!V>*W^N(<K!KK[>^T<%`XA
M1CZ])F<C]0#ZK#33(RP.<E"=@#\3W1.?FF,FBA.09Z+U"6:3[1;N7#*E6S/,
M)M,=9(&T!L=T:@MR)T&Z2BT35YP^)6./0/@60,]A_J;X5X8@MX<L\F3Z]MZ'
M7.8[]'':&LY^L63(F\\DP(#=MV-$+N,T0F\IPUKW\?JM1.-:%I&<IX`\1\(.
MR>T,@"45>KU^!]V`;'YAW-1O[^MKA^9?UC];V^ORA)U;.<3S!UKUF-*D#IMX
MGVJ`[0T^^M<]!1Y[7]<C[I;13?W6GB-WJ_LI]A?ZDMS0XJ?P4?,Q/05_OJ$0
M(:$D^DN&B'D@*'-3B/%ZWY(0'U'^`O&SOYMWAM1()Q+LT;\2%55N!UL-(^H4
MZR1%=TG"+TA_!-KO9O[+G0-1K#KZET.-T9^LV&Q'<(:8M7K!$UCPIIYHJ/5P
M&=K:T\*^QB2D"_5U#IFW*-D8N#VZM;S]`E=2H1^,M=Z72.K'M&_$7C^SW%LA
M9NQU$;&!^QL$F)ZIVY05@>A%PZT?2B%]"?D;!32,&'X7N1"W*"4S'\O-?F^D
M]6,IQ,ZG?"/QAS-+?((!B]./5XMGWQ7(>F^,]5,II'Q(\T:^[\TLY3L?:^0C
M)H,P8%D$C$3YNBX!M#Z40A-*C&S4\\.9U;,YGT\H6H$BDD.LCZ40^0')&^'^
M>&;A-BD-#J.CZP*1F>^-L>KWI9#O$=$;"?]DR'RW'D#):84[UJJ;N1QGM>@C
MXC>2_V!(\O'I*2:K2W_CW66EXZWZA=QG%37`96"CA8]&M<#.L.HZV(ZVZN6X
MHTK(WUV8C!QOOD/7_<7S7[TQ!,3WH-,C)(18>K(1P%CU,EU=)4QL57+N2VQ,
MV:^^&U+IX?BB(9H1W+%6O1SW5R'Q6]&;N;ZN[]4CN/0QRY9A_`C7)!F(52_3
MC5;,PU8?Y[[<QH0-PV<7V5W7![R`!W><52_'+9=+^%;<@KONW6$PZY#1?E$!
M+L6<:E/Q!PY5DLB8#O@U.*9KZ')A7N-CJ=KL7^-C%Z*_)B$P(`HKR?[`$D3*
MA(170F\L1:WI.>P/EF;Z`EPJ#=(,6@#C%3W0_`K<4+:P*L$;CLP=:XZO855>
M*J'X=3$`&4$;4E;ILO4$@_5Q5C9])6"&0X"J:DYA01R'+9-ZH^S8!(OIFA5`
M&`XPJBI53+TXK%LF?0XQ7`+D=-Z6K-J1KE)1)5XLG73=*D`;#G&JZEF-$W%@
MN4PZ5]7N/O=F`Z3*B_`!S>)0M:;&@F2^\GGU-8*4:V0'T.&?))Y\STY5ICH2
MPW%954UK,20.B9=IX@ZQOX0X6`U=$&?!4FZ7[)I!#QK255H,9CI*K+X^RWD0
MA^7+I.`OON^\(I>7.W0XQ'2P6?D`E:!7'-DODY)BSE/W3=.Q:+T=,QEX/@[_
MEV>O["/PC%P4($@V!;A[U:X*GB15%&4(=6?AJ1H7U<UM?`A6:O=4/H#I$+J6
MXN1^B6/&JN)PPB$E="<H)5WS84R'ZXM1MYBW:LSM]IK2$7R!7J@PM_D`IE,"
M"E"VF+%JN*>T9C7/Y,UZGPK0,)^IPAQ1!H]J;8CI79TU)DOPJ.3+2(&TZF9]
M587,ZU0."_-L7<H$5YO95MVL>ZK8*<VX*<PW97`N)SI;,4_<?H<L<9!7#&4U
MS/JE"E!S"G?5\%CM6E^QU8GR2$FB'YGUO`!2S06QM.*"I4V\N[E@]Q&IKSHK
M4JMAUBM6@-GD8[X:+K9,?AN)M!MF77$%6(6<N<(\=Z9CT3&I$;-I&4*<T5;#
MM$=.JB1AY)G'1R5\,XE"U=2$KX.A5L-T[4H&7?*8J(;+98(A("%>*>GR>+#5
M,%T&DT&;?#;R.U;XO?'.[#5U'!23/03(Z=&3Q!*QSH([`Y:Y3U.!K8;I:IL,
M^E9CJQHY0",8`.1!IP.P1P^0I&G;X2*,.IVVX1392'X^3P.V&J9K?C+H7XVM
M:OA=$KR)>N_W?4*>8#"83L";/):B@\EJF.ZTD65ET.>Q&AE'O&[3&A<PJV&Z
MQT<&9?/9*,Q=<\')$3F2(JR'TOOK5%@4]V;(:07GJR/5?=DF;^_4).H]S&F-
M4U,!KX6A*EU35<0H7`FO):'7DM!+T]\$+I8^!G@5+\O4I@<XXM:)[NA#B*.F
M:#+_A!J&$A61JG-411-0:0.H"EJ";J\:K%3#^;CO(L\PX=40E*#5K#9#U4@#
MVV<W-O1F&,Q]C/[<G8!3%7\(6((FM\J,5,,MR6,S:@.FJ^08J`3]=968J(;/
MD<>BVJ:=`EF"YKWJG%3#<9@(FF38KQ6@2]`]6(^;:N2#';6F5MJF)5"F"U0S
M*IK'1C5RLXZ83-V?!1"F*UAS:7;'0C5RKS2;ZJN`F2Z`S:7?`SX*\_M?3A)/
MS*=J%D\\NDPEKP+R)=V=<ZO22#/0./S<=`.(O:ABY-PM0&,"MA0I9.H*(*[Q
M',5I();?-9!S#>241G^#)<0@B$H;-ADT"HN'!*I$`1LY%X;5*XCDT\LJ852P
M^\Q@O26-?3=DM/&F7CJ0X6!+BA+V-:?$S64J+GJVW@4Q*<J:DT,9#I;HJRZ5
MG6K$RL;`A63=#F`,\0NR(9&W!Q-`&`Z.:"DXG97"XF`&T_>V(EEWJ=3:+0]A
M2A0:D?%@>M(*5MR63^C5+-.&J0!J.-XAU0=GY57CZ#*WSICV;!NH"JSA,$8V
M5::R9'I6%E4C0R`5)^LMVJ9[BNM'#2?7DI*LN5(XT_$,#8TK\U.-)),QC.KL
M*9=?`?X=)F0D.SP)@4R'-S(H6LY,-3),OD"/RL6E/#:=!?*B)^J9US1=U2F0
MIL,=&?2MP%$U,D^.9*-S8C8=],B@6"X/5>@SQ+D5ZKD*3??SS.DC3';M+/-5
M]LGW_'WN-B\OI%]I4V%--_'4T;$2,Z9W7L'=*'H;)29:=`5*##'=;5--TIP[
MSP$/E0B]?`'(8^O)P-MU&NQY5`[1H\C,9S;$,)#6?:NB,-V#,XO>L_!8C3MO
M5-Y^+#+9)LN',-V$,X_:)2Q5XZHK%$Z6;==T1\X\FI8R584FN[NC8Y<*+FY"
M&5)FUV=+WR./<.KC=1.+"7B#I/-&I4991Q[`J^CXPF]$F)K@<Y*OFFX,JG.X
M.[$8JG$WWS*_GGF/T(-3:?LA`83IWI_ZEL%EH1KU'_1HI'1%WQMGND^GUL7M
MD/`J-(C9=+[:E*4\`H)LYO9';AA(<_Q3(,UWYE37K`(KIBLY!!?R[Q#-YI3$
M)D4+9O`I7#Q#/)C&R<_INM3&8;Y'9[I6,S%UPIH.(SGBHJ9EYTX5/TY;9XW1
MC\A2:O:LA>F:6JX[I93E*HHE7E/.KRGG%Z>_;,?2\IQ=#NDN2FGTTFG4(\E9
M@KKTXHQF7OPHDKV*<I+HBL1TXSF)#*6F\_\A"=9/Q4;M.>G!#OD.Q<(JQ&`;
MQG^FN3C/0$*)>@^=4235<*QS9*707%<"5:)N17(N3A;//F-/S<'3>-#OM9N3
M3GL\H?__M?,T&71;/S>?OG3&O:?Q9-#ZY>=!O]T9C3O_^M:;_-;N='NMWL3@
M`3SC&RL*\-?#MOYA6RK-_\XC]O:AHZ7OL6AK\PTIG;9Y<&4[>`MXJ(2"$[T6
MOD+FB)'O?_MC+^4L+E*0<`,\8J,H7;KF6TFDJI$S^E+.NGJ*Y#-2V`G5C"X%
M[YZD:E4*=RG'4SW]IK%4V%G5C*8/7SA)53$?X%+Z9NKI5LA+87D>NDH5A''B
MCC7A,[$QBB@901NB%W9T$"I,#?!2BC[5%*?,4V&)$(;6W_379=+78E4<E](K
M4W-=UF"OL`0*,]9P()BVOZ"KEBSRSAM_*=TQ];0L8J6PU`HS&LT;-+J4#ICZ
M4:-$;6BYO;=YW\&ZO%:7=8E;B4=^4=?59>3FIP3AP)`J-=I;EJ&GI421LDZ6
MN>>C<47N0DADX@LN;I$(GD'TVM6"95J"^`A)S9J@8-,C)@X]T8.E/_,B+&D/
MW)[ZTZ9+3K7,[!S",%UV(;NIQ:V`VR&F,RSF("([^K=!1"9[3^X[P*R.C'3>
M(+81$2?@Y<%Y@=6MQW93")<76A(I8"M>B0NV"#6D%U@,JV<2ZFR:KH<0V(3*
M^MAB3_2Y<6K$.AC(]WF(;*30CY@NU56WF<+9KD;U1<3D""Y#;,_9IDMGS`@&
M"',6V[1[C!H6TT6^^A<<=;ZJ\3"'&M.I3>%UT)@N`3Z!4>P8,UT"4J!5"(YA
M(T@"C.Q@_591\Q5@)TK;ZOIX"E$0*EA*#M2FRXKUK2<GL]5X2$1ZBCN-2:GC
MOL#B86V;TN.V&@^7Z&0;'^87RQ-L<V*^P)ICL4$5P.LI7T^Y^#*0RZM.%NM:
M6)Y<_^\.Q%Q>';)6("91>US/[0N-/?@=SREC(.;R2H]U`C&)&N-Z;A<F3X]&
MRHQ;@,R[KO]*>I1+#.W`8'G#EA:]JH8CL&LQ@WXQ`T^(:4D#U:QAZ%_+A,NH
M/WIZ8C8\Q/X+HDOBX^H;@4[/VS9D;=H!>D$!4GJ"0Q_9I10Y])4*CO69JXJ-
M9+A#F#VU9-.6R@VCN*>O#)::[T636!J"9R,7[C$Z\8M;&$[Q.<-E%T4:V(G$
M4Y&$Q'5GJOV$FK0;U!&`X4J.4ZE8<@WCB:`"2U=[3:=^-\442,,E(^>UD'19
M5&/U:$-*K(W2UHSD,,-U(^>V@SW&36<?%J/T73-S]DSB8$HE1643K(8NB`LU
MHF>=).:@AL!PZ<EY#459)/GS%3_&)N3!&:N",FU"9W@VP&RHUI0=I4LE?YJC
MR)38_\[<^GFOV5-">'T$GI&K>I/20V2ZB..\IJ4O&],);X(\VF-&FK;MAUZ0
MGAVK`&JZY"*#FO;UK<-H[@M/OLTH1<$#O",_>GQ'7<$24-.U$<4J.(71_->4
MDVIX1SO=UI8`.9N+U_:).R^N\VX2`@/A`[L9T9DNB3C55%=F/O]]YA(.H\<"
MV"7%11%('W,V3*U3A`I"T\42N:TI/_O5N-P(]TXR!*N42'PJK.D"B1-:"8=3
MTY58)S0('%+2=Q+3M8D#<-,E$J<U"PZSU:BO.N9VL^F.X`OTI%55J;"F"Q].
M:!,<3DU?-D_FR8B2K:.4ZB#K>B'`8;J*X80&(N&X&@57Z@'R0C**3-<G%)QP
MHL%U)5[)YG/<\U[HP;R@-#0)L@LL>-#-0TOAKAK17'KPWE3`VW^$",.]*!2]
M_JL$]]21F*ZAR*AJOMWHL6W8;UJ0N6#?AM")WB3E1"U5[44=B^E:C6(-1H_O
M:JPPZA(L9`.R&A>9Q9C-8/38KO"QI8L\X-D%'5LDR*S&Q76OT36.%.Y,YR,)
MHCO)I9'5K;.^.X/I"#H0+IAG</T*0E0,E^CAQ`(7+.4!T@74AH)MI]@/6`VS
MWMB,:N=$@0H5227J,C8GNJZ/=^U<!M/$$QP*IV`QL-4PZ[$MQ'3TV#4=3"[^
MV+N>!ION<;)3BPS,:ICUU!9K"RF,FMYTSGTV*>1,8CV8==46:B%Z;!?6H=/@
M2;8SG4([&$P[;W1E]&9P1)>O@<>$P)Y%IG^PN]X+O05ZW"25+&BLAPLIXU8X
MO>KR9;II:S%&P>=/^U%9'3360WD\L;I\%98K8'"=X//<I,LEQBNZ,J9UVE2"
MMQ[*4Q:NS%!A^0#&V]&?R08NKNU-7AMX7UP*@-E&."WVJXL<$#7E6\N))+JA
M#",1SV&`;,K;M37.M37.M37.M35.R?3'<SCVV&L=P!V&SRZR!_12@.7=W)1Q
ME*@1C@Y/IS.$\^UV`SP#'OHS5HGG/`*""(N%[CYU[AUNG8?,&N72;=A6[,$B
M!#*PNSV&A!H:(6VX?9V`+]H)U=JC*W=EZR,SO$M*52&8=9F8K,+T&X>+!<"K
MP72,9AZ:TA.E%QP+\#H%M8\G,G&J3#LU!"6<:LJ,56%ZM>!R#ERJDQF&<4@Z
M;W#\"*-D9L@!M&:%*C4RTTZ!,&3+J4+BA<NE7%3"</W%`L6]!8#GV'XT2Z%G
M8C-(D,+<0$E2VHC8KD]"#!7V!RT\!K8,)?I4M@X]1(:W$%VMB)R$NCQ789+V
MD<W>7_!FVV5(8W(*5G0.SK0=1@)2Q![#0:\V'S2@3>X]<O'Q=A]EGJI@Y+MN
MBYLLHW-O0#O91BE-B6=G7>:C;_DD(+N':3=4*NQ(^1`;V**4"=[3E\J>E1.S
MX4TLMR(%NUI^J51A!3C*0HU>JO+B%ZN&ZVS#=:I9[OU/YV-I&V,67$7LF#K?
M3=U`,R$SN9]FE#IOH\W*>Q5F'>>%).-O-#WY@<I-3PYH)-S,(TCO5J>,PWB0
M.D7XPE"G.G]5F%]1^BNA_];U\;9/]/F]*]M/:_E2)%`&IA>'&I49)0,S/(GD
M\A7,H!1^JC!IU@??(<!!_+XD%0@;>>Y9(Z)#8>JD@1J8/R*2]*:3!A;#LTM!
M!8(IIL=C%6;<)C(^AC-VN>QY4Q\OC.1EK"D8P:6/HX)GA8.@`,3$$?"`%,W#
M7SJTZ6.?6-2B`Y\23U680^-PN70C/RUPQ_8<.B'K][!)X30YI1*$;<CIN*E>
M?QUP$X&T-2E)\G;&I>2.5$5A>M*I*4`4,U-GL@JS,&IO'9^1<WL)$[C2G("<
MH47X^!)H4UUXO+$F/71\D?`<<`+*JV".O+EK="MX)O"/D)+3>5%>_OD@)DY7
M!Z0HG:E$,,87=:%812<I"2=GGBIWC$`6Y:+_\1]02P,$%`````@`!HKR0(R@
M##.("0``84D``!$`'`!C<V)R+3(P,3(P-#,P+GAS9%54"0`#G"<'4)PG!U!U
M>`L``00E#@``!#D!``#M6UMSXC@6?I^J^0\:7G:W:HA#TNE)4IV>(EPZ[!#,
MQO1E:VMK2M@"-&-;M"0GH7_]'LDV-E@X)F2KR;(OB;'.]YV;=&29P[M?'P,?
MW1,N*`NO:HVCXQHBH<L\&DZO:A]'W?IY[=?W/_[P[J=Z_<OU71^UF1L%))3H
M%F0FE'CH@<H9ZGRK?Z+D@7#T*>9"0'5T=G2.X/(S\4(B/+SX&?T]\A>H<?XS
M.CENG*#&\>7IR>6;4]2\1?6Z4B/<&0DPDIA/B1S@@(@Y=LE5;2;E_-*RW!D.
MYL`N&-CHL^GBR&6!I;B.WYPJTWVBC.LR'K3)!$>^O*I]C;"O+:TA\#44EZX8
M\\J,&K*4?GAX.'HX/6)\"B+'#>O+;=_1%J?</@W_7)%^'',_E3^UU/`8"Y**
MJU%/+@%YX3,K'ER*^B6\7_I`G">E)<(T%!*';F9$P>C$Q<;%Q86E1U/1D$RQ
M)-Y&\@N+,Y]8B5B*BD1]BO%\B9I@,=:(9$"%NU$_;M1/&VN0.I9R,PP&.1U'
MDHAE:ED42KY8#:@@[M&4W5O)H$&;&W$.LWX3+ADU`#U"S1@8,(B31W=FEE<C
M!@`-[XF09D@\9@"%F+K"C-%#!HB@KAD``^;LR,6<"&-J](A)AYSS#4I@Q`#@
M9+)QHKVU8#3+PIP3]XF)B;FKY^8$N[).'N<^#K%D?-&%S\O(L3",`C.))[FE
M7+-`J`Y2A%,W6Q;RZ261:7E:14*O*B(.0R:QA!+U_AV>SVDX8>JV6I67BGD$
M`*0N/M[UGJAJVI"T@#=#KQ-**A<]8.2!UE!#%$)8*K'4[9$)#:FV"RHAJF<[
M`US:K8^WG<$(-0=M!/][HW^BWJ!KW]TV1SU[\,Y:9TA)(T$\.WROKR&G`NBT
M6E7>$E0B8D)DA-7D7>R[D;]9@;42Y)VB[H`?>FNR)UT:0O6EV!\RH8UM^5B(
M9(=2\:\H:\[$"81_20#7+7O@V/U>NSGJM-%UL]\<M#K(N>ET1LX!IJ'%0H^$
MP-Q2PS[U5-&XQK[:#IT9(5(,,=1Z.2.2@EEQ/K8%F1-S6CTQZ%\KA/\^P$3E
MUD`/!@/2]"7A4+'I/2FLDJ*$.05ORE+@C."?*EH.LKO('G;N=*TZQ%62"ZT-
MDY"W6`#^S6`-0&SC8!=RL%'0G(JSZJEHV;?#N\Y-9^#T/G50WW8.,27Y^"S#
M8W=;-\W!AX[3&S@CN_7;C=UO=^Z<SC\^PH;;[G1[K=XH*6'/AIO3][92^G3V
M8A6P_:.\DK^@6`WZ:Z+H;P>8U-SR:6$QZ_KL0?1"C\+#K"PLL**$.36_;+&R
MFLX-ZO;MSP>YHG*;^3)>(A=G\Y/`-AAS@LZ?DZ#_/Q)8-I_BD'[3NN!H<HT%
MA=`/<R[&2:H@9T[,A3JY4.'Z3$2<P(<\$\*AAS078A.49SO`5#A1$&"^L"<.
MG89P&G$QG!9=_7Z%AM,A+!&7JI<RNH15DS6FI'&\GI*$3>4@QX<R0I0R'F!:
M6F0^PS[,^BDGNKHD5:MPVQSLQGJP4R!:(@\QJ"P(J-2%'DJ`R_0L(V$VP<L$
MS($^*00ZH]!UII4G.<"8]ZFKSA#A=#GQDEB;!LPQ/EV/\1*:S>9##*TS@^<(
MV,>(-\2+7&0-]\V!?5,HR0I9UU"48@\PL'?$@UF%QSY1JYF%CF3NG_#\H?\/
M(PY003YCSG%:E[="F)-QMIZ,C!/%I$BSZ:H27Z7$*&$^P%3I0,R8[Q$N.E\C
M*A?I::MPWQSVMX4UD$/"T59C#S"P0\[NJ?KVM\MX_/IGA!_3?7+3H#G$OZR'
M>`E'$\913(`TPP$&^H[XZ@P*9T*Y&,$J%MA5:D5:6#:,FD-]7BPB&H\T`<HS
M'&"HKR-X:"!".&2JMK;"MV4EX^9P%XZ9*0-**%".XP`#[D3S>=S&@7W57.%%
M/LE>L13B7UW<F(X3PQ$S(T0IHSIP*DZD2`\\01_48T/^:X#\#7.0"T=+#4FJ
M^`&&,#_'*LWLZO.Y<+ATHK$@7R-56#KW_P,/Y^J/ZJ&Z(Q.DFY,N5<_$54W0
M`,)52^[-=/>(:O6JI\U<OX-+1X^!GXHHYI(V*9VH]2@DBE.*I*FDO'D*2-B<
M<`EG>2LUOF:]@#\0\&W]6<W17GGCX_&VW@"$^'OG",SK;1U96PHOZXZ5M@W!
M5=9,!`/@">,2A84VR[*>P;A#L\]<35,"49_J*:ZN;M4;)_73QM&C\&+#MM"_
M]&A+_2EN._WF/LR*FE.`4GE605EI-^0&G5J?$6@17XKT3CVCJNIU27=AF2T&
M6'*]@PVFALTJ1N1QZ8==S##U?U:R(P]<?MK!DD*7:!4KEB!]M8/V8O-H%?49
M*K[<P8#U9M0JZE.,NMA%]7J+:B7=*4A?;:?]J<[J*L7(YWP%I2K2A2J"C;>[
M6%"Q%.:TRUTUES?O5K4FS]+)2+8SKK3-N\JL2#'J8H<Y46@6KA2&==0.B3$W
M1&]G!`L')78DO^;0AI2W)3?'0G*<=LVHQ['?JXG'SW3Z%Q.7<(^&TYXD@3IO
MU!!.I*YJDD?JB4]+P3,69=Y(X[R()^>UD/J^>NN>R@HX=('22(U^X"R:ITHH
MT(-WJ.!>OJ%TI=?#X%L%V?UQ;$@XG("Q3[^I@UU\$G:8'^5>6&JGGI#+.Q0P
MJ"F8+TPN3;`OGO`I'AO'003MG'A4OH2K^E5I_!B/_3)?GQ)\#<ZVF)#VI&IV
M*TG_]]SVR/@EO:Z<Z&KBK\#OPDL_[=[*W=<P:3\3.IW!HU#SGG`\);#[C`FW
M)_H[;*':NUS8+]H4,I/^&D/[N1ULI?9JD6>&87=_]1>3Z@V@R^E<P>Z(2^B]
M(KTERHF<DQ5D8\_BGTE=>BS`-/Q>VXJVMB=$1+QVI/:WH5;T"?L1T6.V]D%`
M8I)OND7GD7"7BI7,[D;S&J;\!@_CN;M[I*KR[-&B:'I_1")NMQJQIN?1N#`/
M,?5Z80O/J7[A#FGPXYH-"WWSTLA%Z(5Y]W%7*`83JC\G6)`VB?_WPJ09TQBB
M2M*O856ECM@\<T7OAJ5NETJ_)K<S-X:<S&&"M\F$<%`#YVKU6SE5!/1/@II"
M$"E*9T!%AM<0GB%G+B&>Z'(6J%*I^.U)H=%+E[]<F50Q@%D@R="'XW;6N1N?
MBUZ.<Q\KROKS]7JSLN'X6R*S/\?>@I$C\BBO?:CW99[DA%:>M61Z_[MMFH;6
M6T-J2J7V)SD&,[/OS$V)J@K8LZ1MTV)JR.;SX/N3YFWL-V7]F?@]FP2Y0[HA
MQ\;1_4EASCQ3ALS#WST!5OP:_/V//_P'4$L!`AX#%`````@`!HKR0/9`WR=^
M>P``A+@%`!$`&````````0```*2!`````&-S8G(M,C`Q,C`T,S`N>&UL550%
M``.<)P=0=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`!HKR0-P4E`X_"0``
M6G4``!4`&````````0```*2!R7L``&-S8G(M,C`Q,C`T,S!?8V%L+GAM;%54
M!0`#G"<'4'5X"P`!!"4.```$.0$``%!+`0(>`Q0````(``:*\D`FT,?)Z1$`
M`$$#`0`5`!@```````$```"D@5>%``!C<V)R+3(P,3(P-#,P7V1E9BYX;6Q5
M5`4``YPG!U!U>`L``00E#@``!#D!``!02P$"'@,4````"``&BO)`,)I7X+\I
M``#G8`(`%0`8```````!````I(&/EP``8W-B<BTR,#$R,#0S,%]L86(N>&UL
M550%``.<)P=0=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`!HKR0/`,'+WN
M%@``A&H!`!4`&````````0```*2!G<$``&-S8G(M,C`Q,C`T,S!?<')E+GAM
M;%54!0`#G"<'4'5X"P`!!"4.```$.0$``%!+`0(>`Q0````(``:*\D",H`PS
MB`D``&%)```1`!@```````$```"D@=K8``!C<V)R+3(P,3(P-#,P+GAS9%54
L!0`#G"<'4'5X"P`!!"4.```$.0$``%!+!08`````!@`&`!H"``"MX@``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Apr. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Business Description and Basis of Presentation [Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Note 1. Organization and Basis of Presentation</b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Background</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Champions Oncology, Inc. (the &#8220;Company&#8221;), is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Company&#8217;s Tumorgraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The Company uses this technology to derive revenue for two customer groups: Personalized Oncology Solutions (&#8220;POS&#8221;) and Translational Oncology Solutions (&#8220;TOS&#8221;). POS assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug studies and related personalized oncology services. The Company&#8217;s TOS business offers a technology platform to pharmaceutical and biotechnology companies using proprietary Tumorgraft studies, which have been shown to be predictive of how drugs may perform in clinical settings.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company has two operating subsidiaries: Champions Oncology (Israel), Limited and Champions Biotechnology U.K., Limited. For the years ended April 30, 2012 and 2011, there were no material revenues earned by these subsidiaries.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Basis of Presentation</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). Certain immaterial reclassifications have been made to prior year amounts to conform to the current year presentation.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>17
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%]E9&%B,&4R-E\S,#1F7S0S-3%?8F4X95\S8S)A
M.31F9F9F8S`B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7
M96(@4&%G92P@86QS;R!K;F]W;B!A<R!A(%=E8B!!<F-H:79E(&9I;&4N("!)
M9B!Y;W4@87)E('-E96EN9R!T:&ES(&UE<W-A9V4L('EO=7(@8G)O=W-E<B!O
M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%]E9&%B,&4R-E\S,#1F7S0S-3%?8F4X95\S
M8S)A.31F9F9F8S`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO961A
M8C!E,C9?,S`T9E\T,S4Q7V)E.&5?,V,R83DT9F9F9F,P+U=O<FMB;V]K+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P@>&UL;G,Z=CTS1")U<FXZ<V-H96UA<RUM:6-R;W-O9G0M
M8V]M.G9M;"(@>&UL;G,Z;STS1")U<FXZ<V-H96UA<RUM:6-R;W-O9G0M8V]M
M.F]F9FEC93IO9F9I8V4B('AM;&YS.G@],T0B=7)N.G-C:&5M87,M;6EC<F]S
M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1$]#54U%3E1?04Y$7T5.5$E465])3D9/4DU!5$E//"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].4T],241!5$5$
M7T)!3$%.0T5?4TA%1513/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0T].4T],241!5$5$7T)!3$%.0T5?4TA%15137U!A/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].4T],241!5$5$
M7U-4051%345.5%-?3T9?3U!%/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0T].4T],241!5$5$7U-4051%345.5%-?3T9?0T]-/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].4T],241!
M5$5$7U-4051%345.5%]/1E]#2$%./"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`V+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^0T].4T],241!5$5$7U-4051%345.5%-?3T9?0T%3
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#`W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].4T],
M241!5$5$7U-4051%345.5%-?3T9?0T%3,3PO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P."YH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/D]R9V%N:7IA=&EO;E]A;F1?0F%S:7-?;V9?
M4')E<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970P.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-U
M;6UA<GE?;V9?4VEG;FEF:6-A;G1?06-C;W5N=#PO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,"YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/D-E<&AA;&]N7T%G<F5E;65N=#PO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970Q,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;6UI=&UE;G1S
M7V%N9%]#;VYT:6YG96YC:65S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^3&EC96YS:6YG7T%G<F5E;65N=',\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,3,N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3:&%R94)A<V5D7U!A>6UE;G1S
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#$T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4F5D965M
M86)L95]#;VUM;VY?4W1O8VM?86YD7U-T/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$U+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^4W1O8VMH;VQD97)S7T5Q=6ET>3PO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970Q-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E!R;W9I<VEO;E]F;W)?
M26YC;VUE7U1A>&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#$W+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^4F5L871E9%]087)T>5]4<F%N<V%C=&EO;G,\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,3@N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y"=7-I;F5S<U]396=M96YT7TEN
M9F]R;6%T:6]N/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#$Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^4W5P<&QE;65N=&%L7U-C:&5D=6QE7V]F7T-A<VA?/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#(P+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^1W)A;G1?26YC;VUE/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#(Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W5B<V5Q=65N=%]%
M=F5N=',\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,C(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`\+W@Z17AC96Q7;W)K<VAE971S/@T*("`\>#I3='EL97-H
M965T($A2968],T0B5V]R:W-H965T<R]R97!O<G0N8W-S(B\^#0H@(#QX.D%C
M=&EV95-H965T/C`\+W@Z06-T:79E4VAE970^#0H@(#QX.E!R;W1E8W13=')U
M8W1U<F4^1F%L<V4\+W@Z4')O=&5C=%-T<G5C='5R93X-"B`@/'@Z4')O=&5C
M=%=I;F1O=W,^1F%L<V4\+W@Z4')O=&5C=%=I;F1O=W,^#0H@/"]X.D5X8V5L
M5V]R:V)O;VL^#0H\+WAM;#X\(5ME;F1I9ETM+3X-"CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`\<#Y4:&ES('!A9V4@<VAO=6QD(&)E(&]P96YE9"!W:71H($UI
M8W)O<V]F="!%>&-E;"!84"!O<B!N97=E<BX\+W`^#0H@(#PO8F]D>3X-"CPO
M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E9&%B,&4R-E\S,#1F7S0S-3%?
M8F4X95\S8S)A.31F9F9F8S`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O
M0SHO961A8C!E,C9?,S`T9E\T,S4Q7V)E.&5?,V,R83DT9F9F9F,P+U=O<FMS
M:&5E=',O4VAE970P,2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG
M.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@
M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15A2044^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^1$]#54U%3E0@04Y$($5.5$E462!)3D9/4DU!5$E/3B`H
M55-$("0I/&)R/DEN($UI;&QI;VYS+"!E>&-E<'0@4VAA<F4@9&%T82P@=6YL
M97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^07!R+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y*=6PN(#`V+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D]C="X@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D5N=&ET>2!296=I<W1R86YT($YA;64\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/D-(04U024].4R!/3D-/3$]'62P@24Y#
M+CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^16YT:71Y($-E;G1R86P@26YD97@@2V5Y/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XP,#`P-S<Q.#4V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#=7)R96YT($9I<V-A;"!996%R
M($5N9"!$871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XM+3`T
M+3,P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%;G1I='D@1FEL97(@0V%T96=O<GD\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/E-M86QL97(@4F5P;W)T:6YG($-O;7!A;GD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1R861I
M;F<@4WEM8F]L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#YC<V)R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%;G1I='D@0V]M;6]N(%-T;V-K+"!3:&%R97,@3W5T<W1A;F1I;F<\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0W+#`W-"PY-#(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M
M96YT(%1Y<&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C$P+4L\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D%M96YD;65N="!&;&%G/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#YF86QS93QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1&]C=6UE;G0@4&5R:6]D($5N9"!$871E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#Y!<'(@,S`L#0H)"3(P,3(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT
M($9I<V-A;"!097)I;V0@1F]C=7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/D99/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y$;V-U;65N="!&:7-C86P@665A<B!&;V-U<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,C`Q,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y(%=E;&PM2VYO
M=VX@4V5A<V]N960@27-S=65R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#Y.;SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^16YT:71Y(%9O;'5N=&%R>2!&:6QE<G,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/DYO/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@0W5R<F5N="!297!O<G1I
M;F<@4W1A='5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y997,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D5N=&ET>2!0=6)L:6,@1FQO870\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,3@N-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?961A8C!E,C9?,S`T9E\T,S4Q7V)E.&5?,V,R83DT9F9F9F,P
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V5D86(P93(V7S,P-&9?
M-#,U,5]B93AE7S-C,F$Y-&9F9F9C,"]7;W)K<VAE971S+U-H965T,#(N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5114%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-/3E-/
M3$E$051%1"!"04Q!3D-%(%-(14544R`H55-$("0I/&)R/DEN(%1H;W5S86YD
M<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y!<'(N(#,P+"`R,#$R/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%P<BX@,S`L(#(P,3$\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^05-31513
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A
M<V@@86YD(&-A<V@@97%U:79A;&5N=',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@-"PW-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#$P+#0U-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@<F5C96EV86)L
M92P@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU.#0\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU.#4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D=R86YT(')E8V5I=F%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU,3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!R97!A:60@97AP96YS97,@86YD(&]T:&5R(&-U<G)E;G0@
M87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-S8\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y4;W1A;"!C=7)R96YT(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-2PU-#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,2PX,S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<W1R:6-T960@8V%S:#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R='D@86YD(&5Q
M=6EP;65N="P@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M-C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ-#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D=O;V1W:6QL/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XV-CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV-CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y4;W1A;"!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C8L.3(R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3(L-C4P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DQ)04))3$E42453+"!2
M141%14U!0DQ%($-/34U/3B!35$]#2R!!3D0@4U1/0TM(3TQ$15)3)R!%455)
M5%D@*$1%1DE#250I/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%C8V]U;G1S('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L-C<V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2PU.#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@;&EA8FEL:71I97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8R-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,P,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R
M960@<F5V96YU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ
M.#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ+#8Q.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E1O=&%L(&-U<G)E;G0@;&EA8FEL:71I97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-#@V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPU,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G0@;&EA
M8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-34\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY-S(\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y4;W1A;"!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-"PP-#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT+#0W,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V]M;6ET;65N=',@86YD(&-O;G1I;F=E;F-I
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P
M.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4F5D965M86)L92!C;VUM;VX@<W1O8VL[("0P+C`P
M,2!P87(@=F%L=64[(#$R+#4S,RPS,S,@8V]N=&EN9V5N=&QY('!U='1A8FQE
M(&-O;6UO;B!S:&%R97,@;W5T<W1A;F1I;F<@87,@;V8@07!R:6P@,S`L(#(P
M,3(@86YD(#(P,3$\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L
M,34Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^."PQ-3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^4W1O8VMH;VQD97)S)R!E<75I='D@*&1E9FEC
M:70I.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y0<F5F97)R960@<W1O8VLL("0Q,"!P87(@=F%L=64[(#4V+#`W-2!S:&%R
M97,@875T:&]R:7IE9#L@;F\@<VAA<F5S(&ES<W5E9"!A;F0@;W5T<W1A;F1I
M;F<@87,@;V8@07!R:6P@,S`L(#(P,3(@86YD(#(P,3$\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL("0N,#`Q('!A
M<B!V86QU93L@,3(U+#`P,"PP,#`@<VAA<F5S(&%U=&AO<FEZ960@:6YC;'5D
M:6YG(')E9&5E;6%B;&4@8V]M;6]N('-T;V-K.R`S-RPW-#`L,S0U(&%N9"`S
M-BPY-38L-C8W('-H87)E<R!I<W-U960@86YD(#,T+#4R.2PP,#`@86YD(#,S
M+#@W,"PP,#`@<VAA<F5S(&]U='-T86YD:6YG(&%S(&]F($%P<FEL(#,P+"`R
M,#$R(&%N9"`R,#$Q+"!R97-P96-T:79E;'D\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E1R96%S=7)Y('-T;V-K+"!A="!C;W-T+"`S
M+#(S-BPP,#`@8V]M;6]N('-H87)E<R!A<R!O9B!!<')I;"`S,"P@,C`Q,B!A
M;F0@,C`Q,3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PR-3(I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,2PR-3(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!9&1I=&EO;F%L('!A:60M:6X@8V%P:71A;#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C$L,C`T/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<L-S@T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-U;75L871E
M9"!D969I8VET/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R-2PQ
M-#,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,38L-#@R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^06-C=6UU;&%T960@;W1H97(@8V]M<')E:&5N<VEV92!L
M;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,C4I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-C@I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5&]T86P@<W1O8VMH;VQD97)S)R!E<75I='D@*&1E9FEC:70I/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@U+#(W."D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&QI86)I
M;&ET:65S+"!R961E96UA8FQE(&-O;6UO;B!S=&]C:R!A;F0@<W1O8VMH;VQD
M97)S)R!E<75I='D@*&1E9FEC:70I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#8L.3(R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`Q,BPV-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7V5D86(P93(V7S,P-&9?-#,U,5]B93AE7S-C
M,F$Y-&9F9F9C,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E9&%B
M,&4R-E\S,#1F7S0S-3%?8F4X95\S8S)A.31F9F9F8S`O5V]R:W-H965T<R]3
M:&5E=#`S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%1$-!13X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T
M<F]N9SY#3TY33TQ)1$%4140@0D%,04Y#12!32$5%5%,@6U!A<F5N=&AE=&EC
M86Q=("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^07!R+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y!<'(N(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y2961E96UA8FQE(&-O;6UO;B!S=&]C:RP@<&%R
M('9A;'5E("AI;B!D;VQL87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2961E96UA8FQE(&-O
M;6UO;B!S=&]C:RP@<VAA<F5S(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,BPU,S,L,S,S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(L-3,S+#,S,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R
M<F5D('-T;V-K+"!P87(@=F%L=64@*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E
M<G)E9"!S=&]C:RP@<VAA<F5S(&%U=&AO<FEZ960\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4V+#`W-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4V+#`W-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K
M+"!S:&%R97,@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4')E9F5R<F5D('-T;V-K+"!S:&%R97,@;W5T<W1A;F1I;F<\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL
M('!A<B!V86QU92`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`P,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T
M;V-K+"!S:&%R97,@875T:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3(U+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,C4L,#`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K
M+"!S:&%R97,@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS-RPW-#`L,S0U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,S8L.34V+#8V-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@
M;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,T
M+#4R.2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS,RPX-S`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y4<F5A<W5R>2!S=&]C:RP@<VAA<F5S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#(S-BPP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#(S-BPP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V5D
M86(P93(V7S,P-&9?-#,U,5]B93AE7S-C,F$Y-&9F9F9C,`T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B]E9&%B,&4R-E\S,#1F7S0S-3%?8F4X95\S
M8S)A.31F9F9F8S`O5V]R:W-H965T<R]3:&5E=#`T+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M6EE!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#3TY33TQ)1$%4140@4U1!
M5$5-14Y44R!/1B!/4$52051)3TY3("A54T0@)"D\8G(^26X@5&AO=7-A;F1S
M+"!E>&-E<'0@4VAA<F4@9&%T82P@=6YL97-S(&]T:&5R=VES92!S<&5C:69I
M960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,CXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^07!R+B`S,"P@,C`Q
M,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y!<'(N(#,P+"`R
M,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D]P97)A=&EN9R!R979E;G5E.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y097)S;VYA;&EZ960@;VYC;VQO9WD@<V]L
M=71I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(L,S,R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`S+#,X,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5')A;G-L871I;VYA;"!O;F-O;&]G>2!S;VQU=&EO;G,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L.#$W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPU,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A
M;"!O<&5R871I;F<@<F5V96YU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-RPQ-#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XV+#@X,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;W-T<R!A;F0@;W!E<F%T:6YG
M(&5X<&5N<V5S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;W-T(&]F('!E<G-O;F%L:7IE9"!O;F-O;&]G>2!S;VQU=&EO
M;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,S4V/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PV-C4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-O<W0@;V8@=')A;G-L871I;VYA;"!O;F-O;&]G>2!S;VQU=&EO;G,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-30S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PX-#8\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A
M<F-H(&%N9"!D979E;&]P;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,BPY,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR+#DQ,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4V%L97,@86YD(&UA<FME=&EN9SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPY,C@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`X-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1V5N97)A;"!A
M;F0@861M:6YI<W1R871I=F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C4L-#4P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-"PV,3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C;W-T<R!A;F0@;W!E<F%T:6YG(&5X
M<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-BPR,30\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,BPQ,3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y,;W-S(&9R;VT@;W!E<F%T:6]N<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH.2PP-C4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH-2PR,S4I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]T:&5R(&EN
M8V]M93H\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1W)A;G0@:6YC;VUE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2PT-C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-H86YG92!I;B!F86ER('9A;'5E(&]F('=A<G)A;G0@;&EA
M8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,3<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S-BD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D]T:&5R("AE>'!E;G-E*2!I;F-O;64\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#$U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5&]T86P@;W1H97(@:6YC;VUE/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,#(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#0T-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,@8F5F
M;W)E(&EN8V]M92!T87@@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH."PV-C,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,RPW.3$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#XH0F5N969I="!F<F]M*2!P<F]V:7-I
M;VX@9F]R(&EN8V]M92!T87@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XD("@X+#8V,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B0@*#,L.#`R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,@<&5R(&-O;6UO;B!S
M:&%R92!O=71S=&%N9&EN9RP@:6YC;'5D:6YG(')E9&5E;6%B;&4@8V]M;6]N
M('-T;V-K+"!B87-I8R!A;F0@9&EL=71E9"`H:6X@9&]L;&%R<R!P97(@<VAA
M<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,3DI/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P
M+C$Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5V5I9VAT960@879E<F%G92!C;VUM;VX@<VAA<F5S(&]U='-T86YD
M:6YG+"!I;F-L=61I;F<@<F5D965M86)L92!C;VUM;VX@<W1O8VLL(&)A<VEC
M(&%N9"!D:6QU=&5D("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT-BPX,34L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,S,L-S<T+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?961A8C!E,C9?,S`T9E\T,S4Q
M7V)E.&5?,V,R83DT9F9F9F,P#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+V5D86(P93(V7S,P-&9?-#,U,5]B93AE7S-C,F$Y-&9F9F9C,"]7;W)K
M<VAE971S+U-H965T,#4N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5+0D%#/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/D-/3E-/3$E$051%1"!35$%414U%3E13($]&($-/35!2
M14A%3E-)5D4@3$]34R`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S
M(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXQ,B!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^07!R+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y!<'(N(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XD("@X+#8V,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B0@*#,L.#`R*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F]R96EG;B!C=7)R96YC>2!T
M<F%N<VQA=&EO;B!A9&IU<W1M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@U-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@V-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#;VUP<F5H96YS:79E(&QO<W,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^)"`H."PW,3@I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@S+#@V-BD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V5D86(P93(V7S,P
M-&9?-#,U,5]B93AE7S-C,F$Y-&9F9F9C,`T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B]E9&%B,&4R-E\S,#1F7S0S-3%?8F4X95\S8S)A.31F9F9F
M8S`O5V]R:W-H965T<R]3:&5E=#`V+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3$Q"23X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#$^/'-T<F]N9SY#3TY33TQ)1$%4140@4U1!5$5-14Y4($]&
M($-(04Y'15,@24X@4U1/0TM(3TQ$15)3)R!%455)5%D@*$1%1DE#250I("A5
M4T0@)"D\8G(^26X@5&AO=7-A;F1S+"!E>&-E<'0@4VAA<F4@9&%T83PO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D-O;6UO;B!3=&]C
M:R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y4
M<F5A<W5R>2!3=&]C:R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y!9&1I=&EO;F%L(%!A:60M26X@0V%P:71A;"!;365M8F5R
M73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y2971A:6YE9"!%
M87)N:6YG<R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y3=&]C:R!3=6)S8W)I<'1I;VX@4F5C96EV86)L92!;365M8F5R73QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y!8V-U;75L871E9"!/
M=&AE<B!#;VUP<F5H96YS:79E($EN8V]M92`H3&]S<RD@6TUE;6)E<ET\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^5&]T86P\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A;&%N8V4@870@07!R+B`S
M,"P@,C`Q,#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H
M,C$Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,34L,3DS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XD("@Q,BPV.#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XD("@W-3`I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@T*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PU-S<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A;&%N
M8V4@*&EN('-H87)E<RD@870@07!R+B`S,"P@,C`Q,#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,S4L-S@P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#8T+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VLM
M8F%S960@8V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,L,3,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,RPQ,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E(&]F(&]P=&EO;G,@86YD
M('=A<G)A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5X97)C:7-E(&]F(&]P=&EO;G,@86YD('=A<G)A;G1S("AI;B!S
M:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#0L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V%N8V5L;&%T:6]N(&]F('-T;V-K('-U8G-C<FEP=&EO;B!R96-E:79A
M8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#<U,"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S4P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!U<F-H87-E(&]F('1R96%S=7)Y('-T;V-K(&9R;VT@8F]A<F0@;65M
M8F5R(&%N9"!C86YC96QL871I;VX@;V8@86-C<G5E9"!S=&]C:R!L:6%B:6QI
M='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#`S,RD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.#@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@X-#4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y0=7)C:&%S92!O9B!T<F5A<W5R>2!S=&]C:R!F<F]M(&)O87)D
M(&UE;6)E<B!A;F0@8V%N8V5L;&%T:6]N(&]F(&%C8W)U960@<W1O8VL@;&EA
M8FEL:71Y("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@R+#$W,BPP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,BPQ-S(L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!R97-T<FEC
M=&5D('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y)<W-U86YC92!O9B!R97-T<FEC=&5D('-T;V-K("AI;B!S:&%R97,I
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3@L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F]R
M96EG;B!C=7)R96YC>2!T<F%N<VQA=&EO;B!A9&IU<W1M96YT/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8T*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8T*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,L.#`R*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S+#@P
M,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D)A;&%N8V4@870@07!R+B`S,"P@,C`Q,3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@Q+#(U,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-RPW.#0\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-BPT.#(I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8X*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"
M86QA;F-E("AI;B!S:&%R97,I(&%T($%P<BX@,S`L(#(P,3$\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,S+#@W,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#(S-BPP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T
M;V-K+6)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,L,S(S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,RPS,C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E(&]F(&]P=&EO;G,@
M86YD('=A<G)A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/CDW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^.3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5X97)C:7-E(&]F(&]P=&EO;G,@86YD('=A<G)A;G1S("AI
M;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,S0L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^27-S=6%N8V4@;V8@<F5S=')I8W1E9"!S=&]C:SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@<F5S
M=')I8W1E9"!S=&]C:R`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3(U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9O<F5I9VX@8W5R<F5N8WD@=')A;G-L
M871I;VX@861J=7-T;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@U-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@U-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@X+#8V,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#@L-C8Q*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC92!A="!!<'(N
M(#,P+"`R,#$R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD
M("@Q+#(U,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#(Q+#(P-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^)"`H,C4L,30S*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,3(U*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-2PR-S@I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"
M86QA;F-E("AI;B!S:&%R97,I(&%T($%P<BX@,S`L(#(P,3(\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,T+#4R.2PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#(S-BPP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V5D86(P93(V
M7S,P-&9?-#,U,5]B93AE7S-C,F$Y-&9F9F9C,`T*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B]E9&%B,&4R-E\S,#1F7S0S-3%?8F4X95\S8S)A.31F
M9F9F8S`O5V]R:W-H965T<R]3:&5E=#`W+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%0TI!1SX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#3TY33TQ)1$%4140@4U1!5$5-14Y4
M4R!/1B!#05-(($9,3U=3("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE
M<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y!<'(N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D%P<BX@,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W!E<F%T:6YG(&%C=&EV:71I97,Z
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE
M="!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#@L-C8Q
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M)"`H,RPX,#(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D%D:G5S=&UE;G1S('1O(')E8V]N8VEL92!N
M970@;&]S<R!T;R!N970@8V%S:"!U<V5D(&EN(&]P97)A=&EN9R!A8W1I=FET
M:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y3=&]C:RUB87-E9"!C;VUP96YS871I;VX@97AP96YS93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,RPS,C,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#$S,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YC;VUE('1A>"`H
M8F5N969I="D@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1&5P<F5C:6%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$P-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C0R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;W-S(&]N(&1I<W!O<V%L(&]F('!R
M;W!E<G1Y(&%N9"!E<75I<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#:&%N9V4@:6X@9F%I<B!V86QU92!O9B!W87)R86YT(&QI
M86)I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#$W*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,V
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D-H86YG97,@:6X@;W!E<F%T:6YG(&%S<V5T<R!A;F0@;&EA
M8FEL:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%C8V]U;G1S(')E8V5I=F%B;&4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@T.3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y'<F%N="!R96-E:79A8FQE/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,3<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U,3<I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5P86ED(&5X<&5N
M<V5S+"!D97!O<VET<R!A;F0@;W1H97(\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C<Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,C$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y297-T<FEC=&5D(&-A<V@\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#$U,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8S-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C<G5E9"!L
M:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S(S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D1E9F5R<F5D(')E=F5N=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#0S,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XV.3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D]T:&5R(&QI86)I;&ET:65S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH-S<I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&-A<V@@=7-E9"!I;B!O
M<&5R871I;F<@86-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH-2PR,C<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH-30I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN=F5S=&EN9R!A8W1I=FET:65S
M.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0
M=7)C:&%S92!O9B!P<F]P97)T>2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@U,3DI/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.#4I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F;W)M('-A
M;&4@;V8@<')O<&5R='D@86YD(&5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y.970@8V%S:"!U<V5D(&EN(&EN=F5S=&EN
M9R!A8W1I=FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U
M,3DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH.#0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D9I;F%N8VEN9R!A8W1I=FET:65S.CPO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<FEV871E('!L
M86-E;65N="!O9B!C;VUM;VX@<VAA<F5S(&%N9"!W87)R86YT<R`H;F5T(&]F
M("0S,#4@:6X@;V9F97)I;F<@8V]S=',I/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.2PP.34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!U<F-H87-E(&]F('1R96%S=7)Y('-T;V-K
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PP,S,I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C
M965D<R!F<F]M(&5X97)C:7-E(&]F(&]P=&EO;G,@86YD('=A<G)A;G1S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY-SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&-A<V@@
M<')O=FED960@8GD@9FEN86YC:6YG(&%C=&EV:71I97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/CDW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^."PP.#,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X8VAA;F=E(')A=&4@969F
M96-T(&]N(&-A<V@@86YD(&-A<V@@97%U:79A;&5N=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#4T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#8P*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN8W)E87-E("AD96-R96%S
M92D@:6X@8V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH-2PW,#,I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPX.#4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@
M97%U:79A;&5N=',L(&)E9VEN;FEN9R!O9B!Y96%R/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,"PT-3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#4W,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@8V%S:"!E
M<75I=F%L96YT<RP@96YD(&]F('EE87(\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@-"PW-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#$P+#0U-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?961A8C!E,C9?,S`T9E\T,S4Q7V)E.&5?
M,V,R83DT9F9F9F,P#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V5D
M86(P93(V7S,P-&9?-#,U,5]B93AE7S-C,F$Y-&9F9F9C,"]7;W)K<VAE971S
M+U-H965T,#@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5*1CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY#3TY33TQ)1$%4140@4U1!5$5-14Y44R!/1B!#05-(($9,3U=3(%M0
M87)E;G1H971I8V%L72`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S
M(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXQ,B!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^07!R+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y!<'(N(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y/9F9E<FEN9R!C;W-T<R`H:6X@9&]L;&%R<RD\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S`U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E9&%B,&4R-E\S,#1F
M7S0S-3%?8F4X95\S8S)A.31F9F9F8S`-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO961A8C!E,C9?,S`T9E\T,S4Q7V)E.&5?,V,R83DT9F9F9F,P
M+U=O<FMS:&5E=',O4VAE970P.2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/D]R9V%N:7IA=&EO;B!A;F0@0F%S:7,@;V8@4')E
M<V5N=&%T:6]N/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y!
M<'(N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D%C8V]U;G1I;F<@4&]L:6-I97,@6T%B<W1R86-T73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"=7-I
M;F5S<R!$97-C<FEP=&EO;B!A;F0@0F%S:7,@;V8@4')E<V5N=&%T:6]N(%M4
M97AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X
M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^
M/&(^3F]T92`Q+B!/<F=A;FEZ871I;VX@86YD($)A<VES(&]F(%!R97-E;G1A
M=&EO;CPO8CX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y
M.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\8CX\:3Y"86-K9W)O
M=6YD/"]I/CPO8CX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
M:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@.7!T.R!M87)G:6XZ
M(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[)SY#:&%M<&EO;G,@3VYC;VQO9WDL($EN8RX@*'1H92`F(S@R,C`[
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M:6YD96YT.B`Y<'0[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE
M<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/E1H92!#;VUP86YY(&AA<R!T
M=V\@;W!E<F%T:6YG('-U8G-I9&EA<FEE<SH@0VAA;7!I;VYS($]N8V]L;V=Y
M("A)<W)A96PI+"!,:6UI=&5D(&%N9"!#:&%M<&EO;G,@0FEO=&5C:&YO;&]G
M>2!5+DLN+"!,:6UI=&5D+B!&;W(@=&AE('EE87)S(&5N9&5D($%P<FEL(#,P
M+"`R,#$R(&%N9"`R,#$Q+"!T:&5R92!W97)E(&YO(&UA=&5R:6%L(')E=F5N
M=65S(&5A<FYE9"!B>2!T:&5S92!S=6)S:61I87)I97,N/"]P/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q
M-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R
M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R<^/&(^/&D^0F%S:7,@;V8@4')E<V5N=&%T:6]N/"]I/CPO
M8CX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G
M:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@.7!T.R!M87)G:6XZ(#!P="`P<'@[
M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY4
M:&4@86-C;VUP86YY:6YG(&-O;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M
M96YT<R!H879E(&)E96X@<')E<&%R960@:6X@86-C;W)D86YC92!W:71H(&=E
M;F5R86QL>2!A8V-E<'1E9"!A8V-O=6YT:6YG('!R:6YC:7!L97,@:6X@=&AE
M(%5N:71E9"!3=&%T97,@;V8@06UE<FEC82`H)B,X,C(P.T=!05`F(S@R,C$[
M*2X@0V5R=&%I;B!I;6UA=&5R:6%L(')E8VQA<W-I9FEC871I;VYS(&AA=F4@
M8F5E;B!M861E('1O('!R:6]R('EE87(@86UO=6YT<R!T;R!C;VYF;W)M('1O
M('1H92!C=7)R96YT('EE87(@<')E<V5N=&%T:6]N+CPO<#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V5D86(P93(V7S,P-&9?
M-#,U,5]B93AE7S-C,F$Y-&9F9F9C,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B]E9&%B,&4R-E\S,#1F7S0S-3%?8F4X95\S8S)A.31F9F9F8S`O
M5V]R:W-H965T<R]3:&5E=#$P+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT
M:6YG(%!O;&EC:65S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y!<'(N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D%C8V]U;G1I;F<@4&]L:6-I97,@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S(%M497AT($)L;V-K73PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^3F]T92`R+B!3
M=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,\+V(^
M/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN
M.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L
M('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^/&D^4')I;F-I<&QE<R!O9B!#
M;VYS;VQI9&%T:6]N/"]I/CPO8CX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM
M97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@.7!T
M.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
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M;G,@:&%V92!B965N(&5L:6UI;F%T960@:6X@8V]N<V]L:61A=&EO;BX\+W`^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P
M="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
M:69Y.R!T97AT+6EN9&5N=#H@.7!T.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z
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M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P
M<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
M<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S
M=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^/&D^57-E(&]F($5S=&EM871E<SPO
M:3X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@
M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#EP=#L@;6%R9VEN.B`P<'0@
M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
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M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`Y<'0[(&UA<F=I;CH@,'!T
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M>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`Y<'0[
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M/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI
M;F1E;G0Z(#EP=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^
M/&D^1F%I<B!686QU93PO:3X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#EP
M=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.R<^5&AE(&-A<G)Y:6YG('9A;'5E(&]F(&-A<V@@
M86YD(&-A<V@@97%U:79A;&5N=',L(&%C8V]U;G1S(')E8V5I=F%B;&4L('!R
M97!A:60@97AP96YS97,L(&1E<&]S:71S(&%N9"!O=&AE<B!R96-E:79A8FQE
M<RP@86-C;W5N=',@<&%Y86)L92P@86YD(&%C8W)U960@;&EA8FEL:71I97,@
M87!P<F]X:6UA=&4@=&AE:7(@9F%I<B!V86QU92!B87-E9"!O;B!T:&4@;&EQ
M=6ED:71Y(&]R('1H92!S:&]R="UT97)M(&UA='5R:71I97,@;V8@=&AE<V4@
M:6YS=')U;65N=',N(%1H92!F86ER('9A;'5E(&AI97)A<F-H>2!P<F]M=6QG
M871E9"!B>2!'04%0(&-O;G-I<W1S(&]F('1H<F5E(&QE=F5L<SH\+W`^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@
M.7!T.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\=&%B;&4@<W1Y;&4]
M,T0G;6%R9VEN+71O<#H@,'!T.R!W:61T:#H@,3`P)3L@9F]N=#H@,3!P="!T
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M+6%L:6=N.B!J=7-T:69Y.R<^/&D^3&5V96P@;VYE/"]I/B`F(S@R,3([(%%U
M;W1E9"!M87)K970@<')I8V5S(&EN(&%C=&EV92!M87)K971S(&9O<B!I9&5N
M=&EC86P@87-S971S(&]R(&QI86)I;&ET:65S.SPO=&0^#0H\+W1R/@T*/"]T
M86)L93X-"CQT86)L92!S='EL93TS1"=M87)G:6XM=&]P.B`P<'0[('=I9'1H
M.B`Q,#`E.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
M<FEF.R!M87)G:6XM8F]T=&]M.B`P<'0[)R!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T
M;W`[)SX-"CQT9"!S='EL93TS1"=W:61T:#H@.7!T.R<^/"]T9#X-"CQT9"!S
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M;&4@<W1Y;&4],T0G;6%R9VEN+71O<#H@,'!T.R!W:61T:#H@,3`P)3L@9F]N
M=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN
M+6)O='1O;3H@,'!T.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,#X-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R<^#0H\=&0@
M<W1Y;&4],T0G=VED=&@Z(#EP=#LG/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$U<'0[)SX\9F]N=#XF(S$X,SL\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R<^/&D^3&5V96P@=&AR964\+VD^
M("8C.#(Q,CL@56YO8G-E<G9A8FQE(&EN<'5T<R!D979E;&]P960@=7-I;F<@
M97-T:6UA=&5S(&%N9"!A<W-U;7!T:6]N<RP@=VAI8V@@87)E(&1E=F5L;W!E
M9"!B>2!T:&4@<F5P;W)T:6YG(&5N=&ET>2!A;F0@<F5F;&5C="!T:&]S92!A
M<W-U;7!T:6]N<R!T:&%T(&$@;6%R:V5T('!A<G1I8VEP86YT('=O=6QD('5S
M92X\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM
M97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@.7!T
M.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
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M96-U<FET:65S('1H870@8VQO<V5D(&1U<FEN9R!!<')I;"`R,#$Q(&%N9"!I
M<R!D:7-C=7-S960@;6]R92!F=6QL>2!I;B!.;W1E(#<N($%S(&]F($%P<FEL
M(#,P+"`R,#$R(&%N9"`R,#$Q+"!T:&5S92!W87)R86YT<R!H860@86X@97-T
M:6UA=&5D(&9A:7(@=F%L=64@;V8@)#4U-2PP,#`@86YD("0Y-S(L,#`P+"!R
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M<VES(&1U<FEN9R!T:&4@>65A<G,@96YD960@07!R:6P@,S`L(#(P,3(@86YD
M(#(P,3$N/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@
M=&5X="UI;F1E;G0Z(#EP=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z
M(#EP=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R<^5&AE(&9O;&QO=VEN9R!T86)L92!P<F5S
M96YT<R!I;F9O<FUA=&EO;B!A8F]U="!O=7(@=V%R<F%N=',@;&EA8FEL:71Y
M+"!W:&EC:"!W87,@;W5R(&]N;'D@9FEN86YC:6%L(&EN<W1R=6UE;G0@;65A
M<W5R960@870@9F%I<B!V86QU92!O;B!A(')E8W5R<FEN9R!B87-I<R!U<VEN
M9R!S:6=N:69I8V%N="!U;F]B<V5R=F%B;&4@:6YP=71S("A,979E;"`S*2!A
M<R!D969I;F5D(&EN($%30R!4;W!I8R`X,C`@870@07!R:6P@,S`@*&1O;&QA
M<G,@:6X@=&AO=7-A;F1S*3H\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@.7!T.R!M87)G:6XZ(#!P="`P<'@[
M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF
M(S$V,#L\+W`^#0H\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#DU)3L@8F]R9&5R
M+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M
M86XL('1I;65S+"!S97)I9CL@;6%R9VEN+6QE9G0Z(#EP=#LG(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E
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M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q
M-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"CQT
M9#XF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-
M"CQT9#XF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O
M=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#<T)3LG
M/D)A;&%N8V4@8F5G:6YN:6YG(&]F('EE87(\+W1D/@T*/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q,"4[)SXH.3<R/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXI/"]T
M9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B0\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3`E
M.R<^+3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED
M=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C
M:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6QE
M9G0Z(#EP=#LG/E1R86YS9F5R<R!T;R`H9G)O;2D@3&5V96P@,SPO=&0^#0H\
M=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#LG/BT\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[)SXM/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G
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M969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^+3PO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T
M;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^*#DS-CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ
M(#%P=#LG/BD\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD
M+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\
M=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
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M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[
M('1E>'0M86QI9VXZ(')I9VAT.R<^*#4U-3PO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^*3PO
M=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E
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M.B`Y<'0[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@
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M;"`S,"P@,C`Q,BP@=&AE(&%L;&]W86YC92!F;W(@=&AE<V4@86-C;W5N=',@
M=V%S("0Q-"PP,#`N(%1H97)E('=A<R!N;R!A;&QO=V%N8V4@<F5C;W)D960@
M9F]R(&]P96X@<F5C96EV86)L97,@870@07!R:6P@,S`L(#(P,3$N($%C8V]U
M;G1S(')E8V5I=F%B;&4@:7,@86QS;R!C;VUP<FES960@;V8@8V5R=&%I;B!U
M;F)I;&QE9"!A8V-O=6YT<R!R96-E:79A8FQE(&9O<B!S97)V:6-E<R!C;VUP
M;&5T960@=6YD97(@5$]3('1H870@:&%V92!N;W0@8F5E;B!B:6QL960@87,@
M;V8@=&AE(&)A;&%N8V4@<VAE970@9&%T92X@07,@;V8@07!R:6P@,S`L(#(P
M,3(@86YD(#(P,3$L('1H92!#;VUP86YY(&AA9"!U;F)I;&QE9"!R96-E:79A
M8FQE<R!O9B`D,3`T+#`P,"!A;F0@)#,P-2PP,#`L(')E<W!E8W1I=F5L>2X\
M+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ
M(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J
M=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\8CX\:3Y297-T<FEC=&5D($-A<V@\
M+VD^/"]B/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[
M(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL
M('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`Y<'0[(&UA<F=I;CH@,'!T
M(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CLG/E1H92!#;VUP86YY(&AA<R!R97-T<FEC=&5D(&-A<V@@;V8@)#$U,"PP
M,#`L('=H:6-H(&ES(&-L87-S:69I960@87,@82!N;VYC=7)R96YT(&%S<V5T
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M<&]R=&EN9R!O<&5R871I;VYS(&]F('1H92!B=7-I;F5S<RX\+W`^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[
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M>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`Y<'0[
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M<W1I9GD[('1E>'0M:6YD96YT.B`Y<'0[(&UA<F=I;CH@,'!T(#!P>#L@9F]N
M=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P
M.SPO<#X-"CQT86)L92!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=W:61T:#H@
M.3`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT.B`Q,'!T('1I
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M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F
M;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C
M96YT97([(&9O;G0M=V5I9VAT.B!B;VQD.R<@8V]L<W!A;CTS1#(^,C`Q,3PO
M=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW
M96EG:'0Z(&)O;&0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$
M,CXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T
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M#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXD/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$P)3LG
M/C4X/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T
M:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M=VED=&@Z(#$E.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[('=I9'1H.B`Q,"4[)SXQ,#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CPO='(^
M#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^0V]M<'5T97(@97%U:7!M96YT(&%N9"!S;V9T=V%R93PO=&0^
M#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#LG/C(X-SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
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M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D
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M9W)E<W,\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!R:6=H=#LG/C(Q-CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E
M>'0M86QI9VXZ(')I9VAT.R<^,C0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D
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M9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/E1O=&%L('!R
M;W!E<G1Y(&%N9"!E<75I<&UE;G0\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXW,S`\+W1D/@T*/'1D
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M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[
M)SY,97-S.B!!8V-U;75L871E9"!D97!R96-I871I;VX\+W1D/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X
M="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H
M=#LG/B@Q-S`\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXI/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[)SXH-C4\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M8F]T=&]M.B`Q<'0[)SXI/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C
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M9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/E!R;W!E<G1Y(&%N
M9"!E<75I<&UE;G0L(&YE=#PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE
M9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^-38P/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O
M;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L
M969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG/C$T-CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T
M;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X
M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^
M/&(^)B,Q-C`[/"]B/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU
M<W1I9GD[('1E>'0M:6YD96YT.B`Y<'0[(&UA<F=I;CH@,'!T(#!P>#L@9F]N
M=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/D1E<')E
M8VEA=&EO;B!E>'!E;G-E('=A<R`D,3`U+#`P,"!A;F0@)#0R+#`P,"!F;W(@
M=&AE('EE87)S(&5N9&5D($%P<FEL(#,P+"`R,#$R(&%N9"`R,#$Q+"!R97-P
M96-T:79E;'DN/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.R<^/&(^/&D^)B,Q-C`[/"]I/CPO8CX\+W`^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P
M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M)SX\8CX\:3Y);7!A:7)M96YT(&]F($QO;F<M3&EV960@07-S971S/"]I/CPO
M8CX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G
M:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@.7!T.R!M87)G:6XZ(#!P="`P<'@[
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M+"`R,#$R(&%N9"`R,#$Q+CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N
M97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@9F]N
M=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQB/CQI
M/D=O;V1W:6QL/"]I/CPO8CX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@.7!T.R!M
M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[)SY';V]D=VEL;"!R97!R97-E;G1S('1H92!E>&-E<W,@
M;V8@=&AE(&-O<W0@;W9E<B!T:&4@9F%I<B!M87)K970@=F%L=64@;V8@=&AE
M(&YE="!A<W-E=',@86-Q=6ER960@:6YC;'5D:6YG(&ED96YT:69I86)L92!A
M<W-E=',N)B,Q-C`[)B,Q-C`[1V]O9'=I;&P@:7,@=&5S=&5D(&%N;G5A;&QY
M+"!O<B!M;W)E(&9R97%U96YT;'D@:68@8VER8W5M<W1A;F-E<R!I;F1I8V%T
M92!P;W1E;G1I86P@:6UP86ER;65N="P@8GD@8V]M<&%R:6YG(&ET<R!F86ER
M('9A;'5E('1O(&ET<R!C87)R>6EN9R!A;6]U;G0N)B,Q-C`[)B,Q-C`[5&AE
M(&1E=&5R;6EN871I;VX@;V8@=VAE=&AE<B!O<B!N;W0@9V]O9'=I;&P@:7,@
M:6UP86ER960@:6YV;VQV97,@<VEG;FEF:6-A;G0@:G5D9VUE;G0N)B,Q-C`[
M)B,Q-C`[06QT:&]U9V@@=&AE($-O;7!A;GD@8F5L:65V97,@:71S(&=O;V1W
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M<W0@9F]R(&=O;V1W:6QL(&EM<&%I<FUE;G0N)B,Q-C`[)B,Q-C`[5&AE(&9I
M<G-T('-T97`@:7,@=&\@<V-R965N(&9O<B!P;W1E;G1I86P@:6UP86ER;65N
M="P@=VAI;&4@=&AE('-E8V]N9"!S=&5P(&UE87-U<F5S('1H92!A;6]U;G0@
M;V8@=&AE(&EM<&%I<FUE;G0L(&EF(&%N>2XF(S$V,#LF(S$V,#M4:&4@9FER
M<W0@<W1E<"!O9B!T:&4@9V]O9'=I;&P@:6UP86ER;65N="!T97-T(&-O;7!A
M<F5S('1H92!F86ER('9A;'5E(&]F(&5A8V@@<F5P;W)T:6YG('5N:70@=VET
M:"!I=',@8V%R<GEI;F<@86UO=6YT+"!I;F-L=61I;F<@9V]O9'=I;&PN)B,Q
M-C`[)B,Q-C`[268@=&AE(&9A:7(@=F%L=64@;V8@=&AE(')E<&]R=&EN9R!U
M;FET(&5X8V5E9',@:71S(&-A<G)Y:6YG('9A;'5E+"!G;V]D=VEL;"!I<R!N
M;W0@:6UP86ER960N)B,Q-C`[)B,Q-C`[268@=&AE(&-A<G)Y:6YG('9A;'5E
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M9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`Y<'0[(&UA<F=I;CH@,'!T(#!P
M>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG
M/E1H92!#;VUP86YY(&AA<R!N;W0@<F5C;V=N:7IE9"!A;GD@:6UP86ER;65N
M="!L;W-S97,@9F]R('1H92!#;VUP86YY)B,X,C$W.W,@9V]O9'=I;&P@9F]R
M('1H92!Y96%R<R!E;F1I;F<@07!R:6P@,S`L(#(P,3(@86YD(#(P,3$N/"]P
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P
M<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
M<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S
M=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^/&D^1&5F97)R960@4F5V96YU93PO
M:3X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@
M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#EP=#L@;6%R9VEN.B`P<'0@
M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
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M/CPO8CX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M
M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@.7!T.R!M87)G:6XZ(#!P="`P
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M<VEO;G,N)B,Q-C`[)B,Q-C`[5&AE)B,Q-C`[)B,Q-C`[;&EA8FEL:71Y+"!W
M:&EC:"!I<R!R96-O<F1E9"!A="!F86ER('9A;'5E(&]N('1H92!A8V-O;7!A
M;GEI;F<@8V]N<V]L:61A=&5D(&)A;&%N8V4@<VAE971S+"!I<R!C86QC=6QA
M=&5D(&)Y('1H92!-;VYT92!#87)L;R!S:6UU;&%T:6]N('9A;'5A=&EO;B!M
M971H;V0N)B,Q-C`[)B,Q-C`[5&AE(&-H86YG92!I;B!F86ER('9A;'5E(&]F
M('1H97-E('=A<G)A;G1S(&ES(')E8V]G;FEZ960@87,@;W1H97(@:6YC;VUE
M(&]R(&5X<&5N<V4@:6X@=&AE(&-O;G-O;&ED871E9"!S=&%T96UE;G1S(&]F
M(&]P97)A=&EO;G,N/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S
M=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^/&D^4F5V
M96YU92!296-O9VYI=&EO;CPO:3X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z
M(#EP=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R<^5&AE($-O;7!A;GD@9&5R:79E<R!R979E
M;G5E(&9R;VT@:71S(%!/4R!A;F0@5$]3(&)U<VEN97-S97,N(%!E<G-O;F%L
M:7IE9"!O;F-O;&]G>2!S;VQU=&EO;G,@87-S:7-T('!H>7-I8VEA;G,@8GD@
M<')O=FED:6YG(&EN9F]R;6%T:6]N('1O(&AE;'`@9W5I9&4@=&AE(&1E=F5L
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M;6%Y('!E<F9O<FT@:6X@8VQI;FEC86P@<V5T=&EN9W,N)B,Q-C`[)B,Q-C`[
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M9"`H:78I(&-O;&QE8W1A8FEL:71Y(&ES(')E87-O;F%B;'D@87-S=7)E9"XF
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M.B`Y<'0[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@
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M('1H92!A<G)A;F=E;65N="!I<R!D96QI=F5R960N)B,Q-C`[)B,Q-C`[1V5N
M97)A;&QY+"!T:&4@0V]M<&%N>2!A8V-O=6YT<R!F;W(@82!D96QI=F5R86)L
M92`H;W(@82!G<F]U<"!O9B!D96QI=F5R86)L97,I('-E<&%R871E;'D@:68Z
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M86QL>2!I;B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-O;G1R;VPN)B,Q-C`[)B,Q
M-C`[06QL(')E=F5N=64@9G)O;2!C;VYT<F%C=',@9&5T97)M:6YE9"!N;W0@
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M="!O9B!T:&4@87)R86YG96UE;G0N/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X
M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^
M/&(^/&D^0V]S="!O9B!097)S;VYA;&EZ960@3VYC;VQO9WD@4V]L=71I;VYS
M/"]I/CPO8CX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y
M.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@.7!T.R!M87)G:6XZ(#!P
M="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
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M9GD[('1E>'0M:6YD96YT.B`Y<'0[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/D-O<W0@;V8@
M5$]3(&-O;G-I<W1S(&]F(&-O<W1S(')E;&%T960@=&\@5$]3(')E=F5N=64N
M)B,Q-C`[)B,Q-C`[1&ER96-T(&-O<W1S(&EN8VQU9&4@;6EC92!P=7)C:&%S
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M;&]P;65N=#PO:3X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#EP=#L@;6%R
M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
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M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`Y<'0[(&UA<F=I;CH@,'!T
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M97)T:7-I;F<@8V]S=',@=V5R92`D,3,U+#`P,"!A;F0@)#8Y+#`P,"!F;W(@
M9FES8V%L(#(P,3(@86YD(#(P,3$L(')E<W!E8W1I=F5L>2X\+W`^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@.7!T
M.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\8CX\:3Y"87-I8R!A
M;F0@1&EL=71I=F4@3&]S<R!097(@0V]M;6]N(%-H87)E/"]I/CPO8CX\+W`^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P
M="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
M:69Y.R!T97AT+6EN9&5N=#H@.7!T.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z
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M97(@;V8@8V]M;6]N('-H87)E<R`H:6YC;'5D:6YG(')E9&5E;6%B;&4@8V]M
M;6]N('-T;V-K*2!O=71S=&%N9&EN9R!F;W(@=&AE('EE87(L('!L=7,@=&AE
M(&1I;'5T:79E(&5F9F5C="!O9B!C;VUM;VX@<W1O8VL@<'5R8VAA<V4@=V%R
M<F%N=',L('-T;V-K(&]P=&EO;G,@86YD(')E<W1R:6-T960@<W1O8VL@=6YI
M=',@=7-I;F<@=&AE('1R96%S=7)Y('-T;V-K(&UE=&AO9"XF(S$V,#LF(S$V
M,#M#;VYT:6YG96YT;'D@:7-S=6%B;&4@<VAA<F5S(&%R92!I;F-L=61E9"!I
M;B!T:&4@8V%L8W5L871I;VX@;V8@8F%S:6,@96%R;FEN9W,@<&5R('-H87)E
M('=H96X@86QL(&-O;G1I;F=E;F-I97,@<W5R<F]U;F1I;F<@=&AE(&ES<W5A
M;F-E(&]F('1H92!S:&%R97,@87)E(&UE="!A;F0@=&AE('-H87)E<R!A<F4@
M:7-S=65D(&]R(&ES<W5A8FQE+B8C,38P.R8C,38P.T-O;G1I;F=E;G1L>2!I
M<W-U86)L92!S:&%R97,@87)E(&EN8VQU9&5D(&EN('1H92!C86QC=6QA=&EO
M;B!O9B!D:6QU=&EV92!E87)N:6YG<R!P97(@<VAA<F4@87,@;V8@=&AE(&)E
M9VEN;FEN9R!O9B!T:&4@<F5P;W)T:6YG('!E<FEO9"!I9BP@870@=&AE(&5N
M9"!O9B!T:&4@<F5P;W)T:6YG('!E<FEO9"P@86QL(&-O;G1I;F=E;F-I97,@
M<W5R<F]U;F1I;F<@=&AE(&ES<W5A;F-E(&]F('1H92!S:&%R97,@87)E('-A
M=&ES9FEE9"!O<B!W;W5L9"!B92!S871I<V9I960@:68@=&AE(&5N9"!O9B!T
M:&4@<F5P;W)T:6YG('!E<FEO9"!W97)E('1H92!E;F0@;V8@=&AE(&-O;G1I
M;F=E;F-Y('!E<FEO9"XF(S$V,#LF(S$V,#M$=64@=&\@=&AE(&YE="!L;W-S
M97,@9F]R('1H92!Y96%R<R!E;F1E9"!!<')I;"`S,"P@,C`Q,B!A;F0@,C`Q
M,2P@8F%S:6,@86YD(&1I;'5T960@;&]S<R!P97(@<VAA<F4@=V5R92!T:&4@
M<V%M92P@87,@=&AE(&5F9F5C="!O9B!P;W1E;G1I86QL>2!D:6QU=&EV92!S
M96-U<FET:65S('=O=6QD(&AA=F4@8F5E;B!A;G1I+61I;'5T:79E+CPO<#X-
M"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T
M(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I
M9GD[('1E>'0M:6YD96YT.B`Y<'0[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/E1H92!F;VQL
M;W=I;F<@=&%B;&4@<F5F;&5C=',@=&AE('1O=&%L('!O=&5N=&EA;"!S:&%R
M92UB87-E9"!I;G-T<G5M96YT<R!O=71S=&%N9&EN9R!A="!!<')I;"`S,"P@
M,C`Q,B!A;F0@,C`Q,2!T:&%T(&-O=6QD(&AA=F4@86X@969F96-T(&]N('1H
M92!F=71U<F4@8V]M<'5T871I;VX@;V8@9&EL=71I;VX@<&5R(&-O;6UO;B!S
M:&%R93H\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M
M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[)SX\8CXF(S$V,#L\+V(^/"]P/@T*/'1A8FQE(&%L:6=N
M/3-$8V5N=&5R('-T>6QE/3-$)W=I9'1H.B`Y,"4[(&)O<F1E<BUC;VQL87!S
M93H@8V]L;&%P<V4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<@;F]W<F%P/3-$;F]W<F%P/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@
M9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L
M:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C
M;VQS<&%N/3-$-B!N;W=R87`],T1N;W=R87`^665A<B!%;F1E9"!!<')I;"`S
M,"P\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O
M;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^
M#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E
M:6=H=#H@8F]L9#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([
M(&9O;G0M=V5I9VAT.B!B;VQD.R<@8V]L<W!A;CTS1#(^,C`Q,CPO=&0^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z
M(&)O;&0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E
M>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N
M/3-$,CXR,#$Q/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,7!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG
M(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT
M9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CLG(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-
M"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C
M8SL@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`W-"4[)SY3=&]C:R!O<'1I;VYS/"]T
M9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H
M.B`Q,"4[)SXQ-"PX-C8L,#,X/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$P)3LG/C$T+#,R
M,"PY-#@\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I
M9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A
M8VMG<F]U;F0M8V]L;W(Z('=H:71E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/E=A<G)A;G1S
M/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R<^,2PT,38L-C8W/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,2PY,3(L,#$Y/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C
M9F9C8SL@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SY297-T
M<FEC=&5D('-T;V-K/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P
M="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[)SXR-2PP,#`\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q
M<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T
M('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#LG/C$P,"PP,#`\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q
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M<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A
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M9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E
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M=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\8CX\:3XF(S$V,#L\+VD^/"]B/CPO
M<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@
M,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CLG/CQB/CQI/E-H87)E+4)A<V5D(%!A>6UE;G1S/"]I/CPO8CX\+W`^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P
M="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
M:69Y.R!T97AT+6EN9&5N=#H@.7!T.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY4:&4@0V]M
M<&%N>2!T>7!I8V%L;'D@<F5C;V=N:7IE<R!E>'!E;G-E(&9O<B!S:&%R92UB
M87-E9"!P87EM96YT<R!B87-E9"!O;B!T:&4@9F%I<B!V86QU92!O9B!A=V%R
M9',@;VX@=&AE(&1A=&4@;V8@9W)A;G0N)B,Q-C`[)B,Q-C`[5&AE($-O;7!A
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M(&9O=7(M;65M8F5R('!E97(@9W)O=7`@;V8@8V]M<&%N:65S(&EN('1H92!#
M;VUP86YY)B,X,C$W.W,@:6YD=7-T<GDN)B,Q-C`[)B,Q-C`[5&AE($-O;7!A
M;GD@9&]E<R!N;W0@86YT:6-I<&%T92!P87EI;F<@82!D:79I9&5N9"P@86YD
M('1H97)E9F]R92P@;F\@97AP96-T960@9&EV:61E;F0@>6EE;&0@=V%S('5S
M960N/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R
M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#EP=#L@;6%R9VEN.B`P<'0@,'!X
M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^
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M861J=7-T960N)B,Q-C`[)B,Q-C`[5&AE($-O;7!A;GD@=VEL;"!R97!O<G0@
M8V%S:"!F;&]W<R!R97-U;'1I;F<@9G)O;2!T87@@9&5D=6-T:6]N<R!I;B!E
M>&-E<W,@;V8@=&AE(&-O;7!E;G-A=&EO;B!C;W-T(')E8V]G;FEZ960@9G)O
M;2!T:&]S92!O<'1I;VYS("AE>&-E<W,@=&%X(&)E;F5F:71S*2!A<R!F:6YA
M;F-I;F<@8V%S:"!F;&]W<RP@:68@=&AE>2!S:&]U;&0@87)I<V4N/"]P/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@
M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.R<^/&(^/&D^26YC;VUE(%1A>&5S/"]I/CPO8CX\
M+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ
M(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J
M=7-T:69Y.R!T97AT+6EN9&5N=#H@.7!T.R!M87)G:6XZ(#!P="`P<'@[(&9O
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M.T%S(&]F($%P<FEL(#,P+"`R,#$R(&%N9"`R,#$Q+"!T:&4@0V]M<&%N>2!P
M<F]V:61E9"!A('9A;'5A=&EO;B!A;&QO=V%N8V4@9F]R(&%L;"!N970@9&5F
M97)R960@=&%X(&%S<V5T<RP@87,@<F5C;W9E<GD@:7,@;F]T(&UO<F4@;&EK
M96QY('1H86X@;F]T(&)A<V5D(&]N(&%N(&EN<W5F9FEC:65N="!H:7-T;W)Y
M(&]F(&5A<FYI;F=S+CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU
M<W1I9GD[('1E>'0M:6YD96YT.B`Y<'0[(&UA<F=I;CH@,'!T(#!P>#L@9F]N
M=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P
M.SPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M
M:6YD96YT.B`Y<'0[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE
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M86YC:6%L('-T871E;65N=',N)B,Q-C`[)B,Q-C`[5&%X('!O<VET:6]N<R!I
M;F-L=61E+"!B=70@87)E(&YO="!L:6UI=&5D('1O+"!T:&4@9F]L;&]W:6YG
M.CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I
M;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S
M+"!S97)I9CLG/B8C,38P.SPO<#X-"CQT86)L92!S='EL93TS1"=M87)G:6XM
M=&]P.B`P<'0[('=I9'1H.B`Q,#`E.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XM8F]T=&]M.B`P<'0[)R!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!T;W`[)SX-"CQT9"!S='EL93TS1"=W:61T:#H@.7!T
M.R<^/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,35P=#LG/CQF;VYT/B8C
M,3@S.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU
M<W1I9GD[)SY!;B!A;&QO8V%T:6]N(&]R('-H:69T(&]F(&EN8V]M92!B971W
M965N('1A>&EN9R!J=7)I<V1I8W1I;VYS.SPO=&0^#0H\+W1R/@T*/"]T86)L
M93X-"CQT86)L92!S='EL93TS1"=M87)G:6XM=&]P.B`P<'0[('=I9'1H.B`Q
M,#`E.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R!M87)G:6XM8F]T=&]M.B`P<'0[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[
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M:6XM=&]P.B`P<'0[('=I9'1H.B`Q,#`E.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XM8F]T=&]M.B`P<'0[)R!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!T;W`[)SX-"CQT9"!S='EL93TS1"=W:61T:#H@
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M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V
M,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT
M+6EN9&5N=#H@.7!T.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM
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M96QY(&=R96%T97(@=&AA;B`U,"4@;&EK96QY('1O(&)E(')E86QI>F5D+B8C
M,38P.R8C,38P.U1H92!#;VUP86YY(&AA<R!N;R!U;G)E8V]G;FEZ960@=&%X
M(&)E;F5F:71S(&%S(&]F($%P<FEL(#,P+"`R,#$R(&%N9"`R,#$Q+CPO<#X-
M"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T
M(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I
M9GD[('1E>'0M:6YD96YT.B`Y<'0[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@
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M86YY)B,X,C$W.W,@8F%L86YC92!S:&5E=',@870@07!R:6P@,S`L(#(P,3(@
M86YD(#(P,3$L(&%N9"!H87,@;F]T(')E8V]G;FEZ960@:6YT97)E<W0@86YD
M+V]R('!E;F%L=&EE<R!I;B!T:&4@<W1A=&5M96YT(&]F(&]P97)A=&EO;G,@
M9F]R(&5I=&AE<B!P97)I;V0N/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^
M/&D^4F5C96YT($%C8V]U;G1I;F<@4')O;F]U;F-E;65N=',\+VD^/"]B/CPO
M<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@
M,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU
M<W1I9GD[('1E>'0M:6YD96YT.B`Y<'0[(&UA<F=I;CH@,'!T(#!P>#L@9F]N
M=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/D1U<FEN
M9R!397!T96UB97(@,C`Q,2P@=&AE($9I;F%N8VEA;"!!8V-O=6YT:6YG(%-T
M86YD87)D<R!";V%R9"`H)B,X,C(P.T9!4T(F(S@R,C$[*2!I<W-U960@06-C
M;W5N=&EN9R!3=&%N9&%R9',@57!D871E("@F(S@R,C`[05-5)B,X,C(Q.RD@
M3F\N(#(P,3$M,#@L("8C.#(R,#M497-T:6YG($=O;V1W:6QL(&9O<B!);7!A
M:7)M96YT)B,X,C(Q.R`H)B,X,C(P.T%352`R,#$Q+3`X)B,X,C(Q.RDN($%3
M52`R,#$Q+3`X(&ES(&EN=&5N9&5D('1O('-I;7!L:69Y('1H92!T97-T:6YG
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M=&5R($1E8V5M8F5R(#$U+"`R,#$Q+"!A;'1H;W5G:"!E87)L>2!A9&]P=&EO
M;B!I<R!P97)M:71T960N(%1H92!#;VUP86YY(&1O97,@;F]T(&%N=&EC:7!A
M=&4@=&AA="!T:&4@861O<'1I;VX@;V8@=&AI<R!G=6ED86YC92!W:6QL(&AA
M=F4@82!M871E<FEA;"!I;7!A8W0@;VX@:71S(&9I;F%N8VEA;"!P;W-I=&EO
M;B!A;F0@<F5S=6QT<R!O9B!O<&5R871I;VYS+CPO<#X-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`Y<'0[(&UA<F=I
M;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S
M+"!S97)I9CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`Y<'0[(&UA<F=I;CH@,'!T(#!P>#L@
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/D1U
M<FEN9R!*=6YE(#(P,3$L('1H92!&05-"(&ES<W5E9"!!4U4@3F\N(#(P,3$M
M,#4L("8C.#(R,#M0<F5S96YT871I;VX@;V8@0V]M<')E:&5N<VEV92!);F-O
M;64F(S@R,C$[("@F(S@R,C`[05-5(#(P,3$M,#4F(S@R,C$[*2X@05-5(#(P
M,3$M,#4@<')O=FED97,@9F]R('1H92!O<'1I;VX@=&\@<')E<V5N="!T:&4@
M=&]T86P@;V8@8V]M<')E:&5N<VEV92!I;F-O;64L('1H92!C;VUP;VYE;G1S
M(&]F(&YE="!I;F-O;64@86YD('1H92!C;VUP;VYE;G1S(&]F(&]T:&5R(&-O
M;7!R96AE;G-I=F4@:6YC;VUE("@F(S@R,C`[3T-))B,X,C(Q.RD@96ET:&5R
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M=V5V97(L(&1U<FEN9R!$96-E;6)E<B`R,#$Q('1H92!&05-"(&ES<W5E9"!!
M4U4@3F\N(#(P,3$M,3(L('=H:6-H(&1E9F5R<R!T:&]S92!C:&%N9V5S(&EN
M($%352`R,#$Q+3`U('1H870@<F5L871E('1O('1H92!P<F5S96YT871I;VX@
M;V8@<F5C;&%S<VEF:6-A=&EO;B!A9&IU<W1M96YT<RX@5&AE($-O;7!A;GD@
M:&%S(&%D;W!T960@=&AI<R!S=&%N9&%R9"P@=VAI8V@@;VYL>2!I;7!A8W1S
M('1H92!D:7-C;&]S=7)E<R!R97%U:7)E9"P@8G5T(&AA<R!N;R!I;7!A8W0@
M;VX@=&AE(&9I;F%N8VEA;"!P;W-I=&EO;B!O<B!R97-U;'1S(&]F(&]P97)A
M=&EO;G,N/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@
M=&5X="UI;F1E;G0Z(#EP=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z
M(#EP=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R<^1'5R:6YG($UA>2`R,#$Q+"!T:&4@1D%3
M0B!I<W-U960@05-5($YO+B`R,#$Q+3`T+"`F(S@R,C`[06UE;F1M96YT<R!T
M;R!!8VAI979E($-O;6UO;B!&86ER(%9A;'5E($UE87-U<F5M96YT(&%N9"!$
M:7-C;&]S=7)E(%)E<75I<F5M96YT<R!I;B!5+E,N($=!05`@86YD($E&4E,F
M(S@R,C$[("@F(S@R,C`[05-#(#(P,3$M,#0F(S@R,C$[*2X@5&AE(&%M96YD
M;65N=',@:6X@05-#(#(P,3$M,#0@=V5R92!I<W-U960@:6X@;W)D97(@=&\@
M86QI9VX@=&AE(&9A:7(@=F%L=64@;65A<W5R96UE;G0@86YD(&1I<V-L;W-U
M<F4@<F5Q=6ER96UE;G1S(&EN($=!05`@86YD($EN=&5R;F%T:6]N86P@1FEN
M86YC:6%L(%)E<&]R=&EN9R!3=&%N9&%R9',N($-O;G-E<75E;G1L>2P@=&AE
M(&%M96YD;65N=',@8VAA;F=E('1H92!W;W)D:6YG('5S960@=&\@9&5S8W)I
M8F4@;6%N>2!O9B!T:&4@<F5Q=6ER96UE;G1S(&EN($=!05`@9F]R(&UE87-U
M<FEN9R!F86ER('9A;'5E(&%N9"!F;W(@9&ES8VQO<VEN9R!I;F9O<FUA=&EO
M;B!A8F]U="!F86ER('9A;'5E(&UE87-U<F5M96YT<RX@2&]W979E<BP@;6%N
M>2!O9B!T:&4@86UE;F1M96YT<R!I;B!!4T,@,C`Q,2TP-"!W:6QL(&YO="!R
M97-U;'0@:6X@82!C:&%N9V4@:6X@=&AE(&%P<&QI8V%T:6]N(&]F('1H92!R
M97%U:7)E;65N=',@:6X@05-#(#@R,"P@1F%I<B!686QU92!-96%S=7)E;65N
M="X@5&AE(&%M96YD;65N=',@:6X@05-5(#(P,3$M,#0@87)E(&5F9F5C=&EV
M92P@;VX@82!P<F]S<&5C=&EV92!B87-I<RP@9F]R('!U8FQI8R!E;G1I=&EE
M<R!F;W(@:6YT97)I;2!A;F0@86YN=6%L('!E<FEO9',@8F5G:6YN:6YG(&%F
M=&5R($1E8V5M8F5R(#$U+"`R,#$Q+B!4:&4@0V]M<&%N>2!H87,@861O<'1E
M9"!T:&ES('-T86YD87)D+"!W:&EC:"!H860@;F\@:6UP86-T(&]N(&ET<R!F
M:6YA;F-I86P@<&]S:71I;VX@;W(@<F5S=6QT<R!O9B!O<&5R871I;VYS+CPO
M<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V5D
M86(P93(V7S,P-&9?-#,U,5]B93AE7S-C,F$Y-&9F9F9C,`T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B]E9&%B,&4R-E\S,#1F7S0S-3%?8F4X95\S
M8S)A.31F9F9F8S`O5V]R:W-H965T<R]3:&5E=#$Q+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0V5P:&%L;VX@06=R965M96YT
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y!<'(N(#,P+"`R
M,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D-E<&AA;&]N($%G<F5E;65N="!;06)S=')A8W1=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-E<&AA;&]N($%G<F5E
M;65N="!;5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
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M9GD[('1E>'0M:6YD96YT.B`Y<'0[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/D]N($UA<F-H
M(#$V+"`R,#$Q+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@86X@86=R965M
M96YT('=I=&@@0V5P:&%L;VXL($EN8RXL("@F(S@R,C`[0V5P:&%L;VXF(S@R
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M+B!);B!!<')I;"`R,#$Q+"!#97!H86QO;B!P86ED(&%N(&EN:71I871I;VX@
M9F5E(&]F("0Q+C0@;6EL;&EO;B!T;R!T:&4@0V]M<&%N>2P@=VAI8V@@:7,@
M<F5F;&5C=&5D('=I=&AI;B!D969E<G)E9"!R979E;G5E(&]N('1H92!C;VYS
M;VQI9&%T960@8F%L86YC92!S:&5E="!A<R!O9B!!<')I;"`S,"P@,C`Q,2X@
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M."PP,#`@=V%S(')E8V]G;FEZ960@9'5R:6YG('1H92!Y96%R(&5N9&5D($%P
M<FEL(#,P+"`R,#$R+B!4:&4@0V]M<&%N>2!A;G1I8VEP871E<R!T:&%T('1H
M92!S='5D:65S('=I;&P@8F4@8V]M<&QE=&5D('=I=&AI;B`Q."!M;VYT:',@
M;V8@=&AE(&5X96-U=&EO;B!O9B!T:&4@86=R965M96YT+CPO<#X-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`Y<'0[
M(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL
M('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`Y<'0[(&UA<F=I;CH@,'!T
M(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CLG/D-E<&AA;&]N('=I;&PL('5N9&5R(&-E<G1A:6X@8V]N9&ET:6]N<RP@
M86QS;R!P87D@=&AE($-O;7!A;GD@=F%R:6]U<R!A;6]U;G1S('5P;VX@86-H
M:65V:6YG(&-E<G1A:6X@;6EL97-T;VYE<RX@4&]T96YT:6%L(&UI;&5S=&]N
M92!P87EM96YT<R!T:&%T(&-O=6QD(&)E(')E8V5I=F5D('5N9&5R('1H92!!
M9W)E96UE;G0@=&]T86P@)#(W(&UI;&QI;VXN(%1H97-E(&UI;&5S=&]N97,@
M87)E(&)A<V5D(&]N('1H92!P97)F;W)M86YC92!O9B!T:&4@8V]M<&]U;F1S
M(&EN('!R96-L:6YI8V%L('1E<W1I;F<@86YD(&%R92!D97!E;F1E;G0@=7!O
M;B!T97-T:6YG('1H92!C;VUP;W5N9"!I;B!C;&EN:6-A;"!S971T:6YG<R!A
M;F0@;V)T86EN:6YG($9$02!A<'!R;W9A;"X@3F\@;6EL97-T;VYE<R!H879E
M(&)E96X@86-H:65V960@=&\@9&%T92X@26X@861D:71I;VXL('5N9&5R(&-E
M<G1A:6X@8V]N9&ET:6]N<RP@0V5P:&%L;VX@=VEL;"!P87D@=&AE($-O;7!A
M;GD@<F]Y86QT:65S(&]N(&%N>2!C;VUM97)C:6%L:7IE9"!P<F]D=6-T<R!D
M979E;&]P960@=6YD97(@=&AE($%G<F5E;65N="X@3F\@<F]Y86QT:65S(&AA
M=F4@8F5E;B!R96-E:79E9"!O<B!E87)N960@=&\@9&%T92X@0V5P:&%L;VX@
M<F5S97)V97,@=&AE(')I9VAT('1O(&5X97)C:7-E(&%N9"!P87D@82!O;F4M
M=&EM92!F964@;V8@:6X@;&EE=2!O9B!T:&4@;6EL97-T;VYE(&]R(')O>6%L
M='D@<&%Y;65N=',N(%1H97-E(&9E97,@<F%N9V4@9G)O;2`D-#8P+#`P,"!T
M;R`D.#@P+#`P,"!P97(@8V]M<&]U;F0N/"]P/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?961A8C!E,C9?,S`T9E\T,S4Q7V)E
M.&5?,V,R83DT9F9F9F,P#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+V5D86(P93(V7S,P-&9?-#,U,5]B93AE7S-C,F$Y-&9F9F9C,"]7;W)K<VAE
M971S+U-H965T,3(N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY#;VUM:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<SQB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^07!R+B`S,"P@,C`Q,CQB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM
M:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<R!$:7-C;&]S=7)E(%M!8G-T<F%C
M=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V]M;6ET;65N=',@86YD($-O;G1I;F=E;F-I97,@1&ES8VQO<W5R92!;5&5X
M="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQB
M/DYO=&4@-"X@0V]M;6ET;65N=',@86YD($-O;G1I;F=E;F-I97,\+V(^/"]P
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P
M<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
M<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S
M=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^/&D^3W!E<F%T:6YG($QE87-E<SPO
M:3X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@
M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#EP=#L@;6%R9VEN.B`P<'0@
M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R<^07,@;V8@07!R:6P@,S`L(#(P,3(L('=E(&QE87-E('1H92!F;VQL;W=I
M;F<@9F%C:6QI=&EE<R!U;F1E<B!N;VXM8V%N8V5L86)L92!O<&5R871I;F<@
M;&5A<V4@86=R965M96YT<SH\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\=&%B;&4@
M<W1Y;&4],T0G;6%R9VEN+71O<#H@,'!T.R!W:61T:#H@,3`P)3L@9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN+6)O
M='1O;3H@,'!T.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R<^#0H\=&0@<W1Y
M;&4],T0G=VED=&@Z(#EP=#LG/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z
M(#`N,C5I;CLG/CQF;VYT/B8C,3@S.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[)SY/;F4@56YI=F5R<VET>2!0;&%Z
M82P@4W5I=&4@,S`W+"!(86-K96YS86-K+"!.97<@2F5R<V5Y(#`W-C`Q+"!W
M:&EC:"P@<VEN8V4@3F]V96UB97(@,C`Q,2P@<V5R=F5S(&%S(&]U<B!C;W)P
M;W)A=&4@:&5A9'%U87)T97)S(&%N9"!C;VYS:7-T<R!O9B!A<'!R;WAI;6%T
M96QY(#,L.#`P('-Q=6%R92!F965T(&]F(&]F9FEC92!S<&%C92X@5&AE(&QE
M87-E(&5X<&ER97,@:6X@07!R:6P@,C`Q-"X@5V4@:6YC=7)R960@)#<Q+#`P
M,"!O9B!R96YT86P@8V]S=',@:6X@9FES8V%L(#(P,3(@<F5L871I=F4@=&\@
M=&AI<R!L96%S92X@3F\@<F5N=&%L(&-O<W1S('=E<F4@:6YC=7)R960@:6X@
M9FES8V%L(#(P,3$@<F5L871I=F4@=&\@=&AI<R!L96%S92X\+W1D/@T*/"]T
M<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y
M.R!M87)G:6XZ(#!P="`P<'@@,'!T(#(W<'0[(&9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\=&%B;&4@
M<W1Y;&4],T0G;6%R9VEN+71O<#H@,'!T.R!W:61T:#H@,3`P)3L@9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN+6)O
M='1O;3H@,'!T.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R<^#0H\=&0@<W1Y
M;&4],T0G=VED=&@Z(#EP=#LG/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z
M(#`N,C5I;CLG/CQF;VYT/B8C,3@S.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[)SXX-34@3F]R=&@@5V]L9F4@4W1R
M965T+"!3=6ET92`V,3DL($)A;'1I;6]R92P@36%R>6QA;F0@,C$R,#4L('=H
M:6-H(&-O;G-I<W1S(&]F(&%P<')O>&EM871E;'D@,2PV-3`@<W%U87)E(&9E
M970@;V8@;&%B;W)A=&]R:65S(&%N9"!O9F9I8V4@<W!A8V4@=VAE<F4@=V4@
M8V]N9'5C="!O<&5R871I;VYS(')E;&%T960@=&\@;W5R('!R:6UA<GD@<V5R
M=FEC92!O9F9E<FEN9W,N)B,Q-C`[(%1H92!L96%S92!E>'!I<F5S(&EN($IU
M;F4@,C`Q-"XF(S$V,#M792!I;F-U<G)E9"`D-C4L,#`P(&%N9"`D-3,L,#`P
M(&]F(')E;G1A;"!C;W-T<R!R96QA=&EV92!T;R!T:&ES(&QE87-E(&EN(&9I
M<V-A;"`R,#$R(&%N9"`R,#$Q+"!R97-P96-T:79E;'DN/"]T9#X-"CPO='(^
M#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@
M;6%R9VEN.B`P<'0@,'!X(#!P="`R-W!T.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'1A8FQE('-T
M>6QE/3-$)VUA<F=I;BUT;W`Z(#!P=#L@=VED=&@Z(#$P,"4[(&9O;G0Z(#$P
M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;BUB;W1T
M;VTZ(#!P=#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#LG/@T*/'1D('-T>6QE
M/3-$)W=I9'1H.B`Y<'0[)SX\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`P
M+C(U:6X[)SX\9F]N=#XF(S$X,SL\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!J=7-T:69Y.R<^,3<@2&%T:61H87(@4W1R965T+"!2
M828C.#(Q-SMA;F%N82P@27-R865L+"!W:&EC:"!C;VYS:7-T<R!O9B!A<'!R
M;WAI;6%T96QY(#$L-3`P('-Q=6%R92!F965T(&%N9"!S97)V97,@87,@;V9F
M:6-E(&AE861Q=6%R=&5R<R!F;W(@0VAA;7!I;VYS($]N8V]L;V=Y+"!)<W)A
M96PN(%1H92!L96%S92!E>'!I<F5S(&EN($IU;'D@,C`Q,CL@:&]W979E<B!T
M:&4@0V]M<&%N>2!P;&%N<R!T;R!E>'1E;F0@=&AI<R!L96%S92X@5V4@:6YC
M=7)R960@)#(Y+#`P,"!A;F0@)#$Q+#`P,"!O9B!R96YT86P@8V]S=',@<F5L
M871I=F4@=&\@=&AI<R!L96%S92!I;B!F:7-C86P@,C`Q,B!A;F0@,C`Q,2P@
M<F5S<&5C=&EV96QY+CPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@9F]N
M=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P
M.SPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M
M:6YD96YT.B`Y<'0[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE
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M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG
M/3-$,#X-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@=VED=&@Z(#@R)3LG/C(P,3,\+W1D/@T*/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$U)3LG/C$V
M,BPP,#`\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I
M9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A
M8VMG<F]U;F0M8V]L;W(Z('=H:71E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB
M;W1T;VTZ(#%P=#LG/C(P,30\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#LG/C$T,2PP,#`\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T
M=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B
M86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
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M9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT
M.R<^,S`S+#`P,#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^
M#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@
M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R<^/&(^/&D^)B,Q-C`[/"]I/CPO8CX\+W`^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[
M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY!
M<R!W92!I;G1E;F0@=&\@97AT96YD('1H92!L96%S92!I;B!)<W)A96PL(&]F
M('1H92!M:6YI;75M(&QE87-E('!A>6UE;G1S(&EN('1H92!T86)L92!A8F]V
M92P@)#(X+#`P,"!A;F0@)#<L,#`P(')E;&%T92!T;R!A;G1I8VEP871E9"!F
M=71U<F4@;&5A<V4@<&%Y;65N=',@:6X@9FES8V%L(#(P,3,@86YD(#(P,30L
M(')E<W!E8W1I=F5L>2X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J
M=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\8CX\:3XF(S$V,#L\+VD^/"]B/CPO
M<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@
M,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CLG/CQB/CQI/E)E<V5A<F-H(&%N9"!$979E;&]P;65N="!-871E<FEA
M;',@4'5R8VAA<V4@06=R965M96YT/"]I/CPO8CX\+W`^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\
M+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN
M9&5N=#H@.7!T.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY);B!&96)R=6%R>2`R,#$P+"!T
M:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!R97-E87)C:"!A;F0@9&5V96QO
M<&UE;G0@;6%T97)I86QS('!U<F-H87-E(&%G<F5E;65N="!W:71H(&$@9F]R
M96EG;B!H;W-P:71A;"!F;W(@=&AE(&%C<75I<VET:6]N(&]F(%1U;6]R1W)A
M9G1S+B8C,38P.R8C,38P.U5N9&5R('1H92!A9W)E96UE;G0L('1H92!#;VUP
M86YY(&UA9&4@;6]N=&AL>2!P87EM96YT<R!T;R!T:&4@9F]R96EG;B!H;W-P
M:71A;"!O9B!A<'!R;WAI;6%T96QY("0S-RPP,#`L(&-O;6UE;F-I;F<@36%R
M8V@@,2P@,C`Q,"!A;F0@96YD:6YG($%P<FEL(#$L(#(P,3$N)B,Q-C`[)B,Q
M-C`[5&AE(&%C8W)U960@;&EA8FEL:71Y(&]U='-T86YD:6YG(&%T($%P<FEL
M(#,P+"`R,#$Q('=A<R`D,30W+#`P,"X@5&AE($-O;7!A;GD@96YT97)E9"!I
M;G1O(&$@375T=6%L(%)E;&5A<V4@06=R965M96YT(&]N($1E8V5M8F5R(#$U
M+"`R,#$Q(&%N9"!R979E<G-E9"!T:&ES(&QI86)I;&ET>2X\+W`^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[
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M>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`Y<'0[(&UA<F=I;CH@
M,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CLG/E1H92!#;VUP86YY(&ES('!A<G1Y('1O(&-E<G1A:6X@;&5G86P@
M;6%T=&5R<R!A<FES:6YG(&EN('1H92!O<F1I;F%R>2!C;W5R<V4@;V8@:71S
M(&)U<VEN97-S+B8C,38P.R8C,38P.U1H92!#;VUP86YY(&AA<R!E=F%L=6%T
M960@:71S('!O=&5N=&EA;"!E>'!O<W5R92!T;R!T:&5S92!L96=A;"!M871T
M97)S(&%N9"!N;W1E9"!N;R!S=6-H(&5X<&]S=7)E<RX@5&AE($-O;7!A;GD@
M:7,@;F]T(&%W87)E(&]F(&%N>2!O=&AE<B!M871T97)S('1H870@=V]U;&0@
M:&%V92!A(&UA=&5R:6%L(&EM<&%C="!O;B!T:&4@0V]M<&%N>28C.#(Q-SMS
M(&9I;F%N8VEA;"!P;W-I=&EO;B!O<B!R97-U;'1S(&]F(&]P97)A=&EO;G,N
M/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI
M;F1E;G0Z(#EP=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^/&D^/"]I/CPO8CXF(S$V
M,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G
M:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[)SX\8CX\:3Y296=I<W1R871I;VX@4&%Y;65N="!!<G)A;F=E
M;65N=',\+VD^/"]B/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU
M<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@
M<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`Y<'0[(&UA<F=I
M;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S
M+"!S97)I9CLG/E1H92!#;VUP86YY(&AA<R!E;G1E<F5D(&EN=&\@<F5G:7-T
M<F%T:6]N(')I9VAT<R!A9W)E96UE;G1S(&EN(&-O;FYE8W1I;VX@=VET:"!A
M('!R:79A=&4@<&QA8V5M96YT(&]F(&ET<R!S96-U<FET:65S+"!W:&EC:"!C
M;&]S960@9'5R:6YG($%P<FEL(#(P,3$@86YD(&ES(&1I<V-U<W-E9"!M;W)E
M(&9U;&QY(&EN($YO=&4@-RXF(S$V,#LF(S$V,#M4:&ES(')E9VES=')A=&EO
M;B!R:6=H=',@86=R965M96YT(&-O;G1A:6YS('!R;W9I<VEO;G,@=&AA="!M
M87D@8V%L;"!F;W(@=&AE($-O;7!A;GD@=&\@<&%Y('!E;F%L=&EE<R!I;B!C
M97)T86EN(&-I<F-U;7-T86YC97,N)B,Q-C`[)B,Q-C`[5&AI<R!R96=I<W1R
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M)B,Q-C`[)B,Q-C`[5&AE($-O;7!A;GD@9&]E<R!N;W0@8F5L:65V92!I="!I
M<R!P<F]B86)L92!T:&%T('!E;F%L='D@<&%Y;65N=',@=VEL;"!B92!M861E
M(&9O<B!T:&4@<F5G:7-T<F%T:6]N(')I9VAT<R!A9W)E96UE;G0@9&ES8W5S
M<V5D(&%B;W9E(&%N9"P@86-C;W)D:6YG;'DL(&AA<R!N;W0@86-C<G5E9"!F
M;W(@<W5C:"!P;W1E;G1I86P@<&5N86QT:65S(&%S(&]F($%P<FEL(#,P+"`R
M,#$R(&%N9"`R,#$Q+CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7V5D86(P93(V7S,P-&9?-#,U,5]B93AE7S-C,F$Y-&9F
M9F9C,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E9&%B,&4R-E\S
M,#1F7S0S-3%?8F4X95\S8S)A.31F9F9F8S`O5V]R:W-H965T<R]3:&5E=#$S
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3&EC
M96YS:6YG($%G<F5E;65N=',\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D%P<BX@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^3&EC96YS:6YG($%G<F5E;65N=',@6T%B
M<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y,:6-E;G-I;F<@06=R965M96YT<R!$:7-C;&]S=7)E(%M497AT($)L
M;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^3F]T
M92`U+B!,:6-E;G-I;F<@06=R965M96YT<SPO8CX\+W`^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\
M+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN
M9&5N=#H@.7!T.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY$=7)I;F<@9FES8V%L(#(P,3$L
M('1H92!#;VUP86YY('=A<R!A('!A<G1Y('1O('-E=F5R86P@9&EF9F5R96YT
M(&QI8V5N<VEN9R!A9W)E96UE;G1S+B!$=7)I;F<@07!R:6P@,C`Q,2P@=&AE
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M<FEN9R!!<')I;"`R,#$Q('=E<F4@<F5T=7)N960@=&\@=&AE('5N9&5R;'EI
M;F<@8V]M<&%N:65S(&%N9"!N;R!A;6]U;G1S('=E<F4@<&%Y86)L92!U;F1E
M<B!T:&5S92!O=&AE<B!A9W)E96UE;G1S('=H96X@=&AE>2!W97)E('1E<FUI
M;F%T960N/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@
M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#EP=#L@;6%R9VEN.B`P<'0@
M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R<^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X
M="UI;F1E;G0Z(#EP=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^26X@1F5B<G5A<GD@,C`Q
M,"P@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&%N(&5X8VQU<VEV92!O<'1I
M;VX@86=R965M96YT('=I=&@@82!#86YA9&EA;B!C;VUP86YY(&9O<B!W:&EC
M:"!I="!P86ED(&%N9"!E>'!E;G-E9"`D-#`L,#`P("A#86YA9&EA;BD@9'5R
M:6YG('1H92!#;VUP86YY)B,X,C$W.W,@9FES8V%L(#(P,3`@>65A<BX@5&AE
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M;W!A<G1I8VQE(&-O;7!O=6YD+B!);B!-87)C:"`R,#$Q+"!T:&4@0V]M<&%N
M>2!E>&5R8VES960@:71S(&]P=&EO;B!T;R!L:6-E;G-E($ER:6YO<&AO<F4@
M0RP@82!L:7!O<V]M86P@9F]R;75L871I;VX@;V8@27)I;F]T96-A;BX@56YD
M97(@=&AE('1E<FUS(&]F('1H92!A9W)E96UE;G0L('1H92!#;VUP86YY)B,X
M,C$W.W,@97AE<F-I<V4@;V8@=&AE(&]P=&EO;B!R97-U;'1E9"!I;B!A;6]U
M;G1S(&1U92!T;R!T:&4@0V%N861I86X@8V]M<&%N>2!O9B`D.#4L,#`P("A#
M86YA9&EA;BD@8V]M<')I<V5D(&]F('1H92!O<'1I;VX@97AE<F-I<V4@<')I
M8V4@86YD(')E:6UB=7)S96UE;G0@=&\@=&AE($-A;F%D:6%N(&-O;7!A;GD@
M9F]R('!A<W0@<&%T96YT(&-O<W1S+"!W:&EC:"!W87,@97AP96YS960@:6X@
M=&AE($-O;7!A;GDF(S@R,3<[<R!F:7-C86P@>65A<B!E;F1E9"!!<')I;"`S
M,"P@,C`Q,2X@5&AE($-O;7!A;GD@<V%T:7-F:65D('1H:7,@;V)L:6=A=&EO
M;B!D=7)I;F<@9FES8V%L(#(P,3(N($]N('1H92!F:7)S="!A;FYI=F5R<V%R
M>2!O9B!T:&4@86=R965M96YT("A-87)C:"`R,#$R*2P@86X@861D:71I;VYA
M;"!L:6-E;G-E(&9E92!O9B`D-#4L,#`P("A#86YA9&EA;BD@8F5C86UE(&1U
M92P@=VAI8V@@:7,@<F5C;V=N:7IE9"!A<R!A(&QI86)I;&ET>2!A<R!O9B!!
M<')I;"`S,"P@,C`Q,BX@0V]M;65N8VEN9R!W:71H('1H92!S96-O;F0@86YN
M:79E<G-A<GD@;V8@=&AE(&%G<F5E;65N="`H36%R8V@@,C`Q,RDL('1H92!#
M;VUP86YY('=I;&P@8F4@;V)L:6=A=&5D('1O('!A>2!A(&UI;FEM=6T@86YN
M=6%L(')O>6%L='D@;V8@)#$P+#`P,"`H0V%N861I86XI+B!5;F1E<B!T:&4@
M=&5R;7,@;V8@=&AE(&QI8V5N<V4@86=R965M96YT+"!T:&4@0V]M<&%N>2!W
M:6QL(&)E(')E<75I<F5D('1O('!A>2!U<"!T;R`D,RXP(&UI;&QI;VX@:6X@
M9&5V96QO<&UE;G0@;6EL97-T;VYE<RP@:68@86-H:65V960N(%5P;VX@8V]M
M;65R8VEA;&EZ871I;VXL('1H92!#;VUP86YY('=O=6QD(&%L<V\@8F4@<F5Q
M=6ER960@=&\@;6%K92!R;WEA;'1Y(&%N9"!S86QE<R!M:6QE<W1O;F4@<&%Y
M;65N=',@8F%S960@=7!O;B!R979E;G5E<RX\+W`^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E9&%B,&4R-E\S,#1F7S0S-3%?
M8F4X95\S8S)A.31F9F9F8S`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O
M0SHO961A8C!E,C9?,S`T9E\T,S4Q7V)E.&5?,V,R83DT9F9F9F,P+U=O<FMS
M:&5E=',O4VAE970Q-"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG
M.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@
M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/E-H87)E+4)A<V5D(%!A>6UE;G1S/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y!<'(N(#,P+"`R,#$R/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1I<V-L;W-U<F4@
M3V8@0V]M<&5N<V%T:6]N(%)E;&%T960@0V]S=',L(%-H87)E+4)A<V5D(%!A
M>6UE;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1&ES8VQO<W5R92!O9B!#;VUP96YS871I;VX@4F5L
M871E9"!#;W-T<RP@4VAA<F4M8F%S960@4&%Y;65N=',@6U1E>'0@0FQO8VM=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=T
M97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P
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M.B`Y<'0[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@
M<F]M86XL('1I;65S+"!S97)I9CLG/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO
M;B!I;B!T:&4@86UO=6YT(&]F("0S+C,@;6EL;&EO;B!A;F0@)#,N,2!M:6QL
M:6]N('=A<R!R96-O9VYI>F5D(&9O<B!T:&4@>65A<G,@96YD960@07!R:6P@
M,S`L(#(P,3(@86YD(#(P,3$L(')E<W!E8W1I=F5L>2XF(S$V,#LF(S$V,#M3
M=&]C:RUB87-E9"!C;VUP96YS871I;VX@8V]S=',@=V5R92!R96-O<F1E9"!A
M<R!F;VQL;W=S("AI;B!T:&]U<V%N9',I.CPO<#X-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-
M"CQT86)L92!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=W:61T:#H@.3`E.R!B
M;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP
M861D:6YG/3-$,#X-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG(&YO=W)A
M<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P/3-$;F]W
M<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&9O;G0M=V5I
M9VAT.B!B;VQD.R<@8V]L<W!A;CTS1#8@;F]W<F%P/3-$;F]W<F%P/EEE87(@
M16YD960@07!R:6P@,S`L/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A
M<#XF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W
M<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([
M(&9O;G0M=V5I9VAT.B!B;VQD.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W
M<F%P/C(P,3(\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N
M="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[
M('1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS
M<&%N/3-$,B!N;W=R87`],T1N;W=R87`^,C`Q,3PO=&0^#0H\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[)R!N
M;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-
M"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N
M;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[
M/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,B!N;W=R
M87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^
M)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC
M;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`W-"4[)SY'96YE
M<F%L(&%N9"!A9&UI;FES=')A=&EV93PO=&0^#0H\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!W:61T:#H@,24[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$P)3LG/C,L,#`Y/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)#PO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q
M,"4[)SXR+#@X-SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4]
M,T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^4V%L
M97,@86YD(&UA<FME=&EN9SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C(T,#PO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C$P
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M(&QE9G0[)SY43U,@8V]S="!O9B!S86QE<SPO=&0^#0H\=&0^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C$P/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
M"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R<^-#`\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD
M+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ
M(#%P=#LG/E!/4R!C;W-T(&]F('-A;&5S/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ
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M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^+3PO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ
M(#%P=#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG
M<F]U;F0M8V]L;W(Z('=H:71E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^
M#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
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M<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M
M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^
M,RPS,C,\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A
M9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E
M>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT
M.R<^,RPQ,S,\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*
M/"]T86)L93X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA
M<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I
M;65S+"!S97)I9CLG/CQB/CQI/B8C,38P.SPO:3X\+V(^/"]P/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^
M/&D^,C`Q,"!%<75I='D@26YC96YT:79E(%!L86X\+VD^/"]B/CPO<#X-"CQP
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P
M>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG
M/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[
M('1E>'0M:6YD96YT.B`Y<'0[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/D]N($9E8G)U87)Y
M(#$X+"`R,#$Q+"!S:&%R96AO;&1E<G,@;W=N:6YG(&$@;6%J;W)I='D@;V8@
M=&AE(&ES<W5E9"!A;F0@;W5T<W1A;F1I;F<@<VAA<F5S(&]F('1H92!#;VUP
M86YY(&5X96-U=&5D(&$@=W)I='1E;B!C;VYS96YT(&%P<')O=FEN9R!T:&4@
M,C`Q,"!%<75I='D@26YC96YT:79E(%!L86X@*"8C.#(R,#LR,#$P($5Q=6ET
M>2!0;&%N)B,X,C(Q.RDN(%1H92!P=7)P;W-E(&]F('1H92`R,#$P($5Q=6ET
M>2!0;&%N(&ES('1O(&=R86YT("AI*2!.;VXM<W1A='5T;W)Y(%-T;V-K($]P
M=&EO;G,[("AI:2D@4F5S=')I8W1E9"!3=&]C:R!!=V%R9',[(&%N9"`H:6EI
M*2!3=&]C:R!!<'!R96-I871I;VX@4FEG:'1S("AC;VQL96-T:79E;'DL('-T
M;V-K+6)A<V5D(&-O;7!E;G-A=&EO;BD@=&\@:71S(&5M<&QO>65E<RP@9&ER
M96-T;W)S(&%N9"!N;VXM96UP;&]Y965S+B!4;W1A;"!S=&]C:R!A=V%R9',@
M=6YD97(@=&AE(#(P,3`@17%U:71Y(%!L86X@<VAA;&P@;F]T(&5X8V5E9"`S
M,"PP,#`L,#`P('-H87)E<R!O9B!C;VUM;VX@<W1O8VLN($]P=&EO;G,@86YD
M(%-T;V-K($%P<')E8VEA=&EO;B!2:6=H=',@97AP:7)E(&YO(&QA=&5R('1H
M86X@=&5N('EE87)S(&9R;VT@=&AE(&1A=&4@;V8@9W)A;G0@86YD('1H92!A
M=V%R9',@=F5S="!A<R!D971E<FUI;F5D(&)Y('1H92!";V%R9"!O9B!$:7)E
M8W1O<G,N($]P=&EO;G,@86YD(%-T;V-K($%P<')E8VEA=&EO;B!2:6=H=',@
M:&%V92!A('-T<FEK92!P<FEC92!N;W0@;&5S<R!T:&%N(#$P,"4@;V8@=&AE
M(&9A:7(@;6%R:V5T('9A;'5E(&]F('1H92!C;VUM;VX@<W1O8VL@<W5B:F5C
M="!T;R!T:&4@;W!T:6]N(&]R(')I9VAT(&%T('1H92!D871E(&]F(&=R86YT
M+CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M
M:6YD96YT.B`Y<'0[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE
M<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQB
M/CQI/C(P,#@@17%U:71Y($EN8V5N=&EV92!0;&%N/"]I/CPO8CX\+W`^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P
M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y
M.R!T97AT+6EN9&5N=#H@.7!T.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P
M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY4:&4@0V]M<&%N
M>2!H87,@<')E=FEO=7-L>2!G<F%N=&5D("AI*2!.;VXM<W1A='5T;W)Y(%-T
M;V-K($]P=&EO;G,[("AI:2D@4F5S=')I8W1E9"!3=&]C:R!!=V%R9',[(&%N
M9"`H:6EI*2!3=&]C:R!!<'!R96-I871I;VX@4FEG:'1S("AC;VQL96-T:79E
M;'DL('-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;BD@=&\@:71S(&5M<&QO>65E
M<RP@9&ER96-T;W)S(&%N9"!N;VXM96UP;&]Y965S('5N9&5R(&$@,C`P."!%
M<75I='D@26YC96YT:79E(%!L86X@*'1H92`F(S@R,C`[,C`P."!%<75I='D@
M4&QA;B8C.#(R,3LI+B8C,38P.R8C,38P.U-U8V@@87=A<F1S(&UA>2!B92!G
M<F%N=&5D(&)Y('1H92!#;VUP86YY)B,X,C$W.W,@0F]A<F0@;V8@1&ER96-T
M;W)S+B8C,38P.R8C,38P.T]P=&EO;G,@9W)A;G1E9"!U;F1E<B!T:&4@,C`P
M."!%<75I='D@4&QA;B!E>'!I<F4@;F\@;&%T97(@=&AA;B!T96X@>65A<G,@
M9G)O;2!T:&4@9&%T92!O9B!G<F%N="!A;F0@=&AE(&%W87)D<R!V97-T(&%S
M(&1E=&5R;6EN960@8GD@=&AE($)O87)D(&]F($1I<F5C=&]R<RX\+W`^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P
M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y
M.R!T97AT+6EN9&5N=#H@.7!T.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P
M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY&;W(@<VAA<F4M
M8F%S960@<&%Y;65N=',@=&\@;F]N+65M<&QO>65E(&-O;G-U;'1A;G1S('5N
M9&5R(&)O=&@@=&AE(#(P,3`@86YD(#(P,#@@17%U:71Y($EN8V5N=&EV92!0
M;&%N+"!T:&4@9F%I<B!V86QU92!O9B!T:&4@<VAA<F4M8F%S960@8V]N<VED
M97)A=&EO;B!I<W-U960@:7,@=7-E9"!T;R!M96%S=7)E('1H92!T<F%N<V%C
M=&EO;BP@87,@;6%N86=E;65N="!B96QI979E<R!T:&ES('1O(&)E(&$@;6]R
M92!R96QI86)L92!M96%S=7)E(&]F(&9A:7(@=F%L=64@=&AA;B!T:&4@<V5R
M=FEC97,@<F5C96EV960N)B,Q-C`[)B,Q-C`[5&AE(&9A:7(@=F%L=64@;V8@
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M;G-A=&EO;B!0;&%N/"]I/CPO8CX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM
M97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@.7!T
M.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[)SY/;B!&96)R=6%R>2`R,BP@,C`Q,"P@=&AE($-O
M;7!E;G-A=&EO;B!#;VUM:71T964@;V8@=&AE($)O87)D(&]F($1I<F5C=&]R
M<R!O9B!T:&4@0V]M<&%N>2!A9&]P=&5D('1H92!$:7)E8W1O<B!#;VUP96YS
M871I;VX@4&QA;B!O9B`R,#$P("AT:&4@)B,X,C(P.T1I<F5C=&]R(%!L86XF
M(S@R,C$[*2!T;R!R97!L86-E('1H92!#;VUP86YY)B,X,C$W.W,@9F]R;65R
M(&-O;7!E;G-A=&EO;B!P;VQI8WD@9F]R(&1I<F5C=&]R<RP@969F96-T:79E
M(&9O<B!T:&4@,C`Q,"!C86QE;F1A<B!Y96%R(&-O;6UE;F-I;F<@2F%N=6%R
M>2`Q+"`R,#$P+B8C,38P.R8C,38P.U5N9&5R('1H92!$:7)E8W1O<B!0;&%N
M+"!I;F1E<&5N9&5N="!D:7)E8W1O<G,@;V8@=&AE($-O;7!A;GD@87)E(&5N
M=&ET;&5D('1O(&%N(&%N;G5A;"!A=V%R9"!O9B!F:79E+7EE87(@<W1O8VL@
M;W!T:6]N<R!T;R!P=7)C:&%S92`U,"PP,#`@<VAA<F5S(&]F('1H92!#;VUP
M86YY)B,X,C$W.W,@=6YR96=I<W1E<F5D(&-O;6UO;B!S=&]C:RP@86YD('1H
M92!#:&%I<FUA;B!O9B!T:&4@0F]A<F0@;V8@=&AE($-O;7!A;GD@:7,@96YT
M:71L960@=&\@86X@86YN=6%L(&%W87)D(&]F(&]P=&EO;G,@=&\@<'5R8VAA
M<V4@,3`P+#`P,"!S:&%R97,@;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!U;G)E
M9VES=&5R960@8V]M;6]N('-T;V-K+B8C,38P.R8C,38P.TEN9&5P96YD96YT
M(&1I<F5C=&]R<R!W:&\@<V5R=F4@;VX@;VYE(&]R(&UO<F4@0F]A<F0@8V]M
M;6ET=&5E<R!W:6QL(&%L<V\@<F5C96EV92!A;B!A;FYU86P@9W)A;G0@;V8@
M9FEV92UY96%R(&]P=&EO;G,@=&\@<'5R8VAA<V4@-3`L,#`P('-H87)E<R!O
M9B!T:&4@0V]M<&%N>28C.#(Q-SMS('5N<F5G:7-T97)E9"!C;VUM;VX@<W1O
M8VL@;W(@-3`L,#`P('-H87)E<R!O9B!R97-T<FEC=&5D('5N<F5G:7-T97)E
M9"!C;VUM;VX@<W1O8VLN)B,Q-C`[)B,Q-C`[5&AE($-O;7!A;GD@=VEL;"!A
M;'-O('!A>2!E86-H(&EN9&5P96YD96YT(&1I<F5C=&]R("0Q-2PP,#`@=&\@
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M('1E>'0M:6YD96YT.B`Y<'0[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/D)L86-K+5-C:&]L
M97,@87-S=6UP=&EO;G,@=7-E9"!T;R!C86QC=6QA=&4@=&AE(&9A:7(@=F%L
M=64@;V8@;W!T:6]N<R!G<F%N=&5D(&1U<FEN9R!T:&4@>65A<G,@96YD960@
M07!R:6P@,S`L(#(P,3(@86YD(#(P,3$@=V5R92!A<R!F;VQL;W=S.CPO<#X-
M"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T
M(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CLG/B8C,38P.SPO<#X-"CQT86)L92!A;&EG;CTS1&-E;G1E<B!S='EL93TS
M1"=W:61T:#H@.3`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD
M.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C
M96YT97([(&9O;G0M=V5I9VAT.B!B;VQD.R<@8V]L<W!A;CTS1#8@;F]W<F%P
M/3-$;F]W<F%P/EEE87(@16YD960@07!R:6P@,S`L/"]T9#X-"CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG
M(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I
M9VAT.B!B;VQD.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT
M+6%L:6=N.B!C96YT97([(&9O;G0M=V5I9VAT.B!B;VQD.R<@8V]L<W!A;CTS
M1#(@;F]W<F%P/3-$;F]W<F%P/C(P,3(\+W1D/@T*/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P
M/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R
M87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG
M:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^,C`Q,3PO
M=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW
M96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*
M/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
M=&5R.R<@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D
M/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M8V5N=&5R.R<@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\
M+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C
M8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#8T)3LG/D5X<&5C=&5D('1E
M<FT@:6X@>65A<G,\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED
M=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([('=I9'1H.B`Q-24[)R!N;W=R87`],T1N;W=R87`^,RXP("T@
M-BXP/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T
M:#H@,24[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=W:61T:#H@,24[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)R!N
M;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([('=I9'1H.B`Q-24[)R!N;W=R87`],T1N;W=R87`^
M,BXW("T@-BXR-3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4]
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M86QI9VXZ(&QE9G0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R
M87`^,"XY)2`M(#(N-R4\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K
M9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/E9O;&%T:6QI
M='D\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R<@;F]W<F%P/3-$;F]W<F%P/CDP)2`M(#$P."4\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)R!N;W=R87`],T1N
M;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<@;F]W<F%P
M/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R<@;F]W<F%P/3-$;F]W<F%P/C$P-24@+2`Q,C(E/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
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M<F%P/3-$;F]W<F%P/C`E/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<@;F]W<F%P/3-$;F]W<F%P/CPO=&0^#0H\=&0@;F]W<F%P/3-$
M;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG(&YO=W)A<#TS1&YO=W)A<#XP)3PO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CPO=&0^#0H\
M+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#EP=#L@;6%R9VEN.B`P
M<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
M<FEF.R<^5&AE('=E:6=H=&5D(&%V97)A9V4@9F%I<B!V86QU92!O9B!S=&]C
M:R!O<'1I;VYS(&=R86YT960@9'5R:6YG('1H92!Y96%R<R!E;F1I;F<@07!R
M:6P@,S`L(#(P,3(@86YD(#(P,3$L('=A<R`D,"XU."!A;F0@)#`N-S,L(')E
M<W!E8W1I=F5L>2X@5&AE($-O;7!A;GDF(S@R,3<[<R!S=&]C:R!O<'1I;VYS
M(&%C=&EV:71Y(&%N9"!R96QA=&5D(&EN9F]R;6%T:6]N(&%S(&]F(&%N9"!F
M;W(@=&AE('EE87)S(&5N9&5D($%P<FEL(#,P+"`R,#$R(&%N9"`R,#$Q(&ES
M(&%S(&9O;&QO=W,@*&1O;&QA<G,@:6X@=&AO=7-A;F1S*3H\+W`^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@.7!T
M.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\=&%B;&4@86QI9VX],T1C
M96YT97(@<W1Y;&4],T0G=VED=&@Z(#DP)3L@8F]R9&5R+6-O;&QA<'-E.B!C
M;VQL87!S93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CLG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('9E<G1I8V%L+6%L:6=N.B!T;W`[)R!N
M;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z
M(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T
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M)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!C96YT97([(&9O;G0M=V5I9VAT.B!B;VQD.R<@8V]L<W!A
M;CTS1#(@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A
M<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N
M;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
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M:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R
M87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L
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M(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M=V5I9VAT.B!B;VQD.R<@
M8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#LG
M(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N
M/3-$,B!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
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M="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO
M=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R87`]
M,T1N;W=R87`^079E<F%G93PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UW96EG
M:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R
M87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L
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M(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M=V5I9VAT.B!B;VQD.R<@
M8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/D1I<F5C=&]R<SPO=&0^#0H\
M=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R
M87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L
M9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS
M<&%N/3-$,B!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
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M=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R
M87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([(&9O;G0M=V5I9VAT.B!B;VQD.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$
M;F]W<F%P/D%G9W)E9V%T93PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UW96EG
M:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CPO='(^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('9E<G1I8V%L+6%L:6=N.B!T
M;W`[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW
M96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^3F]N
M+3PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R
M87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E
M:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O
M;&0[)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^86YD/"]T9#X-"CQT
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M87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
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M="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO
M=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R87`]
M,T1N;W=R87`^26YT<FEN<VEC/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E
M:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=F5R=&EC86PM86QI9VXZ
M('1O<#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@
M;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT
M97([(&9O;G0M=V5I9VAT.B!B;VQD.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$
M;F]W<F%P/D5M<&QO>65E<SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R
M87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,7!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P
M="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+7=E:6=H=#H@8F]L
M9#LG(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#Y%;7!L;WEE97,\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I
M9VAT.B!B;VQD.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O
M;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ
M(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R
M87`],T1N;W=R87`^5&]T86P\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P/3-$;F]W
M<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O
M;&0[)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^4')I8V4\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT
M.B!B;VQD.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[
M)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E
M;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R87`]
M,T1N;W=R87`^3&EF92`H665A<G,I/"]T9#X-"CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS
M1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P/3-$;F]W<F%P
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M1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D
M9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6EN9&5N=#H@+3`N,6EN.R!P861D
M:6YG+6QE9G0Z(#`N,6EN.R!W:61T:#H@,C(E.R!V97)T:6-A;"UA;&EG;CH@
M=&]P.R<^3W5T<W1A;F1I;F<L($UA>2`Q+"`R,#$Q/"]T9#X-"CQT9"!S='EL
M93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q,"4[)SXQ+#8Q
M,"PP,#`\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I
M9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R!W:61T:#H@,3`E.R<^,3(L-S$P+#DT.#PO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M('=I9'1H.B`Q,"4[)SXQ-"PS,C`L.30X/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)#PO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q,"4[)SXP+C@X
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@
M,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED
M=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#L@=VED=&@Z(#$P)3LG/C@N-#PO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B0\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3`E.R<^,2PW
M.#`\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H
M.B`Q)3LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG
M<F]U;F0M8V]L;W(Z('=H:71E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T
M;VTZ(#(N-7!T.R!T97AT+6EN9&5N=#H@+3`N,6EN.R!P861D:6YG+6QE9G0Z
M(#`N,6EN.R!V97)T:6-A;"UA;&EG;CH@=&]P.R<^1W)A;G1E9#PO=&0^#0H\
M=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#LG/C$Q-2PP,#`\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[)SXQ+#,X,"PP,#`\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXQ
M+#0Y-2PP,#`\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[)SXP+C<W/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C
M:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M8F]T=&]M.B`R+C5P=#L@=&5X="UI;F1E;G0Z("TP+C%I;CL@<&%D9&EN9RUL
M969T.B`P+C%I;CL@=F5R=&EC86PM86QI9VXZ('1O<#LG/D5X97)C:7-E9#PO
M=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#LG/B@U,"PP,#`\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SXI/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^+3PO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/B@U,"PP,#`\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXI/"]T9#X-
M"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R<^,"XQ-SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
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M97AT+6EN9&5N=#H@+3`N,6EN.R!P861D:6YG+6QE9G0Z(#`N,6EN.R!V97)T
M:6-A;"UA;&EG;CH@=&]P.R<^1F]R9F5I=&5D/"]T9#X-"CQT9#XF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^+3PO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^
M#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#LG/B@S-#@L-3@Q/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^*3PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#LG/B@S-#@L-3@Q/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^*3PO=&0^#0H\=&0^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C`N.30\+W1D
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M"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6EN9&5N=#H@
M+3`N,6EN.R!P861D:6YG+6QE9G0Z(#`N,6EN.R!V97)T:6-A;"UA;&EG;CH@
M=&]P.R<^17AP:7)E9#PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^*#(V-2PP,#`\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`Q<'0[)SXI/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S
M;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[)SXH,C@V+#,R.3PO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P
M=#LG/BD\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
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M=&5X="UA;&EG;CH@<FEG:'0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXP+C8P
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG
M+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[
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M="UA;&EG;CH@<FEG:'0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS
M1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('9E<G1I
M8V%L+6%L:6=N.B!T;W`[)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
M/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
M/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F
M9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT
M+6EN9&5N=#H@+3`N,6EN.R!P861D:6YG+6QE9G0Z(#`N,6EN.R!V97)T:6-A
M;"UA;&EG;CH@=&]P.R<^3W5T<W1A;F1I;F<L($%P<FEL(#,P+"`R,#$R/"]T
M9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N
M-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE
M.R!T97AT+6%L:6=N.B!R:6=H=#LG/C$L-#$P+#`P,#PO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
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M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[
M)SXQ-"PX-C8L,#,X/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T
M;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^,"XX.#PO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T
M;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('!A9&1I
M;F<M8F]T=&]M.B`R+C5P=#LG/C<N-CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A
M9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E
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M8V%L+6%L:6=N.B!T;W`[)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^
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M/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F
M9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT
M+6EN9&5N=#H@+3`N,6EN.R!P861D:6YG+6QE9G0Z(#`N,6EN.R!V97)T:6-A
M;"UA;&EG;CH@=&]P.R<^5F5S=&5D(&%N9"!E>'!E8W1E9"!T;R!V97-T(&%S
M(&]F($%P<FEL(#,P+"`R,#$R/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@
M;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG/C$L
M-#$P+#`P,#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@
M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N
M.B!R:6=H=#LG/C$S+#0U-BPP,S@\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
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M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@<&%D9&EN9RUB;W1T
M;VTZ(#(N-7!T.R<^,"XX.#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/C<N-CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB
M;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B0\
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M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M,"XQ:6X[('!A9&1I;F<M
M;&5F=#H@,"XQ:6X[('9E<G1I8V%L+6%L:6=N.B!T;W`[)SXF(S$V,#L\+W1D
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M9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB
M;W1T;VTZ(#(N-7!T.R!T97AT+6EN9&5N=#H@+3`N,6EN.R!P861D:6YG+6QE
M9G0Z(#`N,6EN.R!V97)T:6-A;"UA;&EG;CH@=&]P.R<^17AE<F-I<V%B;&4@
M87,@;V8@07!R:6P@,S`L(#(P,3(\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^
M,2PR-#$L-C8W/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE
M.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI
M9VXZ(')I9VAT.R<^-BPU,#(L,38S/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B
M;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^-RPW-#,L.#,P/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU
M<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@<&%D9&EN9RUB;W1T
M;VTZ(#(N-7!T.R<^,"XX.3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/C8N.#PO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB
M;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B0\
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M<F]M86XL('1I;65S+"!S97)I9CLG/CQB/B8C,38P.SPO8CX\+W`^#0H\=&%B
M;&4@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=VED=&@Z(#DP)3L@8F]R9&5R
M+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M
M86XL('1I;65S+"!S97)I9CLG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('9E<G1I8V%L+6%L
M:6=N.B!T;W`[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R
M87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L
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M96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M=V5I9VAT.B!B
M;VQD.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N
M;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@
M8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C
M;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S
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M,T0G9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A
M<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N
M;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
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M9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M=V5I
M9VAT.B!B;VQD.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R
M87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E
M:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O
M;&0[)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-
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M<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#LG
M(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N
M/3-$,B!N;W=R87`],T1N;W=R87`^079E<F%G93PO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A
M<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N
M;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
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M9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M=V5I
M9VAT.B!B;VQD.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/D1I<F5C
M=&]R<SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[)R!N
M;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z
M(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T
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M;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([(&9O;G0M=V5I9VAT.B!B;VQD.R<@8V]L<W!A;CTS
M1#(@;F]W<F%P/3-$;F]W<F%P/D%G9W)E9V%T93PO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[
M/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('9E<G1I
M8V%L+6%L:6=N.B!T;W`[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO
M=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R87`]
M,T1N;W=R87`^3F]N+3PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z
M(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N
M="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^
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M(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
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M<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#LG
M(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N
M/3-$,B!N;W=R87`],T1N;W=R87`^26YT<FEN<VEC/"]T9#X-"CQT9"!S='EL
M93TS1"=F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V
M,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=F5R
M=&EC86PM86QI9VXZ('1O<#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I
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M;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS
M1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT
M+7=E:6=H=#H@8F]L9#LG(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#Y%
M;7!L;WEE97,\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N
M="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[
M('1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS
M<&%N/3-$,B!N;W=R87`],T1N;W=R87`^5&]T86P\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@
M;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`]
M,T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N
M="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^
M4')I8V4\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
M(&9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW
M96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E
M>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N
M/3-$,B!N;W=R87`],T1N;W=R87`^3&EF92`H665A<G,I/"]T9#X-"CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L
M9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W
M<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([
M(&9O;G0M=V5I9VAT.B!B;VQD.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W
M<F%P/E9A;'5E/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,7!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V
M,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=F5R
M=&EC86PM86QI9VXZ('1O<#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N
M/3-$,CXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!C;VQS
M<&%N/3-$,CXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!C
M;VQS<&%N/3-$,CXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([
M)R!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\
M=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([)R!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^
M#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97([)R!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO
M=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-C
M8V9F8V,[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[('1E
M>'0M:6YD96YT.B`M,"XQ:6X[('!A9&1I;F<M;&5F=#H@,"XQ:6X[('=I9'1H
M.B`R,B4[('9E<G1I8V%L+6%L:6=N.B!T;W`[)SY/=71S=&%N9&EN9RP@36%Y
M(#$L(#(P,3`\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z
M(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@=VED=&@Z(#$P)3LG/C$L.#DP+#`P,#PO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q
M,"4[)SXQ+#0R-RPY-#@\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3`E.R<^,RPS,3<L.30X
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@
M,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED
M=&@Z(#$E.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[('=I9'1H.B`Q,"4[)SXP+C<W/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$P)3LG/C0N
M-#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z
M(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I
M9'1H.B`Q)3LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R!W:61T:#H@,3`E.R<^,C4P/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/"]T<CX-
M"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UI;F1E;G0Z("TP
M+C%I;CL@<&%D9&EN9RUL969T.B`P+C%I;CL@=F5R=&EC86PM86QI9VXZ('1O
M<#LG/D=R86YT960\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[)SXW,"PP,#`\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXQ,2PW
M.#$L,#`P/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R<^,3$L.#4Q+#`P,#PO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C`N.#D\
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M<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6EN9&5N
M=#H@+3`N,6EN.R!P861D:6YG+6QE9G0Z(#`N,6EN.R!V97)T:6-A;"UA;&EG
M;CH@=&]P.R<^17AE<F-I<V5D/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^+3PO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/BT\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[)SXM/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4]
M,T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D
M:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M:6YD96YT.B`M,"XQ:6X[('!A9&1I
M;F<M;&5F=#H@,"XQ:6X[('9E<G1I8V%L+6%L:6=N.B!T;W`[)SY&;W)F96ET
M960\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[)SXM/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^+3PO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
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M;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N
M-7!T.R!T97AT+6EN9&5N=#H@+3`N,6EN.R!P861D:6YG+6QE9G0Z(#`N,6EN
M.R!V97)T:6-A;"UA;&EG;CH@=&]P.R<^17AP:7)E9#PO=&0^#0H\=&0^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/B@U
M,#`L,#`P/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M*3PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#LG/B@S-#@L,#`P/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^*3PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/B@X-#@L,#`P/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^*3PO=&0^#0H\=&0^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C`N
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M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UI;F1E
M;G0Z("TP+C%I;CL@<&%D9&EN9RUL969T.B`P+C%I;CL@=F5R=&EC86PM86QI
M9VXZ('1O<#LG/D-H86YG92!I;B!E;7!L;WEE92!S=&%T=7,\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@
M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R
M:6=H=#LG/C$U,"PP,#`\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@
M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R
M:6=H=#LG/B@Q-3`L,#`P/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T.R<^*3PO=&0^#0H\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT
M.R<^+3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D
M9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('!A
M9&1I;F<M8F]T=&]M.B`Q<'0[)SXQ+C$X/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D
M:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
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M;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\
M+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C
M8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@=F5R=&EC86PM86QI9VXZ('1O<#LG/B8C
M,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^
M#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C
M,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE
M/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D
M9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6EN9&5N=#H@+3`N,6EN.R!P861D
M:6YG+6QE9G0Z(#`N,6EN.R!V97)T:6-A;"UA;&EG;CH@=&]P.R<^3W5T<W1A
M;F1I;F<L($%P<FEL(#,P+"`R,#$Q/"]T9#X-"CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG
M/C$L-C$P+#`P,#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
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M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O
M=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[)SXQ-"PS,C`L.30X/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@
M,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)#PO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('!A9&1I;F<M8F]T=&]M
M.B`R+C5P=#LG/C`N.#@\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O
M='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SXX+C0\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T
M=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SXD/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@<&%D9&EN9RUB
M;W1T;VTZ(#(N-7!T.R<^,2PW.#`\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO
M=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-C
M8V9F8V,[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!V97)T:6-A;"UA;&EG;CH@=&]P.R<^)B,Q
M-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
M"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4]
M,T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D
M:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M:6YD96YT.B`M,"XQ:6X[('!A9&1I
M;F<M;&5F=#H@,"XQ:6X[('9E<G1I8V%L+6%L:6=N.B!T;W`[)SY697-T960@
M86YD(&5X<&5C=&5D('1O('9E<W0@87,@;V8@07!R:6P@,S`L(#(P,3$\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU
M<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[
M('1E>'0M86QI9VXZ(')I9VAT.R<^,2PV,3`L,#`P/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^,3(L-S$P+#DT.#PO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB
M;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D
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M9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O
M;3H@,BXU<'0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^,"XX.#PO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N
M-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('!A9&1I;F<M8F]T
M=&]M.B`R+C5P=#LG/C@N-#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M8F]T=&]M.B`R+C5P=#LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SXQ+#<X,#PO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T
M;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G
M8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M
M:6YD96YT.B`M,"XQ:6X[('!A9&1I;F<M;&5F=#H@,"XQ:6X[('9E<G1I8V%L
M+6%L:6=N.B!T;W`[)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\
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M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UI;F1E
M;G0Z("TP+C%I;CL@<&%D9&EN9RUL969T.B`P+C%I;CL@=F5R=&EC86PM86QI
M9VXZ('1O<#LG/D5X97)C:7-A8FQE(&%S(&]F($%P<FEL(#,P+"`R,#$Q/"]T
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M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
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M;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG
M/C,L.3DT+#DW-SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`R+C5P=#LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SXP+C@U/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU
M<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@<&%D9&EN9RUB;W1T
M;VTZ(#(N-7!T.R<^-2XW/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB
M;W1T;VTZ(#(N-7!T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/C4Y-SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ
M(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!M87)G:6XZ(#!P="`P<'@[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\8CXF
M(S$V,#L\+V(^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>3L@=&5X="UI;F1E;G0Z(#EP=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^26YC;'5D960@
M:6X@=&AE(&)A;&%N8V5S(&]U='-T86YD:6YG(&%S(&]F($UA>2`Q+"`R,#$Q
M(&EN('1H92!T86)L92!A8F]V92!A<F4@,3`L,#`P+#`P,"!O<'1I;VYS(&=R
M86YT960@=&\@=&AE($-O;7!A;GDF(S@R,3<[<R!#:&EE9B!%>&5C=71I=F4@
M3V9F:6-E<B!A;F0@:71S)B,Q-C`[4')E<VED96YT(&%T('1H92!T:6UE(&]F
M(&-O;6UE;F-E;65N="!O9B!T:&5I<B!E;7!L;WEM96YT(&EN(&9I<V-A;"`R
M,#$Q+"!O9B!W:&EC:"`U+#`P,"PP,#`@8V]N=&%I;B!O;FQY('-E<G9I8V4M
M8F%S960@=F5S=&EN9R!P<F]V:7-I;VYS(&%N9"`U+#`P,"PP,#`@8V]N=&%I
M;B!B;W1H('-E<G9I8V4@86YD('!E<F9O<FUA;F-E+6)A<V5D('9E<W1I;F<@
M<')O=FES:6]N<RXF(S$V,#LF(S$V,#M4:&4@<V5R=FEC92UB87-E9"!P<F]V
M:7-I;VYS(&]F('1H97-E(&]P=&EO;G,@<')O=FED92!F;W(@=F5S=&EN9R!T
M;R!O8V-U<B!M;VYT:&QY(&]V97(@82!P97)I;V0@;V8@=&AR964@>65A<G,N
M)B,Q-C`[)B,Q-C`[5&AE('!E<F9O<FUA;F-E+6)A<V5D(&-O;F1I=&EO;G,L
M('=H:6-H(&UU<W0@8F4@;65T('!R:6]R('1O('9E<W1I;F<@=&\@;V-C=7(@
M:6YC;'5D93H@*&DI(&-L;W-I;F<@;V8@;VYE(&]R(&UO<F4@9FEN86YC:6YG
M<R!O9B!T:&4@0V]M<&%N>2!I;B!T:&4@86=G<F5G871E(&%M;W5N="!O9B!A
M="!L96%S="`D-2PP,#`L,#`P.R`H:6DI(&)R:6YG:6YG(&EN(&YE=R!#;VUP
M86YY(&UA;F%G96UE;G0[("AI:6DI(&QA=6YC:&EN9R!O9B!P97)S;VYA;&EZ
M960@;65D:6-I;F4@*&]N8V]L;V=Y*2!B=7-I;F5S<SL@86YD("AI=BD@8V]M
M;65N8VEN9R!I;7!L96UE;G1A=&EO;B!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS
M(&)U<VEN97-S('!L86XN)B,Q-C`[)B,Q-C`[5&AE(&1E=&5R;6EN871I;VX@
M87,@=&\@=VAE=&AE<B!T:&5S92!P97)F;W)M86YC92UB87-E9"!C;VYD:71I
M;VYS(&AA=F4@8F5E;B!M970@=V%S('1O(&)E(&UA9&4@8GD@=&AE($-O;7!A
M;GDF(S@R,3<[<R!";V%R9"!O9B!$:7)E8W1O<G,N)B,Q-C`[)B,Q-C`[5&AE
M('-E<G9I8V4M8F%S960@;W!T:6]N<RP@;&EK92!A;&P@;V8@=&AE($-O;7!A
M;GDF(S@R,3<[<R!S97)V:6-E+6)A<V5D(&]P=&EO;G,L(&%R92!E>'!E;G-E
M9"!O;B!A('-T<F%I9VAT+6QI;F4@8F%S:7,N)B,Q-C`[)B,Q-C`[4VEN8V4@
M=&AE('-T<F%I9VAT+6QI;F4@;65T:&]D(&ES(&YO="!A=F%I;&%B;&4@9F]R
M('!E<F9O<FUA;F-E(&]R(&UA<FME="UB87-E9"!S:&%R92UB87-E9"!P87EM
M96YT<RP@=&AE(#4L,#`P+#`P,"!P97)F;W)M86YC92UB87-E9"!O<'1I;VYS
M(&%R92!B96EN9R!E>'!E;G-E9"!O;B!A;B!A8V-E;&5R871E9"!B87-I<RXF
M(S$V,#LF(S$V,#M4:&4@0V]M<&%N>28C.#(Q-SMS($)O87)D(&]F($1I<F5C
M=&]R<R!D971E<FUI;F5D('1H870@:6X@07!R:6P@,C`Q,2!E86-H(&]F('1H
M92!P97)F;W)M86YC92!C;VYD:71I;VYS('5N9&5R('1H92!A=V%R9',@=V5R
M92!M970N)B,Q-C`[)B,Q-C`[07,@82!R97-U;'0L('1H92!A=V%R9',@=VEL
M;"!B92!E>'!E;G-E9"!B87-E9"!O;B!E86-H(&UO;G1H;'D@=F5S=&EN9R!T
M<F%N8VAE+CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[
M('1E>'0M:6YD96YT.B`Y<'0[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-
M"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T
M(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CLG/CQB/CQI/E)E<W1R:6-T960@4W1O8VL@1W)A;G1S/"]I/CPO8CX\+W`^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P
M="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
M:69Y.R!T97AT+6EN9&5N=#H@.7!T.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY!('-U;6UA
M<GD@;V8@=&AE(&%C=&EV:71Y(')E;&%T960@=&\@<F5S=')I8W1E9"!S=&]C
M:R!G<F%N=',@9F]R('1H92!Y96%R<R!E;F1E9"!!<')I;"`S,"P@,C`Q,B!A
M;F0@,C`Q,2!I<R!A<R!F;VQL;W=S("AD;VQL87)S(&EN('1H;W5S86YD<RDZ
M/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN
M.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L
M('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'1A8FQE(&%L:6=N/3-$8V5N=&5R('-T
M>6QE/3-$)W=I9'1H.B`Y,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[
M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)R!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z
M(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
M9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$-B!N
M;W=R87`],T1N;W=R87`^,C`Q,CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N
M;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
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M<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^
M)B,Q-C`[/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$
M,B!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!N;W=R87`],T1N
M;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@
M8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C
M;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^5V5I9VAT960\+W1D/@T*/'1D
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M;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O
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M;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O
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M;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
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M)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
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M="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-
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M;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#LG(&YO
M=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$
M,B!N;W=R87`],T1N;W=R87`^1F%I<B!686QU93PO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[
M/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)R!N;W=R
M87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO
M=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+7=E
M:6=H=#H@8F]L9#LG(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#Y3:&%R
M97,\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O
M;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG
M:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M
M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$
M,B!N;W=R87`],T1N;W=R87`^4&5R(%-H87)E/"]T9#X-"CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG(&YO
M=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P/3-$
M;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&9O;G0M
M=V5I9VAT.B!B;VQD.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/E-H
M87)E<SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@
M9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T
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M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@
M;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X]
M,T0R/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P
M86X],T0R/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O
M;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9#XF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG
M(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CPO
M='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('=I9'1H.B`T."4[)SY.;VYV97-T960L(&)E9VEN;FEN
M9R!O9B!P97)I;V0\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED
M=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#L@=VED=&@Z(#$P)3LG/C$P,"PP,#`\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXD/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$P)3LG
M/C`N.3`\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I
M9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R!W:61T:#H@,3`E.R<^,S,L-3(V/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)#PO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q
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M86QI9VXZ(')I9VAT.R<^-3`L,#`P/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,"XW-3PO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\
M=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#LG/C(P-2PU-34\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[)SXP+CDP/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@
M<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SY697-T960\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[)SXH,3(U+#`P,#PO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/BD\+W1D/@T*/'1D/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXP+C@W/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
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M=#LG/D9O<F9E:71E9#PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
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M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I
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M('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!R:6=H=#LG/BT\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I
M;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R!P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG
M+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4]
M,T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
M"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\
M='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/DYO;G9E<W1E9"P@96YD
M(&]F('!E<FEO9#PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[)SXR-2PP,#`\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T
M=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SXD/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@<&%D9&EN9RUB
M;W1T;VTZ(#(N-7!T.R<^,"XW-3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N
M-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE
M.R!T97AT+6%L:6=N.B!R:6=H=#LG/C$P,"PP,#`\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N
M-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SXD/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T
M.R<^,"XY,#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\
M+W1A8FQE/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!M87)G
M:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[)SX\8CXF(S$V,#L\+V(^/"]P/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#EP=#L@;6%R9VEN.B`P
M<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
M<FEF.R<^5&AE('1O=&%L(&9A:7(@=F%L=64@;V8@<VAA<F5S('9E<W1E9"!D
M=7)I;F<@=&AE('EE87)S(&5N9&5D($%P<FEL(#,P+"`R,#$R(&%N9"`R,#$Q
M('=A<R`D.#0L,#`P(&%N9"`D,3,S+#`P,"P@<F5S<&5C=&EV96QY+B!!<R!O
M9B!!<')I;"`S,"P@,C`Q,BP@=&AE<F4@=V%S("0Q.2PP,#`@;V8@=6YR96-O
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M+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ
M(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J
M=7-T:69Y.R!T97AT+6EN9&5N=#H@.7!T.R!M87)G:6XZ(#!P="`P<'@[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY!<R!O
M9B!!<')I;"`S,"P@,C`Q,BP@=&AE($-O;7!A;GD@:&%S('=A<G)A;G1S(&]U
M='-T86YD:6YG(&9O<B!T:&4@<'5R8VAA<V4@;V8@,2PT,38L-C8W('-H87)E
M<R!O9B!I=',@8V]M;6]N('-T;V-K+"!A;&P@;V8@=VAI8V@@=V5R92!E>&5R
M8VES86)L92XF(S$V,#LF(S$V,#M/9B!T:&5S92!W87)R86YT<RP@,2PR-C8L
M-C8W('=E<F4@:7-S=65D(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@07!R:6P@
M,C`Q,2!F:6YA;F-I;F<@87)R86YG96UE;G0@86YD(&%R92!A8V-O=6YT960@
M9F]R(&%S(&QI86)I;&ET:65S(&%S(&9U<G1H97(@9&ES8W5S<V5D(&EN($YO
M=&4@-RXF(S$V,#LF(S$V,#M!8W1I=FET>2!R96QA=&5D('1O('1H97-E('=A
M<G)A;G1S+"!W:&EC:"!E>'!I<F4@870@=F%R:6]U<R!D871E<R!T:')O=6=H
M($%P<FEL(#(P,38L(&ES('-U;6UA<FEZ960@87,@9F]L;&]W<R`H9&]L;&%R
M<R!I;B!T:&]U<V%N9',I.CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N
M97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-"CQT86)L92!A
M;&EG;CTS1&-E;G1E<B!S='EL93TS1"=W:61T:#H@.3`E.R!B;W)D97(M8V]L
M;&%P<V4Z(&-O;&QA<'-E.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
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M87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([(&9O;G0M=V5I9VAT.B!B;VQD.R<@8V]L<W!A;CTS1#(@
M;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO
M=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R87`]
M,T1N;W=R87`^5V5I9VAT960\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M=V5I
M9VAT.B!B;VQD.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([
M(&9O;G0M=V5I9VAT.B!B;VQD.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W
M<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O
M;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A
M<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N
M;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
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M:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R
M87`^079E<F%G93PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O
M;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW
M96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#LG(&YO
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M;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O
M;G0M=V5I9VAT.B!B;VQD.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P
M/D%V97)A9V4\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD
M.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M=V5I
M9VAT.B!B;VQD.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/E)E;6%I
M;FEN9SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[)R!N
M;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z
M(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^06=G<F5G871E
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M)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F
M;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG
M:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^17AE<F-I
M<V4\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W
M<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UW
M96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT
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M)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E
M;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R87`]
M,T1N;W=R87`^4VAA<F5S/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A
M<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
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M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@
M;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT
M97([(&9O;G0M=V5I9VAT.B!B;VQD.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$
M;F]W<F%P/DQI9F4@*%EE87)S*3PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N
M;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
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M:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CPO='(^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)R!N;W=R87`],T1N;W=R87`^
M)B,Q-C`[/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$
M,B!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!N;W=R87`],T1N
M;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!C;VQS
M<&%N/3-$,B!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!N;W=R
M87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([
M)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT
M9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!N;W=R87`],T1N
M;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97([)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T
M9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CPO='(^#0H\
M='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('=I9'1H.B`T."4[)SY/=71S=&%N9&EN9RP@36%Y(#$L(#(P,3$\
M+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED
M=&@Z(#$P)3LG/C$L.3$R+#`Q.3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B0\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3`E.R<^,"XW,SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q
M)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[('=I9'1H.B`Q,"4[)SXS+C<\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXD/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$P)3LG/C4R-#PO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^
M)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC
M;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^1W)A;G1E9#PO=&0^#0H\=&0^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG
M/BT\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[)SXM/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC
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M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R<^,C,T/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R
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M=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#LG/BT\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
M/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K
M9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB
M;W1T;VTZ(#%P=#LG/D5X<&ER960\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#LG/BT\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*
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M:'0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!P861D:6YG+6)O='1O;3H@,7!T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\
M='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
M"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C
M8SL@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/D]U='-T
M86YD:6YG+"!!<')I;"`S,"P@,C`Q,CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[
M)SXQ+#0Q-BPV-C<\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O
M;3H@,BXU<'0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^,"XY,3PO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N
M-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('!A9&1I;F<M8F]T
M=&]M.B`R+C5P=#LG/C,N.#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M8F]T=&]M.B`R+C5P=#LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SXP/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@
M,BXU<'0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.B!C96YT97([(&UA<F=I;CH@,'!T(#!P>#L@9F]N
M=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQB/B8C
M,38P.SPO8CX\+W`^#0H\=&%B;&4@86QI9VX],T1C96YT97(@<W1Y;&4],T0G
M=VED=&@Z(#DP)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N
M="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#LG
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M:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S
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M="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M=V5I9VAT
M.B!B;VQD.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`]
M,T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H
M=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[
M)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^5V5I9VAT960\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P/3-$;F]W
M<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O
M;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M=V5I9VAT.B!B;VQD.R<@8V]L
M<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/D%V97)A9V4\+W1D/@T*/'1D('-T
M>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P/3-$;F]W<F%P/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[)R!N
M;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([(&9O;G0M=V5I9VAT.B!B;VQD.R<@8V]L<W!A;CTS
M1#(@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T
M9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)R!N;W=R87`]
M,T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H
M=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[
M)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^3G5M8F5R/"]T9#X-"CQT
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M=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`]
M,T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([(&9O;G0M=V5I9VAT.B!B;VQD.R<@8V]L<W!A;CTS1#(@;F]W
M<F%P/3-$;F]W<F%P/D%G9W)E9V%T93PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-
M"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)R!N;W=R87`],T1N
M;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@
M8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C
M;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^;V8\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R
M87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
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M="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO
M=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R87`]
M,T1N;W=R87`^26YT<FEN<VEC/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E
M:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG(&YO=W)A<#TS1&YO=W)A
M<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
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M(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
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M;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T
M.R!F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S
M;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+7=E:6=H=#H@8F]L9#LG
M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#Y,:69E("A996%R<RD\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I
M9VAT.B!B;VQD.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O
M;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ
M(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R
M87`],T1N;W=R87`^5F%L=64\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P/3-$;F]W
M<F%P/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X],T0R/B8C,38P.SPO
M=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X],T0R/B8C,38P
M.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X],T0R/B8C
M,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X],T0R
M/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y
M;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('=I9'1H.B`T."4[)SY/=71S=&%N9&EN9RP@36%Y(#$L(#(P,3`\+W1D/@T*
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$P
M)3LG/C<T."PY.#,\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!W:61T:#H@,24[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$P)3LG/C`N,S8\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T
M:#H@,3`E.R<^,BXQ/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@=VED=&@Z(#$E.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q,"4[)SXS-C<\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO
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M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT
M9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N
M9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SY%>&5R8VES960\+W1D
M/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[)SXH,3`S+#8S,3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/BD\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[)SXP+C(P/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
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M#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#LG/BT\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[)SXM/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
M"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R
M;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T
M=&]M.B`Q<'0[)SY%>'!I<F5D/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[)SXM/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@
M,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@<&%D9&EN9RUB;W1T;VTZ
M(#%P=#LG/BT\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R!P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
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M=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT
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M9&EN9RP@07!R:6P@,S`L(#(P,3$\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^
M,2PY,3(L,#$Y/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ
M(#(N-7!T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/C`N-S,\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P
M=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!P861D:6YG+6)O='1O
M;3H@,BXU<'0[)SXS+C<\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T
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M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E9&%B,&4R-E\S,#1F
M7S0S-3%?8F4X95\S8S)A.31F9F9F8S`-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO961A8C!E,C9?,S`T9E\T,S4Q7V)E.&5?,V,R83DT9F9F9F,P
M+U=O<FMS:&5E=',O4VAE970Q-2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/E)E9&5E;6%B;&4@0V]M;6]N(%-T;V-K(&%N9"!3
M=&]C:R!0=7)C:&%S92!787)R86YT/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y!<'(N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)E9&5E;6%B;&4@0V]M;6]N(%-T
M;V-K(&%N9"!3=&]C:R!0=7)C:&%S92!787)R86YT(%M!8G-T<F%C=%T\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5D965M
M86)L92!#;VUM;VX@4W1O8VL@86YD(%-T;V-K(%!U<F-H87-E(%=A<G)A;G0@
M6U1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P
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M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`Y
M<'0[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M
M86XL('1I;65S+"!S97)I9CLG/D]N($UA<F-H(#(T+"`R,#$Q+"!T:&4@0V]M
M<&%N>2!E;G1E<F5D(&EN=&\@82!396-U<FET:65S(%!U<F-H87-E($%G<F5E
M;65N="!W:71H('-E=F5R86P@86-C<F5D:71E9"!I;G9E<W1O<G,@9F]R('1H
M92!S86QE(&]F(&%N(&%G9W)E9V%T92`Q,BPU,S,L,S,S('-H87)E<R!O9B!T
M:&4@0V]M<&%N>28C.#(Q-SMS($-O;6UO;B!3=&]C:R!A="!A('!U<F-H87-E
M('!R:6-E(&]F("0P+C<U('!E<B!S:&%R92P@;W(@86=G<F5G871E('!R;V-E
M961S(&]F("0Y+C0@;6EL;&EO;BP@)#4P,"PP,#`@;V8@=VAI8V@@=V%S('-O
M;&0@=&\@;V9F:6-E<G,@86YD(&1I<F5C=&]R<R!O9B!T:&4@0V]M<&%N>2X@
M07,@<&%R="!O9B!T:&ES('1R86YS86-T:6]N+"!T:&4@0V]M<&%N>2!A;'-O
M(&ES<W5E9"!W87)R86YT<R!T;R!P=7)C:&%S92!A;B!A9V=R96=A=&4@,2PR
M-C8L-C8W('-H87)E<R!O9B!#;VUM;VX@4W1O8VL@870@86X@97AE<F-I<V4@
M<')I8V4@;V8@)#`N.3`@<&5R('-H87)E+B!4:&5S92!W87)R86YT<R!E>'!I
M<F4@9FEV92!Y96%R<R!A9G1E<B!T:&4@8VQO<VEN9R!D871E+"!W:&EC:"!O
M8V-U<G)E9"!O;B!!<')I;"`T+"`R,#$Q+B!4:&4@4V5C=7)I=&EE<R!0=7)C
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M;VX@<VAA<F5S(&AE;&0@8GD@<W5C:"!I;G9E<W1O<G,@*'1H92`F(S@R,C`[
M4'5T($]P=&EO;B8C.#(R,3LI(&9O<B!C87-H(&9O<B`D,"XW-2!P97(@<VAA
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M96-U<FET:65S(%!U<F-H87-E($%G<F5E;65N="X\+W`^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@.7!T.R!M87)G
M:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@.7!T.R!M87)G:6XZ(#!P="`P<'@[
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M)#DS-BPP,#`@86YD(&ES(&%L<V\@;F5T(&]F(&1I<F5C="!A;F0@:6YC<F5M
M96YT86P@8V]S=',@87-S;V-I871E9"!W:71H('1H92!396-U<FET:65S(%!U
M<F-H87-E($%G<F5E;65N="!O9B`D,S`U+#`P,"X\+W`^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@.7!T.R!M87)G
M:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@.7!T.R!M87)G:6XZ(#!P="`P<'@[
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M>'0M:6YD96YT.B`Y<'0[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T
M:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-"CQP
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`Y
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M:"`S,"UD87D@<&5R:6]D(&EN('=H:6-H(&$@4F5G:7-T<F%T:6]N($1E9F%U
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M97(@=&AI<R!R96=I<W1R871I;VX@<&%Y;65N="!A<G)A;F=E;65N="!I<R`D
M-#$L,#`P(&9O<B!E86-H(#,P+61A>2!P97)I;V0@:6X@=VAI8V@@82!R96=I
M<W1R871I;VX@9&5F875L="!E>&ES=',[(&AO=V5V97(L(&%S(&]F('1H92!D
M871E(&]F('1H:7,@9FEL:6YG+"!T:&4@0V]M<&%N>2!D;V5S(&YO="!B96QI
M979E('1H97-E('!E;F%L=&EE<R!T;R!B92!P<F]B86)L92!A;F0@86-C;W)D
M:6YG;'DL(&AA<R!N;W0@97-T86)L:7-H960@86X@86-C<G5A;"!F;W(@<W5C
M:"!R96=I<W1R871I;VX@<&%Y;65N="!A<G)A;F=E;65N=',N/"]P/@T*/'`@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#EP
M=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#EP=#L@;6%R9VEN.B`P
M<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
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M86YC92!S:&5E=',L('1O=&%L960@)#DS-BPP,#`@870@=&AE('1I;64@;V8@
M=&AE(&-L;W-E(&]F('1H92!396-U<FET:65S(%!U<F-H87-E($%G<F5E;65N
M="X@07,@;V8@07!R:6P@,S`L(#(P,3$L('1H92!F86ER('9A;'5E(&]F('1H
M97-E('=A<G)A;G1S(&EN8W)E87-E9"`D,S8L,#`P('1O("0Y-S(L,#`P+B!$
M=7)I;F<@=&AE('EE87(@96YD960@07!R:6P@,S`L(#(P,3(L('1H92!F86ER
M('9A;'5E(&]F('1H97-E('=A<G)A;G1S(&1E8W)E87-E9"!B>2`D-#$W+#`P
M,"!T;R`D-34U+#`P,"X@5&AE(&-H86YG92!I;B!F86ER('9A;'5E(&]F('1H
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M.B`Y<'0[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@
M<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-"CQT86)L92!S='EL
M93TS1"=W:61T:#H@.3`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G
M:6XM;&5F=#H@,"XU:6X[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H
M=#H@8F]L9#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&9O
M;G0M=V5I9VAT.B!B;VQD.R<@8V]L<W!A;CTS1#8^665A<B!%;F1E9"!!<')I
M;"`S,"P\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
M(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z
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M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I
M9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(^
M)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS
M1#(^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S
M='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@=VED=&@Z(#<T)3LG/D5X<&5C=&5D('1E<FT@:6X@>65A<G,\+W1D/@T*
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$P
M)3LG/C,N.3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@
M,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q,"4[)SXU+C`\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO
M=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('=H
M:71E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/E)I<VLM9G)E92!I;G1E<F5S="!R871E<SPO
M=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#LG/C`N-CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG/B4\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[)SXR+C`\+W1D/@T*/'1D('-T>6QE/3-$)W1E
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M>'0M86QI9VXZ(')I9VAT.R<^,3`R/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)3PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C$P,CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B4\+W1D/@T*/"]T<CX-"CQT<B!S
M='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M)SY$:79I9&5N9"!Y:65L9#PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C`\+W1D/@T*/'1D('-T>6QE
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M;65S+"!S97)I9CLG/CQB/B8C,38P.SPO8CX\+W`^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@.7!T.R!M87)G:6XZ
M(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
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M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7V5D86(P93(V7S,P-&9?-#,U,5]B93AE
M7S-C,F$Y-&9F9F9C,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E
M9&%B,&4R-E\S,#1F7S0S-3%?8F4X95\S8S)A.31F9F9F8S`O5V]R:W-H965T
M<R]3:&5E=#$V+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^4W1O8VMH;VQD97)S)R!%<75I='D\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D%P<BX@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W1O8VMH;VQD97)S)R!%
M<75I='D@3F]T92!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K:&]L9&5R<R<@17%U:71Y($YO=&4@
M1&ES8VQO<W5R92!;5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA
M<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I
M;65S+"!S97)I9CLG/CQB/DYO=&4@."X@4W1O8VMH;VQD97)S)B,X,C$W.R!%
M<75I='D\+V(^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^/&D^4')E9F5R
M<F5D(%-T;V-K/"]I/CPO8CX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@.7!T.R!M
M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[)SY4:&4@0V]M<&%N>2!H87,@-38L,#<U('-H87)E<R!O
M9B!397)I97,@02`Q,B4@<')E9F5R<F5D('-T;V-K(&%U=&AO<FEZ960@86YD
M(&YO('-H87)E<R!I<W-U960@86YD(&]U='-T86YD:6YG(&%T($%P<FEL(#,P
M+"`R,#$R(&%N9"`R,#$Q+CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`Y<'0[(&UA<F=I;CH@,'!T(#!P>#L@
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C
M,38P.SPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA
M<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I
M;65S+"!S97)I9CLG/CQB/CQI/D-O;6UO;B!3=&]C:SPO:3X\+V(^/"]P/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@
M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>3L@=&5X="UI;F1E;G0Z(#EP=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^3VX@1F5B<G5A
M<GD@,3@L(#(P,3$L('1H92!#;VUP86YY)B,X,C$W.W,@0F]A<F0@;V8@1&ER
M96-T;W)S(&%P<')O=F5D('1H92!A;65N9&UE;G0@86YD(')E<W1A=&5M96YT
M(&]F('1H92!#;VUP86YY)B,X,C$W.W,@0V5R=&EF:6-A=&4@;V8@26YC;W)P
M;W)A=&EO;B`H;W(@)B,X,C(P.T-H87)T97(F(S@R,C$[*2!A;F0@<W5B;6ET
M=&5D('1H92!A;65N9&5D(&%N9"!R97-T871E9"!#:&%R=&5R('1O('1H92!#
M;VUP86YY)B,X,C$W.W,@<VAA<F5H;VQD97)S(&9O<B!A<'!R;W9A;"XF(S$V
M,#LF(S$V,#M/;B!&96)R=6%R>2`Q."P@,C`Q,2P@<VAA<F5H;VQD97)S(&]W
M;FEN9R!A(&UA:F]R:71Y(&]F('1H92!I<W-U960@86YD(&]U='-T86YD:6YG
M('-H87)E<R!O9B!T:&4@0V]M<&%N>2!E>&5C=71E9"!A('=R:71T96X@8V]N
M<V5N="!A<'!R;W9I;F<@=&AE(&%M96YD960@86YD(')E<W1A=&5D($-H87)T
M97(N)B,Q-C`[)B,Q-C`[26X@86-C;W)D86YC92!W:71H(')E9W5L871I;VYS
M(&]F('1H92!396-U<FET:65S(&%N9"!%>&-H86YG92!#;VUM:7-S:6]N+"!T
M:&4@86UE;F1E9"!A;F0@<F5S=&%T960@0VAA<G1E<B!W87,@9FEL960@=VET
M:"!T:&4@4T5#(&]N($UA<F-H(#<L(#(P,3$N($%M;VYG(&]T:&5R(&-H86YG
M97,L('1H92!A;65N9&5D(&%N9"!R97-T871E9"!#:&%R=&5R(&-H86YG97,@
M=&AE(&YA;64@;V8@=&AE($-O;7!A;GD@=&\@)B,X,C(P.T-H86UP:6]N<R!/
M;F-O;&]G>2P@26YC+B8C.#(R,3L@86YD(&EN8W)E87-E<R!T:&4@875T:&]R
M:7IE9"!S:&%R97,@=VAI8V@@=&AE($-O;7!A;GD@;6%Y(&ES<W5E(&9R;VT@
M-3`L,#`P+#`P,"!S:&%R97,@;V8@0V]M;6]N(%-T;V-K('1O(#$R-2PP,#`L
M,#`P('-H87)E<R!O9B!#;VUM;VX@4W1O8VLN)B,Q-C`[)B,Q-C`[/"]P/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@
M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>3L@=&5X="UI;F1E;G0Z(#EP=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^07,@;V8@07!R
M:6P@,S`L(#(P,3`L('1H92!#;VUP86YY(&AA9"!E>&5C=71E9"!S=6)S8W)I
M<'1I;VX@86=R965M96YT<R!F;W(@=&AE('!R:79A=&4@<&QA8V5M96YT(&]F
M(#$L,#`P+#`P,"!S:&%R97,@;V8@=6YR96=I<W1E<F5D(&-O;6UO;B!S=&]C
M:R!F;W(@)#`N-S4@<&5R('-H87)E(&]R("0W-3`L,#`P+B!4:&4@86UO=6YT
M('=A<R!R969L96-T960@87,@82!S=6)S8W)I<'1I;VX@<F5C96EV86)L92!A
M<R!A(&-O;G1R82UE<75I='D@86-C;W5N="!O;B!T:&4@8F%L86YC92!S:&5E
M="!A<R!O9B!!<')I;"`S,"P@,C`Q,"X@26X@,C`Q,2P@=&AE($-O;7!A;GD@
M8F5C86UE(&%W87)E('1H870@=&AE(&%M;W5N="!W87,@=6YC;VQL96-T:6)L
M92!I;B!F=6QL(&%N9"!T:&4@9G5L;"!A;6]U;G0@=V%S(')E=F5R<V5D(&%G
M86EN<W0@861D:71I;VYA;"!P86ED+6EN(&-A<&ET86PN/"]P/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q
M-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R
M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R<^/&(^/&D^5')E87-U<GD@4W1O8VL\+VD^/"]B/CPO<#X-
M"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T
M(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I
M9GD[('1E>'0M:6YD96YT.B`Y<'0[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/DEN($UA>2`R
M,#`Y+"!T:&4@0F]A<F0@;V8@1&ER96-T;W)S(&%P<')O=F5D(&$@<W1O8VL@
M<F5P=7)C:&%S92!A9W)E96UE;G0@=VET:"!A($)O87)D(&UE;6)E<B!W:&EC
M:"!O8FQI9V%T960@=&AE($-O;7!A;GD@=&\@<'5R8VAA<V4@=7`@=&\@87!P
M<F]X:6UA=&5L>2`D-#`W+#`P,"!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-O
M;6UO;B!S=&]C:R!H96QD(&)Y('1H92!";V%R9"!M96UB97(@=&AR;W5G:"!!
M<')I;"!O9B`R,#$Q('!R;W9I9&EN9R!T:&%T('1H92!";V%R9"!M96UB97(@
M8V]N=&EN=65D(&AI<R!S97)V:6-E<R!U;F1E<B!A(&-O;G-U;'1I;F<@86=R
M965M96YT(&5X96-U=&5D(&-O;F-U<G)E;G1L>2!W:71H('1H92!S=&]C:R!R
M97!U<F-H87-E(&%G<F5E;65N="XF(S$V,#LF(S$V,#M5;F1E<B!T:&4@<W1O
M8VL@<F5P=7)C:&%S92!A9W)E96UE;G0L('1H92!#;VUP86YY(&UA9&4@86X@
M:6YI=&EA;"!P=7)C:&%S92!O9B`D,3(U+#`P,"!O9B!T:&4@0V]M<&%N>28C
M.#(Q-SMS('-H87)E<R!O9B!C;VUM;VX@<W1O8VLL(&%N9"!M87D@:&%V92!B
M965N(')E<75I<F5D('1O(&UA:V4@<75A<G1E<FQY('!U<F-H87-E<R!O9B`D
M,S$L,C4P(&]F('1H92!#;VUP86YY)B,X,C$W.W,@8V]M;6]N('-T;V-K(&AE
M;&0@8GD@=&AE($)O87)D(&UE;6)E<B!A9G1E<B!T:&4@96YD(&]F(&5A8V@@
M9FES8V%L('%U87)T97(N)B,Q-C`[)B,Q-C`[5&AE('!U<F-H87-E('!R:6-E
M('!E<B!S:&%R92!O9B!T:&4@8V]M;6]N('-T;V-K(&9O<B!E86-H('!U<F-H
M87-E(&ES(&5Q=6%L('1O('1H92!L97-S97(@<')I8V4@;V8@)#`N-3`@;W(@
M-3`E(&]F('1H92!A=F5R86=E(&-L;W-I;F<@<')I8V4@;V8@=&AE('-T;V-K
M(&%S('%U;W1E9"!O;B!T:&4@3U1#($)U;&QE=&EN($)O87)D(&9O<B!T:&4@
M,S`M9&%Y('1R861I;F<@<&5R:6]D(&5N9&EN9R!O;B!T:&4@9&%Y(&)E9F]R
M92!T:&4@9&%T92!O9B!E86-H('!U<F-H87-E(&%S(&QO;F<@87,@=&AE(&-O
M;G-U;'1I;F<@86=R965M96YT(')E;6%I;F5D(&EN(&5F9F5C="X\+W`^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P
M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y
M.R!T97AT+6EN9&5N=#H@.7!T.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P
M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY5;F1E<B!T:&4@
M86=R965M96YT+"!T:&4@0V]M<&%N>2!H87,@<&%I9"!T:&ES($)O87)D(&UE
M;6)E<B!A<'!R;WAI;6%T96QY("0W,RPP,#`@86YD("0R,3@L,#`P(&9O<B!T
M:&4@<'5R8VAA<V4@;V8@,3<Q+#@X,R!A;F0@-#<T+#(X.28C,38P.R8C,38P
M.W-H87)E<R!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!F
M;W(@=&AE('EE87)S(&5N9&5D($%P<FEL(#,P+"`R,#$Q(&%N9"!!<')I;"`S
M,"P@,C`Q,"P@<F5S<&5C=&EV96QY+CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T
M:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-"CQP
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`Y
M<'0[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M
M86XL('1I;65S+"!S97)I9CLG/D5F9F5C=&EV92!-87D@,C`Q,"P@=&AE($-O
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M960@07!R:6P@,S`L(#(P,3$L('1H92!#;VUP86YY(')E8VQA<W-I9FEE9"`D
M,3$T+#`P,"!F<F]M(&%C8W)U960@<W1O8VL@<'5R8VAA<V4@;VX@=&AE(&)A
M;&%N8V4@<VAE970@:6YT;R!A9&1I=&EO;F%L('!A:60M:6X@8V%P:71A;"P@
M=VAI8V@@<F5P<F5S96YT960@=&AE(')E;6%I;FEN9R!A;6]U;G0@;V8@=&AE
M('!U<F-H87-E('!R:6-E(')E<75I<F5D('5N9&5R('1H92!R97!U<F-H87-E
M(&%R<F%N9V5M96YT(&%F=&5R('1H92!T97)M:6YA=&EO;B!O9B!T:&4@8V]N
M<W5L=&EN9R!A9W)E96UE;G0N/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#EP=#L@
M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
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M,BPR-3`L,#`P('-H87)E<R!O9B!T:&4@8V]M;6]N('-T;V-K+"!S=6)J96-T
M('1O('1H92!P<FEC:6YG(&9O<FUU;&$@9&5S8W)I8F5D(&%B;W9E+B!);B!!
M<')I;"`R,#$Q+"!T:&4@0V]M<&%N>2!R97!U<F-H87-E9"`R+#`P,"PP,#`@
M<VAA<F5S(&]F('1H92!#;VUP86YY)B,X,C$W.W,@8V]M;6]N('-T;V-K(&9R
M;VT@=&AE($)O87)D($UE;6)E<B!O9B!T:&4@0V]M<&%N>2P@9F]R(&$@8V%S
M:"!P=7)C:&%S92!P<FEC92!O9B`D,"XT."!P97(@<VAA<F4L(&]R(&%N(&%G
M9W)E9V%T92!P=7)C:&%S92!P<FEC92!O9B`D.38P+#`P,"X@5&AE($-O;7!A
M;GD@<F5P=7)C:&%S960@=&AE('-H87)E<R!U<VEN9R!P<F]C965D<R!F<F]M
M('1H92`D.2PT,#`L,#`P(')E8V5I=F5D('5N9&5R('1H92!396-U<FET:65S
M(%!U<F-H87-E($%G<F5E;65N="!T:&%T(&-L;W-E9"!I;B!!<')I;"`R,#$Q
M(&%N9"!I<R!D97-C<FEB960@:6X@3F]T92`W+CPO<#X-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO
M<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD
M96YT.B`Y<'0[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N
M97<@<F]M86XL('1I;65S+"!S97)I9CLG/E1H92!#;VUP86YY(&AA<R!N;W0@
M<F5P=7)C:&%S960@86YY('-H87)E<R!I;B!F:7-C86P@,C`Q,BX\+W`^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E9&%B,&4R
M-E\S,#1F7S0S-3%?8F4X95\S8S)A.31F9F9F8S`-"D-O;G1E;G0M3&]C871I
M;VXZ(&9I;&4Z+R\O0SHO961A8C!E,C9?,S`T9E\T,S4Q7V)E.&5?,V,R83DT
M9F9F9F,P+U=O<FMS:&5E=',O4VAE970Q-RYH=&UL#0I#;VYT96YT+51R86YS
M9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z
M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E!R;W9I<VEO;B!F;W(@26YC;VUE(%1A
M>&5S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y!<'(N(#,P
M+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/DEN8V]M92!487@@1&ES8VQO<W5R92!;06)S=')A8W1=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN8V]M92!4
M87@@1&ES8VQO<W5R92!;5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[
M(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL
M('1I;65S+"!S97)I9CLG/CQB/DYO=&4@.2X@4')O=FES:6]N(&9O<B!);F-O
M;64@5&%X97,\+V(^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S
M=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#EP=#L@;6%R9VEN
M.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L
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M93TS1"=W:61T:#H@.3`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<@8V5L
M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B
M;VQD.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N
M.B!C96YT97([(&9O;G0M=V5I9VAT.B!B;VQD.R<@8V]L<W!A;CTS1#$T(&YO
M=W)A<#TS1&YO=W)A<#Y996%R($5N9&5D($%P<FEL(#,P+"`R,#$R/"]T9#X-
M"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H
M=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/"]T<CX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG(&YO=W)A<#TS1&YO=W)A<#XF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
M(&9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&9O;G0M=V5I9VAT.B!B;VQD.R<@
M8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/D9E9&5R86P\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B
M;VQD.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[)R!N
M;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E
M<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N
M;W=R87`^4W1A=&4\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P/3-$;F]W<F%P/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@
M9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L
M:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C
M;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^1F]R96EG;CPO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O
M;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
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M(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q
M-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)R!N
M;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R
M87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-
M"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!N;W=R87`]
M,T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^)B,Q-C`[
M/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!N
M;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^
M)B,Q-C`[/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-
M"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N
M;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[
M/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@
M(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`T."4[)SY#=7)R96YT/"]T
M9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B0\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3`E
M.R<^+3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED
M=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('=I9'1H.B`Q)3LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R!W:61T:#H@,3`E.R<^,3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B0\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3`E.R<^*#,\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG
M/BD\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^
M)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H
M.B`Q,"4[)SXH,CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
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M:6=N.B!L969T.R<^*3PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
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M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG
M/B@R+#<V,SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG
M/BD\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R
M.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P=#LG
M/D-H86YG92!I;B!V86QU871I;VX@86QL;W=A;F-E/"]T9#X-"CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M
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M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^
M,3<R/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D
M:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ
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M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^,BPW-C,\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T
M=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B
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M='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^5&]T86P\+W1D/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE
M.R!T97AT+6%L:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R
M:6=H=#LG/BT\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[
M('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I
M9VAT.R<^,3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
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M<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M
M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^
M*#(\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I
M;F<M8F]T=&]M.B`R+C5P=#LG/BD\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P
M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M)SXF(S$V,#L\+W`^#0H\=&%B;&4@86QI9VX],T1C96YT97(@<W1Y;&4],T0G
M=VED=&@Z(#DP)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG
M(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N
M=&5R.R!F;VYT+7=E:6=H=#H@8F]L9#LG(&-O;'-P86X],T0Q-"!N;W=R87`]
M,T1N;W=R87`^665A<B!%;F1E9"!!<')I;"`S,"P@,C`Q,3PO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O
M;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[
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M9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P
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M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M
M=V5I9VAT.B!B;VQD.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T
M97AT+6%L:6=N.B!C96YT97([(&9O;G0M=V5I9VAT.B!B;VQD.R<@8V]L<W!A
M;CTS1#(@;F]W<F%P/3-$;F]W<F%P/D9O<F5I9VX\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@
M;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`]
M,T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N
M="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^
M5&]T86P\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
M(&9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO
M=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CLG(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0^)B,Q
M-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0^
M)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\
M=&0^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X],T0R/B8C,38P.SPO=&0^
M#0H\=&0^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R
M;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`T."4[
M)SY#=7)R96YT/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H
M.B`Q)3LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R!W:61T:#H@,3`E.R<^+3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B0\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3`E.R<^+3PO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B0\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@
M,3`E.R<^,3$\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!W:61T:#H@,24[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#L@=VED=&@Z(#$P)3LG/C$Q/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*
M/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SY$969E<G)E9#PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
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M*3PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
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M('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SY#:&%N9V4@:6X@=F%L=6%T:6]N(&%L
M;&]W86YC93PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P
M=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L
M:60[('1E>'0M86QI9VXZ(')I9VAT.R<^,2PQ,#`\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
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M,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E
M>'0M86QI9VXZ(')I9VAT.R<^-C@\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S
M;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L
M:6=N.B!R:6=H=#LG/C$L,S,U/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-
M"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
M"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO
M<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P
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M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^)#PO
M=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@
M9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG/BT\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N
M-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T
M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D
M;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^,3$\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N
M-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T
M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D
M;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^,3$\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG
M/B8C,38P.SPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQB/B8C,38P.SPO
M8CX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT
M+6EN9&5N=#H@.7!T.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM
M97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY!(')E8V]N8VEL:6%T:6]N
M(&)E='=E96X@=&AE($-O;7!A;GDF(S@R,3<[<R!E9F9E8W1I=F4@=&%X(')A
M=&4@86YD('1H92!5;FET960@4W1A=&5S('-T871U=&]R>2!T87@@<F%T92!F
M;W(@=&AE('EE87)S(&5N9&5D($%P<FEL(#,P+"`R,#$R(&%N9"`R,#$Q(&ES
M(&%S(&9O;&QO=W,Z/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S
M=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^)B,Q-C`[/"]B/CPO<#X-"CQT86)L
M92!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=W:61T:#H@.3,E.R!B;W)D97(M
M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG
M/3-$,#X-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG(&YO=W)A<#TS1&YO
M=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P/3-$;F]W<F%P/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&9O;G0M=V5I9VAT.B!B
M;VQD.R<@8V]L<W!A;CTS1#8@;F]W<F%P/3-$;F]W<F%P/EEE87(@16YD960@
M07!R:6P@,S`L/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,7!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V
M,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG(&YO
M=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P/3-$
M;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&9O;G0M
M=V5I9VAT.B!B;VQD.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/C(P
M,3(\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O
M;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG
M:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M
M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$
M,B!N;W=R87`],T1N;W=R87`^,C`Q,3PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`]
M,T1N;W=R87`^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!N
M;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^
M)B,Q-C`[/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-
M"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N
M;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[
M/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@
M(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`W-"4[)SY&961E<F%L(&EN
M8V]M92!T87@@870@<W1A='5T;W)Y(')A=&4\+W1D/@T*/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$P)3LG/C,T+C`\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG
M/B4\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@
M=VED=&@Z(#$P)3LG/C,T+C`\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B4\+W1D/@T*/"]T<CX-"CQT<B!S='EL
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M.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R<^-"XU/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y
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M=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^
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M=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#LG/B@R+CD\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q
M<'0[)SXI/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
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M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G
M8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[('1E>'0M9&5C;W)A=&EO;CH@;F]N93LG/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M9&5C
M;W)A=&EO;CH@;F]N93LG/DEN8V]M92!T87@@97AP96YS93PO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=&5X="UD96-O<F%T:6]N
M.B!N;VYE.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M
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M;3H@,7!T.R!T97AT+61E8V]R871I;VXZ(&YO;F4[)SXE)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+61E8V]R
M871I;VXZ(&YO;F4[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@
M=&5X="UD96-O<F%T:6]N.B!N;VYE.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
M9VXZ(')I9VAT.R!T97AT+61E8V]R871I;VXZ(&YO;F4[)SXH,"XS/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O
M;3H@,7!T.R!T97AT+61E8V]R871I;VXZ(&YO;F4[)SXI)3PO=&0^#0H\+W1R
M/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R<^/&(^)B,Q-C`[/"]B/B8C,38P.SPO<#X-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`Y<'0[
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M97,@87,@;V8@07!R:6P@,S`L(#(P,3(@86YD(#(P,3$@8V]N<VES="!O9B!T
M:&4@9F]L;&]W:6YG("AI;B!T:&]U<V%N9',I.CPO<#X-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`Y<'0[(&UA<F=I
M;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S
M+"!S97)I9CLG/B8C,38P.SPO<#X-"CQT86)L92!A;&EG;CTS1&-E;G1E<B!S
M='EL93TS1"=W:61T:#H@.3`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E
M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<@
M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT
M.B!B;VQD.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L
M:6=N.B!C96YT97([(&9O;G0M=V5I9VAT.B!B;VQD.R<@8V]L<W!A;CTS1#8@
M;F]W<F%P/3-$;F]W<F%P/D%S(&]F($%P<FEL(#,P+#PO=&0^#0H\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[
M)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T
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M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P/3-$;F]W
M<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&9O;G0M=V5I
M9VAT.B!B;VQD.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/C(P,3$\
M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M
M=V5I9VAT.B!B;VQD.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\
M+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
M"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CLG(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T
M9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&-E;G1E<CLG(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[
M/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@
M(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`W-"4[)SY!8V-R=65D(&QI
M86)I;&ET:65S/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H
M.B`Q)3LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R!W:61T:#H@,3`E.R<^-C(\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXD/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$P)3LG/CD\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P
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M>'0M86QI9VXZ(')I9VAT.R<^.#`\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXH-#PO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/BD\+W1D/@T*/"]T<CX-"CQT
M<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A
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M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/BT\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W
M:&ET93L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SY3=&]C:RUB87-E9"!C;VUP96YS871I;VX@
M97AP96YS93PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#LG/C(L-C@U/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,2PX-C,\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
M/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F
M9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/D-A<&ET86QI>F5D(')E<V5A<F-H(&%N9"!D
M979E;&]P;65N="!C;W-T<SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C<Y.#PO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C$L
M,3@R/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO
M<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^1F]R96EG;B!N970@;W!E<F%T:6YG
M(&QO<W,@8V%R<GDM9F]R=V%R9#PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C(V-3PO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG
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M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@
M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R
M:6=H=#LG/C(L-#<X/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG
M:'0[)SXS-C,\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT
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M.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/E1O=&%L(&1E9F5R<F5D('1A>"!A
M<W-E=',\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[)SXV+#,W,SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C,L-C$Q/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
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M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^*#8L,S<S/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O
M;3H@,7!T.R<^*3PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
M<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^*#,L-C$Q/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T
M.R<^*3PO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L
M;W(Z("-C8V9F8V,[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y
M;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P
M861D:6YG+6)O='1O;3H@,BXU<'0[)SY.970@9&5F97)R960@=&%X(&%S<V5T
M/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/@T*/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@
M=&5X="UA;&EG;CH@<FEG:'0[)SXM/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T
M97AT+6%L:6=N.B!R:6=H=#LG/BT\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO
M=&0^#0H\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`Y<'0[(&UA<F=I;CH@,'!T(#!P>#L@
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C
M,38P.SPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E
M>'0M:6YD96YT.B`Y<'0[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T
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M87@@87-S971S(&%S(&]F($%P<FEL+"`S,"P@,C`Q,BXF(S$V,#LF(S$V,#M&
M;W(@=&AE('EE87)S(&5N9&5D($%P<FEL(#,P+"`R,#$R(&%N9"`R,#$Q+"!T
M:&4@0V]M<&%N>2!R96-O<F1E9"!A('9A;'5A=&EO;B!A;&QO=V%N8V4@;V8@
M)#8L,S<S+#`P,"!A;F0@)#,L-C$Q+#`P,"P@<F5S<&5C=&EV96QY+B8C,38P
M.R8C,38P.U1H92!I;F-R96%S92!I;B!V86QU871I;VX@86QL;W=A;F-E(&9R
M;VT@9FES8V%L('EE87(@,C`Q,2!T;R`R,#$R(&ES(&1U92!T;R!D969E<G)E
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M:6ME;'D@=&AA;B!N;W0@8F4@<F5A;&EZ960N)B,Q-C`[)B,Q-C`[0VAA;F=E
M<R!I;B!V86QU871I;VX@86QL;W=A;F-E<R!F<F]M('!E<FEO9"!T;R!P97)I
M;V0@87)E(&EN8VQU9&5D(&EN('1H92!T87@@<')O=FES:6]N(&EN('1H92!P
M97)I;V0@;V8@8VAA;F=E+B8C,38P.R8C,38P.TEN(&1E=&5R;6EN:6YG('=H
M971H97(@82!V86QU871I;VX@86QL;W=A;F-E(&ES(')E<75I<F5D+"!T:&4@
M0V]M<&%N>2!T86ME<R!I;G1O(&%C8V]U;G0@86QL(&5V:61E;F-E('=I=&@@
M<F5G87)D('1O('1H92!U=&EL:7IA=&EO;B!O9B!A(&1E9F5R<F5D('1A>"!A
M<W-E="!I;F-L=61I;F<@<&%S="!E87)N:6YG<R!H:7-T;W)Y+"!E>'!E8W1E
M9"!F=71U<F4@96%R;FEN9W,L('1H92!C:&%R86-T97(@86YD(&IU<FES9&EC
M=&EO;B!O9B!S=6-H(&5A<FYI;F=S+"!U;G-E='1L960@8VER8W5M<W1A;F-E
M<R!T:&%T+"!I9B!U;F9A=F]R86)L>2!R97-O;'9E9"P@=V]U;&0@861V97)S
M96QY(&%F9F5C="!U=&EL:7IA=&EO;B!O9B!A(&1E9F5R<F5D('1A>"!A<W-E
M="P@8V%R<GEB86-K(&%N9"!C87)R>69O<G=A<F0@<&5R:6]D<RP@86YD('1A
M>"!S=')A=&5G:65S('1H870@8V]U;&0@<&]T96YT:6%L;'D@96YH86YC92!T
M:&4@;&EK96QI:&]O9"!O9B!R96%L:7IA=&EO;B!O9B!A(&1E9F5R<F5D('1A
M>"!A<W-E="X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y
M.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@.7!T.R!M87)G:6XZ(#!P
M="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[)SY!<R!O9B!!<')I;"`S,"P@,C`Q,B!A;F0@,C`Q,2P@=&AE($-O;7!A
M;GDF(S@R,3<[<R!E<W1I;6%T960@52Y3+B!N970@;W!E<F%T:6YG(&QO<W,@
M8V%R<GDM9F]R=V%R9',@=V5R92!A<'!R;WAI;6%T96QY("0V+#@R-2PP,#`@
M86YD("0Y,C@L,#`P+"!R97-P96-T:79E;'DN)B,Q-C`[)B,Q-C`[07,@;V8@
M07!R:6P@,S`L(#(P,3(@86YD(#(P,3$L('1H92!#;VUP86YY)B,X,C$W.W,@
M9F]R96EG;B!N970@;W!E<F%T:6YG(&QO<W,@8V%R<GDM9F]R=V%R9"!W87,@
M87!P<F]X:6UA=&5L>2`D,2PQ,S@L,#`P(&%N9"`D-SDP+#`P,"P@<F5S<&5C
M=&EV96QY+B8C,38P.R8C,38P.U1H92!#;VUP86YY)B,X,C$W.W,@9F5D97)A
M;"!A;F0@<W1A=&4@;F5T(&]P97)A=&EN9R!L;W-S97,@8F5G:6X@97AP:7)I
M;F<@:6X@,C`R.2X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
M:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@.7!T.R!M87)G:6XZ
M(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[)SY4:&4@0V]M<&%N>2!F:6QE<R!I;F-O;64@=&%X(')E='5R;G,@
M:6X@=F%R:6]U<R!J=7)I<V1I8W1I;VYS('=I=&@@=F%R>6EN9R!S=&%T=65S
M(&]F(&QI;6ET871I;VYS+B8C,38P.R8C,38P.T%S(&]F($%P<FEL(#,P+"`R
M,#$R+"!T:&4@96%R;&EE<W0@=&%X('EE87(@<W1I;&P@<W5B:F5C="!T;R!E
M>&%M:6YA=&EO;B!F;W(@<W1A=&4@<'5R<&]S97,@:7,@9FES8V%L(#(P,#DN
M)B,Q-C`[)B,Q-C`[5&AE($-O;7!A;GDF(S@R,3<[<R!T87@@>65A<G,@9F]R
M('!E<FEO9',@96YD:6YG($%P<FEL(#,P+"`Q.3DU(&%N9"!F;W)W87)D(&%R
M92!S=6)J96-T('1O(&5X86UI;F%T:6]N(&)Y('1H92!5;FET960@4W1A=&5S
M(&%N9"!C97)T86EN('-T871E<R!D=64@=&\@=&AE(&-A<G)Y+69O<G=A<F0@
M;V8@=6YU=&EL:7IE9"!N970@;W!E<F%T:6YG(&QO<W-E<RX\+W`^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@.7!T
M.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@.7!T.R!M87)G:6XZ(#!P
M="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[)SY/;B!!=6=U<W0@."P@,C`Q,2P@=&AE($-O;7!A;GD@=V%S(&YO=&EF
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M;VX@86YD($%F9F]R9&%B;&4@0V%R92!!8W0@;V8@,C`Q,"!F;W(@=&AE(#(P
M,#D@86YD(#(P,3`@=&%X('EE87)S+B!4:&4@97AA;6EN871I;VX@8V]M;65N
M8V5D(&]N(%-E<'1E;6)E<B`S,"P@,C`Q,2!A;F0@=V%S(&-O;7!L971E9"!D
M=7)I;F<@=&AE(&9O=7)T:"!Q=6%R=&5R(&]F('1H92!Y96%R(&5N9&5D($%P
M<FEL(#,P+"`R,#$R+B!4:&4@875D:70@<F5S=6QT960@:6X@82!D:7-A;&QO
M=V%N8V4@=&\@=&AE(&YE="!O<&5R871I;F<@;&]S<R!C87)R>2UF;W)W87)D
M<R!O9B`D-C`W+#`P,"X@5&AI<R!D:7-A;&QO=V%N8V4@=V%S(&]F9G-E="!B
M>2!A(&-O<G)E<W!O;F1I;F<@:6YC<F5A<V4@=&\@86UO<G1I>F%B;&4@:6YT
M86YG:6)L92!A<W-E=',@<F5L871E9"!T;R!C87!I=&%L:7IE9"!R97-E87)C
M:"!A;F0@9&5V96QO<&UE;G0@97AP96YD:71U<F5S(&]F("0U-#(L,#`P+CPO
M<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V5D
M86(P93(V7S,P-&9?-#,U,5]B93AE7S-C,F$Y-&9F9F9C,`T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B]E9&%B,&4R-E\S,#1F7S0S-3%?8F4X95\S
M8S)A.31F9F9F8S`O5V]R:W-H965T<R]3:&5E=#$X+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4F5L871E9"!087)T>2!4<F%N
M<V%C=&EO;G,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%P
M<BX@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^4F5L871E9"!087)T>2!4<F%N<V%C=&EO;G,@6T%B<W1R
M86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y296QA=&5D(%!A<G1Y(%1R86YS86-T:6]N<R!$:7-C;&]S=7)E(%M497AT
M($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^
M3F]T92`Q,"X@4F5L871E9"!087)T>2!4<F%N<V%C=&EO;G,\+V(^/"]P/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@
M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>3L@=&5X="UI;F1E;G0Z(#EP=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q
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M;&ES:&5D(&%N9"!A9W)E960@=&\@8GD@=&AE('!A<G1I97,N/"]P/@T*/'`@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X
M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^
M)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@
M=&5X="UI;F1E;G0Z(#EP=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^1'5R:6YG('1H92!Y
M96%R<R!E;F1E9"!!<')I;"`S,"P@,C`Q,B!A;F0@,C`Q,2P@=&AE($-O;7!A
M;GD@<&%I9"!O;F4@;V8@:71S(&1I<F5C=&]R<R!A;F0@9F]R;65R($-H:65F
M($5X96-U=&EV92!/9F9I8V5R+"`D,3@L,#`P(&%N9"`D,30S+#`P,"P@<F5S
M<&5C=&EV96QY+"!I;B!C;VYS=6QT:6YG(&9E97,@86YD('-A;&%R>2XF(S$V
M,#LF(S$V,#M$=7)I;F<@=&AE('EE87)S(&5N9&5D($%P<FEL(#,P+"`R,#$R
M(&%N9"P@,C`Q,2P@=&AE($-O;7!A;GD@<&%I9"!C97)T86EN(&UE;6)E<G,@
M;V8@;W5R($)O87)D(&]F($1I<F5C=&]R<R`D,30Q+#`P,"!A;F0@)#8P+#`P
M,"P@<F5S<&5C=&EV96QY+"!F;W(@8V]N<W5L=&EN9R!S97)V:6-E<R!U;G)E
M;&%T960@=&\@=&AE:7(@9'5T:65S(&%S(&)O87)D(&UE;6)E<G,N)B,Q-C`[
M)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@
M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#EP=#L@;6%R9VEN.B`P<'0@
M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R<^1'5R:6YG('1H92!Y96%R<R!E;F1E9"!!<')I;"`S,"P@,C`Q,B!A;F0@
M,C`Q,2P@=&AE($-O;7!A;GD@<F5C;V=N:7IE9"!A<'!R;WAI;6%T96QY("0R
M,"PP,#`@86YD("0R,#$L,#`P+"!R97-P96-T:79E;'DL(&EN(')E=F5N=65S
M(&9R;VT@8V]M<&%N:65S('=H;W-E(&)O87)D(&UE;6)E<G,@=V5R92!A;'-O
M(&UE;6)E<G,@;V8@;W5R($)O87)D(&]F($1I<F5C=&]R<RXF(S$V,#LF(S$V
M,#M/9B!T:&5S92!A;6]U;G1S+"!N;R!R96QA=&5D(')E8V5I=F%B;&5S('=E
M<F4@;W5T<W1A;F1I;F<@87,@;V8@07!R:6P@,S`L(#(P,3(@86YD(#(P,3$N
M/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M961A8C!E,C9?,S`T9E\T,S4Q7V)E.&5?,V,R83DT9F9F9F,P#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V5D86(P93(V7S,P-&9?-#,U,5]B93AE
M7S-C,F$Y-&9F9F9C,"]7;W)K<VAE971S+U-H965T,3DN:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY"=7-I;F5S<R!396=M96YT
M($EN9F]R;6%T:6]N/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y!<'(N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/E-E9VUE;G0@4F5P;W)T:6YG(%M!8G-T<F%C=%T\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V5G
M;65N="!297!O<G1I;F<@1&ES8VQO<W5R92!;5&5X="!";&]C:UT\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE
M<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQB/DYO=&4@,3$N($)U<VEN
M97-S(%-E9VUE;G0@26YF;W)M871I;VX\+V(^/"]P/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^)B,Q-C`[
M/"]B/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E
M>'0M:6YD96YT.B`Y<'0[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T
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M:&%R9V5S(&]R(&)E;F5F:71S+"!A;F0@:6YC;VUE('1A>&5S("@F(S@R,C`[
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M8G5S:6YE<W,@<V5G;65N="`H:6X@=&AO=7-A;F1S*3H\+W`^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@.7!T.R!M
M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\=&%B;&4@<W1Y;&4],T0G=VED
M=&@Z(#@U)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@=&5X="UD96-O<F%T:6]N.B!N;VYE.R<^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UW96EG:'0Z(&)O;&0[
M('1E>'0M9&5C;W)A=&EO;CH@;F]N93LG(&YO=W)A<#TS1&YO=W)A<#Y996%R
M($5N9&5D($%P<FEL(#,P+"`R,#$R/"]T9#X-"CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@=&5X="UD96-O
M<F%T:6]N.B!N;VYE.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T
M97AT+6%L:6=N.B!C96YT97([(&9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+61E
M8V]R871I;VXZ(&YO;F4[)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^
M4&5R<V]N86QI>F5D(#QB<B`@+SY/;F-O;&]G>2`\8G(@("\^4V]L=71I;VYS
M(#QB<B`@+SXH4$]3*3PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[('1E>'0M9&5C;W)A=&EO;CH@
M;F]N93LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!T
M97AT+61E8V]R871I;VXZ(&YO;F4[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
M<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[
M('1E>'0M9&5C;W)A=&EO;CH@;F]N93LG(&-O;'-P86X],T0R(&YO=W)A<#TS
M1&YO=W)A<#Y4<F%N<VQA=&EO;F%L(#QB<B`@+SY/;F-O;&]G>2`\8G(@("\^
M4V]L=71I;VYS(#QB<B`@+SXH5$]3*3PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[('1E>'0M9&5C
M;W)A=&EO;CH@;F]N93LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT
M.B!B;VQD.R!T97AT+61E8V]R871I;VXZ(&YO;F4[)R!N;W=R87`],T1N;W=R
M87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG
M:'0Z(&)O;&0[('1E>'0M9&5C;W)A=&EO;CH@;F]N93LG(&-O;'-P86X],T0R
M(&YO=W)A<#TS1&YO=W)A<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R!T97AT+61E8V]R871I;VXZ(&YO;F4[)SX\
M8CXF(S$V,#L\+V(^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
M=&5R.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[('1E>'0M9&5C;W)A=&EO;CH@;F]N93LG/CQB
M/E5N86QL;V-A=&5D/"]B/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&-E;G1E<CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R!T97AT+61E8V]R871I;VXZ(&YO;F4[
M)SX\8CY#;W)P;W)A=&4\+V(^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[('1E>'0M9&5C;W)A=&EO;CH@;F]N
M93LG/CQB/D]V97)H96%D/"]B/CPO<#X-"CPO=&0^#0H\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[('1E>'0M
M9&5C;W)A=&EO;CH@;F]N93LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I
M9VAT.B!B;VQD.R!T97AT+61E8V]R871I;VXZ(&YO;F4[)R!N;W=R87`],T1N
M;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW
M96EG:'0Z(&)O;&0[('1E>'0M9&5C;W)A=&EO;CH@;F]N93LG(&-O;'-P86X]
M,T0R(&YO=W)A<#TS1&YO=W)A<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&-E;G1E<CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R!T97AT+61E8V]R871I;VXZ(&YO;F4[
M)SX\8CXF(S$V,#L\+V(^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M8V5N=&5R.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[('1E>'0M9&5C;W)A=&EO;CH@;F]N93LG
M/CQB/B8C,38P.SPO8CX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97([(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@
M<F]M86XL('1I;65S+"!S97)I9CL@=&5X="UD96-O<F%T:6]N.B!N;VYE.R<^
M/&(^)B,Q-C`[/"]B/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
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M/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)#PO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q,"4[
M)SXR+#,S,CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@
M,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('=I9'1H.B`Q)3LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R!W:61T:#H@,3`E.R<^-"PX,3<\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXD/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$P)3LG
M/BT\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H
M.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W
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M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG
M/B@R+#,S,3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG
M/BD\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R<^*#(L-3,S/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^*3PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
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M969T.R<^*3PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[)SXH.3,V/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^*3PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
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M/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
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M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^*3PO=&0^#0H\=&0^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/B@U+#,S
M.3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/BD\+W1D
M/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F
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M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^+3PO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB
M;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T
M.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#LG/BT\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
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M/BD\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF
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M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/E-E9VUE
M;G0@<')O9FET("AL;W-S*3PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE
M9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^*#$L-S4Q/"]T
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M(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[)SXH,2PU-3`\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T
M=&]M.B`R+C5P=#LG/BD\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R
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M;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[
M)SXD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^*#DL,#8U/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O
M;3H@,BXU<'0[)SXI/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^)B,Q
M-C`[/"]B/CPO<#X-"CQT86)L92!S='EL93TS1"=W:61T:#H@.#4E.R!B;W)D
M97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
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M,S`L(#(P,3$\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+61E8V]R871I;VXZ(&YO;F4[
M)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E
M;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[('1E>'0M9&5C;W)A=&EO;CH@;F]N
M93LG(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#Y097)S;VYA;&EZ960@
M/&)R("`O/D]N8V]L;V=Y(#QB<B`@+SY3;VQU=&EO;G,@/&)R("`O/BA03U,I
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M;&%T:6]N86P@/&)R("`O/D]N8V]L;V=Y(#QB<B`@+SY3;VQU=&EO;G,@/&)R
M("`O/BA43U,I/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
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M<F%P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!M87)G:6XZ
M(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[('1E>'0M9&5C;W)A=&EO;CH@;F]N93LG/CQB/B8C,38P.SPO8CX\
M+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&UA<F=I;CH@
M,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CL@=&5X="UD96-O<F%T:6]N.B!N;VYE.R<^/&(^56YA;&QO8V%T960\
M+V(^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!M87)G
M:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[('1E>'0M9&5C;W)A=&EO;CH@;F]N93LG/CQB/D-O<G!O<F%T
M93PO8CX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&UA
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M;F]W<F%P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!M87)G
M:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[('1E>'0M9&5C;W)A=&EO;CH@;F]N93LG/CQB/B8C,38P.SPO
M8CX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&UA<F=I
M;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S
M+"!S97)I9CL@=&5X="UD96-O<F%T:6]N.B!N;VYE.R<^/&(^)B,Q-C`[/"]B
M/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;6%R9VEN
M.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L
M('-E<FEF.R!T97AT+61E8V]R871I;VXZ(&YO;F4[)SX\8CXF(S$V,#L\+V(^
M/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!M87)G:6XZ
M(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[('1E>'0M9&5C;W)A=&EO;CH@;F]N93LG/CQB/D-O;G-O;&ED871E
M9#PO8CX\+W`^#0H\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+61E8V]R871I;VXZ(&YO
M;F4[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@
M<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('=I9'1H.B`T."4[)SY.970@<F5V96YU93PO=&0^#0H\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXD/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$P)3LG/C,L,S@R/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E
M.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I
M9'1H.B`Q,"4[)SXS+#4P,#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B0\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3`E.R<^+3PO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B0\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@
M,3`E.R<^-BPX.#(\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE
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M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG
M/B@Q+#@P-CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG
M/BD\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[)SXM/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T
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M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/BT\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[)SXM/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE
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M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG
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M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^*3PO=&0^#0H\=&0^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/B@T+#4S
M,SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/BD\+W1D
M/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F
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M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^+3PO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB
M;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^+3PO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ
M(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^*#,L,3,S/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@
M,7!T.R<^*3PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P
M=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L
M:60[('1E>'0M86QI9VXZ(')I9VAT.R<^*#,L,3,S/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T.R<^
M*3PO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z
M('=H:71E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^
M4V5G;65N="!P<F]F:70@*&QO<W,I/"]T9#X-"CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG
M;CH@;&5F=#LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[)SXQ+#<Q
M-SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN
M9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P
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M9&1I;F<M8F]T=&]M.B`R+C5P=#LG/BD\+W1D/@T*/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
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M9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI
M9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^*#4L
M,C,U/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D
M:6YG+6)O='1O;3H@,BXU<'0[)SXI/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@
M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R<^/&(^)B,Q-C`[)B,Q-C`[/"]B/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>"`P<'0@,"XR-6EN.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^*#$I
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M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P
M<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
M<FEF.R<^/&(^)B,Q-C`[/"]B/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`Y<'0[(&UA<F=I;CH@,'!T(#!P
M>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG
M/D%L;"!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(')E=F5N=64@:7,@<F5C;W)D
M960@:6X@=&AE(%5N:71E9"!3=&%T97,@86YD('-U8G-T86YT:6%L;'D@86QL
M(&]F(&ET<R!L;VYG+6QI=F5D(&%S<V5T<R!A<F4@:6X@=&AE(%5N:71E9"!3
M=&%T97,N/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?961A8C!E,C9?,S`T9E\T,S4Q7V)E.&5?,V,R83DT9F9F9F,P#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V5D86(P93(V7S,P-&9?-#,U
M,5]B93AE7S-C,F$Y-&9F9F9C,"]7;W)K<VAE971S+U-H965T,C`N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=7!P;&5M96YT
M86P@4V-H961U;&4@;V8@0V%S:"!&;&]W($EN9F]R;6%T:6]N/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y!<'(N(#,P+"`R,#$R/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U<'!L
M96UE;G1A;"!#87-H($9L;W<@16QE;65N=',@6T%B<W1R86-T73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H($9L;W<L
M(%-U<'!L96UE;G1A;"!$:7-C;&]S=7)E<R!;5&5X="!";&]C:UT\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE
M<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQB/DYO=&4@,3(N(%-U<'!L
M96UE;G1A;"!38VAE9'5L92!O9B!#87-H($9L;W<@26YF;W)M871I;VX\+V(^
M/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN
M.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L
M('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^4W5P<&QE;65N=&%L(&-A<V@@9FQO
M=R!I;F9O<FUA=&EO;B!I<R!A<R!F;VQL;W=S("AI;B!T:&]U<V%N9',I.CPO
M<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@
M,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CLG/B8C,38P.SPO<#X-"CQT86)L92!S='EL93TS1"=W:61T:#H@.3`E
M.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XM;&5F=#H@,"XU:6X[
M)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R('-T>6QE
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M;'-P86X],T0V/EEE87(@16YD960@07!R:6P@,S`L/"]T9#X-"CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG
M/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&9O;G0M=V5I9VAT
M.B!B;VQD.R<@8V]L<W!A;CTS1#(^,C`Q,CPO=&0^#0H\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O
M;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E
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M#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M)SXM/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#LG/BT\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O
M=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUL969T
M.B`Y<'0[)SY#87-H('!A:60@9F]R(&EN8V]M92!T87AE<SPO=&0^#0H\=&0^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG
M/BT\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[)SXM/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C
M:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^
M#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M,"XQ:6X[('!A9&1I;F<M;&5F=#H@
M,"XQ:6X[)SY3=7!P;&5M96YT86P@9&ES8VQO<W5R92!O9B!N;VXM8V%S:"!I
M;G9E<W1I;F<@86YD(&9I;F%N8VEN9R!A8W1I=FET:65S.CPO=&0^#0H\=&0^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG
M/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T
M>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M<&%D9&EN9RUL969T.B`P+C(U:6X[('=I9'1H.B`W-"4[)SY3=&]C:R!S=6)S
M8W)I<'1I;VX@<F5C96EV86)L93PO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3`E.R<^+3PO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H
M.B`Q,"4[)SXH-S4P/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
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M=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#LG/C$Y,CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG
M/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#LG/BT\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CPO=&%B;&4^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E9&%B,&4R
M-E\S,#1F7S0S-3%?8F4X95\S8S)A.31F9F9F8S`-"D-O;G1E;G0M3&]C871I
M;VXZ(&9I;&4Z+R\O0SHO961A8C!E,C9?,S`T9E\T,S4Q7V)E.&5?,V,R83DT
M9F9F9F,P+U=O<FMS:&5E=',O4VAE970R,2YH=&UL#0I#;VYT96YT+51R86YS
M9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z
M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D=R86YT($EN8V]M93QB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ
M,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^07!R+B`S,"P@,C`Q,CQB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY'<F%N="!)
M;F-O;64@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y'<F%N="!);F-O;64@6U1E>'0@0FQO8VM=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=T97AT+6%L
M:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM
M97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\8CY.;W1E(#$S+B!'<F%N
M="!);F-O;64\+V(^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S
M=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#EP=#L@;6%R9VEN
M.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L
M('-E<FEF.R<^26X@3V-T;V)E<B`R,#$P+"!T:&4@0V]M<&%N>2!W87,@;F]T
M:69I960@=&AA="!I="!W87,@87=A<F1E9"!T;W1A;"!C87-H(&=R86YT<R!O
M9B!A<'!R;WAI;6%T96QY("0Q+C4@;6EL;&EO;B!U;F1E<B!T:&4@475A;&EF
M>6EN9R!4:&5R87!E=71I8R!$:7-C;W9E<GD@4')O:F5C="!P<F]G<F%M(&%D
M;6EN:7-T97)E9"!U;F1E<B!S96-T:6]N(#0X1"!O9B!T:&4@26YT97)N86P@
M4F5V96YU92!#;V1E+"!O9B!W:&EC:"!A<'!R;WAI;6%T96QY("0Q+C`@;6EL
M;&EO;B!R96QA=&5D('1O('%U86QI9GEI;F<@97AP96YS97,@=&AE($-O;7!A
M;GD@:&%D('!R979I;W5S;'D@:6YC=7)R960@9'5R:6YG(&9I<V-A;"`R,#$P
M(&%N9"`D,"XU(&UI;&QI;VX@<F5L871E9"!T;R!Q=6%L:69Y:6YG(&5X<&5N
M<V5S('=H:6-H('1H92!#;VUP86YY(&5X<&5C=&5D('1O(&EN8W5R(&1U<FEN
M9R!F:7-C86P@,C`Q,2X@26X@3F]V96UB97(@,C`Q,"P@=&AE($-O;7!A;GD@
M<F5C96EV960@87!P<F]X:6UA=&5L>2`D,2XP(&UI;&QI;VX@<F5L871E9"!T
M;R!T:&4@,C`Q,"!E>'!E;F1I='5R97,N(%1H92!#;VUP86YY(')E8V5I=F5D
M(&$@9FEN86P@<&%Y;65N="!O9B`D,"XU(&UI;&QI;VX@<F5L871E9"!T;R`R
M,#$Q(&5X<&5N9&ET=7)E<R!O;B!&96)R=6%R>2`Q,RP@,C`Q,BX\+W`^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!M87)G:6XZ(#!P="`P<'@[
M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF
M(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T
M97AT+6EN9&5N=#H@.7!T.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY/;B!!=6=U<W0@."P@
M,C`Q,2!T:&4@0V]M<&%N>2!W87,@;F]T:69I960@=&AA="!I="!W87,@<V5L
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M87)E($%C="!O9B`R,#$P(&9O<B!T:&4@,C`P.2!A;F0@,C`Q,"!T87@@>65A
M<G,N(%1H92!E>&%M:6YA=&EO;B!C;VUM96YC960@9'5R:6YG('1H92!S96-O
M;F0@<75A<G1E<B!O9B!F:7-C86P@,C`Q,BX\+W`^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@.7!T.R!M87)G:6XZ
M(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[)SX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y
M.R!T97AT+6EN9&5N=#H@.7!T.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P
M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N
M=#H@.7!T.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[)SY4:&4@25)3(&5X<&%N9&5D(&ET<R!S
M8V]P92!T;R!I;F-L=61E('1H92!F:7-C86P@>65A<B`R,#$Q('1A>"!R971U
M<FXL('=H:6-H('=A<R!F:6QE9"!I;B!*86YU87)Y(#(P,3(N(%1H92!E>&%M
M:6YA=&EO;G,@;V8@9FES8V%L(#(P,#D@86YD(#(P,3`@=V5R92!C;VUP;&5T
M960@:6X@=&AE(&9O=7)T:"!Q=6%R=&5R(&]F(&9I<V-A;"`R,#$R+B!4:&4@
M97AA;6EN871I;VX@;V8@9FES8V%L(#(P,3$@8V]M<&QE=&5D(&EN('1H92!F
M:7)S="!Q=6%R=&5R(&]F(&9I<V-A;"`R,#$S+B!4:&4@875D:70@;V8@86QL
M('1H<F5E(&9I<V-A;"!Y96%R<R`H,C`P.2P@,C`Q,"P@86YD(#(P,3$I(')E
M<W5L=&5D(&EN(&YO(&%D9&ET:6]N86P@=&%X(&1U92!O<B!R96-E:79A8FQE
M+CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7V5D86(P93(V7S,P-&9?-#,U,5]B93AE7S-C,F$Y-&9F9F9C,`T*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E9&%B,&4R-E\S,#1F7S0S-3%?8F4X
M95\S8S)A.31F9F9F8S`O5V]R:W-H965T<R]3:&5E=#(R+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W5B<V5Q=65N="!%=F5N
M=',\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%P<BX@,S`L
M(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^4W5B<V5Q=65N="!%=F5N=',@6T%B<W1R86-T73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=6)S97%U96YT($5V
M96YT<R!;5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@
M,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CLG/CQB/DYO=&4@,30N(%-U8G-E<75E;G0@179E;G1S/"]B/CPO<#X-
M"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`Y<'0[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@
M<F]M86XL('1I;65S+"!S97)I9CLG/CQB/CQI/B8C,38P.SPO:3X\+V(^/"]P
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E
M;G0Z(#EP=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^3F]N92X\+W`^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E9&%B,&4R-E\S,#1F7S0S
M-3%?8F4X95\S8S)A.31F9F9F8S`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z
M+R\O0SHO961A8C!E,C9?,S`T9E\T,S4Q7V)E.&5?,V,R83DT9F9F9F,P+U=O
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M2%)E9CTS1")3:&5E=#`Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970P,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#,N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`T+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970P-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,#8N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`W+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P."YH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,#DN:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#$P+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,2YH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3(N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#$S+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970Q-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,34N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$V+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970Q-RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,3@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$Y+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R,"YH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,C$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#(R+FAT;6PB+SX-"CPO>&UL/@T*+2TM+2TM/5].97AT4&%R=%]E
G9&%B,&4R-E\S,#1F7S0S-3%?8F4X95\S8S)A.31F9F9F8S`M+0T*
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EJF">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS [Parenthetical] (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Apr. 30, 2012</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Offering costs (in dollars)</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 305<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceInitialPublicOffering</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EQEAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Apr. 30, 2012</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 4,754<span></span></td>
        <td class="nump">$ 10,457<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
        <td class="nump">584<span></span></td>
        <td class="nump">585<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Grant receivable</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">517<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump">205<span></span></td>
        <td class="nump">276<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">5,543<span></span></td>
        <td class="nump">11,835<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
        <td class="nump">150<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump">560<span></span></td>
        <td class="nump">146<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
        <td class="nump">669<span></span></td>
        <td class="nump">669<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">6,922<span></span></td>
        <td class="nump">12,650<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>LIABILITIES, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">1,676<span></span></td>
        <td class="nump">1,580<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
        <td class="nump">625<span></span></td>
        <td class="nump">302<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
        <td class="nump">1,185<span></span></td>
        <td class="nump">1,618<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">3,486<span></span></td>
        <td class="nump">3,500<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant liability</a></td>
        <td class="nump">555<span></span></td>
        <td class="nump">972<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump">4,041<span></span></td>
        <td class="nump">4,472<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount', window );">Redeemable common stock; $0.001 par value; 12,533,333 contingently puttable common shares outstanding as of April 30, 2012 and 2011</a></td>
        <td class="nump">8,159<span></span></td>
        <td class="nump">8,159<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $10 par value; 56,075 shares authorized; no shares issued and outstanding as of April 30, 2012 and 2011</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.001 par value; 125,000,000 shares authorized including redeemable common stock; 37,740,345 and 36,956,667 shares issued and 34,529,000 and 33,870,000 shares outstanding as of April 30, 2012 and 2011, respectively</a></td>
        <td class="nump">38<span></span></td>
        <td class="nump">37<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost, 3,236,000 common shares as of April 30, 2012 and 2011</a></td>
        <td class="num">(1,252)<span></span></td>
        <td class="num">(1,252)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
        <td class="nump">21,204<span></span></td>
        <td class="nump">17,784<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(25,143)<span></span></td>
        <td class="num">(16,482)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
        <td class="num">(125)<span></span></td>
        <td class="num">(68)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
        <td class="num">(5,278)<span></span></td>
        <td class="nump">19<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, redeemable common stock and stockholders' equity (deficit)</a></td>
        <td class="nump">$ 6,922<span></span></td>
        <td class="nump">$ 12,650<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e653-108580<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 130<br><br><br><br> -Paragraph 14, 17, 26<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name FASB Staff Position (FSP)<br><br><br><br> -Number FAS115-1/124-1<br><br><br><br> -Paragraph 15D<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e637-108580<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e681-108580<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapitalCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br> -Section S99<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Publisher FASB<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Concepts (CON)<br><br><br><br> -Number 6<br><br><br><br> -Paragraph 25<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Section 45<br><br><br><br> -SubTopic 10<br><br><br><br> -Topic 210<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7<br><br><br><br> -Footnote 1<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7, 26<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 5<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Chapter 3<br><br><br><br> -Section A<br><br><br><br> -Paragraph 7, 8<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair values as of the balance sheet date of all liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments, and which are expected to be extinguished or otherwise disposed of after one year or beyond the normal operating cycle, if longer, net of the effects of master netting arrangements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 107<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name FASB Staff Position (FSP)<br><br><br><br> -Number FIN39-1<br><br><br><br> -Paragraph 10A, 10B<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Chapter 3<br><br><br><br> -Section A<br><br><br><br> -Paragraph 7<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 10<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13433-108611<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 133<br><br><br><br> -Paragraph 4, 17<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13495-108611<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeLiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date, which is the cumulative amount paid and (if applicable) the fair value of any noncontrolling interest in the acquiree, adjusted for any amortization recognized prior to the adoption of any changes in generally accepted accounting principles (as applicable) and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 142<br><br><br><br> -Paragraph 45<br><br><br><br> -Subparagraph e<br><br><br><br> -Clause 1<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 142<br><br><br><br> -Paragraph 43<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 141R<br><br><br><br> -Paragraph 68<br><br><br><br> -Subparagraph l<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 142<br><br><br><br> -Paragraph 45<br><br><br><br> -Subparagraph e<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 141R<br><br><br><br> -Paragraph 34<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905597&amp;loc=d3e13816-109267<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 141R<br><br><br><br> -Paragraph 72<br><br><br><br> -Subparagraph d<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Goodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GrantsReceivableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 129<br><br><br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 5<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Section A<br><br><br><br> -Paragraph 4<br><br><br><br> -Chapter 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Section 45<br><br><br><br> -SubTopic 10<br><br><br><br> -Topic 210<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph b, c<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>As of the reporting date, the carrying amount of noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. The noncontrolling interest holder's ownership (or holders' ownership) may be in the form of common shares (regardless of class), limited partnership units (regardless of class), non-preferential membership interests, or any other form of common equity regardless of investee entity legal form.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 480<br><br><br><br> -SubTopic 10<br><br><br><br> -Subparagraph (12)(c)<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 3A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6802392&amp;loc=SL6540498-122764<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 480<br><br><br><br> -SubTopic 10<br><br><br><br> -Subparagraph 14<br><br><br><br> -Paragraph 3A<br><br><br><br> -Section S99<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6802392&amp;loc=SL6540498-122764<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Emerging Issues Task Force (EITF)<br><br><br><br> -Number D-98<br><br><br><br> -Paragraph 43<br><br><br><br> -Subparagraph b<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 480<br><br><br><br> -SubTopic 10<br><br><br><br> -Subparagraph 15<br><br><br><br> -Paragraph 3A<br><br><br><br> -Section S99<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6802392&amp;loc=SL6540498-122764<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Emerging Issues Task Force (EITF)<br><br><br><br> -Number D-98<br><br><br><br> -Paragraph 43<br><br><br><br> -Subparagraph c<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph 27<br><br><br><br> -Appendix A<br><br><br><br> -Subparagraph c<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 480<br><br><br><br> -SubTopic 10<br><br><br><br> -Subparagraph (16)(c)<br><br><br><br> -Paragraph 3A<br><br><br><br> -Section S99<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6802392&amp;loc=SL6540498-122764<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash and equivalents whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph A3<br><br><br><br> -Appendix A<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name FASB Technical Bulletin (FTB)<br><br><br><br> -Number 85-6<br><br><br><br> -Paragraph 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TreasuryStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ELLBI">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (USD $)<br>In Thousands, except Share data</strong></div>
        </th>
        <th class="th">
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Treasury Stock [Member]</div>
        </th>
        <th class="th">
          <div>Additional Paid-In Capital [Member]</div>
        </th>
        <th class="th">
          <div>Retained Earnings [Member]</div>
        </th>
        <th class="th">
          <div>Stock Subscription Receivable [Member]</div>
        </th>
        <th class="th">
          <div>Accumulated Other Comprehensive Income (Loss) [Member]</div>
        </th>
        <th class="th">
          <div>Total</div>
        </th>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Apr. 30, 2010</a></td>
        <td class="nump">$ 37<span></span></td>
        <td class="num">$ (219)<span></span></td>
        <td class="nump">$ 15,193<span></span></td>
        <td class="num">$ (12,680)<span></span></td>
        <td class="num">$ (750)<span></span></td>
        <td class="num">$ (4)<span></span></td>
        <td class="nump">$ 1,577<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Apr. 30, 2010</a></td>
        <td class="nump">35,780,000<span></span></td>
        <td class="nump">1,064,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">3,133<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">3,133<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised', window );">Exercise of options and warrants</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">20<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">20<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised', window );">Exercise of options and warrants (in shares)</a></td>
        <td class="nump">104,000<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_AdjustmentsToAdditionalPaidInCapitalCancellationOfStockSubscriptionReceivable', window );">Cancellation of stock subscription receivable</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(750)<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">750<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Purchase of treasury stock from board member and cancellation of accrued stock liability</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(1,033)<span></span></td>
        <td class="nump">188<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(845)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Purchase of treasury stock from board member and cancellation of accrued stock liability (in shares)</a></td>
        <td class="num">(2,172,000)<span></span></td>
        <td class="nump">2,172,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock (in shares)</a></td>
        <td class="nump">158,000<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(64)<span></span></td>
        <td class="num">(64)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(3,802)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(3,802)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Apr. 30, 2011</a></td>
        <td class="nump">37<span></span></td>
        <td class="num">(1,252)<span></span></td>
        <td class="nump">17,784<span></span></td>
        <td class="num">(16,482)<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(68)<span></span></td>
        <td class="nump">19<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Apr. 30, 2011</a></td>
        <td class="nump">33,870,000<span></span></td>
        <td class="nump">3,236,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">3,323<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">3,323<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised', window );">Exercise of options and warrants</a></td>
        <td class="nump">1<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">97<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">98<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised', window );">Exercise of options and warrants (in shares)</a></td>
        <td class="nump">534,000<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock (in shares)</a></td>
        <td class="nump">125,000<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(57)<span></span></td>
        <td class="num">(57)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(8,661)<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(8,661)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Apr. 30, 2012</a></td>
        <td class="nump">$ 38<span></span></td>
        <td class="num">$ (1,252)<span></span></td>
        <td class="nump">$ 21,204<span></span></td>
        <td class="num">$ (25,143)<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="num">$ (125)<span></span></td>
        <td class="num">$ (5,278)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Apr. 30, 2012</a></td>
        <td class="nump">34,529,000<span></span></td>
        <td class="nump">3,236,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_AdjustmentsToAdditionalPaidInCapitalCancellationOfStockSubscriptionReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate adjustment to additional paid in capital for cancellation of stock subscription receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>csbr_AdjustmentsToAdditionalPaidInCapitalCancellationOfStockSubscriptionReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>csbr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) and warrants exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>csbr_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>csbr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued during the period as a result of the exercise of stock options and warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>csbr_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>csbr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415241&amp;loc=d3e4534-113899<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6576910&amp;loc=d3e11149-113907<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A91<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6576910&amp;loc=d3e11178-113907<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 39<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tax effect of the adjustment that results from the process of translating subsidiary financial statements and foreign equity investments into functional currency of the reporting entity. While for technical reasons this element has no balance attribute, the default assumption is a credit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 25<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e640-108580<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph c(3)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued and outstanding as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A3<br><br> -Appendix A<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4, 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares that have been repurchased and retired during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Apr. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Note 14. Subsequent Events</b></p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>&#160;</i></b></p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">None.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.1.0.1
 *
 */

var moreDialog = null;
var Show = {
    Default:'raw',

    more:function( obj ){
        var bClosed = false;
        if( moreDialog != null )
        {
			try
			{
				bClosed = moreDialog.closed;
			}
			catch(e)
			{
				//Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control
				// that somtimes causes it to throw when checking the closed property on a child window that has been
				//closed.  So if the exception occurs we assume the window is closed and move on from there.
				bClosed = true;
			}

			if( !bClosed ){
				moreDialog.close();
			}
        }

        obj = obj.parentNode.getElementsByTagName( 'pre' )[0];
		var hasHtmlTag = false;
		var objHtml = '';
		var raw = '';

		//Check for raw HTML
		var nodes = obj.getElementsByTagName( '*' );
		if( nodes.length ){
			objHtml = obj.innerHTML;
		}else{
			if( obj.innerText ){
				raw = obj.innerText;
			}else{
				raw = obj.textContent;
			}

			var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g );
			if( matches && matches.length ){
				objHtml = raw;

				//If there is an html node it will be 1st or 2nd,
				//   but we can check a little further.
				var n = Math.min( 5, matches.length );
				for( var i = 0; i < n; i++ ){
					var el = matches[ i ].toString().toLowerCase();
					if( el.indexOf( '<html' ) >= 0 ){
						hasHtmlTag = true;
						break;
					}
				}
			}
		}

        if( objHtml.length ){
			var html = '';

			if( hasHtmlTag ){
				html = objHtml;
			}else{
				html = '<html>'+
					"\n"+'<head>'+
					"\n"+'    <title>Report Preview Details</title>'+
					"\n"+'    <style type="text/css">'+
					"\n"+'    body {'+
					"\n"+'    }'+
					"\n"+'    table {'+
					"\n"+'    }'+
					"\n"+'    </style>'+
					"\n"+'</head>'+
					"\n"+'<body>'+
						objHtml +
					"\n"+'</body>'+
					"\n"+'</html>';
			}

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write( html );
			moreDialog.document.close();

			if( !hasHtmlTag ){
				moreDialog.document.body.style.margin = '0.5em';
			}
        }
        else
        {
			//default view logic
			var lines = raw.split( "\n" );
			var longest = 0;

			if( lines.length > 0 ){
				for( var p = 0; p < lines.length; p++ ){
					longest = Math.max( longest, lines[p].length );
				}
			}

			//Decide on the default view
			this.Default = longest < 120 ? 'raw' : 'formatted';

			//Build formatted view
			var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ;
			var formatted = '';

			if( text.length > 0 ){
				if( text.length == 1 ){
					text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ;
					formatted = "<p>"+ text.join( "<br /><br />\n" ) +"</p>";
				}else{
					for( var p = 0; p < text.length; p++ ){
						formatted += "<p>" + text[p] + "</p>\n";
					}
				}
			}else{
				formatted = '<p>' + raw + '</p>';
			}

			html = '<html>'+
				"\n"+'<head>'+
				"\n"+'    <title>Report Preview Details</title>'+
				"\n"+'    <style type="text/css">'+
				"\n"+'    body {'+
				"\n"+'       background-color: #f0f9ee;'+
				"\n"+'       font-family: Arial, san-serif; font-size: 0.8em;'+
				"\n"+'    }'+
				"\n"+'    table {'+
				"\n"+'       font-size: 1em;'+
				"\n"+'    }'+
				"\n"+'    </style>'+
				"\n"+'</head>'+
				"\n"+'<body>'+
				"\n"+'    <table border="0" width="100%">'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            formatted: <a href="javascript:void(0);" onclick="opener.Show.toggle( window, this );">'+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +'</a>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <div id="formatted" style="display: none;">'+formatted+'</div>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <pre id="raw" style="display: none; font-size: 1.2em;">'+raw+'</pre>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    </table>'+
				"\n"+'</body>'+
				"\n"+'</html>';

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write(html);
			moreDialog.document.close();

			this.toggle( moreDialog );
        }

		moreDialog.document.title = 'Report Preview Details';
    },

    toggle:function( win, domLink ){
        var domId = this.Default;

        var doc = win.document;
        var domEl = doc.getElementById( domId );
        domEl.style.display = 'block';

        this.Default = domId == 'raw' ? 'formatted' : 'raw';

        if( domLink ){
            domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed';
        }

        var domElOpposite = doc.getElementById( this.Default );
        domElOpposite.style.display = 'none';
    },

	LastAR : null,
	showAR : function ( link, id, win ){
		if( Show.LastAR ){
			Show.hideAR();
		}

		var ref = link;
		do {
			ref = ref.nextSibling;
		} while (ref && ref.nodeName != 'TABLE');

		if (!ref || ref.nodeName != 'TABLE') {
			var tmp = win ?
				win.document.getElementById(id) :
				document.getElementById(id);

			if( tmp ){
				ref = tmp.cloneNode(true);
				ref.id = '';
				link.parentNode.appendChild(ref);
			}
		}

		if( ref ){
			ref.style.display = 'block';
			Show.LastAR = ref;
		}
	},

	toggleNext : function( link ){
		var ref = link;

		do{
			ref = ref.nextSibling;
		}while( ref.nodeName != 'DIV' );

		if( ref.style &&
			ref.style.display &&
			ref.style.display == 'none' ){
			ref.style.display = 'block';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '+', '-' );
			}else{
				link.innerText = link.innerText.replace( '+', '-' );
			}
		}else{
			ref.style.display = 'none';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '-', '+' );
			}else{
				link.innerText = link.innerText.replace( '-', '+' );
			}
		}
	},

	hideAR : function(){
		Show.LastAR.style.display = 'none';
	}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ECJAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Apr. 30, 2012</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (8,661)<span></span></td>
        <td class="num">$ (3,802)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
        <td class="nump">3,323<span></span></td>
        <td class="nump">3,133<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
        <td class="num">(2)<span></span></td>
        <td class="nump">11<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
        <td class="nump">105<span></span></td>
        <td class="nump">42<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Change in fair value of warrant liability</a></td>
        <td class="num">(417)<span></span></td>
        <td class="nump">36<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_IncreaseDecreaseInAccountReceivable', window );">Accounts receivable</a></td>
        <td class="nump">1<span></span></td>
        <td class="num">(493)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_IncreaseOrDecreaseInGrantReceivable', window );">Grant receivable</a></td>
        <td class="nump">517<span></span></td>
        <td class="num">(517)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets', window );">Prepaid expenses, deposits and other</a></td>
        <td class="nump">71<span></span></td>
        <td class="nump">217<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities', window );">Restricted cash</a></td>
        <td class="num">(150)<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
        <td class="nump">96<span></span></td>
        <td class="nump">636<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
        <td class="nump">323<span></span></td>
        <td class="nump">62<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
        <td class="num">(433)<span></span></td>
        <td class="nump">697<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other liabilities</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(77)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
        <td class="num">(5,227)<span></span></td>
        <td class="num">(54)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
        <td class="num">(519)<span></span></td>
        <td class="num">(85)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds form sale of property and equipment</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
        <td class="num">(519)<span></span></td>
        <td class="num">(84)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_ProceedsFromIssuanceOfRedeemableCommonSharesAndWarrantsInPrivatePlacement', window );">Private placement of common shares and warrants (net of $305 in offering costs)</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">9,095<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury stock</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(1,033)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of options and warrants</a></td>
        <td class="nump">97<span></span></td>
        <td class="nump">21<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
        <td class="nump">97<span></span></td>
        <td class="nump">8,083<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Exchange rate effect on cash and cash equivalents</a></td>
        <td class="num">(54)<span></span></td>
        <td class="num">(60)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Increase (decrease) in cash and cash equivalents</a></td>
        <td class="num">(5,703)<span></span></td>
        <td class="nump">7,885<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of year</a></td>
        <td class="nump">10,457<span></span></td>
        <td class="nump">2,572<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of year</a></td>
        <td class="nump">$ 4,754<span></span></td>
        <td class="nump">$ 10,457<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_IncreaseDecreaseInAccountReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The (increase) decrease during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>csbr_IncreaseDecreaseInAccountReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>csbr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The (increase) decrease during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets,or income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>csbr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_IncreaseOrDecreaseInGrantReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The (increase) decrease in amount due during the reporting period in Governmental, corporate, or foundation grants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>csbr_IncreaseOrDecreaseInGrantReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>csbr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_ProceedsFromIssuanceOfRedeemableCommonSharesAndWarrantsInPrivatePlacement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from entity's raising of capital via issuance of common shares and warrants in public placement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>csbr_ProceedsFromIssuanceOfRedeemableCommonSharesAndWarrantsInPrivatePlacement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>csbr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7<br><br> -Footnote 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 8, 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7, 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in cash and cash equivalents. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 45<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 289<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6889476&amp;loc=d3e330036-122817<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredIncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Depreciation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The effect of exchange rate changes on cash balances held in foreign currencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 25<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4A<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6935481&amp;loc=SL5618551-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnDerivativeInstrumentsNetPretax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the sale price or salvage price and the book value of a property, plant, and equipment asset that was sold or retired during the reporting period. This element refers to the gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnSaleOfPropertyPlantEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other current operating liabilities not separately disclosed in the statement of cash flows.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as operating activities. This may include cash restricted for regulatory purposes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from financing activity for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from investing activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow to reacquire common stock during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 20<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsForRepurchaseOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 16<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromWarrantExercises</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EDCAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS [Parenthetical] (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Apr. 30, 2012</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Redeemable common stock, par value (in dollars per share)</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable common stock, shares outstanding</a></td>
        <td class="nump">12,533,333<span></span></td>
        <td class="nump">12,533,333<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
        <td class="nump">$ 10<span></span></td>
        <td class="nump">$ 10<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="nump">56,075<span></span></td>
        <td class="nump">56,075<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">125,000,000<span></span></td>
        <td class="nump">125,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">37,740,345<span></span></td>
        <td class="nump">36,956,667<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump">34,529,000<span></span></td>
        <td class="nump">33,870,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares</a></td>
        <td class="nump">3,236,000<span></span></td>
        <td class="nump">3,236,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of stock classified as temporary equity; generally not indicative of the fair market value per share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 28<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TemporaryEquityParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 28<br><br> -Subparagraph b<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.27(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TemporaryEquitySharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TreasuryStockShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Provision for Income Taxes<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Apr. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Note 9. Provision for Income Taxes</b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The components of the provision for income taxes are as follows (in thousands):</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table align="center" style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="14" nowrap="nowrap">Year Ended April 30, 2012</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Federal</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">State</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Foreign</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Total</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; width: 48%;">Current</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">-</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">1</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">(3</td>
<td style="text-align: left; width: 1%;">)</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">(2</td>
<td style="text-align: left; width: 1%;">)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Deferred</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(2,523</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(172</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(68</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(2,763</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt;">Change in valuation allowance</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">2,523</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">172</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">68</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">2,763</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt;">Total</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">-</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">(3</td>
<td style="text-align: left; padding-bottom: 2.5pt;">)</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">(2</td>
<td style="text-align: left; padding-bottom: 2.5pt;">)</td>
</tr>
</table>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table align="center" style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="14" nowrap="nowrap">Year Ended April 30, 2011</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Federal</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">State</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Foreign</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Total</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; width: 48%;">Current</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">-</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">-</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">11</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">11</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Deferred</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(1,100</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(167</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(68</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(1,335</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt;">Change in valuation allowance</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">1,100</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">167</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">68</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">1,335</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt;">Total</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">-</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">-</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">11</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">11</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>&#160;</b></p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">A reconciliation between the Company&#8217;s effective tax rate and the United States statutory tax rate for the years ended April 30, 2012 and 2011 is as follows:</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>&#160;</b></p>
<table align="center" style="width: 93%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">Year Ended April 30,</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2012</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2011</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; width: 74%;">Federal income tax at statutory rate</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 10%;">34.0</td>
<td style="text-align: left; width: 1%;">%</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 10%;">34.0</td>
<td style="text-align: left; width: 1%;">%</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">State income tax, net of federal benefit</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">2.3</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">4.5</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;">Permanent differences</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1.5</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(0.7</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Other</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(3.0</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">2.5</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;">Change in valuation allowance</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(31.9</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(35.2</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt;">Changes in tax rates</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(2.9</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(5.4</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; text-decoration: none;">
<td style="text-align: left; padding-bottom: 1pt; text-decoration: none;">Income tax expense</td>
<td style="padding-bottom: 1pt; text-decoration: none;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; text-decoration: none;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right; text-decoration: none;"><font style="text-underline-style: double;">-</font></td>
<td style="text-align: left; padding-bottom: 1pt; text-decoration: none;">%&#160;</td>
<td style="padding-bottom: 1pt; text-decoration: none;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; text-decoration: none;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right; text-decoration: none;">(0.3</td>
<td style="text-align: left; padding-bottom: 1pt; text-decoration: none;">)%</td>
</tr>
</table>
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>&#160;</b>&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.&#160;&#160;Significant components of the Company&#8217;s deferred tax assets and liabilities as of April 30, 2012 and 2011 consist of the following (in thousands):</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table align="center" style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">As of April 30,</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2012</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2011</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; width: 74%;">Accrued liabilities</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">62</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">9</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Depreciation and amortization</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">80</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(4</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;">State taxes</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">5</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Stock-based compensation expense</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">2,685</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1,863</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;">Capitalized research and development costs</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">798</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1,182</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Foreign net operating loss carry-forward</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">265</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">198</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt;">Net operating loss carry-forward</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">2,478</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">363</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;">Total deferred tax assets</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">6,373</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">3,611</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt;">Less: Valuation allowance</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(6,373</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(3,611</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt;">Net deferred tax asset</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">-</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">-</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Management has evaluated the available evidence about future tax planning strategies, taxable income and other possible sources of realization of deferred tax assets and has established a full valuation allowance against its net deferred tax assets as of April, 30, 2012.&#160;&#160;For the years ended April 30, 2012 and 2011, the Company recorded a valuation allowance of $6,373,000 and $3,611,000, respectively.&#160;&#160;The increase in valuation allowance from fiscal year 2011 to 2012 is due to deferred tax assets generated relative to stock compensation and net operating loss carryforwards.&#160;&#160;The Company has established a valuation allowance against its deferred tax assets as it is currently more-likely-than-not that all or a portion of a deferred tax asset will not be realized.&#160;&#160;The valuation allowance reduces deferred tax assets to an amount that management believes will more likely than not be realized.&#160;&#160;Changes in valuation allowances from period to period are included in the tax provision in the period of change.&#160;&#160;In determining whether a valuation allowance is required, the Company takes into account all evidence with regard to the utilization of a deferred tax asset including past earnings history, expected future earnings, the character and jurisdiction of such earnings, unsettled circumstances that, if unfavorably resolved, would adversely affect utilization of a deferred tax asset, carryback and carryforward periods, and tax strategies that could potentially enhance the likelihood of realization of a deferred tax asset.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">As of April 30, 2012 and 2011, the Company&#8217;s estimated U.S. net operating loss carry-forwards were approximately $6,825,000 and $928,000, respectively.&#160;&#160;As of April 30, 2012 and 2011, the Company&#8217;s foreign net operating loss carry-forward was approximately $1,138,000 and $790,000, respectively.&#160;&#160;The Company&#8217;s federal and state net operating losses begin expiring in 2029.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company files income tax returns in various jurisdictions with varying statues of limitations.&#160;&#160;As of April 30, 2012, the earliest tax year still subject to examination for state purposes is fiscal 2009.&#160;&#160;The Company&#8217;s tax years for periods ending April 30, 1995 and forward are subject to examination by the United States and certain states due to the carry-forward of unutilized net operating losses.</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On August 8, 2011, the Company was notified that it was selected for a tax examination by the Internal Revenue Service (IRS) on the Application for Certification of Qualified Investments Eligible for Credits and Grants Under the Qualifying Therapeutic Discovery Project program filed under the Patient Protection and Affordable Care Act of 2010 for the 2009 and 2010 tax years. The examination commenced on September 30, 2011 and was completed during the fourth quarter of the year ended April 30, 2012. The audit resulted in a disallowance to the net operating loss carry-forwards of $607,000. This disallowance was offset by a corresponding increase to amortizable intangible assets related to capitalized research and development expenditures of $542,000.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 136, 172<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 43, 44, 45, 46, 47, 48, 49<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EXRAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>DOCUMENT AND ENTITY INFORMATION (USD $)<br>In Millions, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Apr. 30, 2012</div>
        </th>
        <th class="th">
          <div>Jul. 06, 2012</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">CHAMPIONS ONCOLOGY, INC.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0000771856<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--04-30<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Smaller Reporting Company<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
        <td class="text">csbr<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">47,074,942<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-K<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Apr. 30,
         2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">FY<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-Known Seasoned Issuer</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 18.7<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document as an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type is limited to the same value as the supporting SEC submission type, minus any "/A" suffix. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, 497, NCSR, N-CSR, N-CSRS, N-Q, 10-KT, 10-QT, 20-FT, POS AM and Other.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCurrentReportingStatus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityPublicFloat</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityVoluntaryFilers</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityWellKnownSeasonedIssuer</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Trading symbol of an instrument as listed on an exchange.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_TradingSymbol</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related Party Transactions<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Apr. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions Disclosure [Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Note 10. Related Party Transactions</b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Related party transactions include transactions between the Company and its shareholders, management, or affiliates.&#160;&#160;The following transactions were in the normal course of operations and were measured at the exchange amount, which is the amount of consideration established and agreed to by the parties.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">During the years ended April 30, 2012 and 2011, the Company paid one of its directors and former Chief Executive Officer, $18,000 and $143,000, respectively, in consulting fees and salary.&#160;&#160;During the years ended April 30, 2012 and, 2011, the Company paid certain members of our Board of Directors $141,000 and $60,000, respectively, for consulting services unrelated to their duties as board members.&#160;&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">During the years ended April 30, 2012 and 2011, the Company recognized approximately $20,000 and $201,000, respectively, in revenues from companies whose board members were also members of our Board of Directors.&#160;&#160;Of these amounts, no related receivables were outstanding as of April 30, 2012 and 2011.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for related party transactions, including the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 3A<br><br> -Section 04<br><br> -Paragraph b<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 57<br><br> -Paragraph 1-4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 4<br><br> -Section 08<br><br> -Paragraph k<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EZYAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Apr. 30, 2012</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLossAbstract', window );"><strong>Operating revenue:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_PersonalizedOncologySolutions', window );">Personalized oncology solutions</a></td>
        <td class="nump">$ 2,332<span></span></td>
        <td class="nump">$ 3,382<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_TranslationalOncologySolutions', window );">Translational oncology solutions</a></td>
        <td class="nump">4,817<span></span></td>
        <td class="nump">3,500<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNet', window );">Total operating revenue</a></td>
        <td class="nump">7,149<span></span></td>
        <td class="nump">6,882<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Costs and operating expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_CostOfPersonalizedOncologySolutions', window );">Cost of personalized oncology solutions</a></td>
        <td class="nump">2,356<span></span></td>
        <td class="nump">1,665<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_CostOfTranslationalOncologySolutions', window );">Cost of translational oncology solutions</a></td>
        <td class="nump">2,543<span></span></td>
        <td class="nump">1,846<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">2,937<span></span></td>
        <td class="nump">2,910<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
        <td class="nump">2,928<span></span></td>
        <td class="nump">1,085<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump">5,450<span></span></td>
        <td class="nump">4,611<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total costs and operating expenses</a></td>
        <td class="nump">16,214<span></span></td>
        <td class="nump">12,117<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
        <td class="num">(9,065)<span></span></td>
        <td class="num">(5,235)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_GrantIncome', window );">Grant income</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,465<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Change in fair value of warrant liability</a></td>
        <td class="nump">417<span></span></td>
        <td class="num">(36)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other (expense) income</a></td>
        <td class="num">(15)<span></span></td>
        <td class="nump">15<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
        <td class="nump">402<span></span></td>
        <td class="nump">1,444<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income tax expense</a></td>
        <td class="num">(8,663)<span></span></td>
        <td class="num">(3,791)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">(Benefit from) provision for income tax</a></td>
        <td class="num">(2)<span></span></td>
        <td class="nump">11<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (8,661)<span></span></td>
        <td class="num">$ (3,802)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share outstanding, including redeemable common stock, basic and diluted (in dollars per share)</a></td>
        <td class="num">$ (0.19)<span></span></td>
        <td class="num">$ (0.11)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_WeightedAverageNumberOfSharesBasicAndDiluted', window );">Weighted average common shares outstanding, including redeemable common stock, basic and diluted (in shares)</a></td>
        <td class="nump">46,815,000<span></span></td>
        <td class="nump">33,774,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_CostOfPersonalizedOncologySolutions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total costs related to personalized oncology solutions during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>csbr_CostOfPersonalizedOncologySolutions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>csbr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_CostOfTranslationalOncologySolutions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total costs related to translational oncology solutions during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>csbr_CostOfTranslationalOncologySolutions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>csbr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_GrantIncome">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of other income amounts, resulting from grant income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>csbr_GrantIncome</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>csbr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_PersonalizedOncologySolutions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue during the period from personalized oncology solutions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>csbr_PersonalizedOncologySolutions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>csbr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_TranslationalOncologySolutions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue during the period from translational oncology solutions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>csbr_TranslationalOncologySolutions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>csbr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_WeightedAverageNumberOfSharesBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The average number of shares or units issued and outstanding that are used in calculating basic and diluted EPS.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>csbr_WeightedAverageNumberOfSharesBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>csbr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4A<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6935481&amp;loc=SL5618551-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnDerivativeInstrumentsNetPretax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 10<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Income Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 45<br><br> -Subparagraph a, b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpenseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLossAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLossAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of other income amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Audit and Accounting Guide (AAG)<br><br> -Number AAG-BRD<br><br> -Chapter 4<br><br> -Paragraph 80<br><br> -Subparagraph Exhibit 4-4<br><br> -IssueDate 2006-05-01<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNonoperatingIncome</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51<br><br> -Subparagraph g<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 2<br><br> -Paragraph 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 86<br><br> -Paragraph 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueServicesNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue during the period from services rendered in the normal course of business, after deducting allowances and discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 1<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(d))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SalesRevenueServicesNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SellingAndMarketingExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Apr. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Note 4. Commitments and Contingencies</b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Operating Leases</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">As of April 30, 2012, we lease the following facilities under non-cancelable operating lease agreements:</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 9pt;"></td>
<td style="width: 0.25in;"><font style="font-family: symbol;">&#183;</font></td>
<td style="text-align: justify;">One University Plaza, Suite 307, Hackensack, New Jersey 07601, which, since November 2011, serves as our corporate headquarters and consists of approximately 3,800 square feet of office space. The lease expires in April 2014. We incurred $71,000 of rental costs in fiscal 2012 relative to this lease. No rental costs were incurred in fiscal 2011 relative to this lease.</td>
</tr>
</table>
<p style="text-align: justify; margin: 0pt 0px 0pt 27pt; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 9pt;"></td>
<td style="width: 0.25in;"><font style="font-family: symbol;">&#183;</font></td>
<td style="text-align: justify;">855 North Wolfe Street, Suite 619, Baltimore, Maryland 21205, which consists of approximately 1,650 square feet of laboratories and office space where we conduct operations related to our primary service offerings.&#160; The lease expires in June 2014.&#160;We incurred $65,000 and $53,000 of rental costs relative to this lease in fiscal 2012 and 2011, respectively.</td>
</tr>
</table>
<p style="text-align: justify; margin: 0pt 0px 0pt 27pt; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 9pt;"></td>
<td style="width: 0.25in;"><font style="font-family: symbol;">&#183;</font></td>
<td style="text-align: justify;">17 Hatidhar Street, Ra&#8217;anana, Israel, which consists of approximately 1,500 square feet and serves as office headquarters for Champions Oncology, Israel. The lease expires in July 2012; however the Company plans to extend this lease. We incurred $29,000 and $11,000 of rental costs relative to this lease in fiscal 2012 and 2011, respectively.</td>
</tr>
</table>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Future minimum lease payments due each fiscal year are as follows (in thousands):</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table align="center" style="width: 75%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; width: 82%;">2013</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 15%;">162,000</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt;">2014</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">141,000</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt;">Total</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">303,000</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>&#160;</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">As we intend to extend the lease in Israel, of the minimum lease payments in the table above, $28,000 and $7,000 relate to anticipated future lease payments in fiscal 2013 and 2014, respectively.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>&#160;</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Research and Development Materials Purchase Agreement</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In February 2010, the Company entered into a research and development materials purchase agreement with a foreign hospital for the acquisition of TumorGrafts.&#160;&#160;Under the agreement, the Company made monthly payments to the foreign hospital of approximately $37,000, commencing March 1, 2010 and ending April 1, 2011.&#160;&#160;The accrued liability outstanding at April 30, 2011 was $147,000. The Company entered into a Mutual Release Agreement on December 15, 2011 and reversed this liability.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>&#160;</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Legal Matters</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company is party to certain legal matters arising in the ordinary course of its business.&#160;&#160;The Company has evaluated its potential exposure to these legal matters and noted no such exposures. The Company is not aware of any other matters that would have a material impact on the Company&#8217;s financial position or results of operations.</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i></i></b>&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Registration Payment Arrangements</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company has entered into registration rights agreements in connection with a private placement of its securities, which closed during April 2011 and is discussed more fully in Note 7.&#160;&#160;This registration rights agreement contains provisions that may call for the Company to pay penalties in certain circumstances.&#160;&#160;This registration payment arrangement primarily relates to the Company&#8217;s ability to file a registration statement within a particular time period, have a registration statement declared effective within a particular time period and to maintain the effectiveness of the registration statement for a particular time period.&#160;&#160;The Company does not believe it is probable that penalty payments will be made for the registration rights agreement discussed above and, accordingly, has not accrued for such potential penalties as of April 30, 2012 and 2011.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14435-108349<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 14<br><br> -Paragraph 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 9, 10, 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Cephalon Agreement<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Apr. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_CephalonAgreementAbstract', window );"><strong>Cephalon Agreement [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_CephalonAgreementTextBlock', window );">Cephalon Agreement [Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Note 3. Cephalon Agreement</b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On March 16, 2011, the Company entered into an agreement with Cephalon, Inc., (&#8220;Cephalon&#8221;), a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd., pursuant to which the Company conducts TumorGraft studies on proprietary chemical compounds provided by Cephalon to determine the activity or response of a compound in potential clinical indications. In April 2011, Cephalon paid an initiation fee of $1.4 million to the Company, which is reflected within deferred revenue on the consolidated balance sheet as of April 30, 2011. As models, along with required reports, are delivered, the deferred revenue will be recognized on a proportionate basis in accordance with the Company&#8217;s revenue recognition policies. Under this agreement, revenue of $918,000 was recognized during the year ended April 30, 2012. The Company anticipates that the studies will be completed within 18 months of the execution of the agreement.</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Cephalon will, under certain conditions, also pay the Company various amounts upon achieving certain milestones. Potential milestone payments that could be received under the Agreement total $27 million. These milestones are based on the performance of the compounds in preclinical testing and are dependent upon testing the compound in clinical settings and obtaining FDA approval. No milestones have been achieved to date. In addition, under certain conditions, Cephalon will pay the Company royalties on any commercialized products developed under the Agreement. No royalties have been received or earned to date. Cephalon reserves the right to exercise and pay a one-time fee of in lieu of the milestone or royalty payments. These fees range from $460,000 to $880,000 per compound.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_CephalonAgreementAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>csbr_CephalonAgreementAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>csbr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_CephalonAgreementTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure relating to cephalon agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>csbr_CephalonAgreementTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>csbr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Business Segment Information<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Apr. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting Disclosure [Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Note 11. Business Segment Information</b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>&#160;</b></p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company operates in two segments, POS and TOS. The accounting policies of the Company&#8217;s segments are the same as those described in Note 2. The Company evaluates performance of its segments based on profit or loss from operations before stock compensation expense, depreciation and amortization, interest expense, interest income, gain on sale of assets, special charges or benefits, and income taxes (&#8220;segment profit&#8221;). Management uses segment profit information for internal reporting and control purposes and considers it important in making decisions regarding the allocation of capital and other resources, risk assessment, and employee compensation, among other matters. The following tables summarize, for the periods indicated, operating results by business segment (in thousands):</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom; text-decoration: none;">
<td style="text-align: left; font-weight: bold; text-decoration: none;" nowrap="nowrap">Year Ended April 30, 2012</td>
<td style="padding-bottom: 1pt; font-weight: bold; text-decoration: none;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold; text-decoration: none;" colspan="2" nowrap="nowrap">Personalized <br  />Oncology <br  />Solutions <br  />(POS)</td>
<td style="padding-bottom: 1pt; font-weight: bold; text-decoration: none;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold; text-decoration: none;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold; text-decoration: none;" colspan="2" nowrap="nowrap">Translational <br  />Oncology <br  />Solutions <br  />(TOS)</td>
<td style="padding-bottom: 1pt; font-weight: bold; text-decoration: none;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold; text-decoration: none;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold; text-decoration: none;" colspan="2" nowrap="nowrap">
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif; text-decoration: none;"><b>&#160;</b></p>
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif; text-decoration: none;"><b>Unallocated</b></p>
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif; text-decoration: none;"><b>Corporate</b></p>
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif; text-decoration: none;"><b>Overhead</b></p>
</td>
<td style="padding-bottom: 1pt; font-weight: bold; text-decoration: none;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold; text-decoration: none;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold; text-decoration: none;" colspan="2" nowrap="nowrap">
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif; text-decoration: none;"><b>&#160;</b></p>
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif; text-decoration: none;"><b>&#160;</b></p>
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif; text-decoration: none;"><b>&#160;</b></p>
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif; text-decoration: none;"><b>Consolidated</b></p>
</td>
<td style="padding-bottom: 1pt; font-weight: bold; text-decoration: none;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; width: 48%;">Net revenue</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">2,332</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">4,817</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">-</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">7,149</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Direct cost of services</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(2,331</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(2,533</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(4,864</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;">Sales and marketing costs</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(1,752</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(936</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(2,688</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Other operating expenses</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(2,898</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(2,441</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(5,339</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt;">Stock compensation expense (1)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">-</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">$</td>
<td style="border-bottom: black 1pt solid; text-align: right;">-</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(3,323</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(3,323</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt;">Segment profit (loss)</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">(1,751</td>
<td style="text-align: left; padding-bottom: 2.5pt;">)</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">(1,550</td>
<td style="text-align: left; padding-bottom: 2.5pt;">)</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">(5,764</td>
<td style="text-align: left; padding-bottom: 2.5pt;">)</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">(9,065</td>
<td style="text-align: left; padding-bottom: 2.5pt;">)</td>
</tr>
</table>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>&#160;</b></p>
<table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom; text-decoration: none;">
<td style="text-align: left; font-weight: bold; text-decoration: none;" nowrap="nowrap">Year Ended April 30, 2011</td>
<td style="padding-bottom: 1pt; font-weight: bold; text-decoration: none;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold; text-decoration: none;" colspan="2" nowrap="nowrap">Personalized <br  />Oncology <br  />Solutions <br  />(POS)</td>
<td style="padding-bottom: 1pt; font-weight: bold; text-decoration: none;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold; text-decoration: none;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold; text-decoration: none;" colspan="2" nowrap="nowrap">Translational <br  />Oncology <br  />Solutions <br  />(TOS)</td>
<td style="padding-bottom: 1pt; font-weight: bold; text-decoration: none;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold; text-decoration: none;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold; text-decoration: none;" colspan="2" nowrap="nowrap">
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif; text-decoration: none;"><b>&#160;</b></p>
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif; text-decoration: none;"><b>Unallocated</b></p>
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif; text-decoration: none;"><b>Corporate</b></p>
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif; text-decoration: none;"><b>Overhead</b></p>
</td>
<td style="padding-bottom: 1pt; font-weight: bold; text-decoration: none;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold; text-decoration: none;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold; text-decoration: none;" colspan="2" nowrap="nowrap">
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif; text-decoration: none;"><b>&#160;</b></p>
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif; text-decoration: none;"><b>&#160;</b></p>
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif; text-decoration: none;"><b>&#160;</b></p>
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif; text-decoration: none;"><b>Consolidated</b></p>
</td>
<td style="padding-bottom: 1pt; font-weight: bold; text-decoration: none;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; width: 48%;">Net revenue</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">3,382</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">3,500</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">-</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">6,882</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Direct cost of services</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(1,665</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(1,806</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(3,471</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;">Sales and marketing costs</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(980</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(980</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Other operating expenses</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(2,809</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(1,724</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(4,533</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt;">Stock compensation expense (1)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">-</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">-</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(3,133</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(3,133</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt;">Segment profit (loss)</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1,717</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">(1,115</td>
<td style="text-align: left; padding-bottom: 2.5pt;">)</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">(5,837</td>
<td style="text-align: left; padding-bottom: 2.5pt;">)</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">(5,235</td>
<td style="text-align: left; padding-bottom: 2.5pt;">)</td>
</tr>
</table>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>&#160;&#160;</b></p>
<p style="text-align: justify; margin: 0pt 0px 0pt 0.25in; font: 10pt times new roman, times, serif;">(1) Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>&#160;</b></p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">All of the Company&#8217;s revenue is recorded in the United States and substantially all of its long-lived assets are in the United States.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SegmentReportingAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8595-108599<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8538-108599<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 33<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8971-108599<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 34<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8981-108599<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 29<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8864-108599<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8380-108599<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 35<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8984-108599<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 41<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e9038-108599<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 32<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8933-108599<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 131<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8906-108599<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8844-108599<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 40<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e9031-108599<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 42<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e9054-108599<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 31<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8924-108599<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SegmentReportingDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Redeemable Common Stock and Stock Purchase Warrant<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Apr. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_RedeemableCommonStockAndStockPurchaseWarrantAbstract', window );"><strong>Redeemable Common Stock and Stock Purchase Warrant [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_RedeemableCommonStockAndStockPurchaseWarrantTextBlock', window );">Redeemable Common Stock and Stock Purchase Warrant [Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Note 7. Redeemable Common Stock and Stock Purchase Warrant</b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On March 24, 2011, the Company entered into a Securities Purchase Agreement with several accredited investors for the sale of an aggregate 12,533,333 shares of the Company&#8217;s Common Stock at a purchase price of $0.75 per share, or aggregate proceeds of $9.4 million, $500,000 of which was sold to officers and directors of the Company. As part of this transaction, the Company also issued warrants to purchase an aggregate 1,266,667 shares of Common Stock at an exercise price of $0.90 per share. These warrants expire five years after the closing date, which occurred on April 4, 2011. The Securities Purchase Agreement contains certain anti-dilution protections for the investors and certain registration rights with respect to the shares of Common Stock issued to the investors. Furthermore, investors will have the right to require the Company to redeem the purchased common shares held by such investors (the &#8220;Put Option&#8221;) for cash for $0.75 per share upon a change of control or sale of substantially all of the company&#8217;s assets. The Put Option will terminate upon the achievement of certain financial milestones by the Company, the sale of 25% of the common shares purchased by an investor, with respect only to the shares owned by such investor, or in certain other circumstances as outlined in the Securities Purchase Agreement.</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Due to the Put Option described above, the Company has accounted for Common Stock issued under the Securities Purchase Agreement as temporary equity, which is reflected under the caption &#8220;redeemable common stock&#8221; on the accompanying consolidated balance sheets. The total amount allocated to these common shares was $8.2 million. This allocation is equal to the total proceeds of $9.4 million, less the amount allocated to the warrants of $936,000 and is also net of direct and incremental costs associated with the Securities Purchase Agreement of $305,000.</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The warrants issued in connection with the Securities Purchase Agreement contain certain exercise price reset provisions. Under these provisions, the exercise price of the warrants may be adjusted downward should the Company have future sales of its Common Stock for no consideration or for a consideration per share less than the Per Share Price (as such term is defined in the Securities Purchase Agreement).</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company has granted demand registration rights in connection with the investment in common shares and the common shares underlying the warrants. These rights include the requirement of the Company to file certain registration statements within a specified time period and to have these registration statements declared effective within a specified time period. If the Company is not able to comply with these registration requirements, the Company will be required to pay cash penalties equal to 1.0% of the aggregate Purchase Price paid by the investors for each 30-day period in which a Registration Default, as defined in the Securities Purchase Agreement, exists. The Company may become subject to these penalty provisions if it fails to have a registration statement for the common shares declared effective, or to maintain the effectiveness of such registration statement. The total amount of potential penalties under this registration payment arrangement is $41,000 for each 30-day period in which a registration default exists; however, as of the date of this filing, the Company does not believe these penalties to be probable and accordingly, has not established an accrual for such registration payment arrangements.</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company has accounted for the warrants issued in connection with the Securities Purchase Agreement as a liability based on the exercise price reset provisions described above. This liability, which is recorded at fair value on the accompanying consolidated balance sheets, totaled $936,000 at the time of the close of the Securities Purchase Agreement. As of April 30, 2011, the fair value of these warrants increased $36,000 to $972,000. During the year ended April 30, 2012, the fair value of these warrants decreased by $417,000 to $555,000. The change in fair value of these warrants has been, and will be, recognized as other income (expense) on the Company&#8217;s consolidated statements of operations. The fair value of these warrants was calculated by the Monte Carlo simulation valuation method. Assumptions used to calculate the fair value of these warrants were as follows:</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6">Year Ended April 30,</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2">2012</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2">2011</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; width: 74%;">Expected term in years</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 10%;">3.9</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 10%;">5.0</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Risk-free interest rates</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.6</td>
<td style="text-align: left;">%</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">2.0</td>
<td style="text-align: left;">%</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;">Volatility</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">102</td>
<td style="text-align: left;">%</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">102</td>
<td style="text-align: left;">%</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Dividend yield</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0</td>
<td style="text-align: left;">%</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0</td>
<td style="text-align: left;">%</td>
</tr>
</table>
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>&#160;</b></p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company will continue to adjust the warrant liability for changes in fair value until the earlier of the exercise of the warrants, at which time the liability will be reclassified to stockholders' equity, or expiration of the warrants.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_RedeemableCommonStockAndStockPurchaseWarrantAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>csbr_RedeemableCommonStockAndStockPurchaseWarrantAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>csbr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_RedeemableCommonStockAndStockPurchaseWarrantTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity-based compensation plans and award types, including multiple equity-based payment arrangements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>csbr_RedeemableCommonStockAndStockPurchaseWarrantTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>csbr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Licensing Agreements<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Apr. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_LicensingAgreementsAbstract', window );"><strong>Licensing Agreements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_LicensingAgreementsDisclosureTextBlock', window );">Licensing Agreements Disclosure [Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Note 5. Licensing Agreements</b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">During fiscal 2011, the Company was a party to several different licensing agreements. During April 2011, the Company terminated all of these licensing agreements with the exception of the agreement concerning Irinophore C, which is described further below. All rights related to all other licensing agreements that were terminated during April 2011 were returned to the underlying companies and no amounts were payable under these other agreements when they were terminated.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In February 2010, the Company entered into an exclusive option agreement with a Canadian company for which it paid and expensed $40,000 (Canadian) during the Company&#8217;s fiscal 2010 year. The option agreement granted the Company the exclusive right to review Irinophore C, a nanoparticle drug compound, for the treatment of various forms of cancer, including melanoma, prostate, breast, and lung cancer through April 2011. During the option year, the Company performed various TumorGraft testing on the nanoparticle compound. In March 2011, the Company exercised its option to license Irinophore C, a liposomal formulation of Irinotecan. Under the terms of the agreement, the Company&#8217;s exercise of the option resulted in amounts due to the Canadian company of $85,000 (Canadian) comprised of the option exercise price and reimbursement to the Canadian company for past patent costs, which was expensed in the Company&#8217;s fiscal year ended April 30, 2011. The Company satisfied this obligation during fiscal 2012. On the first anniversary of the agreement (March 2012), an additional license fee of $45,000 (Canadian) became due, which is recognized as a liability as of April 30, 2012. Commencing with the second anniversary of the agreement (March 2013), the Company will be obligated to pay a minimum annual royalty of $10,000 (Canadian). Under the terms of the license agreement, the Company will be required to pay up to $3.0 million in development milestones, if achieved. Upon commercialization, the Company would also be required to make royalty and sales milestone payments based upon revenues.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_LicensingAgreementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>csbr_LicensingAgreementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>csbr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_LicensingAgreementsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure related to several different licensing agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>csbr_LicensingAgreementsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>csbr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Share-Based Payments<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Apr. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Note 6. Share-Based Payments</b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Stock-based compensation in the amount of $3.3 million and $3.1 million was recognized for the years ended April 30, 2012 and 2011, respectively.&#160;&#160;Stock-based compensation costs were recorded as follows (in thousands):</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table align="center" style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">Year Ended April 30,</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2012</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2011</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; width: 74%;">General and administrative</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">3,009</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">2,887</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Sales and marketing</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">240</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">105</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;">Research and development</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">39</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">101</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">TOS cost of sales</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">10</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">40</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt;">POS cost of sales</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">25</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">-</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt;">Total stock-based compensation expense</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">3,323</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">3,133</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>&#160;</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>2010 Equity Incentive Plan</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On February 18, 2011, shareholders owning a majority of the issued and outstanding shares of the Company executed a written consent approving the 2010 Equity Incentive Plan (&#8220;2010 Equity Plan&#8221;). The purpose of the 2010 Equity Plan is to grant (i) Non-statutory Stock Options; (ii) Restricted Stock Awards; and (iii) Stock Appreciation Rights (collectively, stock-based compensation) to its employees, directors and non-employees. Total stock awards under the 2010 Equity Plan shall not exceed 30,000,000 shares of common stock. Options and Stock Appreciation Rights expire no later than ten years from the date of grant and the awards vest as determined by the Board of Directors. Options and Stock Appreciation Rights have a strike price not less than 100% of the fair market value of the common stock subject to the option or right at the date of grant.</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>2008 Equity Incentive Plan</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company has previously granted (i) Non-statutory Stock Options; (ii) Restricted Stock Awards; and (iii) Stock Appreciation Rights (collectively, stock-based compensation) to its employees, directors and non-employees under a 2008 Equity Incentive Plan (the &#8220;2008 Equity Plan&#8221;).&#160;&#160;Such awards may be granted by the Company&#8217;s Board of Directors.&#160;&#160;Options granted under the 2008 Equity Plan expire no later than ten years from the date of grant and the awards vest as determined by the Board of Directors.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">For share-based payments to non-employee consultants under both the 2010 and 2008 Equity Incentive Plan, the fair value of the share-based consideration issued is used to measure the transaction, as management believes this to be a more reliable measure of fair value than the services received.&#160;&#160;The fair value of the award is expensed over the period service is provided to the Company; however, it is ultimately measured at the price of the Company&#8217;s common stock or the fair value of stock options using the Black-Scholes valuation model on the date that the commitment for performance by the non-employee consultant has been reached or performance is complete, which is generally the vesting date of the award.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Director Compensation Plan</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On February 22, 2010, the Compensation Committee of the Board of Directors of the Company adopted the Director Compensation Plan of 2010 (the &#8220;Director Plan&#8221;) to replace the Company&#8217;s former compensation policy for directors, effective for the 2010 calendar year commencing January 1, 2010.&#160;&#160;Under the Director Plan, independent directors of the Company are entitled to an annual award of five-year stock options to purchase 50,000 shares of the Company&#8217;s unregistered common stock, and the Chairman of the Board of the Company is entitled to an annual award of options to purchase 100,000 shares of the Company&#8217;s unregistered common stock.&#160;&#160;Independent directors who serve on one or more Board committees will also receive an annual grant of five-year options to purchase 50,000 shares of the Company&#8217;s unregistered common stock or 50,000 shares of restricted unregistered common stock.&#160;&#160;The Company will also pay each independent director $15,000 to offset the tax liability in respect of any unregistered restricted stock awards.&#160;&#160;All unregistered common stock options and unregistered restricted stock issued under the Director Plan vest quarterly at a rate of 25%. For the initial Director Plan year, an independent director could have chosen to receive a cash fee equal to the value of the unregistered restricted common stock that would have otherwise been granted.&#160;&#160;The Chairman of the Board was also entitled to the same arrangement for his services on Board committees at a rate of twice that of an independent director.&#160;&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Stock Option Grants</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Black-Scholes assumptions used to calculate the fair value of options granted during the years ended April 30, 2012 and 2011 were as follows:</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table align="center" style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">Year Ended April 30,</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2012</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2011</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; width: 64%;">Expected term in years</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: center; width: 15%;" nowrap="nowrap">3.0 - 6.0</td>
<td style="text-align: left; width: 1%;" nowrap="nowrap">&#160;</td>
<td style="width: 1%;" nowrap="nowrap">&#160;</td>
<td style="text-align: left; width: 1%;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; width: 15%;" nowrap="nowrap">2.7 - 6.25</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Risk-free interest rates</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">0.4% - 2.3%</td>
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">0.9% - 2.7%</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;">Volatility</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">90% - 108%</td>
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">105% - 122%</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Dividend yield</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">0%</td>
<td style="text-align: left;" nowrap="nowrap"></td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">0%</td>
<td style="text-align: left;"></td>
</tr>
</table>
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The weighted average fair value of stock options granted during the years ending April 30, 2012 and 2011, was $0.58 and $0.73, respectively. The Company&#8217;s stock options activity and related information as of and for the years ended April 30, 2012 and 2011 is as follows (dollars in thousands):</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table align="center" style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: left; vertical-align: top;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Weighted</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left; vertical-align: top;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Weighted</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Average</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left; vertical-align: top;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Directors</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Average</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Remaining</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Aggregate</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left; vertical-align: top;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Non-</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">and</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Exercise</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Contractual</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Intrinsic</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left; vertical-align: top;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Employees</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Employees</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Total</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Price</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Life (Years)</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Value</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left; vertical-align: top;" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; width: 22%; vertical-align: top;">Outstanding, May 1, 2011</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 10%;">1,610,000</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 10%;">12,710,948</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 10%;">14,320,948</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">0.88</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 10%;">8.4</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">1,780</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top;">Granted</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">115,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1,380,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1,495,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.77</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top;">Exercised</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(50,000</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(50,000</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.17</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top;">Forfeited</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(348,581</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(348,581</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.94</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top;">Expired</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(265,000</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(286,329</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(551,329</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 1pt;">0.60</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; vertical-align: top;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top;">Outstanding, April 30, 2012</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1,410,000</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">13,456,038</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">14,866,038</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 2.5pt;">0.88</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 2.5pt;">7.6</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 2.5pt;">$</td>
<td style="text-align: right; padding-bottom: 2.5pt;">0</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; vertical-align: top;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top;">Vested and expected to vest as of April 30, 2012</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1,410,000</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">13,456,038</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">14,866,038</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 2.5pt;">0.88</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 2.5pt;">7.6</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 2.5pt;">$</td>
<td style="text-align: right; padding-bottom: 2.5pt;">0</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top;">Exercisable as of April 30, 2012</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1,241,667</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">6,502,163</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">7,743,830</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 2.5pt;">0.89</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 2.5pt;">6.8</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 2.5pt;">$</td>
<td style="text-align: right; padding-bottom: 2.5pt;">0</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table>
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>&#160;</b></p>
<table align="center" style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: left; vertical-align: top;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Weighted</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left; vertical-align: top;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Weighted</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Average</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left; vertical-align: top;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Directors</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Average</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Remaining</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Aggregate</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left; vertical-align: top;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Non-</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">and</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Exercise</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Contractual</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Intrinsic</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left; vertical-align: top;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Employees</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Employees</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Total</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Price</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Life (Years)</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Value</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left; vertical-align: top;">&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; width: 22%; vertical-align: top;">Outstanding, May 1, 2010</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 10%;">1,890,000</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 10%;">1,427,948</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 10%;">3,317,948</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">0.77</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 10%;">4.4</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">250</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top;">Granted</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">70,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">11,781,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">11,851,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.89</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top;">Exercised</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top;">Forfeited</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top;">Expired</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(500,000</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(348,000</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(848,000</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.58</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top;">Change in employee status</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">150,000</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(150,000</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">-</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 1pt;">1.18</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; vertical-align: top;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top;">Outstanding, April 30, 2011</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1,610,000</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">12,710,948</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">14,320,948</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 2.5pt;">$</td>
<td style="text-align: right; padding-bottom: 2.5pt;">0.88</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 2.5pt;">8.4</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 2.5pt;">$</td>
<td style="text-align: right; padding-bottom: 2.5pt;">1,780</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; vertical-align: top;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top;">Vested and expected to vest as of April 30, 2011</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1,610,000</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">12,710,948</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">14,320,948</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 2.5pt;">$</td>
<td style="text-align: right; padding-bottom: 2.5pt;">0.88</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 2.5pt;">8.4</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 2.5pt;">$</td>
<td style="text-align: right; padding-bottom: 2.5pt;">1,780</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in; vertical-align: top;">Exercisable as of April 30, 2011</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1,533,333</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">2,461,644</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">3,994,977</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 2.5pt;">$</td>
<td style="text-align: right; padding-bottom: 2.5pt;">0.85</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 2.5pt;">5.7</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 2.5pt;">$</td>
<td style="text-align: right; padding-bottom: 2.5pt;">597</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table>
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>&#160;</b></p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Included in the balances outstanding as of May 1, 2011 in the table above are 10,000,000 options granted to the Company&#8217;s Chief Executive Officer and its&#160;President at the time of commencement of their employment in fiscal 2011, of which 5,000,000 contain only service-based vesting provisions and 5,000,000 contain both service and performance-based vesting provisions.&#160;&#160;The service-based provisions of these options provide for vesting to occur monthly over a period of three years.&#160;&#160;The performance-based conditions, which must be met prior to vesting to occur include: (i) closing of one or more financings of the Company in the aggregate amount of at least $5,000,000; (ii) bringing in new Company management; (iii) launching of personalized medicine (oncology) business; and (iv) commencing implementation of the Company&#8217;s business plan.&#160;&#160;The determination as to whether these performance-based conditions have been met was to be made by the Company&#8217;s Board of Directors.&#160;&#160;The service-based options, like all of the Company&#8217;s service-based options, are expensed on a straight-line basis.&#160;&#160;Since the straight-line method is not available for performance or market-based share-based payments, the 5,000,000 performance-based options are being expensed on an accelerated basis.&#160;&#160;The Company&#8217;s Board of Directors determined that in April 2011 each of the performance conditions under the awards were met.&#160;&#160;As a result, the awards will be expensed based on each monthly vesting tranche.</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Restricted Stock Grants</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">A summary of the activity related to restricted stock grants for the years ended April 30, 2012 and 2011 is as follows (dollars in thousands):</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table align="center" style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">2012</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">2011</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Weighted</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Weighted</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Average</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Average</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Grant Date</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Grant Date</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Total</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Fair Value</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Total</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Fair Value</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Shares</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Per Share</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Shares</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Per Share</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; width: 48%;">Nonvested, beginning of period</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 10%;">100,000</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">0.90</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 10%;">33,526</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">0.80</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Granted</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">50,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.75</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">205,555</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.90</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;">Vested</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(125,000</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.87</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(133,397</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.87</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Forfeited</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(5,684</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.77</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt;">Expired</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">-</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">-</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt;">Nonvested, end of period</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">25,000</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 2.5pt;">$</td>
<td style="text-align: right; padding-bottom: 2.5pt;">0.75</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">100,000</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 2.5pt;">$</td>
<td style="text-align: right; padding-bottom: 2.5pt;">0.90</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table>
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>&#160;</b></p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The total fair value of shares vested during the years ended April 30, 2012 and 2011 was $84,000 and $133,000, respectively. As of April 30, 2012, there was $19,000 of unrecognized stock compensation expense related to nonvested restricted stock awards. This cost is expected to be recognized over a weighted average period of 0.3 years.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Stock Purchase Warrants</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">As of April 30, 2012, the Company has warrants outstanding for the purchase of 1,416,667 shares of its common stock, all of which were exercisable.&#160;&#160;Of these warrants, 1,266,667 were issued in connection with the April 2011 financing arrangement and are accounted for as liabilities as further discussed in Note 7.&#160;&#160;Activity related to these warrants, which expire at various dates through April 2016, is summarized as follows (dollars in thousands):</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table align="center" style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Weighted</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Weighted</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Average</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Number</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Average</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Remaining</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Aggregate</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">of</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Exercise</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Contractual</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Intrinsic</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Shares</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Price</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Life (Years)</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Value</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; width: 48%;">Outstanding, May 1, 2011</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 10%;">1,912,019</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">0.73</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 10%;">3.7</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">524</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Granted</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;">Exercised</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(495,352</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.20</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">234</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Forfeited</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt;">Expired</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">-</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 1pt;">-</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt;">Outstanding, April 30, 2012</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1,416,667</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 2.5pt;">$</td>
<td style="text-align: right; padding-bottom: 2.5pt;">0.91</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 2.5pt;">3.8</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 2.5pt;">$</td>
<td style="text-align: right; padding-bottom: 2.5pt;">0</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table>
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>&#160;</b></p>
<table align="center" style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Weighted</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Weighted</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Average</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Number</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Average</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Remaining</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Aggregate</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">of</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Exercise</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Contractual</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Intrinsic</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Shares</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Price</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Life (Years)</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Value</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; width: 48%;">Outstanding, May 1, 2010</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 10%;">748,983</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">0.36</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 10%;">2.1</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">367</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Granted</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1,266,667</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.90</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;">Exercised</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(103,631</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.20</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(83</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Forfeited</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt;">Expired</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">-</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 1pt;">-</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt;">Outstanding, April 30, 2011</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1,912,019</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 2.5pt;">$</td>
<td style="text-align: right; padding-bottom: 2.5pt;">0.73</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 2.5pt;">3.7</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 2.5pt;">$</td>
<td style="text-align: right; padding-bottom: 2.5pt;">524</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 93-6<br><br> -Paragraph 53<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64, 65, A240<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Apr. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Note 8. Stockholders&#8217; Equity</b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Preferred Stock</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company has 56,075 shares of Series A 12% preferred stock authorized and no shares issued and outstanding at April 30, 2012 and 2011.</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Common Stock</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On February 18, 2011, the Company&#8217;s Board of Directors approved the amendment and restatement of the Company&#8217;s Certificate of Incorporation (or &#8220;Charter&#8221;) and submitted the amended and restated Charter to the Company&#8217;s shareholders for approval.&#160;&#160;On February 18, 2011, shareholders owning a majority of the issued and outstanding shares of the Company executed a written consent approving the amended and restated Charter.&#160;&#160;In accordance with regulations of the Securities and Exchange Commission, the amended and restated Charter was filed with the SEC on March 7, 2011. Among other changes, the amended and restated Charter changes the name of the Company to &#8220;Champions Oncology, Inc.&#8221; and increases the authorized shares which the Company may issue from 50,000,000 shares of Common Stock to 125,000,000 shares of Common Stock.&#160;&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">As of April 30, 2010, the Company had executed subscription agreements for the private placement of 1,000,000 shares of unregistered common stock for $0.75 per share or $750,000. The amount was reflected as a subscription receivable as a contra-equity account on the balance sheet as of April 30, 2010. In 2011, the Company became aware that the amount was uncollectible in full and the full amount was reversed against additional paid-in capital.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Treasury Stock</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In May 2009, the Board of Directors approved a stock repurchase agreement with a Board member which obligated the Company to purchase up to approximately $407,000 of the Company&#8217;s common stock held by the Board member through April of 2011 providing that the Board member continued his services under a consulting agreement executed concurrently with the stock repurchase agreement.&#160;&#160;Under the stock repurchase agreement, the Company made an initial purchase of $125,000 of the Company&#8217;s shares of common stock, and may have been required to make quarterly purchases of $31,250 of the Company&#8217;s common stock held by the Board member after the end of each fiscal quarter.&#160;&#160;The purchase price per share of the common stock for each purchase is equal to the lesser price of $0.50 or 50% of the average closing price of the stock as quoted on the OTC Bulletin Board for the 30-day trading period ending on the day before the date of each purchase as long as the consulting agreement remained in effect.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Under the agreement, the Company has paid this Board member approximately $73,000 and $218,000 for the purchase of 171,883 and 474,289&#160;&#160;shares of the Company&#8217;s common stock for the years ended April 30, 2011 and April 30, 2010, respectively.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Effective May 2010, the Company terminated the consulting agreement with the Board member which correspondingly terminated the stock repurchase agreement.&#160;&#160;Because the requirement for the Company to transfer cash in exchange for the shares of common stock ended with the termination of the consulting agreement, during the year ended April 30, 2011, the Company reclassified $114,000 from accrued stock purchase on the balance sheet into additional paid-in capital, which represented the remaining amount of the purchase price required under the repurchase arrangement after the termination of the consulting agreement.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Furthermore, under the stock repurchase agreement, the Company, at its option for one year following the termination of the consulting agreement, may purchase all or any part of the shares that have not been previously purchased, up to but not to exceed, 2,250,000 shares of the common stock, subject to the pricing formula described above. In April 2011, the Company repurchased 2,000,000 shares of the Company&#8217;s common stock from the Board Member of the Company, for a cash purchase price of $0.48 per share, or an aggregate purchase price of $960,000. The Company repurchased the shares using proceeds from the $9,400,000 received under the Securities Purchase Agreement that closed in April 2011 and is described in Note 7.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company has not repurchased any shares in fiscal 2012.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable).  Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187143-122770<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 4<br><br> -Section 08<br><br> -Paragraph d<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Chapter 1<br><br> -Section B<br><br> -Paragraph 7, 11A<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 20: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 21: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 22: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 23: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Grant Income<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Apr. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_GrantIncomeAbstract', window );"><strong>Grant Income [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_GrantIncomeTextBlock', window );">Grant Income [Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Note 13. Grant Income</b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In October 2010, the Company was notified that it was awarded total cash grants of approximately $1.5 million under the Qualifying Therapeutic Discovery Project program administered under section 48D of the Internal Revenue Code, of which approximately $1.0 million related to qualifying expenses the Company had previously incurred during fiscal 2010 and $0.5 million related to qualifying expenses which the Company expected to incur during fiscal 2011. In November 2010, the Company received approximately $1.0 million related to the 2010 expenditures. The Company received a final payment of $0.5 million related to 2011 expenditures on February 13, 2012.</p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On August 8, 2011 the Company was notified that it was selected for a tax examination by the Internal Revenue Service (IRS) on the Application for Certification of Qualified Investments Eligible for Credits and Grants Under the Qualifying Therapeutic Discovery Project program filed under the Patient Protection and Affordable Care Act of 2010 for the 2009 and 2010 tax years. The examination commenced during the second quarter of fiscal 2012.</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The IRS expanded its scope to include the fiscal year 2011 tax return, which was filed in January 2012. The examinations of fiscal 2009 and 2010 were completed in the fourth quarter of fiscal 2012. The examination of fiscal 2011 completed in the first quarter of fiscal 2013. The audit of all three fiscal years (2009, 2010, and 2011) resulted in no additional tax due or receivable.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_GrantIncomeAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>csbr_GrantIncomeAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>csbr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_GrantIncomeTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure relating to grant income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>csbr_GrantIncomeTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>csbr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EKBAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Apr. 30, 2012</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (8,661)<span></span></td>
        <td class="num">$ (3,802)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease', window );">Foreign currency translation adjustment</a></td>
        <td class="num">(57)<span></span></td>
        <td class="num">(64)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
        <td class="num">$ (8,718)<span></span></td>
        <td class="num">$ (3,866)<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e540-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A5<br><br> -Appendix A<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph c(3)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 8, 9, 10, 11, 12, 13, 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508144<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e557-108580<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ComprehensiveIncomeNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Adjustment that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency of the reporting entity, net of tax.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 20<br><br> -Subparagraph (b),(c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6915805&amp;loc=d3e32211-110900<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920433&amp;loc=d3e998-108581<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 24<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph c(3)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 14, 17, 19, 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 52<br><br> -Paragraph 13, 20, 31<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Apr. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Note 2. Summary of Significant Accounting Policies</b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Principles of Consolidation</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries: Biomerk, Inc., Champions Biotechnology U.K., Limited and Champions Oncology (Israel), Limited. All material intercompany balances and transactions have been eliminated in consolidation.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The financial statements of the Company&#8217;s foreign subsidiaries, all of which have a functional currency other than the U.S. dollar, have been translated into the U.S. dollar for the Company&#8217;s consolidated financial statements for each period being presented. Translation gains and losses are recognized as a component of accumulated other comprehensive loss in the accompanying consolidated balance sheets. The Company is subject to foreign exchange rate fluctuations in connection with the Company&#8217;s international operations.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Use of Estimates</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Cash and Cash Equivalents</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company considers all highly liquid investments purchased with an original maturity of three months or less, to be cash equivalents. At various times, the Company has amounts on deposit at financial institutions in excess of federally insured limits.</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Fair Value</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The carrying value of cash and cash equivalents, accounts receivable, prepaid expenses, deposits and other receivables, accounts payable, and accrued liabilities approximate their fair value based on the liquidity or the short-term maturities of these instruments. The fair value hierarchy promulgated by GAAP consists of three levels:</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 9pt;"></td>
<td style="width: 15pt;"><font style="font-family: symbol;">&#183;</font></td>
<td style="text-align: justify;"><i>Level one</i> &#8212; Quoted market prices in active markets for identical assets or liabilities;</td>
</tr>
</table>
<table style="margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 9pt;"></td>
<td style="width: 15pt;"><font style="font-family: symbol;">&#183;</font></td>
<td style="text-align: justify;"><i>Level two</i> &#8212; Inputs other than level one inputs that are either directly or indirectly observable; and</td>
</tr>
</table>
<table style="margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 9pt;"></td>
<td style="width: 15pt;"><font style="font-family: symbol;">&#183;</font></td>
<td style="text-align: justify;"><i>Level three</i> &#8212; Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.</td>
</tr>
</table>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter. The Company has one liability measured at fair value on a recurring basis, which are warrants that were issued in connection with a private placement of the Company&#8217;s securities that closed during April 2011 and is discussed more fully in Note 7. As of April 30, 2012 and 2011, these warrants had an estimated fair value of $555,000 and $972,000, respectively, which was calculated by the Monte Carlo simulation valuation method using level three inputs. The Company has no assets that are measured at fair value on a recurring basis and there were no assets or liabilities measured at fair value on a non-recurring basis during the years ended April 30, 2012 and 2011.</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The following table presents information about our warrants liability, which was our only financial instrument measured at fair value on a recurring basis using significant unobservable inputs (Level 3) as defined in ASC Topic 820 at April 30 (dollars in thousands):</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 95%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 9pt;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2">2012</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2">2011</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; width: 74%;">Balance beginning of year</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">(972</td>
<td style="text-align: left; width: 1%;">)</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">-</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-left: 9pt;">Transfers to (from) Level 3</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-left: 9pt;">Total gains (losses) included in earnings</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">417</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(36</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-left: 9pt;">Purchases/issuances/settlements, net</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">-</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(936</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt;">Balance end of year</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">(555</td>
<td style="text-align: left; padding-bottom: 2.5pt;">)</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">(972</td>
<td style="text-align: left; padding-bottom: 2.5pt;">)</td>
</tr>
</table>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Accounts Receivable</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Accounts receivable represent amounts due under agreements with pharmaceutical and biotechnology companies for TOS and amounts due under agreements with patients for POS. At each reporting period, the Company evaluates open accounts receivable for collectability and records an allowance for potentially uncollectible accounts. As of April 30, 2012, the allowance for these accounts was $14,000. There was no allowance recorded for open receivables at April 30, 2011. Accounts receivable is also comprised of certain unbilled accounts receivable for services completed under TOS that have not been billed as of the balance sheet date. As of April 30, 2012 and 2011, the Company had unbilled receivables of $104,000 and $305,000, respectively.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Restricted Cash</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company has restricted cash of $150,000, which is classified as a noncurrent asset. This restricted cash serves as collateral for corporate credit cards to provide financial assurance that the Company will fulfill its obligations. The cash is held in custody by the issuing bank, is restricted as to withdrawal or use, and is currently invested in an interest-bearing Certificate of Deposit (&#8220;CD&#8221;). Though the initial CD matures in the second quarter of fiscal 2013, the cash will be reinvested into another CD to continue use of the corporate cards. The Company accounts for this CD as a non-current asset supporting operations of the business.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>&#160;</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Property and Equipment</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Property and equipment is recorded at cost and primarily consists of laboratory equipment, furniture and fixtures, and computer hardware and software. Depreciation is calculated on a straight-line basis over the estimated useful lives of the various assets ranging from three to seven years. Property and equipment consisted of the following (in thousands):</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table align="center" style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6">April 30,</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2">2012</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2">2011</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; width: 74%;">Furniture and fixtures</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">58</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">10</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Computer equipment and software</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">287</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">119</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;">Laboratory equipment</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">167</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">56</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Leasehold improvements</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">2</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">2</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt;">Sortware in-progress</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">216</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">24</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;">Total property and equipment</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">730</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">211</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt;">Less: Accumulated depreciation</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(170</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(65</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt;">Property and equipment, net</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">560</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">146</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>&#160;</b></p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Depreciation expense was $105,000 and $42,000 for the years ended April 30, 2012 and 2011, respectively.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>&#160;</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Impairment of Long-Lived Assets</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Impairment losses are to be recognized when the carrying amount of a long-lived asset is not recoverable or exceeds its fair value.&#160;&#160;The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that a carrying value may not be recoverable.&#160;&#160;The Company uses estimates of future cash flows over the remaining useful life of a long- lived asset or asset group to determine the recoverability of the asset.&#160;&#160;These estimates only include the net cash flows directly associated with, and that are expected to arise as a direct result of, the use and eventual disposition of the asset or asset group.&#160;&#160;The Company has not recognized any impairment losses for the Company&#8217;s long-lived assets for the years ending April 30, 2012 and 2011.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Goodwill</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Goodwill represents the excess of the cost over the fair market value of the net assets acquired including identifiable assets.&#160;&#160;Goodwill is tested annually, or more frequently if circumstances indicate potential impairment, by comparing its fair value to its carrying amount.&#160;&#160;The determination of whether or not goodwill is impaired involves significant judgment.&#160;&#160;Although the Company believes its goodwill is not impaired, changes in strategy or market conditions could significantly impact the judgments and may require future adjustments to the carrying value of goodwill.&#160;&#160;The Company uses a two-step process to test for goodwill impairment.&#160;&#160;The first step is to screen for potential impairment, while the second step measures the amount of the impairment, if any.&#160;&#160;The first step of the goodwill impairment test compares the fair value of each reporting unit with its carrying amount, including goodwill.&#160;&#160;If the fair value of the reporting unit exceeds its carrying value, goodwill is not impaired.&#160;&#160;If the carrying value of the reporting unit&#8217;s net assets, including goodwill, exceeds the fair value of the reporting unit, then the Company determines the implied fair value of goodwill.&#160;&#160;If the carrying value of goodwill exceeds its implied fair value, then an impairment of goodwill has occurred and an impairment loss would be recognized for the difference between the carrying amount and the implied fair value of goodwill as a component of operating income.&#160;&#160;The implied fair value of goodwill is calculated by subtracting the fair value of tangible and intangible assets associated with the reporting unit from the fair value of the unit. The Company tests for goodwill impairment at the operating segment level.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company has not recognized any impairment losses for the Company&#8217;s goodwill for the years ending April 30, 2012 and 2011.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Deferred Revenue</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Deferred revenue represents payments received in advance for services to be performed.&#160;&#160;When services are rendered, deferred revenue is then recognized as earned.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Warrant Liability</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Warrant liability represents the fair value of warrants issued in connection with the Securities Purchase Agreement as liabilities based on the certain exercise price reset provisions.&#160;&#160;The&#160;&#160;liability, which is recorded at fair value on the accompanying consolidated balance sheets, is calculated by the Monte Carlo simulation valuation method.&#160;&#160;The change in fair value of these warrants is recognized as other income or expense in the consolidated statements of operations.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Revenue Recognition</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company derives revenue from its POS and TOS businesses. Personalized oncology solutions assist physicians by providing information to help guide the development of personalized treatment plans for their patients using our core offerings, including testing oncology drugs and drug combinations on personalized TumorGrafts, and through other services. Translational oncology solutions offer a preclinical TumorGraft platform to pharmaceutical and biotechnology companies using proprietary TumorGraft studies, which have been shown to be predictive of how drugs may perform in clinical settings.&#160;&#160;The Company recognizes revenue when the following four basic criteria are met: (i) a contract has been entered into with its customers; (ii) delivery has occurred or services rendered to its customers; (iii) the fee is fixed and determinable as noted in the contract; and (iv) collectability is reasonably assured.&#160;&#160;The Company utilizes a proportional performance revenue recognition model for its TOS business, under which it recognizes revenue as performance occurs, based on the relative outputs of the performance that have occurred up to that point in time under the respective agreement, typically the delivery of reports to its customers documenting the results of testing protocols.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">When a POS or TOS arrangement involves multiple elements, the items included in the arrangement (deliverables) are evaluated to determine whether they represent separate units of accounting.&#160;&#160;The Company performs this evaluation at the inception of an arrangement and as each item in the arrangement is delivered.&#160;&#160;Generally, the Company accounts for a deliverable (or a group of deliverables) separately if: (i) the delivered item(s) has standalone value to the customer, and (ii) if the Company has given the customer a general right of return relative to the delivered item(s) and the delivery or performance of the undelivered item(s) or service(s) is probable and substantially in the Company&#8217;s control.&#160;&#160;All revenue from contracts determined not to have separate units of accounting is recognized based on consideration of the most substantive delivery factor of all the elements in the contract or if there is no predominant deliverable upon delivery of the final element of the arrangement.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Cost of Personalized Oncology Solutions</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Cost of POS consists of costs related to POS revenue earned from implantations, drug studies, oncology panels, and gene sequencing services, as well as indirect internal costs, such as salaries for personnel directly engaged in these services. Direct costs associated with implantation revenues are primarily related to mice purchases and maintenance and shipping of tumor tissue. Direct study costs are primarily incurred from mice purchases and maintenance and drug purchases. Direct panel costs are primarily related to physicians&#8217; honorariums and any panel participation costs such as travel, lodging and meals. Direct gene sequencing costs are primarily related to costs billed from the gene sequencing service provider. All costs are expensed as incurred.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Cost of Translational Oncology Solutions</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Cost of TOS consists of costs related to TOS revenue.&#160;&#160;Direct costs include mice purchases and maintenance costs for studies completed internally and charges from CROs for studies handled externally. Indirect costs include salaries for personnel directly engaged in providing TOS services. All costs of performing studies in-house are expensed as incurred.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Research and Development</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Research and development costs represent both costs incurred internally for research and development activities, including personnel costs and mice purchases and maintenance, as well as costs incurred externally to facilitate research activities, such as tumor tissue procurement and characterization expenses.&#160;&#160;All research and development costs are expensed as incurred.&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Sales and Marketing</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Selling and marketing expenses represent costs incurred to promote the Company&#8217;s services offered, including salaries, benefits and related costs of our sales and marketing personnel, and represent costs of advertising and other selling and marketing expenses. All sales and marketing costs, including advertising costs, are expensed as incurred. Advertising costs were $135,000 and $69,000 for fiscal 2012 and 2011, respectively.</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Basic and Dilutive Loss Per Common Share</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Basic loss per share is calculated by dividing loss available to common shareholders by the weighted average number of common shares (including redeemable common stock) outstanding for the year.&#160;&#160;Diluted loss per share is calculated based on the weighted average number of common shares (including redeemable common stock) outstanding for the year, plus the dilutive effect of common stock purchase warrants, stock options and restricted stock units using the treasury stock method.&#160;&#160;Contingently issuable shares are included in the calculation of basic earnings per share when all contingencies surrounding the issuance of the shares are met and the shares are issued or issuable.&#160;&#160;Contingently issuable shares are included in the calculation of dilutive earnings per share as of the beginning of the reporting period if, at the end of the reporting period, all contingencies surrounding the issuance of the shares are satisfied or would be satisfied if the end of the reporting period were the end of the contingency period.&#160;&#160;Due to the net losses for the years ended April 30, 2012 and 2011, basic and diluted loss per share were the same, as the effect of potentially dilutive securities would have been anti-dilutive.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The following table reflects the total potential share-based instruments outstanding at April 30, 2012 and 2011 that could have an effect on the future computation of dilution per common share:</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>&#160;</b></p>
<table align="center" style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: left;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">Year Ended April 30,</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2">2012</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2">2011</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; width: 74%;">Stock options</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 10%;">14,866,038</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 10%;">14,320,948</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Warrants</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1,416,667</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1,912,019</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt;">Restricted stock</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">25,000</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">100,000</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt;">Total common stock equivalents</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">16,307,705</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">16,332,967</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>&#160;</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Share-Based Payments</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company typically recognizes expense for share-based payments based on the fair value of awards on the date of grant.&#160;&#160;The Company uses the Black-Scholes option pricing model to estimate fair value.&#160;&#160;The Black-Scholes option valuation model was developed for use in estimating the fair value of short-traded options that have no vesting restrictions and are fully transferable.&#160;&#160;The option pricing model requires the Company to estimate certain key assumptions such as expected life, volatility, risk free interest rates and dividend yield to determine the fair value of share-based awards.&#160;&#160;These assumptions are based on historical information and management judgment.&#160;&#160;The risk-free interest rate used is based on the United States treasury security rate with a term consistent with the expected term of the award at the time of the grant.&#160;&#160;The expected holding period of options are based on the Company&#8217;s historical experience.&#160;&#160;The volatility rates are based upon a weighted average of the Company&#8217;s volatility and the weighted average of a four-member peer group of companies in the Company&#8217;s industry.&#160;&#160;The Company does not anticipate paying a dividend, and therefore, no expected dividend yield was used.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company expenses share-based payments over the period that the awards are expected to vest, net of estimated forfeitures.&#160;&#160;If actual forfeitures differ from management&#8217;s estimates, compensation expense is adjusted.&#160;&#160;The Company will report cash flows resulting from tax deductions in excess of the compensation cost recognized from those options (excess tax benefits) as financing cash flows, if they should arise.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Income Taxes</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Deferred income taxes have been provided to show the effect of temporary differences between the recognition of expenses for financial and income tax reporting purposes and between the tax basis of assets and liabilities, and their reported amounts in the consolidated financial statements.&#160;&#160;In assessing the realizability of deferred tax assets, the Company assesses the likelihood that deferred tax assets will be recovered through tax planning strategies or from future taxable income, and to the extent that recovery is not likely or there is insufficient operating history, a valuation allowance is established.&#160;&#160;The Company adjusts the valuation allowance in the period management determines it is more likely than not that net deferred tax assets will or will not be realized.&#160;&#160;As of April 30, 2012 and 2011, the Company provided a valuation allowance for all net deferred tax assets, as recovery is not more likely than not based on an insufficient history of earnings.</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Tax positions are positions taken in a previously filed tax return or positions expected to be taken in a future tax return that are reflected in measuring current or deferred income tax assets and liabilities reported in the consolidated financial statements.&#160;&#160;Tax positions include, but are not limited to, the following:</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 9pt;"></td>
<td style="width: 15pt;"><font style="font-family: symbol;">&#183;</font></td>
<td style="text-align: justify;">An allocation or shift of income between taxing jurisdictions;</td>
</tr>
</table>
<table style="margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 9pt;"></td>
<td style="width: 15pt;"><font style="font-family: symbol;">&#183;</font></td>
<td style="text-align: justify;">The characterization of income or a decision to exclude reportable taxable income in a tax return; or</td>
</tr>
</table>
<table style="margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 9pt;"></td>
<td style="width: 15pt;"><font style="font-family: symbol;">&#183;</font></td>
<td style="text-align: justify;">A decision to classify a transaction, entity or other position in a tax return as tax exempt.</td>
</tr>
</table>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company reflects tax benefits only if it is more likely than not that we will be able to sustain the tax position, based on its technical merits.&#160;&#160;If a tax benefit meets this criterion, it is measured and recognized based on the largest amount of benefit that is cumulatively greater than 50% likely to be realized.&#160;&#160;The Company has no unrecognized tax benefits as of April 30, 2012 and 2011.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company&#8217;s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties on the Company&#8217;s balance sheets at April 30, 2012 and 2011, and has not recognized interest and/or penalties in the statement of operations for either period.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Recent Accounting Pronouncements</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">During September 2011, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2011-08, &#8220;Testing Goodwill for Impairment&#8221; (&#8220;ASU 2011-08&#8221;). ASU 2011-08 is intended to simplify the testing of goodwill for impairment by permitting an entity to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test, which is currently required for all companies that report goodwill. The amendments are effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011, although early adoption is permitted. The Company does not anticipate that the adoption of this guidance will have a material impact on its financial position and results of operations.</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">During June 2011, the FASB issued ASU No. 2011-05, &#8220;Presentation of Comprehensive Income&#8221; (&#8220;ASU 2011-05&#8221;). ASU 2011-05 provides for the option to present the total of comprehensive income, the components of net income and the components of other comprehensive income (&#8220;OCI&#8221;) either in a single continuous statement of comprehensive income or in two separate but consecutive statements. Regardless of which format is chosen, the amendments establish a requirement for entities to present on the face of the financial statements reclassification adjustments for items that are reclassified from OCI to net income in the statement(s) where the components of net income and the components of OCI are presented. The amendments in ASU 2011-05 are effective, on a retrospective basis, for public entities for interim and annual periods beginning after December 15, 2011; however, during December 2011 the FASB issued ASU No. 2011-12, which defers those changes in ASU 2011-05 that relate to the presentation of reclassification adjustments. The Company has adopted this standard, which only impacts the disclosures required, but has no impact on the financial position or results of operations.</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 9pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">During May 2011, the FASB issued ASU No. 2011-04, &#8220;Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRS&#8221; (&#8220;ASC 2011-04&#8221;). The amendments in ASC 2011-04 were issued in order to align the fair value measurement and disclosure requirements in GAAP and International Financial Reporting Standards. Consequently, the amendments change the wording used to describe many of the requirements in GAAP for measuring fair value and for disclosing information about fair value measurements. However, many of the amendments in ASC 2011-04 will not result in a change in the application of the requirements in ASC 820, Fair Value Measurement. The amendments in ASU 2011-04 are effective, on a prospective basis, for public entities for interim and annual periods beginning after December 15, 2011. The Company has adopted this standard, which had no impact on its financial position or results of operations.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 22<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Version>2.4.0.6</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>37</ContextCount>
  <ElementCount>119</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>6</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>001 - Document - DOCUMENT AND ENTITY INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/DocumentAndEntityInformation</Role>
      <ShortName>DOCUMENT AND ENTITY INFORMATION</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/StatementOfFinancialPositionClassified</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>003 - Statement - CONSOLIDATED BALANCE SHEETS [Parenthetical]</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS [Parenthetical]</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/StatementOfIncomeAlternative</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/StatementOfOtherComprehensiveIncome</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>006 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/CONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT</Role>
      <ShortName>CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/StatementOfCashFlowsIndirect</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS [Parenthetical]</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/ConsolidatedStatementsOfCashFlowsParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS [Parenthetical]</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>009 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/OrganizationAndBasisOfPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>010 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>011 - Disclosure - Cephalon Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/CephalonAgreement</Role>
      <ShortName>Cephalon Agreement</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>012 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/Commitmentsandcontingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>013 - Disclosure - Licensing Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/LicensingAgreements</Role>
      <ShortName>Licensing Agreements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>014 - Disclosure - Share-Based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/ShareBasedPayments</Role>
      <ShortName>Share-Based Payments</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>015 - Disclosure - Redeemable Common Stock and Stock Purchase Warrant</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/RedeemableCommonStockAndStockPurchaseWarrant</Role>
      <ShortName>Redeemable Common Stock and Stock Purchase Warrant</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>016 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>017 - Disclosure - Provision for Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/ProvisionForIncomeTaxes</Role>
      <ShortName>Provision for Income Taxes</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>018 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>019 - Disclosure - Business Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/BusinessSegmentInformation</Role>
      <ShortName>Business Segment Information</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>020 - Disclosure - Supplemental Schedule of Cash Flow Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/SupplementalScheduleOfCashFlowInformation</Role>
      <ShortName>Supplemental Schedule of Cash Flow Information</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>021 - Disclosure - Grant Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/GrantIncome</Role>
      <ShortName>Grant Income</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>022 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/SupplementalCashFlowInformation</Role>
      <ShortName>Subsequent Events</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Process Flow-Through: 002 - Statement - CONSOLIDATED BALANCE SHEETS</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Apr. 30, 2010'</Log>
    <Log type="Info">Process Flow-Through: 003 - Statement - CONSOLIDATED BALANCE SHEETS [Parenthetical]</Log>
    <Log type="Info">Process Flow-Through: 004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</Log>
    <Log type="Info">Process Flow-Through: 005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</Log>
    <Log type="Info">Process Flow-Through: 007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</Log>
    <Log type="Info">Process Flow-Through: 008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS [Parenthetical]</Log>
  </Logs>
  <InputFiles>
    <File>csbr-20120430.xml</File>
    <File>csbr-20120430.xsd</File>
    <File>csbr-20120430_cal.xml</File>
    <File>csbr-20120430_def.xml</File>
    <File>csbr-20120430_lab.xml</File>
    <File>csbr-20120430_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Supplemental Schedule of Cash Flow Information<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Apr. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">Cash Flow, Supplemental Disclosures [Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Note 12. Supplemental Schedule of Cash Flow Information</b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Supplemental cash flow information is as follows (in thousands):</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6">Year Ended April 30,</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2">2012</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2">2011</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;">Supplemental cash flow information:</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-left: 9pt;">Cash paid for interest</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-left: 9pt;">Cash paid for income taxes</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in;">Supplemental disclosure of non-cash investing and financing activities:</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-left: 0.25in; width: 74%;">Stock subscription receivable</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 10%;">-</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 10%;">(750</td>
<td style="text-align: left; width: 1%;">)</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-left: 0.25in;">Purchases of property and equipment included in accounts payable</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">192</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
</tr>
</table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 32<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashFlowSupplementalDisclosuresTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowElementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
